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Abstract 
Histone deacetylases (HDAC) are a family of enzymes, which serve as epigenetic modulators. Their biological 
function has been related to DNA transcription and regulation of various biochemical pathways. 
Development of isoform selective HDAC inhibitors could be useful for dissecting the individual biochemical 
pathways associated with each HDAC isoform and these compounds could potentially serve as anti-cancer 
drugs. Macrocyclic peptides and depsipeptides is an interesting class of HDAC inhibitors, which are found in 
Nature. These compounds are characterized by being highly potent and moderate selective HDAC inhibitors 
and we turned our attention to a class of cyclic tetrapeptides, known as azumamides. We developed a 
synthetic route, which allowed us to complete the total synthesis of azumamides A–E. This is the first 
reported total synthesis of azumamide B–D and our results validate the proposed structures. The key step in 
this route is a diastereoselective Mannich reaction, which enabled us to prepare two site-specifically edited 
epimeric azumamide analogs, where the stereochemistry in the unique β-amino acid was inverted. The two 
epimeric homologs were screened together with azumamide A−E against the entire panel of recombinant 
HDAC isoforms. Thus, providing the first full profiling of the azumamides. The epimers were inactive against 
the full panel of HDAC enzymes and show that the β-amino acid scaffold is highly sensitive to modifications 
in the stereochemistry. The profiling of the natural products showed that the azumamides are poor inhibitors 
of class IIa HDACs, but potent inhibitors of HDAC1–3, 10, and 11 (IC50 values between 14 to 67 nM). 
Furthermore we showed that carboxylic acid containing compounds (azumamide C and E) were more potent 
than their carboxyamide counterparts (azumamide A and B). Isoform selectivity was observed in class I and 
class IIb. In class I, azumamides C and E were 60–350-fold more potent towards HDAC1–3 over HDAC8 and 
in class IIb they were >200-fold more potent against HDAC10 over HDAC6. Finally, we found that azumamide 
C was ∼2-fold more potent than azumamide E, which indicate having a tyrosine residue in the macrolactam 
ring increase the activity compared to the phenylalanine homolog.    
 
The synthetic route was elaborated to produce structurally edited azumamide analogs. A series of β2-
desmethylated compounds were synthesized in parallel to a series of β2-dimethylated analogs. Having 
observed the importance of the aromatic amino acid in the azumamides, a tryptophan-series was also 
prepared. The synthesis of these compounds underline the broad perspective and flexibility of the developed 
Mannich strategy. The dimethylated analogs were found to be poor HDAC inhibitors and only the tryptophan-
containing compound showed activity below 20 µM. The removal of the β2-methyl group induced a 1.5–18-
fold loss in potency across the different isoforms. The methyl group was found to be less important for 
inhibition of HDAC 6 and 8 (1.5−3-fold decrease in activity). Based on NMR solution structures we hypothesize 
that the β2-methyl group, found in the natural products, guides the β3-side chain towards the active site. 
Judging from the biochemical data on the desmethylated series, this directing feature is important for the 
activity of this type of inhibitors. Furthermore, a β3-propyl azumamide C analog was developed in order to 
investigate the effect of the zinc-binding moiety. Preliminary testing showed that this compound was active 
against HDAC3 with an IC50 of 3 µM. The straight forward synthesis of the β-amino acid required for this 
analog also illustrate the effectiveness of the developed Mannich reaction. 
 
On a different project, a promising Bsmoc-based scaffold was probed to serve as a linker in anti-body drug 
conjugates (ADC) and preliminary results encourage further investigations of this strategy.      
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Resumé 
Histone deacetylaser (HDAC) er en familie af enzymer, der fungerer som epigenetiske modulatorer. Deres 
biologiske funktion er blevet relateret til transskription af DNA og regulering af forskellige biokemiske 
processer. Udviklingen af isoform selektive HDAC inhibitorer kunne være nyttig i forhold til at identificere de 
biokemiske processer, som er forbundet med de enkelte HDAC isoformer og disse inhibitorer kunne have 
potentiale som anti-cancer lægemidler. Makrocykliske peptider er en interessant klasse af HDAC inhibitorer. 
Disse molekyler er karakteriseret ved at være potente og moderate selektive HDAC inhibitorer og vi 
fokuserede på en klasse af naturligt forekommende cykliske tetrapeptider, kendt som azumamider. Vi 
udviklede en syntesevej som gjorde os i stand til at syntetisere azumamid A–E. Dette er den første 
totalsyntese af azumamid B–D og vores resultater bekræfter de originale strukturer. Det vigtigste trin i vores 
syntesevej er en diastereoselektiv Mannich-reaktion, som gjorde det muligt at syntetisere to azumamid 
epimere, hvor vi har vendt stereokemien i den unikke β-aminosyre. Disse to epimere blev screenet sammen 
med azumamid A–E mod alle 11 HDAC enzymer. Dette resulterede in den første fyldestgørende HDAC 
karakterisering af azumamiderne. De to epimere var inaktive mod samtlige HDAC enzymer og illustrerer at 
β-aminosyren er følsom for modifikationer i stereokemien. Karakteriseringen af azumamid A–E viste a 
azumamiderne er svage inhibitorer af klasse I enzymerne, men potente mod HDAC1–3, 10 og 11 med IC50-
værdier mellem 14 nM til 67 nM.  Derudover viste vores resultater at de azumamider, som indeholder 
carboxylsyrer (azumamid C og E) er mere potente end de azumamider som indeholder et amid (azumamid A 
og B). Vi observerede isoform-selektivitet i klasse I og IIb. I klasse I var azumamid C og E mellem 60 og 350 
gange mere potente mod HDAC1–3 i forhold til HDAC8 og i klasse II var de mere end 200 gange mere potente 
mod HDAC10 i forhold til HDAC6. Vores resultater indikerede også at det er mere favorabelt at have tyrosin 
i det cykliske peptid i forhold til phenylalanin.   
Vi har anvendt vores fleksible og robuste syntesevej til at syntetisere en række azumamid analoger. Vi 
syntetiserede både en serie af β2-desmethylerede og β2-dimethylerede analoger. På baggrund af resultaterne 
med azumamiderne valgte vi også at syntetisere en serie af analoger, hvor vi introducerer tryptophan i stedet 
for tyrosin og phenylalanin. Syntesen af disse analoger viser at vores syntesevej er fleksibel og kan anvendes 
til at producere nye azumamid analoger. De dimethylerede analoger viste sig at være dårlige HDAC 
inhibitorer og kun det molekyle som indeholdt tryptophan var aktivt ved koncentrationer under 20 µM. De 
desmethylerede analoger var mellem 1,5 og 18 gange dårligere en naturstofferne til at inhibere de fleste 
enzymer. De isoformer som var mindst påvirkede af demethyleringen var HDAC6 og 8. Baseret på NMR 
strukturer af disse molekyler foreslår vi at β2-methyl gruppen, som er til stede i azumamiderne, kan dirigerer 
den zink-bindende β3-sidekæde mod det aktive site. Ud fra den biokemiske screening af de desmethylerede 
analoger ser det ud til a denne dirigering er vigtig for aktiviteten af disse molekyler.  
For at undersøge effekten af den zink-bindende gruppe, fremstillede vi også en β3-propyl azumamid C analog. 
Denne analog blev testet på HDAC3 og viste sig at være aktiv med en IC50 på 3 µM. Denne analog kunne også 
syntetiseres ved hjælp af vores Mannich strategi og bekræftede endnu en gang den brede anvendelse af 
vores syntesevej. 
Jeg har også arbejdet på at udvikle en ny linker til fremstillingen af anti-body drug conjugates. I et forsøg på 
at validere konceptet bag denne linker, syntetiserede jeg en række forskellige molekyler med baggrund i 
Bsmoc-beskyttelsesgruppen. Stabilitetstestning af disse molekyler indikerede at denne strategi kunne danne 
baggrund for udviklingen af nye linkere.     
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1 Introduction 
1.1 Epigenetics 
In living organisms the hereditary information is stored in the DNA, which exist as a double-stranded helical 
structure. DNA pass on the genetic information from one generation to another and it determines which 
proteins that are available to the organism. DNA is transcribed into mRNA by the RNA polymerase and 
subsequent translation by the ribosome creates the target protein. Cells within an organism contain the same 
DNA and therefore have the potential to differentiate into many different specialized cell types. The 
differentiation of a specific cell is regulated by transcription and translation of specific DNA regions. These 
DNA regions code for proteins that are specific for a given cell phenoptype. The underlying mechanism that 
regulates and controls cell differentiation, is complex. In order to understand the different factors involved, 
it is advantageous to examine how the DNA is organized and stored within the cells. The double-stranded 
DNA is wrapped around core histone proteins to create the nucleosome. The nucleosome particle is build up 
of 145 bp of DNA, which is coiled 1.7 times around one histone protein octamer.1 These octamers consist of 
two copies of each of the four core histone proteins: H2A, H2B, H3, and H4. The nucleosomes are anchored 
to the DNA strand by H1.2, 3 The histone proteins organize on the DNA strand like “beads on a string” and fold 
up to produce chromatin 30 nm fibers (Figure 1-1). Kornberg4 and Olins5 were the first to report this ordered 
structure using electron microscopy. The 30 nm fibers are condensed into loops (around 300 nm in length), 
which are further folded into larger fibers (250 nm wide). The coiling and compression of the 250 nm wide 
fiber results in a chromatid, which make up one-half of the chromosome during cell division.   
 
Figure 1-1. Illustration of DNA packaging in cells. (Adapted from Annunziato, A.)6 
The transcription and translation of specific genes can be regulated by external modifications, which do not 
change the DNA sequence. The study of these modifications is termed epigenetics. One of the most studied 
epigenetic modifications is DNA-methylation. Methylation of DNA occurs on two nucleobases, cytosine (C) 
and adenine (A), and is catalyzed by DNA methyl transferases. The primary target for methylation of the DNA 
is the cytosine component of CpG islands, where a cytosine is found next to a guanine (G). These CpG islands 
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are often found in promoter regions on the DNA and in general the methylation of CpG islands is associated 
with gene silencing. When the CpG dinucleotide is methylated the different transcription factors are unable 
to recognize the DNA, leading to gene silencing. Furthermore, it is believed that methylated CpG islands 
attract proteins called methyl-CpG-binding domains (MBD), which are involved in transcriptional repression.7  
Another well described epigenetic mechanism is acetylation of lysine side chains in proteins which interact 
with the DNA. There is an abundance of lysine residues in the amino-terminal tail of all four core histone 
proteins. Post-translational modifications of these tails, and in particular of the lysine residues, play a key 
role in gene expression as well as histone assembly and deposition.8,9  
A variety of post-translational modifications can occur on the N-terminal tails of histones. The most important 
modifications are acetylation and methylation, however phosphorylation and adenosine diphosphate ribose 
(ADP)-ribosylation have also been found.9 Histone methylation occurs primarily on the side chain of lysine 
residues, but methylation of arginine side chains have also been observed.10 The methylation state is 
controlled by histone lysine methyltransferases (KMTs) and demethylases (KDMs). Lysine residues can be 
either mono-,di- or tri-methylated and the different methylation degrees can lead to either transcriptional 
activation or repression. Furthermore, methylation is mostly found in H3 and H4 on specific lysine residues. 
For instance, methylation of H3K4, H3K36, and H3K79, found in the coding region or around the transcription 
start site of the gene, is associated with gene activation. In contrast, methylation of H3K9 and H3K27 in the 
promoter region results in silencing of the gene.11 The methyl group functions as a recruiter of either 
repressive proteins or activator proteins, depending on which lysine it is located on. Therefore, the 
methylation state is closely related to the transcriptional balance in the cell. Tight regulation of the KMT and 
KDM activities is essential to maintain the transcriptional balance and misregulation is believed to promote 
cancer.12, 13 The mechanisms and biological pathways responsible for cancer development in cells with a 
poorly regulated histone methylation state is not clear. However, activation of oncogenes and silencing of 
tumor-suppressor genes is likely to be involved.13  
1.2 Histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
The acetylation/deactylation of histones takes place on the ε-amino groups of the lysine residues and the 
equilibrium is regulated by histone acetyl transferases (HATs) and histone deacetylases (HDACs). HATs 
catalyze the acetylation of the amino groups and the HDACs catalyze the reverse reaction (Scheme 1-1).  
 
Scheme 1-1. Lysine modifications catalyzed by HDACs and HATs. 
HDACs also target non-histone proteins and currently these enzymes are often referred to as lysine 
deactylases (KDACs), as to describe their function rather than their target.14 Deacetylation of the ε-amino 
group results in a positive charge on the nitrogen at physiological pH. This positive charge can interact 
strongly with the negative charges on the DNA backbone and the DNA–histone complex will adapt a compact 
and folded structure that impairs transcription.15, 16 In the acetylated form, the nitrogen atom will be neutral 
and the interaction between the histones and the DNA is significantly weaker. This reduced interaction allows 
a more flexible and unfolded DNA–histone complex and the DNA can be accessed by the transcriptional 
machinery (Figure 1-2).   
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Figure 1-2. The roles of HATs and HDACs in DNA transcription. (Adapted from Chiu et al.)17 
The first mammalian HDAC was isolated by Stuart Schreiber in 199618 and in the same year David Allis cloned 
the first HAT.8 Today, the HDAC family consists of 18 isoforms where HDAC11 was the last enzyme to enter 
the family.19 The HDACs are categorized into four classes (Table 1-1). The grouping of isoforms is based on 
the structural resemblance to the homologous yeast proteins.20 Class I (HDAC1, 2, 3, and 8), class II (HDAC4, 
5, 6, 7, 9, and 10) and class IV (HDAC11) are Zn2+ dependent enzymes, whereas class III, called sirtuins (SIRT1–
7)21 are nicotinamide adenine dinucleotide (NAD)-dependent.22 Class II HDACs are further divided into two 
sub classes, class IIa (HDAC4, 5, 7, and 9) and class IIb (HDAC6 and 10).  
Table 1-1. Classification of the KDAC family. 
Class  HDAC isoform  Catalytic requirements  
I  HDAC1-3, HDAC8  Zn2+  
IIa  HDAC4, 5, HDAC7, HDAC9  Zn2+   
IIb  HDAC6, HDAC10  Zn2+ 
III  SIRT1-7  NAD+  
IV  HDAC11  Zn2+ 
 
1.2.1 Class I HDACs 
Gregoretti and co-workers have performed phylogenetic analysis on HDAC and shown that HDAC1 and 2 may 
originate from a single metazoan HDAC1/2 protein.22 This hypothesis is supported by the evidence that 
HDAC1 and 2 both exist in similar complexes in vivo, including NurD23, CoREST24, and Sin3.25, 26 The enzymes 
are similar in function and sequence, but if HDAC1 is removed in embryonic mouse cells, the cell growth is 
impaired and proliferation is disturbed.27 This result shows that HDAC2 is unable to perform all the functions 
performed by HDAC1. The major structural difference between HDAC1 and 2, is a region found in the C-
termini of HDAC2. This region is predicted to form α-helical coils, which could mediate interaction with other 
proteins. In HDAC1, the same region is not believed to have the same preference for formation of α-helical 
coils. This structural variance could explain some of the functional differences observed between the two 
isoforms. Interestingly HDAC1 has been found to form dimers with itself and HDAC2.28, 29 A HDAC association 
domain (HAD), which is located in the N-terminus of HDAC1, was reported to be essential for dimerization. 
HDAC1 and 2 are primarily found in the nucleus of the cell in contrast to HDAC3, which is able to translocate 
to the cytoplasm.30, 31 Translocation of HDAC3 to the cytoplasm can indicate that this isoform, at least in part, 
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has non-nuclear substrates. The translocation can to some extent be attributed to interaction of HDAC3 with 
chromosome region maintenance 1 (CRM1), which is believed to bind a region between residue 180–313 and 
direct the enzyme to the cytoplasm. HDAC3 forms homo-dimers and trimers in vivo and participate in 
multiprotein complexes.30 Key complexes have been found to be N-CoR1, N-CoR2, (Nuclear Receptor 
Corepressor 1 or 2) and SMRT (Silencing Mediator for Retinoid or Thyroid-hormone receptors).32, 33 Analogous 
to HDAC1 and 2, the domain associated with self-assembly is found within the first 122 residues in the N-
terminal. Interestingly, the SMRT/NCoR HDAC3 complex interacts with the class II enzymes: HDAC4, 5, 7, and 
10.34 The last member of class I is HDAC8, which seems to be different in terms of function and the ability for 
form complexes. HDAC8 is phylogenetic distinct from the remaining class I enzymes and displays a lower 
preference for acetylated substrates. Furthermore, inhibitors of HDAC1–3, are often less active against 
HDAC8.35    
1.2.2 Class II HDACs 
Class II HDACs are divided into two subclasses as shown in Table 1-1. Class IIa include HDAC4, 5, 7, and 9. All 
four proteins contain a highly conserved C-terminal catalytic domain.36 Interestingly, the expression of class 
IIa HDAC has been found to be tissue-specific. These enzymes are primarily found in muscle cells, and in 
particular in skeletal and heart muscle cells, whereas class I HDACs are ubiquitously expressed.36 In terms of 
cellular distribution, the class IIa HDACs shuttle between the nucleus and the cytoplasm and the activity of 
the enzymes is controlled by the cellular localization.37, 38 The shuttling of class II HDACs is mediated through 
binding to a family of proteins, known as 14-3-3 proteins. The 14-3-3 proteins facilitate the transport of the 
enzymes from the nucleus to the cytoplasm and is associated with transcriptional repression. The 
phosphorylation of three serine residues, found in the N-terminal of the HDAC enzymes, is essential for 
binding to 14-3-3 proteins.39 Similar to HDAC3, class IIa HDACs also interact with SMRT and N-CoR1/2 through 
domains found in the C-terminal (Figure 1-3). Interestingly, class II enzymes only display deacetylase activity 
when bound to the SMRT/NCoR–HDAC3 complex, but no activity is observed in vitro when bound to 
SMRT/NCoR alone. Thus, class IIa HDACs may not be functional enzymes on their own, but contribute to the 
recruitment of the SMRT/NCoR–HDAC3 complex.36 HDAC4 has been shown to self-associate through a 17 
residue domain found in the N-terminal.40 A similar domain is found in HDAC5 and 9, but currently the self-
assembly of these isoforms has not been reported. The same N-terminal domain is involved in the interaction 
between class IIa HDACs and one of their major targets: myocyte enhancer factor 2 (MEF2)(Figure 1-3). MEF2 
proteins are key players in the functional delivery of class IIa HDACs to their DNA targets.  MEF2 recognize 
specific promoter regions on the DNA and thus carry the HDACs to their site of action.41 MEF2 delivery to 
specific promoter regions is critical for myocyte development and disturbance of this pathway is associated 
with defects in myocyte differentation.36 In a similar manner class IIa enzymes can associate with methyl CpG 
binding protein 2 (MeCP2), which also recruit the HDAC complexes to their DNA targets. Both MEF2 and 
MeCP2 directed delivery of class IIa HDACs results in transcriptional repression.42 
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Figure 1-3. Schematic representation of the different proteins which interact with class II HDACs. (Adapted from Kasler 
and co-workers)36  
HDAC6 and 10 constitute class IIb and it is believed that HDAC10 originates from a HDAC6-like protein.22 In 
spite of this common ancestor, HDAC6 and 10 are structurally and functionally different. In terms of 
subcellular localization, HDAC6 is primarily cytosolic, but is known to shuttle to the nucleus. HDAC10 shuttle 
between the nucleus and the cytoplasm, with a slight preference for the nucleus. HDAC6 and 10 are 
characterized by two identical HDAC domains, however in HDAC10 the C-terminal domain is truncated and 
catalytic inactive.43 HDAC10 interacts with HDAC3 and SMRT, which connects it to class IIa. In contrast, HDAC6 
does not show this HDAC3/SMRT interaction and instead has been found to associate with HDAC11.19 In 
2002, Yao and co-workers reported that HDAC6 can deacetylate α-tubulin.44 This non-histone substrate is 
associated with cell motility and this result indicate that posttranslational modifications are involved in a 
broad variety of cellular functions. 
1.2.3 Class III HDACs – Sirtuins 
Class III HDACs (SIRT1–7) are different from the remaining three HDAC classes as they do not require a zinc 
atom for their catalytic activity. In contrast, these enzymes require NAD to deacetylate lysine residues. The 
mammalian family has seven members and the NAD-dependent activity was first investigated by Frye in 
199945, who showed that SIRT2 was able to transfer a radioactive labeled phosphor from NAD to bovine 
serum albumin (BSA). The functional activity was elaborated to include ADP-ribosyltransferase to histones 
and eventually to deactylation of histones at lysine 16 in H4.46 However, the sirtuins are weak deacetylases 
of histone substrates compared to HDAC1–11. The target scope for the sirtuins has recently been expanded 
to include removal of crotonyl, malonyl, and succinyl groups from the lysine side chains in histones and other 
proteins (reviewed by Olsen).47 As NAD is involved in the energy balance of the cell it was quickly 
hypothesized that sirtuins could be involved in cell metabolism. Subsequent studies have shown that sirtuins 
are indeed key players in ageing, nutritional balance, and metabolism.48, 49 The known molecular target for 
sirtuins are slightly different from the other HDACs. Sirtuins seem to be more involved in post-translational 
modifications of non-histone proteins than class I, II, and IV HDACs, which primarily target histones. The 
interesting biochemistry of SIRT1–7 has not been studied in this work and these enzymes will not be 
discussed further in this thesis.              
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1.2.4 Class IV HDAC11 
Class IV only include HDAC11, which was isolated in 2002.19 This enzyme is the smallest member of the HDAC 
family and the catalytic domain constitute most of the peptide sequence. As mentioned in section 1.2.2 
HDAC11 interacts with HDAC6, but is has not been shown to interact with complexes associated with class I 
and IIa enzymes. HDAC11 is believed to be a nuclear protein and it displays some deacetylase activity. 
However, the biological target has not yet been identified and little is known about the cellular function.            
1.2.5 Concluding remarks 
It is important to note that HDAC inhibitors may display different activities in experiments with isolated 
recombinant enzymes compared to experiments performed in cells or in vivo. When HDACs are found as a 
part of multiprotein complexes, the overall folding and structure of the enzyme may change compared to 
the recombinant purified version. However, functional assay data and cell experiments seem to correlate 
well for HDAC enzymes.50, 51, 52 
1.3 Histone deacetylases as anticancer agents 
The acetylation level of the histone tails has been correlated to cancer development and HDAC inhibitors 
have proven to be promising anticancer agents. 53, 54, 55 Numerous mechanisms have been proposed to explain 
this observation. First, HDAC inhibitors can induce apoptosis in a broad variety of cancer cell lines. HDAC 
inhibitors are believed to modulate a variety of cellular pathways. The most important extrinsic pathway, is 
the death receptor pathway, which is triggered by TNF-related apoptosis-inducing ligand (TRAIL).56 Studies 
have shown that HDAC inhibitors increase expression of death receptors (DR4 and DR5) and sensitize 
malignant cells to TRAIL-mediated apoptosis. 57, 58, 59 The intrinsic apoptotic pathway (mitochondrial 
mediated), which is associated with cell stress, free radical generation, and misfolding of proteins, also plays 
a key role in the apoptotic properties of HDAC inhibitors.  When subjected to stress or abnormal growth, the 
normal cell will activate pro-apoptotic proteins (BAD and BAK), which sets off a cascade of reactions resulting 
in activation of caspase 3 and apoptosis. This self-destructing “protection mechanism” is impaired in many 
cancer cells.60, 61, 62 There is evidence that the level of HDACs is elevated in these cancer cells and this 
increased HDAC activity favors the condensed and compact chromatin structure (Figure 1-2).63 This leads to 
transcriptional repression of the genes coding for pro-apoptotic proteins. HDAC inhibitors can shift the 
chromatin structure towards the relaxed form and promote transcription of the pro-apoptotic genes. 64,57, 65 
Furthermore, anti-apoptotic proteins (Bcl-2 and Bcl-xL) are down regulated by HDAC inhibitors, leading to an 
overall pro-apoptotic state in the cell.64 Finally, p53-mediated activation of p21, which results in G1 arrest in 
the cell cycle, seems to be induced by HDAC inhibitors.66 Several of the above mentioned pathways indirectly 
induce p53, but recent studies also suggest that the acetylation level of p53, which is regulated by HDACs 
and HATs, is a critical factor in the induction of apoptosis.67, 68 HDAC inhibitors exhibit many other interesting 
biological functions and it is important to remember that HDACs modulate many non-histone targets as well. 
This activity might be the key to many of the observed cellular effects. Mann and co-workers reported the 
acetylation of 1750 proteins and the presence of 3600 lysine acetylation sites by high-resolution mass 
spectrometry (HRMS).69 The acetylated proteins were not restricted to the nucleus of the cell as many 
cytoplasmic proteins also were found to be acetylated. Generally, proteins involved in all aspects of the 
cellular function was acetylated, but acetylation was especially abundant in proteins involved in the cell cycle, 
RNA splicing, chromatin remodeling, ribosomal proteins, and DNA damage repair. Interestingly, KMTs and 
HDMs were found to be extensively acetylated, which suggest a direct link between the two major post-
translational histone modifications. In order to evaluate the effect of HDAC inhibitors on the acetylation 
pattern of the proteins, two different HDAC inhibitors were tested (SAHA (1.01) and MS-275 (1.08), Figure 
1-4). Remarkably, only 10% of the available acetylation sites were up-regulated by the inhibitors, suggesting 
a highly site specific activity of the inhibitors. The two inhibitors also resulted in increased acetylation of 
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different proteins, which could reflect that the two inhibitors inhibit different HDAC isoforms. In relation to 
cancer, it was shown that many oncogene or tumor-suppressor proteins were acetylated. The specific 
biochemical functions associated with acetylation of the majority of these non-histone proteins are not yet 
understood, but it is likely that these proteins are somehow involved in the development of cancer. 
Overexpression of different HDAC isoforms has been associated with different cancer types and an overview 
is presented in Table 1-2.  
Table 1-2. Proposed correlation between overexpression of HDAC isoforms and various cancers. (Adapted from 
Bertrand, P.)70 
HDAC isoform  Cancers associated with overexpression 
HDAC1  Lung, breast, prostate, gastric, colorectal 
HDAC2  Colorectal, gastric 
HDAC3  Lung, solid tumors 
HDAC4 Unknown 
HDAC5  Downregulated in colon and acute myeloid leukaemia 
HDAC6 Breast 
HDAC7 Unknown 
HDAC8 Several cancer forms 
HDAC9 Unknown 
HDAC10 Unknown 
HDAC11 Unknown 
 
Even though the mechanism is not fully understood, it is well established, that HDAC inhibitors are efficient 
molecules for inducing apotosis and targeting cancer cells. The major concern associated with HDAC 
inhibitors as drugs, is the destructive phenotype observed with deletion of HDAC genes.71, 72   However, HDAC 
inhibitors are remarkably well tolerated in vivo. A plausible explanation is that HDACs participate in 
multiprotein transcriptional complexes (Sin3, NurD, CoREST). Complete removal of the HDAC from such 
complexes may render them completely inactive, whereas inhibition with small molecules will leave the 
complexes intact and somewhat functional.73 Another interesting aspect is the shortage of isoform selective 
HDAC inhibitors. Most of the compounds developed so far are primarily defined as class specific inhibitors. 
The development of isoform selective HDAC inhibitors, would be an extremely important tool for 
understanding the individual biological roles of the different isoforms, and such compounds have great 
potential as drugs.74, 54  
The therapeutic potential of HDAC inhibitors is not limited to cancer treatment. The anti-epileptic and mood-
stabilizing drug, valproic acid (1.04, Figure 1-4) is identified as HDAC1 inhibitor, thus linking these nervous 
system disorders to histone acetylation.75, 76 Transcriptional dysregulation is central to the pathogenesis of 
Huntington`s disease, which is initiated by mutations in the hutingtin gene. HDAC inhibitors have been shown 
to be effective in a mouse model of Huntigton`s disease and epigenetic modification could be effective in 
treatment of Huntington`s disease.77 Nestler and co-workers studied gene expression and chromatin 
remodeling in mice subjected to chronic defeat stress and subsequent treatment with the anti-depressant 
drug, imipramine. 78 Chronic defeat stress is a well-established mimic of depression and it was observed that 
imipramine administration increased histone acetylation in promoters regions, which were repressed before 
imipramine treatment. The increase in histone acetylation was associated with downregulation of HDAC5. 
Interestingly, viral-mediated expression of HDAC5 abolished the anti-depressant effect of imipramine, which 
underscore the importance of histone acetylation pattern, and hence chromatin remodeling, in the 
pathogenesis of depression.              
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In summary, HDAC inhibitors have great potential as drugs, within a widespread of diseases and medical 
conditions. However, the mechanisms involved in the observed therapeutic benefits are complex and poorly 
understood. The emergence of potent and selective HDAC inhibitors, as well as improved disease models, 
have founded a solid background for understanding the complex roles of HDACs.    
1.4 HDAC inhibitors 
HDAC inhibitors can be classified in many different ways, but in this work, they have been classified according 
to their chemical structure and divided into four major classes: hydroxamic acids, cyclic peptides, short-chain 
fatty acids, and benzamides (Figure 1-4).79    
 
Figure 1-4. Classification of HDAC inhibitors. 
The first HDAC inhibitor to be approved by the FDA for clinical treatment was suberoylanilide hydroxamic 
acid (SAHA, 1.01). SAHA (Trade name: Zolinza) was approved for the treatment of cutaneous T-cell lymphoma 
(CTCL) in 2006. The structure was inspired by the observation that dimethylsulfoxide (DMSO) inhibited 
murine-virus-infected erythroleukemia cells (MELC).80 This discovery led to the development of compounds 
bearing two polar groups, which were separated by a methylene chain. One of these structures was 
hexamethylenebisacetamide (HMBA).  
Further studies established that substituting the acetamide functionalities in HMBA with hydroxamic acids 
increased potency.81 In order to probe if two polar groups were necessary for activity and to evaluate the 
incorporation of a hydrophobic group, one of the hydroxamic acid functionalities was substituted to an 
anilide.82 These modifications resulted in SAHA. The biological mechanism responsible for the promising anti-
cancer effect of SAHA was not clear and the molecular target was first identified two years later by Breslow 
and coworkers.83 They realized the similarity in chemical structure between trichostatin A (TSA, 1.02), a 
known HDAC inhibitor, and SAHA. Indeed, they found that SAHA was able to inhibit all class I and II HDACs. 
After this discovery, SAHA was characterized intensively and commenced phase I clinical trials in 2003.84  
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In 2009, the cyclic peptide romidepsin (Trade name: Istodax, 1.06) was the second HDAC inhibitors to be 
approved for treatment of CTCL. Several HDAC inhibitors are currently in clinical trials for treating various 
cancers (Table 1-3).74   
Table 1-3. Selection of HDAC inhibitors and their clinical indications.74 
Inhibitor Clinical phase (positive response against)  
SAHA I-III (Refractory solid tumours and leukaemias) 
FK-228 I/II (T-cell cutaneous or peripheral lymphoma and solid tumours) 
MS-275 I/II (none observed) 
Valproic acid I/II (Leukaemias and myelodysplasia) 
The chemical structures of the compounds shown in figure 1-3, do not appear to be structurally related, but 
they share a common pharmacophore, which is found in many HDAC inhibitors  
Figure 1-5). From the pharmacophore model it can be hypothesized that the inhibitors mimic the substrate 
for HDACs (1.10). In the substrate, the acetylated amine functionality of lysine, which coordinates to the zinc 
atom, is separated from the rest of the bulky protein by an alkyl linker. The inhibitors, exemplified by trapoxin 
B (1.09) in Figure 1-5, show the same structural arrangement, where the zinc-coordinating functionality is 
separated from the rest of the molecule by an alkyl linker.  
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Figure 1-5. The pharmacophore model proposed for HDAC inhibitors. The cap group is shown in blue, the linker in 
green, and the zinc-binding functionality in red.  
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The pharmacophore model has been confirmed by X-ray structures and modeling experiments of different 
HDAC inhibitors in histone deacetylase-like protein (HDLP), HDAC4, HDAC7, and HDAC8.85, 86, 87, 88, 89, 90 
Furthermore, X-ray structures without co-crystalized inhibitors have been reported on HDAC1 and HDAC3.91, 
92 Four different hydroxamic acid inhibitors were co-crystallized with HDAC8 in 2008 by Tari and co-workers.90 
The SAHA–HDAC8 co-crystal structure is shown in Figure 1-6.     
 
Figure 1-6. Crystal structure of SAHA (sticks) bound to HDAC8 (surface mesh). The zinc atom is shown as a sphere. 
(PDB: 1T69) 
From this structure several general features can be highlighted. In Figure 1-6, the hydrophobic cap group of 
SAHA is positioned on the surface of the protein. In SAHA the cap group is an aniline moiety, which can 
participate in favorable interactions with hydrophobic regions near the entrance to the 11 Å channel, leading 
to the internal cavity. In trapoxin B the cap group is the cyclic tetrapeptide core (Figure 1-5). The linker 
connects the cap group of SAHA to the zinc-binding group. The linker is found inside the 11 Å channel and 
the length is important for activity.93 The linker can have favorable hydrophobic interactions with the residues 
that forms the channel (see section 1.4.2).70 The function of the zinc-binding group is to chelate the Zn2+ in 
the internal cavity (see section 1.4.3) .70 Several mechanism have been proposed for the zinc-catalyzed 
deacetylation of lysine side chains. Based on DFT calculations on HDLP, Geerlings and co-workers proposed 
a mechanism where a zinc-bound hydroxide ion, which also makes a hydrogen bond to Tyr297, attacks the 
amide carbon to create a tetrahedral transition state (Figure 1-7).94  
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Figure 1-7. Proposed mechanism for the HDAC catalyzed deacetylation of lysine side chains. Amino acid numbering 
correspond to HDLP residues. (Adapted from Geerlings and co-workers).94  
The amide carbon is activated by coordination to the zinc atom and hydrogen bonding to His131 (I). According 
to calculations, the tetrahedral transition will place an excess of negative charge between the nitrogen of 
His132 and the amide nitrogen. This state is energetically unfavorable and a proton transfer from His131 to 
His132 will produce a state that is lower in energy (III). The tetrahedral intermediate is now setup to break 
the amide bond, which produces the free amine of the lysine and acetic acid (IV). His132 is converted back 
to the neutral form and a proton transfer from acetic acid to the free amine gives the acetate byproduct. To 
complete the catalytic cycle a water molecule may bind to the Zn+ and re-protonate His131. A broad variety 
of functional groups have been used to mimic the natural amide substrate. As previously discussed, 
hydroxamic acids are excellent zinc-chelators, but also carboxylic acids, thiols, and ortho anilines have been 
used. Mechanistic considerations, as shown in Figure 1-7, have inspired the development of zinc-binding 
groups, which mimic the different intermediates found in the catalytic cycle. Boronic acid derivatives mimic 
the initial step in the catalytic cycle where the boron atom is attacked by a water molecule, which creates a 
stable tetrahedral boronic acid complex.95 Also sulfones, sulfoxides96, and trifluoromethyl ketones97  have 
been prepared to mimic the tetrahedral intermediate (see section 1.4.3).  
The different HDAC inhibitors display different binding mechanisms. The majority of the compounds shown 
in Figure 1-4 display a fast on/fast off inhibitory mechanism, but the benzamides are an exception. Gottesfeld 
and co-workers showed that SAHA-inspired benzamide inhibitor (1.11, Figure 1-8) was a slow tight-binding 
inhibitor of HDAC1–3.98    
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Figure 1-8. Benzamide HDAC inhibitors displaying a slow on/slow off binding mechanism. 
In contrast to SAHA, which is a fast on/fast off inhibitor, compound 1.11 showed a time-dependent inhibitory 
profile. Even after 2 hours the IC50 for compound 1.11 was still decreasing, whereas SAHA reached its 
maximum inhibitory effect within 15 minutes. On HDAC3 a 15-fold decrease in IC50 was observed when pre-
incubating the inhibitor for 3 hours compared to no pre-incubation. Steiner and co-workers reported similar 
results for the benzamide inhibitor 1.12. They elaborated on the impact of binding kinetics on gene 
transcription and cell death.99 As expected hyperacetylation was delayed with compound 1.12 compared to 
SAHA and this delay was transferred to gene expression. Interestingly, compound 1.12 and SAHA was co-
crystalized with HDAC2 with 1.6 and 1.9 Å resolution, respectively. Analysis of these co-crystal structures 
showed that the two inhibitors chelate the zinc-atom in a similar fashion and the difference in kinetics could 
be caused by a rearrangement in the protein structure. In order to fit the amino-benzamide–thiophene 
moiety into the foot pocket of the binding cavity, Leu-144 has to move and considerable rearrangement of 
the protein is necessary. Furthermore, a stabilizing intramolecular hydrogen bond in compound 1.12, 
between one of the amine hydrogens and the carbonyl oxygen from the neighboring amide, has to be broken 
in order to achieve zinc-binding and inhibitor–protein hydrogen bonds. The combination of protein 
rearrangement and breaking of a stabilizing intramolecular hydrogen bond in the inhibitor, could explain the 
“slow on” aspect and the formation favorable inhibitor–protein hydrogen bonds can explain the “slow off” 
aspect.99            
1.4.1  Isoform selectivity obtained from cap group modifications 
In terms of selectivity, the general trend observed when moving from simple phenyl derived cap groups (1.01 
and 1.08) to more complex cyclic peptide cap groups, is an increase in isoform selectivity.  The selectivity is 
explained by an increase in favorable interactions between the cap group and the regions surrounding the 
entrance to the channel.100, 93, 52, 101 An excellent example is tubacin (1.13), which is derived from SAHA (Figure 
1-9).  
  
Figure 1-9. Structure of Tubacin and MI-192. The cap groups are shown in blue. 
The introduction of a bulky and hydrophobic substituent in the para-position of the aromatic ring in SAHA 
induced a 7-fold increase in the selectivity towards HDAC6 compared to HDAC1. Molecular dynamics 
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calculations have shown an important hydrophobic interaction between the 2,3-diphenyl oxazole moiety of 
tubacin and Phe181 and Phe182 in HDAC6. This interaction is not possible in HDAC1 and could explain the 
observed selectivity.102 If the cap group is further elaborated to cyclic peptide or depsipeptide scaffolds, the 
selectivity towards class I isoforms generally increases. Trapoxin B displays more than 3000-fold selectivity 
towards HDAC1 over HDAC6.93  However, selectivity within class I is difficult to achieve, even with large and 
complex cap groups. A recent breakthrough by Cockerill and co-workers showed how modifications in the 
cap moiety of mocetinostat (1.07) resulted in the selective inhibitor MI-192 (1.14, Figure 1-9).103 MI-192 
displays 160-fold selectivity towards HDAC2 (IC50= 30 nM) and 300-fold selectivity towards HDAC3 (IC50= 16 
nM), compared to HDAC1 (IC50= 4.8 µM). Within class I, this is by far the most isoform selective HDAC inhibitor 
ever reported and this discovery indicates that the synthesis of selective inhibitors within this class is 
challenging, but not impossible. Unfortunately, the structural features responsible for the selectivity was not 
addressed in this work, but hopefully such studies will contribute to the overall structure pharmacophore of 
HDAC inhibitors.      
1.4.2 Isoform selectivity obtained from linker modifications 
Modifications to the linker part of known HDAC inhibitors have revealed class I-selective inhibitors. Most 
work has been done on hydroxamic acid derivatives. Incorporation of an amide and a phenyl ring in the linker 
part of TSA (1.02) resulted in compound SK-7041 (1.15, Figure 1-10). Unlike TSA, compound 1.15 was 
selective for HDAC1 and 2 compared to HDAC3, 4, 5, and 6.104 Analyses of the crystal structures of HDLP, 
FB188 HDAH, and HDAC8 revealed the presence of two Phe residues (Phe152 and Phe208) in the 11 Å 
channel. The two aromatic rings from these residues are oriented in a way where favorable pi–pi interactions 
with the aromatic group in the linker is possible. 85 Insertion of phenyl rings and indole motifs in the linker 
section has resulted in the development of HDAC8 selective inhibitors. Compound 1.17 demonstrated more 
than 290-fold selectivity towards HDAC8 over HDAC1–3, 6, and 10. The isoform selectivity is attributed to a 
hydrophobic sub-pocket found only in HDAC8. This pocket forms when Phe152 is moved away from its 
normal position (Figure 1-11).90, 105   
 
Figure 1-10. Selective HDAC inhibitors with modified linkers. The linker modification is shown in green. 
This sub-pocket has only been observed with compound 1.16 (CRAA-A, Figure 1-10), but it is likely that the 
HDAC8 selectivity observed with other aromatic linkers could be explained by this unique pocket. 
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Figure 1-11. Crystal structure of HDAC8 (blue) bound to CRA-a (1.16, sticks). Phe152 is marked in red and the sub-
pocket is found below F152 (PDB: 1VKG). 
1.4.3 Isoform selectivity obtained from zinc-binding group modifications 
Selectivity has also been obtained by exploring an 14 Å cavity found deep within the internal cavity of HDLP, 
FB188 HDAH, and HDAC8.  This cavity seems to be reserved for class I HDACs.70 The cavity may facilitate 
removal of the acetate byproduct after deacetylation. By introducing a thienyl substituent (compound 1.18, 
in Figure 1-12) in the 5-position of the benzamide zinc-binding group of MS-275 (1.08, Figure 1-4), a 5-fold 
selectivity for HDAC1 over HDAC2 was observed compared with the parent compound.106 Even higher 
selectivity was observed with a similar compound, where the cap group of compound 1.08 was modified to 
obtain the 2-aminophenyl benzamide derivative (1.19). 
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Figure 1-12. Isoform selective inhibitors within class I. 
Compound 1.19 shows a 10-fold and 20-fold selectivity towards HDAC1 compared to HDAC2 and HDAC3, 
respectively.107 This result implies that the combination of cap group and zinc-binding group modifications 
could result in isoform selective HDAC inhibitors. 
Trifluoromethylketones (TFMK) have emerged as interesting zinc-binding groups (Figure 1-13). Davidsen and 
co-workers synthesized a series of SAHA-inspired TFMKs (1.21, Figure 1-13), which demonstrated low µM 
activity against a mixture of HDAC1 and 2.108 Furthermore, these compounds displayed anti-proliferative 
activity.  The discovery of TFMKs as HDAC inhibitors was further investigated by Steinkühler and co-
workers.109 They reported class II enzyme activity against an “unnatural” trifluoroacetamide substrate (1.20, 
Figure 1-13). Class II enzymes demonstrate low deacetylase activity against standard acetylated HDAC 
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substrates, which has made it difficult to develop screening assays against this class. The discovery of 1.20 
provided a useful substrate for developing class II screening assays.  
 
Figure 1-13. Compounds with trifluoromethylketones as zinc-binding groups.  
Compound 1.21 showed preferential inhibition of HDAC4 with 42-fold and 4-fold selectivity compared to 
HDAC1 and HDAC3, respectively. Improved HDAC4 selectivity was reported with the 5-
(trifluoroacetyl)thiophene-2-carboxamide 1.22, which exhibited 31-fold selectivity over HDAC1 and 55-fold 
selectivity over HDAC3.97 In the same study, a derivate of 1.22 was crystalized in HDAC4 and this structure 
showed that the trifuoromethylketones chelate the zinc atom in its hydrated form. The hydrated form is a 
result of a nucleophilic attack of water on the carbonyl and subsequent protonation. Furthermore, the co-
crystal structure revealed a small pocket in the bottom of the active site, which accommodates the 
trifluoromethyl group. Altering the carboxyamide part of 1.22 to an 1,2,4-oxadiazole moiety (1.23) increased 
the HDAC4/HDAC1 selectivity to over 100-fold.110        
1.5 Cyclic peptide inhibitors  
1.5.1 Macrocyclic peptides 
Macrocyclic peptide HDAC inhibitors are often natural products or natural product analogs. This family 
includes apicidins (Figure 1-15), azumamides (Table 1-4), chlamydocin (Figure 1-14), trapoxin (Figure 1-14), 
microsporins (Figure 1-14), and HC-toxins (Figure 1-14). These inhibitors are characterized by having a ring 
size between 12–14 atoms and being constructed of either four α-amino acids or one β-amino acid in 
combination with three α-amino acids.  
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Figure 1-14. HDAC inhibitors with a macrocyclic peptide scaffold. 
A common feature of these compounds is the presence of a terminal zinc-coordinating functionality (α,β-
epoxyketone, ethyl ketone, carboxyamide or carboxylic acid) in one of the unusual amino acid side chains.  
Ethyl ketone containing cyclic peptides: Apicidins and microsporins  
The apicidin family include apicidin (1.05)111 and apicidin A–F (1.28–1.35, Figure 1-15).112, 113  
 
Figure 1-15. The apicidin family. The biological data is obtained from inhibition assays on partially purified HDAC from 
human Hela extracts.114    
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Apicidin (1.05) was first isolated in 1996 from Fusarium pallidoroserum111 and the structure was elucidated 
in the same paper.  The compound displayed broad spectrum antiprotozoal activity and the molecular target 
was recognized to be the apicomplexan histone deacetylase.115 Following the discovery of apicidin, isolation 
of structurally related compounds provided the rest of the current family, with apicidin F (1.35) being 
discovered in 2013.113 The first total synthesis of apicidin was reported by Singh and Mou in 2001.116 All nine 
apicidins contain three standard α-amino acids and an unusual α-amino acid residue, which is believed to 
mimic the lysine substrate for HDAC. The presence of a zinc-binding group is important for obtaining high 
potency. For instance, apicidin E (1.34), which has an aliphatic side chain, is inactive. Apicidin D2 (1.32) and 
apicidin D3 (1.33) contain a weak zinc-binding functionality (hydroxyl group) in the side chain at C-8 and C-9, 
respectively. Apicidin D2 is 400-fold less active than apicidin (1.05) and this difference reflects the weaker 
zinc-binding properties of a hydroxyl group vs a ketone. Apicidin D3, where the hydroxyl group is shifted to 
C-9, is inactive and oxidizing the C-9 hydroxyl to the ketone did not restore the activity. These results show 
that the C-8 ketone is critical for activity. The α-hydroxy keto containing compound (1.31) is the most potent 
HDAC inhibitor in the family and the activity is independent of the stereochemistry at C-9. The superior 
activity of this compound can be attributed to improved zinc-binding properties of a α-hydroxy ketone vs a 
ketone.  Furthermore, the presence of an aromatic amino acid residue next to the extended amino acid is 
required for high activity.114 Interestingly, apicidin is found in three different conformations in DMSO.117 
These three conformations are found in an 80:15:5 ratio and the major conformation is the all trans 
conformation (t-t-t-t) and the second-most-populated conformation is the cis–trans–trans–trans (c-t-t-t).  
The cis-amide bond was found to be located between the pipecolic acid residue and isoleucine. Rich and co-
workers had proposed that the bioactive conformation of the related cyclic tetrapeptides (HC-toxin, 1.24 and 
chlamydocin, 1.25) was the less populated (c-t-t-t) conformation.118 This trend was confirmed to include 
apicidin in 2009.119 Ghadiri and co-workers designed apicidin analogs, where the pipecolic acid residue was 
substituted with a 1,4-disubstituted 1,2,3-triazole or a 1,5-disubstituted 1,2,3-triazole to lock the amide bond 
in the trans and cis conformation, respectively. The NMR solution structures of the triazole analogs were 
compared to the known (t-t-t-t) and (c-t-t-t) conformations of apicidin to validate if the analogs provided a 
faithful mimic of these conformations. The overlays revealed a significant overlap in the cyclic peptide 
backbone and the Cα–Cβ vectors were found to be similar. The biological testing showed that the 1,5-
disubstituted 1,2,3-triazole analog with a (c-t-t-t)  conformation was 2–3-fold more active against HDAC1 and 
3 compared to the all trans compound. This work presents strong evidence that the conformations observed 
in NMR solution structures of cyclic tetrapeptides, not necessarily reflect the bioactive conformations.     
Microsporin A (1.26) and B (1.27) were isolated in 2007 by Silverman and co-workers (Figure 1-14).120 The 
two compounds were isolated from the marine sponge Microsporum cf. gypseum and in the same paper the 
total synthesis of microsporin A was reported. Microsporin A is a potent HDAC inhibitor and display promising 
anticancer activity against human colon adenocarcinoma (HCT-116). Microsporin B (1.27), which differ from 
microsporin A (1.26) by having a hydroxyl group at C-8 instead of carbonyl group, was more than 10-fold less 
potent against HCT-116. This result confirms the importance of the C-8 carbonyl in these type of compounds.        
α,β-epoxyketone containing cyclic peptides: HC-toxin, chlamodycin, and trapoxin 
HC-toxin (1.24, Figure 1-14) is the only compound in the family, which do not contain an aromatic amino acid. 
The structure of HC-toxin was correctly assigned by Walton and co-workers121 in 1983 by using NMR 
spectroscopy and the first total synthesis was achieved by Kawai and Rich.122 The α,β-epoxyketone moiety, 
which is also found in chlamydocin (1.25) and trapoxin B (1.09), is essential to activity. It is hypothesized that 
a nucleophilic residue in the catalytic site of the HDAC enzyme attacks the epoxide, leading to a covalent 
bond between the enzyme and cyclic peptide.123 Related structures have been isolated and these compounds 
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were denominated, HC-toxin II (substitution of the alanine adjacent to the α,β-epoxyketone residue to a 
glycine) and HC-toxin III (substitution of proline to 3-hydroxyproline).124 
Chlamydocin (1.25) is similar to Trapoxin B (1.08) in overall structure, but a aminoisobutyric acid (Aib) residue 
has replaced one of the phenylalanine residues in peptide backbone. It was isolated in 1974125 and a crystal 
structure for the dihydro-analog was reported in 1976.126 This crystal structure established the 
stereochemistry of the C-9 stereocenter to be the (S)-configuration. The stereochemistry have been found 
to be important for activity as compound 1.36, which has the (R)-configuration in the 9-position, showed a 
decrease in activity. Furthermore, substituting the Aib residue to an aromatic residue (compound 1.37) 
increased activity.127  
 
Figure 1-16. Chlamydocin analogs. Modifications are shown in blue. 
Trapoxin A and B (1.09, Figure 1-14) were isolated in 1990 and the crystal structure of Trapoxin A, which 
contains an (R)-pipecolic acid residue instead of an (R)-proline residue, was reported in the year after.128, 129. 
Both compounds were cytotoxic towards cancer cells. The molecular target was identified to be HDACs and 
it was shown that these potent inhibitors bind irreversible to the enzymes.123 Actually, the irreversible binding 
abilities of trapoxin B was used to isolate the first mammalian HDAC by construction of a trapoxin B-based 
affinity matrix. 18, 123 
Expanding the macrocyclic ring 
The cyclic tetrapeptide architecture was systematically investigated by Ghadiri and coworkers.130 They 
designed a series of cyclic tetrapeptide frameworks, which were inspired by natural products. In this work, 
one or two β-amino acid residues was inserted in the macrocyclic ring (Figure 1-17).  
 
Figure 1-17. Cyclic tetrapeptides with one or two β-amino acids. Modifications are shown in blue. The HDAC inhibition 
assays were performed on Hela nuclear extracts.  
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The incorporation of a single β-amino acid in position C (1.38) was well tolerated and produced a compound 
with HDAC activity comparable to apicidin. Incorporation of β-amino acids in position B and D resulted in 
compounds with a 22–53-fold decrease in activity. The compounds containing two β-amino acids were 
generally found to be less potent than apicidin (1.40). The biological data was combined with high-resolution 
NMR solution structures to provide interesting information about the structural requirements necessary for 
high potency. In general, the chirality of the unnatural (S)-2-amino-8-oxodecanoic acid (S-Aoda, 1.39), as well 
as the presence of an aromatic amino acid in position B, was found to be highly important in terms of potency. 
Furthermore, small changes in the orientation of the C2–C3 vector (see Figure 1-17) in Aoda mediated a 
significant loss in potency. Finally, optimal distances between the C2 of tryptophan to C2 in Aoda and C2 in 
leucine were determined to be 5.0–5.3 Å and 5.1–5.3 Å, respectively (Figure 1-18). 
 
Figure 1-18. Optimal distances found in potent cyclic tetra peptides. (Adapted from Ghadiri and co-workers)130 
Hybrid structures 
Hybrid structures have been prepared, where the structural features of different HDAC inhibitors have been 
combined. An excellent example is the preparation of cyclic hydroxamic acid-containing peptides (CHAPs) by 
Horinouchi and co-workers.93 The cyclic peptide scaffold from epoxyketone containing compounds (e.g. 
trapoxin B (1.09) and chlamodycin (1.25)) was combined with other zinc-binding groups, e.g. hydroxamic acid 
moiety from TSA (1.02). A selection of the resulting potent hybrid structures is shown in Figure 1-19.    
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Figure 1-19. Cyclic hydroxamic acid-containing peptides developed by Horinouchi and co-workers.93  
Trapoxins have been found to bind irreversibly to the HDAC enzymes with the exception of HDAC6. 
Irreversible inhibition is probably mediated by alkylating key residues in the active site.131 Introduction of a 
hydroxamic acid moiety on a trapoxin peptide produced a highly potent compound (1.41), which displayed 
reversible inhibition of HDAC1. This suggest that the epoxyketone functionality is responsible for the 
irreversible binding. The length of the aliphatic chain in the side chain was also explored. CHAPs with 4-, 5-, 
and 6-carbon chains were synthesized and the optimal length was found to be the 5-carbon chain. The 5-
carbon chain creates a length between the cyclic tetrapeptide core and the hydroxamic acid, which 
corresponds to the length between the peptide backbone and the acetylated nitrogen of a lysine (Figure 1-5).  
1.5.2 Macrocyclic depsipeptides 
A family of macrocyclic HDAC inhibitors, which is closely related to the cyclic tetrapeptides, is the 
depsipeptides. Spiruchostatin, (1.44), Largazole (1.45), and FK-228 (1.06, Figure 1-4) are examples of 
compounds from this family (Figure 1-20).132      
 
Figure 1-20. Macrocyclic depsipeptide HDAC inhibitors. 
A common feature shared by the depsipeptide HDAC inhibitors is the requirement for pre-activation in order 
to release a free thiol, which acts as a potent zinc-binding group. In the case of spiruchostatin (1.44) and FK-
228 (1.06) the zinc-binding free thiols are produced by reduction of the disulfide bridge.133, 52 Largazole (1.45) 
needs activation by enzymatic hydrolysis of the thioester to give the free thiol.134 In 2011, a co-crystal 
structure of an HDAC8–largazole complex was reported with a 2.14 Å resolution (Figure 1-21).89 This structure 
confirms the overall binding mode of macrocyclic HDAC inhibitors and illustrates how the macrocyclic ring 
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accommodates on the surface of the protein. Furthermore, this work emphasis the importance of the 
thiolate-zinc coordination geometry, which in this X-ray structure is very close to optimal. 
 
 
Figure 1-21. Crystal structure of largazole (1.45, sticks) in HDAC8 (blue, surface). The zinc atom is shown in magneta. 
(PDB: 2RQD) 
1.5.3 The azumamides 
An interesting class of cyclic petide HDAC inhibitors is the azumamides. The azumamides are natural 
products, which were isolated from the marine sponge Mycale izuensis by Fusetani and coworkers in 2006 
(Table 1-4).135 These compounds are cyclic tetrapeptides with a unique di-substituted β-amino acid and an 
unusual all retro-reverso configuration compared to the compounds in Figure 1-14.   
Table 1-4. The structure and IC50-values of azumamide A–E. a The IC50-values were determined on a lysate from K562 
human leukemia cells.135 The numbering shown in the β-amino acid will be used throughout this thesis.  
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Azumamide R1 R2 R3 IC50a (nM) 
A (AzuA) NH2 H Me 45 
B (AzuB) NH2 OH Me 110 
C (AzuC) OH OH Me 110 
D (AzuD) NH2 H H 1300 
E (AzuE) OH H Me 64 
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In spite of their weak zinc-binding groups (carboxylic acid or carboxyamide) the azumamides are still 
relatively potent HDAC inhibitors and they exhibit ∼100-fold selectivity towards class I HDACs compared to 
class II.136 Currently, three total syntheses of azumamide E have been reported and azumamide A has been 
prepared as well. However, Azumamide B–D has not yet been synthesized. The three total syntheses are 
presented below. 
De Riccardis route 
The first synthesis was reported by De Riccardis and coworkers in 2006.137 The β-amino acid building block 
was prepared in 14 steps and an overall yield of 19% from 3-(benzyloxy)propanol (Scheme 1-2). The chiral 
centers were constructed by a highly diastereo- and enantioselective crotylation reaction using a chiral 
borane. Reductive ozonolysis of the terminal alkene followed by protection group manipulations afforded 
the alcohol 1.48. Mesylation of the alcohol followed by an SN2 reaction with sodium azide afforded the 
correct stereochemistry at the β3-position. Subsequent reduction of the azide and Boc-protection of the 
resulting amine provided compound 1.50. The benzylether protecting group was removed and the alcohol 
oxidized to the aldehyde (1.51). The (Z)-double bond was installed with a Wittig reaction and followed by 
deprotection of the silylprotected alcohol and oxidation to the acid to give the desired β-amino acid building 
block (1.53).             
 
Scheme 1-2. Reagents and conditions: (a) (COCl)2, DMSO, Et3N, CH2Cl2, 98%; i) (+)-Ipc2BOMe, (E)-2-butene, tBuOK, 
nBuLi, BF3·Et2O, THF, –78° C; ii) Ac2O, pyridine, CH2Cl2, 80%; (b) O3, CH2Cl2, then PPh3; i) NaBH4, EtOH; ii) K2CO3, MeOH; 
iii) TPSCl, DMAP, pyridine, CH2Cl2, 57%, over 4 steps; (c) MsCl, Et3N, THF; i) NaN3, DMF, 60° C , 89% over two steps; (d) 
H2, Pt2O, EtOAc; i) Boc2O, Et3N, CH2Cl2, 92% over two steps; (e) H2, Pd/C, EtOH; i) (COCl)2, DMSO, Et3N, CH2Cl2, 93% 
over two steps; (f) KHMDS, Ph3PBr(CH2)3COOEt, aldehyde 1.51 THF, –78° C to RT, 76%; (g) HF/pyridine, pyridine; i) 
TEMPO, phosphate buffer, NaClO2, NaClO, MeCN, 75% over two steps. 
The β-amino acid was coupled to the tripeptide H2N-(D)-Val-(D)-Ala-(D)-Phe-OtBu in solution followed by 
removal of the tBu-protecting group and the resulting tetrapeptide was cyclized, by preparing the active ester 
with pentafluorophenyl diphenylphosphinate (FDPP). The cyclization proceeded in 37% yield and three days 
were needed to achieve complete conversion. Hydrolysis of the ethyl ester gave azumamide E (5%) and 
subsequent amidation with diphenylphosphoryl azide (DPPA) afforded azumamide A (2%).  
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Scheme 1-3. Reagents and conditions: (a) FDPP, iPr2NEt, DMF, 3 days, 37%; (b) LiOH, H2O/THF, 0° C, 75%; (c) DPPA, 
NH4Cl, Et3N, DMF, 54%. 
In another study by De Riccardis and coworkers, the DMSO solution-state structure of azumamide E was 
docked in histone deacetylase-like protein (HDLP). The docking model proposed important hydrophobic 
interactions between the surface of the protein and the macrocyclic core, since the hydrophobic side chain 
of D-phenylalanine was found to accommodate a hydrophobic pocket near the entrance to the 11 Å 
channel.136  
 
Figure 1-22. Docking of azumamide E in HDLP. Azumamide E is represented with a sticks (yellow) and balls (by atom 
type). HDLP is illustrated as both a molecular surface and sticks and balls. (Adapted from De Riccardis and co-
workers)136  
Ganesan route 
The second total synthesis was reported by Ganesan and coworkers.138 In this work, both β-amino acid 
stereocenters were constructed in one step by a diastereoselective Mannich reaction (Scheme 1-4). The 
chiral sulfinyl imine (1.58) was prepared in six steps from pent-4-ynoic acid (1.56). Protection of the acid, as 
the 1,2,3-trichloroethyl ester (Tce), followed by allylation and dihydroxylation of the terminal alkene 
provided the diol 1.57. Reduction of the alkyne moiety with Lindlar catalyst and oxidative cleavage of the 
vicinal diols resulted in a fragile aldehyde, which was condensed with Ellmans chiral sulfinyl amine (R)-2-
methylpropane-2-sulfinamide). The key step in this route is the Mannich reaction between the titanium 
enolate of PMB-propionate and the chiral sulfinyl imine (1.58). This reaction nicely provided the β-amino 
ester with the desired stereochemistry. However, low yields were reported for the last two steps. This was 
attributed to the low stability of the sulfinyl imine (1.58) and the aldehyde precursor. Removal of the PMB-
group gave the β-amino acid building block (1.59) in 16% over 8 steps. 
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Scheme 1-4. Reagents and conditions: (a) 2,2,2-trichloroethanol, DIC, DMAP, CH2Cl2; i) Allylbromide, , K2CO3, CuCl, 
DMF: ii) OsO4, NMO, aq. THF, 78% over three steps; (b) H2, Lindlar cat., EtOAc; i) NaIO4, aq., CH2Cl2; ii) H2NSOtBu, 
CuSO4, CH2Cl2, 53% over three steps; (c) CH3CH2CO2PMB, LDA, TiCl(O-iPr)3, THF; i) TFA, anisole, 37%, over two steps.  
Building block 1.59 was elaborated to the linear tetrapeptide by coupling to the dipeptide H2N-(D)-Val-(D)-
Ala-OAll in solution, followed by deallylation and coupling to Boc-(D)-Phe-OH (Scheme 1-5).  
 
Scheme 1-5. Reagents and conditions: (a) HATU, iPr2NEt, DMF/CH2Cl2, 85% (including deprotection); (b) Zn, AcOH, 
94%; (c) EDC, HOBt, NH3, 92%.   
After removal of the N- and C-terminal protection groups, the linear peptide (1.60) was cyclized using a slow 
addition protocol.138 In this protocol a solution of the linear peptide in DMF–CH2Cl2 (1:10) was added slowly 
to a solution of HATU and base in CH2Cl2. Overall yields between 52–85% were observed for the deprotection 
and cyclization steps. The trichloroethyl ester was reductively removed with zinc to give azumamide E. 
Azumamide E was subsequent amidated with EDC/HOBt and ammonia to afford azumamide A in good yield. 
Bhadra route 
The latest report on total synthesis of azumamide E was published by Bhadra and coworkers.139 They 
obtained the β-amino ester (1.67) in impressive 29% yield over 10 steps (Scheme 1-6).    
 
 
Scheme 1-6. Reagents and conditions: (a) PMBCl, NaH, THF, (Bu)4NI; i) CuI, NaI, K2CO3, HOCH2CCCH2Cl, DMF, 82% over 
two steps; (b) LiAlH4, Et2O, 74%; i) (+)-diethyl tartrate, Ti(O-iPr)4, TBHP, CH2Cl2, 97%; ii)  IBX; iii) NaCIO2, NaH2PO4, 2-
metyl-2-butene; iv), CH2N2, 74% over three steps; (c) (CH2)2CuLi, Et2O, 78%; (d) Pd/CuCO3, quinoline, benzene, 99%; i) 
PPh3, DIAD, DPPA, THF, 86%; (e) PPh3, THF/H2O.     
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4-pentyne-1-ol was PMB-protected and coupled to 4-chlorobutyne-1-ol to give the bis(acetylene) 1.63. 
Selective reduction of the triple bond of the propargylic moiety gave the E-alkene, which was subjected to 
Sharpless asymmetric epoxidation to give the epoxide (1.64). The alcohol functionality was transformed to 
the corresponding methyl ester in a three-step procedure. Regioselective opening of the epoxide with lithium 
dimethyl cuprate afforded the correct stereochemistry in the 2-position (1.65). Hydrogenation of the alkyne 
followed by conversion of the alcohol to the azide under Mitzunobu conditions, established the correct 
stereochemistry in the 3-position. Finally, reduction of the azide with a Staudinger reaction afforded the free 
amine (1.67), which was coupled to the tripeptide Boc-(D)-Val-(D)-Ala-(D)-Phe-OH (Scheme 1-7). 
 
Scheme 1-7. Reagents and conditions: (a) EDCI, HOBt, CH2Cl2, 79%; (b) DDQ, CH2Cl2/H2O, 95%; i) BAIB, TEMPO, 
MeCN/H2O, 85%.   
After removal of the N- and C-terminal protecting groups the linear tetrapeptide (1.68) was cyclized using 
EDC/HOBt, to afford the cyclic peptide (1.69) in 77% yield. Oxidative removal of the PMB group, followed by 
TEMPO-mediated oxidation of the alcohol to the acid, provided azumamide E in good yield. The three routes 
are compared in Table 1-5. 
Table 1-5. Comparison of reported total synthesis for azumamide E.a The yield is calculated from the longest linear 
sequence. 
Group steps, β-aa yield, β-aa  (%) total steps total yielda (%) 
De Riccardis 14 19 18 5 
Ganesan 8 16 15 6 
Bhadra 10 29 16 11 
 
If the three synthetic routes are compared, in terms of obtaining the β-amino acid building block, it is clear 
that Ganesan has the shortest route, but also the lowest yield. The short synthesis can be attributed to the 
diastereoselective Mannich reaction, where both stereocenters are constructed in the same step. In the two 
other routes, the desired stereochemistry in the 2-position is prepared first, while at the same time obtaining 
the undesired chirality in the 3-position. Full inversion of the stereochemistry in the 3-position is then 
achieved by transformation of the hydroxyl group into a leaving group and subsequent addition of a 
nucleophile. Bhadra´s route is superior in terms of yield, and is only one step longer than Ganesan´s.      
1.5.4 Azumamide analogs       
The importance of the zinc-binding moiety in the azumamides was investigated by Ganesan and coworkers.138 
They exchanged the zinc-binding group in azumamide E to a hydroxamic acid (1.70, Figure 1-23). This resulted 
in a 15-fold increase in activity.138 The increase in activity is attributed to the increased zinc-chelation abilities 
of the hydroxamic acid compared to the carboxylic acid.140 However, the strong coordination properties of 
the hydroxamic acid functionality could cause problems in relation to unwanted binding to other metal 
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centers found in non-target proteins. Promiscuous binding to other metal proteins could lead to problems 
with toxicity. Several azumamide analogs, beside the hydroxamic acid compound, have been prepared 
(Figure 1-23).   
 
Figure 1-23. Reported azumamide analogs and their HDAC activity. Modifications are shown in blue.* Inactive up to 50 
µM. 139, 136, 138  
The β2,3-epimerized analog (1.71) was inactive and the enantiomer of azumamide E (1.73) showed a 
significant reduction in potency.136 The lack of activity observed with the β2,3-epimer 1.71, can be explained 
by the altered C3–C4-vector of the β-amino acid. Inversion of the stereochemistry in the 3-position, will direct 
the zinc-binding side chain away from the 11 Å tunnel. However, the stereochemistry in the 2-position is also 
inverted. Therefore, the effects of the individual stereocenters cannot be evaluated from compound 1.71. 
The sugar amino acid-containing analog (1.72) showed increased potency (96% inhibition at 20 µM) 
compared to azumamide E (71% at 20 µM) against HeLa extract.139   
1.6  Specific aim of the project 
Azumamide E is the only azumamide which has been subjected to HDAC profiling (HDAC1–9).138, 137, 139 
However, in vitro profiling against recombinant HDACs has improved significantly since azumamide E data 
was published. Especially, data on class IIa enzymes should be reevaluated as later studies have proven that 
the observed activity can be attributed to the presence of endogenous co-purified class I HDACs. 141, 34 In 
order to explore the HDAC profile of the azumamides, and elucidate any selectivities, we decided to 
synthesize the complete selection of natural products and screen the compounds against HDAC1–11. 
Furthermore, the total syntheses of azumamide B–D have not been reported and this study would allow 
validation of the proposed structures.135 Based on the principles of diverted total synthesis (DTS), described 
by Danishefsky142, the synthetic route should also allow access to structurally edited analogs by subtle 
changes in the synthetic route.       
1.7  Background for synthesis of azumamides and epimeric analogs 
We envisioned two major challenges in the synthesis of the azumamides. Firstly, the preparation of the β2,3-
amino acid building block could be challenging as two stereocenters have to be prepared. Secondly, the 
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cyclization of small peptides in known to be difficult. The next section will present a brief overview over 
different methods for β-amino acid synthesis.   
1.8  β-amino acids  
There has been developed a broad variety of methods for preparing β-amino acids. The β-amino acids that 
will be discussed here have been divided into four groups based on their substitution pattern; β2-amino acids, 
β3-amino acids, β2,3-amino acids, and β2,2,3 -amino acids (Figure 1-24).        
 
Figure 1-24. General structure of β-amino acids. 
A β2,3-amino acid needs to be prepared for the synthesis of the azumamides. In the interest of developing 
azumamide analogs with modifications in the β-amino acids, this section will also include a short discussion 
of some of the relevant protocols developed for synthesis of β2-amino acids, β3-amino acids, and β2,2,3 -amino 
acids. Focus will be directed to methodologies, which will produce scaffolds relevant to this project.             
1.9  Methods for the preparation of β2-amino acids   
Several methods have been developed for the synthesis of β2-amino acids. Seebach has successfully 
employed a modified version of Evans auxillary to direct the stereochemistry in a diastereoselective 
aminomethylation (Scheme 1-8).143 By this method both enantiomers of the β2-amino acid can be accessed 
from the enantiomerically pure oxazolidinones.  
 
 
Scheme 1-8. Seebachs β2-amino acid synthesis using 4-isopropyl-5,5-diphenyloxazolidin-2-one. Reagents and 
conditions:  (a) TiCl4, Et3N or iPr2NEt; (b) TiCl4, CbzNCH2OMe, CH2Cl2, 0 ºC.  
A different approach was reported by Goodman and coworkers.144 In their work, pseudoephedrine was used 
as chiral auxillary for the diastereoselective alkylation of β-alanine (Scheme 1-9).    
 
Scheme 1-9. Reagents and conditions: (a) RX, LiHMDS, LiCl, THF, –5 → 0 ºC; (b) H2O, heat. The yield is calculated from 
1.81. 
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Compared to the ozazolidinone used by Seebach, pseudoephedrine is cheaper and commercially available. 
Only a couple of methods have been discussed here, but several others have been developed. Protocols using 
chiral isoxazolidinones145, chiral pyrimidinone146, C–H activation147, and Oppolzer’s sultam148 have been 
reported.  
1.10  Methods for the preparation of β3-amino acids  
1.10.1 Homologation and the use of α-amino acids.  
A classical approach for preparing β3-amino acids is by Arndt–Eistert homologation of α-amino acids. This 
procedure has been reported by Liberek and coworkers (Scheme 1-10, top).149 The N-protected α-amino acids 
were converted to the corresponding diazoketones (1.85) and subsequent treatment with silver(I) oxide and 
water provided the β3-amino acids with retention of configuration. 
 
Scheme 1-10. Top: Reagents and conditions: (a) iBuOCOCl; i) CH2N2; (b) Ag2O; i) H2O. Bottom: Reagents and conditions: 
(c) TsCl; i) NaCN; (d) NaOH.    
Starting from α-amino alcohols another homologation strategy has been described by Kibayashi and co-
workers (Scheme 1-10, bottom).150 First, the hydroxyl group is tosylated and displaced with cyanide. The 
resulting nitrile (1.88) is then hydrolyzed to afford the β3-amino acids. Furthermore, aspartic acid and 
aspargine are obvious starting materials for preparing β3-amino acids. For aspartic acid, the side chain 
carboxylic acid can be protected and the free acid transformed into a good leaving group by selective 
reduction to the alcohol. Subsequent tosylation of the alcohol and substitution to the iodide allows alkylation 
and thus incorporation of a β3-side chain.151  
1.10.2 β3-amino acids obtained from acrylates via Michael additions and hydrogenations 
Michael addition of amines to β-substituted acrylates creates a new stereocenter. To control the 
stereochemistry of the product, a chiral input from either the amine or the acrylate is required.  
 
Scheme 1-11. Reagents and conditions: (a) Pd(OH)2/C, ammonium formate. (Adapted from Hawkins and Lewis.)152  
Scheme 1-11 shows the Michael addition of a chiral lithium amide (1.90) to different tert-butyl acrylates.152 
With (E)-alkyl esters high diastereoselectivity was observed. Hydrogenolysis of the benzylic C–N bonds was 
performed with Pearlman`s catalyst to give the β3-amino esters (1.92).  
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The first reported asymmetric hydrogenation of β-amino acrylates was published by Noyori and co-workers 
in 1991.153 Noyori used a ruthenium catalyzed protocol with (R)-BINAP as ligand and obtained >85% ee for 
most (E)-enamine esters. However, low enantioselectivity was observed with (Z)-enamine esters and 
protection of the amine was required. In 2004, these problems were overcome by Malan and co-workers, 
who developed a protocol using rhodium and ferrocenophosphine ligands (1.94, Scheme 1-12).154 High yields 
and high ee were observed for unprotected (Z)-enamine methyl esters.   
 
Scheme 1-12. Rhodium-catalyzed hydrogenation of β-amino acrylates reported by Hsiao and co-workers.154  
The major drawbacks of metal-catalyzed asymmetric hydrogenations are the use of expensive transition state 
metals and the strict regulations concerning heavy metals in drug intermediates.155 
1.10.3 Mannich reactions 
One of the most well studied reactions, for preparing β-amino acids by C–C bond formation, is the Mannich 
reaction. The Mannich reaction was first described and characterized by Carl Mannich in 1912. 156 He 
reported the condensation reaction between formaldehyde, ammonia, and antipyrin to yield a tertiary 
amine.  Since this discovery, the Mannich reaction has been modified and explored extensively. This has lead 
to more advanced and practically useful variants.157 Mannich reactions are especially valuable in the synthesis 
of therapeutical agents (e.g. morphine)158 and complex natural products containing nitrogen atoms (e.g. 
strychnine).159           
A wide variety of asymmetric Mannich reactions has been developed. The addition of nucleophiles to imines 
is a direct and fast method for obtaining β-amino acid derivatives. The chiral input can originate from a chiral 
auxillary or from asymmetric catalysis. Utilizing chiral auxiliaries, the strategy can be divided into two 
categories, having the stereodetermining moiety placed in either the imine-part or in the nucleophilic part. 
The catalytic approach can be subdivided into metal -and organo-catalyzed reactions.   
1.10.4 Organocatalytic Mannich reactions 
For organocatalytic asymmetric synthesis of β3-amino acids, the addition of nucleophiles to N-functionalized 
aldimines has been studied extensively (Scheme 1-13).160 Jacobsen was the first to report an organocatalytic 
asymmetric Mukaiyama-Mannich-type reaction between a silyl ketene acetal (1.96) and N-Boc aryl imines 
(Scheme 1-13).161 Jacobsen designed a thiourea catalyst (1.98), which provided high ee and high yields. The 
reaction was sensitive to modifications in both the silyl and alkoxy moieties of the nucleophile. Smith and co-
workers prepared a catalyst (1.99) for the same system, which displayed superior catalytic properties.162    
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Scheme 1-13. Left: Mukaiyama-Mannich reactions reported by Jacobsen161 and Smith162. Right: Developed catalysts. 
Acetaldehyde can also be utilized in the enantioselective addition to N-Boc imines.163 The enantioselectivity 
is induced by adding 20 mol% of (S)-proline. The β-amino aldehydes (1.103) obtained in this reaction can be 
oxidized to the Boc-protected β3-amino acids (1.104) under Pinnik oxidation conditions in excellent yields 
(Scheme 1-14). 
 
Scheme 1-14. Left: Mannich reactions between aldehydes and N-Boc imines. Reagents and conditions: (a) NaClO2. 
Right: Amino sulfonamide catalyst developed by Maruoka and co-workers. 
Excellent enantioselectivity was observed, but the reported yields were only low to moderate. The low yields 
were attributed to the high nucleophilicity of the enamine intermediate, which facilitated side reactions. This 
system was optimized by Maruoka and co-workers, who developed an axially chiral bifunctional amino 
sulfonamide catalyst (1.105), which increased both yield (70–92%) and the ee (98–99%).164 The catalyst was 
designed to reduce the nucleophilicity of the intermediate enamine by incorporation of a dibenzylic 
secondary amine moiety. Interestingly, aliphatic imines worked well in both studies. 
1.10.5 Mannich reactions with chiral auxillaries 
The use of a chiral oxazolidinone enolate, for the preparation of β3-amino acids, has been reported by Wang 
and co-workers.165 High selectivities and good yields were observed for the addition of (S)-4-benzyl-2-
oxazolidinone acetamide enolate (1.106) to N-tosyl arylaldehyde imines (Scheme 1-15). The scope of this 
study was limited to aryl-substituted imines, yet it nicely demonstrates the use of chiral nucleophiles for 
asymmetric preparation of β-aryl β-amino acid derivatives.      
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Scheme 1-15. Addition of a chiral lithium enolate to N-tosyl arylaldehyde imines. (Adapted from Wang and co-
workers)165 
Ellman and co-workers reported a highly diastereoselective Mannich type reaction between methyl acetate 
enolates and chiral sulfinyl imines (Scheme 1-16).166 Transmetalation of the lithium enolate to the titanium 
enolate improved selectivity and dr > 90% was achieved with two equivalents of ClTi(O-iPr)3. 
 
Scheme 1-16. Left: Reagents and conditions: (a) LDA (2.1 equiv), THF, –78 ºC, 30 min; then Ti(O-iPr)3Cl (2.0 equiv), THF, 
–78 ºC, 30 min; then imine (1.111), –78 ºC. Right: Proposed six-membered Zimmerman–Traxler transition state. 166 
Different sulfinyl imines were investigated in the reaction shown above. The results are presented in Table 
1-6. 
Table 1-6. Screening of different imines in the Mannich reaction shown in Scheme 1-16.   
entry R dr yield, % 
1 Me 99:1 94 
2 i-Pr 98:2 85 
3 i-Bu 98:2 80 
4 Ph 98:2 90 
5 3-pyridine 95:5 70 
 
Both the nature of metal ion and solvent affected the selectivity. The six-membered Zimmerman–Traxler-
type transition state (1.113),  facilitating the diastereoselectivity observed by Ellman, has been well validated 
by other groups.166, 167, 168 The transition state was first proposed by Davis and coworkers. They investigated 
the diastereoselective asymmetric synthesis of cis-N-(p-toluenesulfinyl)-2-carbomethoxyaziridines  via a 
Darzens-type reaction of the lithium enolate of methyl bromoacetate with sulfinyl imines.168 The The 
transition state is obtained by attack of the enolate from the least hindered side of the sulfinyl imine (Scheme 
1-16, right). Coordination of the sulfinyl oxygen to titanium stabilizes the transition state.  
This approach is attractive for the preparation of β3-amino acids, as the free amine or the free carboxylic acid 
can be obtained in one step by treatment with acid or base, respectively. As shown in Table 1-6, both aliphatic 
and aromatic sulfinyl imines work well in this reaction.   
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1.11  Methods for the preparation of β2,3-amino acids  
Many of the methods introduced for the synthesis of β3-amino acids (section 1.10) can be elaborated to 
produce β2,3-amino acids.  
1.11.1 Michael addition of chiral lithium amides to α,β-disubstituted acrylates 
Parallel to the methodology showed in Scheme 1-11, Davies and co-workers reported the diastereoselective 
1,4-addition of a chiral lithium amide (1.115) to (E)-tert-butyl 2-methylcinnamate (1.118a, Scheme 1-17).169 
After in situ protonation of the intermediate enolate with a hindered acid, the β-amino ester (1.114) was 
isolated.  Removal of the protection groups provided (2S,3S)-α-methyl-β-phenylalanine in 69% yield over two 
steps. Performing the reaction with tert-butyl cinnamate (1.118b), followed by methylation of the isolated 
β-amino esters, via the lithium enolate, nicely provided the (2R,3S)-adduct (1.117).        
 
Scheme 1-17. Reagents and conditions: (a) 1.118a or 1.118b, toluene; (b) 2,6-di-tertbutylphenol, THF; (c) LDA, THF; 
then MeI. 
This specific reaction was only explored with a phenyl group in the β-position and the general scope of this 
methodology was not elaborated. However, Lewis and Hawkins reported a similar protocol. They reported 
the addition of the chiral amide (1.90, Scheme 1-11) to tert-butyl crotonate, and subsequent trapping of the 
enolate with methyl iodide, provided the anti-product (de: 86%, yield: 71%).170 The syn-product was prepared 
by the addition of 1.90 to (E)-tert-butyl 2-methylbut-2-enoate and protonation with ammonium chloride (de: 
67%, yield: 63%). 
1.11.2 Organocatalytic Mannich reactions 
Addition of acetaldehyde to N-boc imines, as shown in Scheme 1-14, has been extended to other 
aldehydes.171 This methodology effectively and selectively produced the syn-Mannich products shown below.     
 
Scheme 1-18. Proline catalyzed addition of aldehydes to N-Boc imines. Reagents and conditions: (a) NaH2PO4, 2-
methyl-2-butene, NaClO2. R= nBu, iPr, Me.171 
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Excellent ee and de was observed with aromatic imines, but aliphatic imines did not produce the desired 
product. The aldehyde functionality was efficiently oxidized to the free carboxylic acid with sodium chlorite. 
The proposed mechanism for the diastereoselective Mannich reaction is shown below (Scheme 1-19). 
 
Scheme 1-19. Mechanism for the diastereoselective (S)-proline-catalyzed Mannich reaction between aldehydes and N-
Boc imines.172 X= Boc, PT= proton-transfer. 
Condensation of the aldehyde and proline produces an iminium ion (1.127), which is in equilibrium with the 
energetically favored (E)-enamine (1.128). The enamine attacks the N-Boc protected imine from the si-face. 
This selectivity is mediated by the proton-transfer interaction between the carboxylic acid and the imine 
nitrogen (1.129). Furthermore, the R-group is positioned antiperiplanar to the imine group to minimize steric 
strain. As a result, C–C bond formation occurs on the re-face of the enamine and this selectivity is also 
controlled by the proton-transfer. The proton-transfer also enhances the electrophilicity of the imine.172 
Finally, the iminium specie (1.131) is hydrolysed to regenerate the catalyst and produce the β-amino 
aldehydes (1.132).     
1.11.3 Metal catalyzed Mannich reactions 
Recently, efficient metal-catalyzed asymmetric Mannich reactions have been developed. An excellent 
example was published by Shibasaki and co-workers in 2007.173 Shibasaki developed a catalytic system 
composed of lithium aryloxide and a lanthanum aryloxide–pybox complex (Scheme 1-20). This system 
catalyzed the highly enantioselective Mannich reaction between 2-thiophenesulfonyl imines (1.134) and 
1,1,1-trichlorobutan-2-one (Scheme 1-20). Both aryl, heteroaryl, alkenyl, and aliphatic imines worked well 
under these conditions and the Mannich products could effectively be elaborated to the N-boc protected β-
amino esters.   
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Scheme 1-20. Lanthium catalyzed Mannich reactions developed by Shibaski and co-workers.173 Reagents and 
conditions: (a) NaOMe, MeOH, i) Boc2O, DMAP. 
1.11.4 Mannich reactions with chiral auxillaries 
The Mannich reaction between acetate enolates and chiral sulfinyl imines, shown in Scheme 1-16, has been 
further developed to include propionate enolates.166 This reaction allowed access to α-methylated β-amino 
esters (1.139).    
 
Scheme 1-21. Diastereoselective Mannich reaction. (Adapted from Ellman and co-workers)166 
Different propionate esters and sulfinylimines were tested to explore the scope of this reaction (Table 1-7). 
Good selectivities were observed in all cases, except for entry 3. The reduction in selectivity reported for 
entry 3 could be explained by the increase in bulk, when moving from methyl- and PMB-esters to tert-butyl 
esters. 2-benzyl- and 2-(4-methoxy benzyl) propionate esters also worked well for the introduction of benzyl 
substituents in the α-position.166  
Table 1-7. Screening of different imines and propionate esters in the Mannich reaction shown in Scheme 1-21. 
entry R1 R2 d.r.b yield, % 
1 Me Me 92:7:1:0 96 
2 Me i-Bu 95:3:2:0 81 
3 CMe3 i-Bu 59:19:17:5 87 
4 4-MeOBn i-Bu 88:12:0:0 85 
5 Me Ph 96:4:0:0 85 
 
1.12 Methods for the preparation of β2,2,3-amino acids 
1.12.1 Alkylation at the α-position 
The most obvious approach to prepare β2,2,3-amino acids, where the two α-substituents are identical, is to 
perform a simple double α-alkylation of the β3-amino esters or to perform a mono alkylation of β2,3-amino 
esters.174,175  
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1.12.2 Metal catalyzed Mannich reactions 
Metal catalyzed enantioselective Mannich reactions between a silyl ketene acetal (1.140) and an imine 
(1.141) have been reported by Kobayashi176 and Yamashita177 to produce the enantiomeric α-dimethylated 
β-amino esters (1.142 and 1.143) in good yields and with high enantioselectivities (Scheme 1-22). 
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Scheme 1-22. Metal catalyzed Mannich reactions producing β2,2,3-amino acids. NMI= N-methyl imidazole.  
Noteworthy, the two protocols produce enantiomers with the exact same substrates and differ only in the 
choice of metal center and ligands. A quaternary stereocenter at the α-position can also be prepared by metal 
catalysis. Shibasaki and co-workers prepared α-tetrasubstituted anti-α,β-diamino esters in high yields (67–
96%) and good diastereomeric ratios (86:14–>97:3) using nickel catalyzed addition of α-nitro esters to N-Boc 
imines.178 Both aromatic, hetereoaromatic, and aliphatic imines were found to work well under these 
conditions.       
1.12.3 Organocatalytic Mannich reactions 
Formation of a quaternary stereocenter at the α-position can also be achieved with organocatalysis. 
Equivivalent to the diastereoselective preparation of β2,3-amino acids from aldehydes and N-Boc imines, 
shown in Scheme 1-18 , Barbas and coworkers investigated the diastereoselective Mannich reaction between 
α,α-disubstituted aldehydes (1.147) and N-paramethoxyphenyl (PMP) protected imines (1.148) to yield β2,2,3-
amino aldehydes (1.149, Table 1-8).179  
Table 1-8. Mannich reactions catalyzed by (S)-proline.  
 
entry R syn:anti ee (syn) yield, % 
1 Phe 85:15 86 66 
2 thiophene 83:17 92 80 
3 4-methylPh 75:25 88 82 
4 (4-iPr)Bn 61:39 96 80 
5 (4-tert-Bu)Bn 60:40 99 80 
6 3,4-dioxolBn 70:30 88 91 
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The selectivities presented in Table 1-8 are lower than the selectivities obtained from linear aldehydes 
(Scheme 1-18). The decreased selectivity can be explained by the difference in the energetic barriers between 
the intermediate cis- and trans-enamines produced from linear aldehydes and from α,α-disubstituted 
aldehydes. The cis-trans energy barrier for the enamines of α,α-disubstituted aldehydes is often significantly 
lower than for the corresponding linear aldehydes.179 The geometry of the enamine is important for the 
stereochemistry in the 2-position and a mixture of cis- and trans-enamines will reduce the selectivity. The 
Mannich products can be oxidized to the N-PMP β2,2,3-amino acids in good yields.179     
1.12.4 Mannich reactions with chiral auxillaries 
Ellman and coworkers have investigated the Mannich reaction between methyl isobutyrate and different (R)-
sulfinyl imines (1.151, Scheme 1-23). Excellent diastereoselectivity (99:1) was observed for these reactions.166 
This protocol works well with aliphatic and aromatic imines and provides the β-amino esters (1.152) in good 
yields.  
 
Scheme 1-23. Diastereoselective Mannich reactions between methyl isobutyrate ester enolates and chiral sulfinyl 
imines. Yields are shown in parentheses. (Adapted from Ellman and co-workers)166 
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2 Synthesis of azumamides and epimeric analogs 
2.1  Retrosynthesis of the azumamides 
Retrosynthetic analysis reveales two major challenges in obtaining the azumamides. First, the 
macrolactamization step is particular difficult for small cyclic peptides.180, 181 This general observation is 
confirmed by previous work done on the azumamides, where the yields of the macrolactamization step  is 
ranging from 0 to 85%. It seems that both the cyclization point and the choice of coupling reagent play critical 
roles in this step.139, 136, 138, 135 We initially found it attractive to assemble the tripeptide fragment (2.02) on 
resin using standard solid-phase peptide synthesis (SPPS) and prepare the β-amino acid fragment in solution 
and couple this building block as the last residue (Scheme 2-1). This convergent route would result in a 
cyclization point between the β-amino acid and the aromatic amino acid residue.    
 
Scheme 2-1. Retrosynthetic analysis of the azumamides. 
The second challenge is the synthesis of the β2,3-amino acid fragment (2.03). Especially, preparation of the 
two adjacent stereocenters could be challenging, however as accounted for in the previous chapter several 
potential options are available. A Wittig reaction was chosen to install the cis-double bond in the side chain. 
This reaction could be utilized to introduce different functionalities in the side chain by using different Wittig 
reagents. The aldehyde (2.04) could be obtained by oxidation of the corresponding alcohol. The arguments 
for choosing our specific route is presented below. 
2.2  Choice of route for preparation of the β-amino acid present in the 
azumamides 
The synthetic route was designed with the intention to develop a short, efficient, and flexible protocol for 
obtaining the desired β2,3-amino acid. To shorten down the route, the two stereocenters should be prepared 
in one step and the substrates should be readily available. To avoid the use of expensive metal catalysts, the 
focus was set on using chiral auxillaries. A common drawback of many of the methods presented in section 
1.11 is the requirement of aromatic imines. An aliphatic β3-side chain is required in the target β-amino acid 
and the protocols that were limited to aromatic imines, were discarded. Ellman´s Mannich reaction- 
approach (1.11.4) fulfill all the requirements listed above and this methodology has been used by Ganesan 
in the synthesis of azumamides. Using Ellman´s chiral tert-butylsulfinyl auxiliary we expected to be able to 
direct the stereochemistry in the Mannich reaction. The tert-butylsulfinyl group thus serves both as a chiral 
auxillary and an amine protection group. Furthermore, these Mannich reactions produce β-amino esters, 
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which easily can be hydrolyzed to give the free acids. By performing the Mannich reaction with different α-
substituted esters, this methodology also provides an elegant way to incorporate different substituents in 
the 2-position of the β-amino acid. 
Ganesan reported problems with the stability of the sulfinyl imine (1.58, Scheme 1-4) and the aldehyde 
required to prepare the imine (Scheme 1-4). The instability resulted in low yields in the final steps of the β-
amino acid synthesis.138 For this reason we chose to perform the Mannich reaction at an earlier stage in our 
synthetic route (Scheme 2-2) and prepare sulfinyl imine 2.07 insted. 
 
Scheme 2-2.  Retrosynthesis of key intermediate (2.04). 
We envisioned that the key imine intermediate (2.07) could be obtained from an appropriately protected 
1,3-propanediol and the commercially available (R)-tert-butylsulfinamide (2.09). A silylether was chosen for 
the protection of the alcohol functionality as this group can be cleaved under mild conditions with fluoride. 
 
 
Scheme 2-3. Retrosynthesis of key sulfinylimine (2.07). 
2.3 Synthesis of β-amino acids 
2.3.1 Synthesis of chiral sulfinyl imine 2.14 
Monoprotection of 1,3-propanediol with NaH and triisopropylsilylchloride provided alcohol 2.13, which was 
oxidized to the corresponding aldehyde under Swern conditions (Scheme 2-4).182 Copper(II)sulfate mediated 
condensation of the aldehyde with (R)-tert-butyl sulfinamide provided the desired chiral sulfinyl imine (2.14) 
in 54% yield over three steps. Sulfinyl imine 2.14 is stable and can be stored in the freezer for years and only 
the (E)-imine was observed in the NMR spectra.           
 
Scheme 2-4. Reagents and conditions: (a) NaH (1.0 equiv), dry THF, 30 min; then triisopropyl chloride (1.1 equiv) in dry 
THF, 20 h. (b) DMSO (3.2 equiv), (COCl)2 (1.6 equiv), CH2Cl2, –78 °C, 25 min; then alcohol (2.13), 30 min; then Et3N (5.2 
equiv), –78° C, 40 min. (c) (R)-tert-butyl sulfinamide (0.95 equiv), CuSO4 (2.6 equiv), dry CH2Cl2, 16 h, then CuSO4 (0.6 
equiv), 25 h.  
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2.3.2 Screening of propionate esters for the diastereoselective Mannich reaction  
Based on Ellman´s and Ganesan´s results, an optimization study was performed, where various propionate 
esters were screened in the Mannich reaction with sulfinylimine 2.14 (Table 2-1). 
Table 2-1. Mannich reaction screen. Reagents and conditions: 2.92 (2.0 equiv), LDA (2.1 equiv), THF, –78° C, 30 min, 
then Ti(O-iPr)3Cl (4.2 equiv), 30 min, –78° C, then imine (2.14).       
 
entry R1 additive enolatea d.r.b major isomer 
1 Me TiCl(O-iPr)3 E 47:39:10:4 NDc 
2 Et TiCl(O-iPr)3 E 49:29:11:11 ND 
3 Allyl TiCl(O-iPr)3 E 46:34:10:10 ND 
4 PMB TiCl(O-iPr)3 E 46:33:11:10 ND 
5 tBu TiCl(O-iPr)3 E 60:26:8:6 (2S,3S)d 
6 tBu HMPA E 71:15:14:0 (2S,3S)e 
 aMajor configuration of the enolate as determined by NMR and by trapping 
with tBuMe2SiCl. bDiastereomeric ratio determined by 1H NMR. cND = not 
determined. dDetermined by X-ray crystallography on its desilylated 
homologue. eDetermined by comparison of spectroscopic data with the 
compound from entry 5.          
In disagreement with the previously reported experiments, poor diastereoselectivities were observed with 
methyl, ethyl, allyl, and PMB propionates.166, 138 This could indicate the presence of an alternative transition 
state. The best selectivity was observed with tert-butyl propionate (entry 5). However, the major product 
was not the expected (2S,3R)-diastereomer, as would be expected from the transition state mode proposed 
by Ellman, but the (2S,3S) diastereoisomer (Figure 2-1).This observation confirms the possibility of an 
alternative transition state  
 
Figure 2-1. X-ray structure of the desilylated product from Table 2-1 , entry 5.   
To investigate this observation, we conducted the Mannich reaction with addition of HMPA (3.0 equiv), which 
should break up the six-membered transition state by coordinating the metal ion. This resulted in the same 
major diastereoisomer as Table 2-1, entry 5 (Figure 2-2), further supporting the hypothesis of an alternative 
transition state.  
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Figure 2-2. Overlay of crude 1H NMR of the products obtained from Table 2-1, entry 5 (blue) and Table 2-1, entry 6 
(red). 
The HMPA experiment could suggest the absence of a metal coordinated six-membered transition state in 
the Mannich reaction. Others have reported similar “anti-Ellman” selectivities and the possibility of a 
nonchelated open transition state has been rationalized.183, 184, 185, 186 Aitken and co-workers proposed an 
open transition state for the formation of the major diastereoisomer (2.19) in the Mannich reaction shown 
in Scheme 2-5.183       
 
Scheme 2-5. Key Mannich reaction reported in the synthesis of the β-amino acid constituents of Microslerodermins C, 
D and E.  
In Scheme 2-5 the diastereoselectivity was highly sensitive towards substituent changes in the enolate. The 
selectivity decreased to (78:22:0:0) if the methyl ester was changed to an allyl ester. Furthermore, a 2-O-
trityl-protected methyl ester resulted in decomposition of the starting material.      
The imine 2.14 is believed to adopt its lowest energy conformation in the open transition state. The 
conformation of tert-butanesulfinimines has been studied by several groups through computational 
calculations.187, 188 Exploring the rotation around the N–S bond, two conformations (C1 and C2) can be drawn 
(Figure 2-3).   
NH major 
diastereomer 
NH major 
diastereomer 
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Figure 2-3. Conformations of chiral sulfinyl imines. (Adapted from Chemla and co-workers )187  
The conformation in C1 is favored by three stabilizing features. First, the oxygen atom can participate in an 
intermolecular electrostatic interaction between the aldimine C–H and O. This interaction is not possible in 
C2. The second feature is the antiperiplaner geometry found between the S–O bond and the lone pair on the 
nitrogen atom. This orientation minimizes electronic repulsion between the lone pairs on oxygen and 
nitrogen. Finally, the antibinding σ* S–O orbital can participate in a negative hyperconjugative interaction 
with the lone pair on the nitrogen (nN). If the R-group is (E)-allylbenzene the energy difference between the 
two conformations is 24.34 kJ/mol.187 In the open transition state, one face of the imine is shielded by the 
tert-butyl group and the enolate attacks from the opposite face (re-face). By flipping the enolate, two 
reaction pathways can be hypothesized, which leads to C2-epimers (Figure 2-4, A and B). 
 
Figure 2-4.  Open transition state of the Mannich reaction and the expected products. All enolates are in the E-
configuration and the sulfur has the R-stereochemistry. (R= CH2CH2OSi(iPr)3). 
In Figure 2-4, transition state B looks favored compared to A, as the sterical clash between the methyl group 
and the R-group is removed in transition state B. Newman projections of the transition states reveal another 
important interaction (Figure 2-5). 
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Figure 2-5. Newman projections of the two possible transition states (A and B) for the Mannich reaction. 
In TS A the two bulky tert-butyl groups come closer together, compared to TS B. This unfavorable sterical 
clash also favors TS B. The (2S,3S)-stereochemistry (2.24) predicted by transition state B is in agreement with 
the major isomer observed in Table 2-1 (entry 5 and 6). The descreased selectivity observed in Table 2-1, 
entry 5, compared to entry 6, could be attributed to a small amount of the sulfinylimine reacting through the 
expected six-membered transition state in the presence of titanium.  
2.3.3 Exploring the alcohol protection group 
To address whether disruption of the six-membered transition state was a consequence of the bulky 
triisopropylsilyl ether, the less bulky benzyl (2.30), para-methoxybenzyl (2.28), and triethylsilyl (2.27) ether 
protected sulfinylimines were prepared (Scheme 2-6.). The low yield observed in the preparation of the 
triethylsilyl protected imine (2.27) was attributed to the instability of both imine (2.27) and alcohol (2.25) 
during purification. The imines in Scheme 2-6 were subjected to the Mannich conditions using tert-butyl 
propionate (Table 2-2).   
 
Scheme 2-6. Reagents and conditions: (a) NaH (1.0 equiv), dry THF, 35 min; then Et3SiCl (1.0 equiv) in dry THF, 16 h. (b) 
NaH (0.95 equiv), TBAI (0.05 equiv), PMBCl (1.0 equiv), 17 h; (c) (COCl)2 (2.2 equiv), DMSO (4.8 equiv), –78° C, 30 min, 
then alcohol 2.26, –78° C, 30 min, then Et3N (7.3 equiv), –78° C→ rt, 30 min; (d)  DMP (1.1 equiv), CH2Cl2, 45 min; (e) 
(R)-tert-butyl sulfinamide (1.0 equiv), CuSO4 (4–6.4 equiv), dry CH2Cl2, 16–20 h; (f) (CO)2Cl2 (1.1 equiv), DMSO (2.2 
equiv), –78° C, 20 min, then alcohol 2.29, –78° C, 20 min, then Et3N (5.0 equiv), –78° C→ rt, 30 min; (g) (R)-tert-butyl 
sulfinylamide (1.0 equiv), CuSO4 (2.2 equiv), dry CH2Cl2, then crude aldehyde from step f (1.1 equiv), 22 h.      
The major product was still found to be the (2S,3S) diastereoisomer and the selectivities were slightly 
increased for the PMB- and triethyslilyl-protected imines. Even though higher selectivities were obtained 
with these protection groups, the isolated yield of the major diastereoisomer was lower compared to entry 
5 and 6 in Table 2-1. The lower isolated yield was associated with problems in the chromatographic 
separation of the diastereomers.  
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Table 2-2. Screening of different alcohol protecting groups. 
entry auxiliary R additive enolatea d.r.b major isomer 
1 R OBn TiCl(O-iPr)3 E 70:18:12:0 NDc 
2 R OPMB TiCl(O-iPr)3 E 77:13:10:0 (2S,3S)d 
3 R OSi(Et)3 TiCl(O-iPr)3 E 75:21:4:0 (2S,3S)e 
aMajor configuration of the enolate as determined by NMR and by trapping with tBuMe2SiCl. 
bDiastereomeric ratio determined by 1H NMR. cND = not determined. dDetermined by 
comparison of spectroscopic data with the compound from entry 5. eDetermined by X-ray 
crystallography on its desilylated homologue. 
The (2S,3S)-stereochemistry, obtained from the Mannich reaction, is somewhat unexpected, but this β-amino 
scaffold could be elaborated to the interesting β3-epimeric azumamides via building block 2.31 (Scheme 2-7). 
This β3-azumamide epimer will give useful information about the specific stereochemical requirements in the 
3-position in the β-amino acid. The synthesis of 2.31 is presented in the experimental section (Figure S1).  
 
Scheme 2-7. β-amino acid building block required for the synthesis of β3-epimeric azumamides. 
Changing the chirality of the sulfur from R to S, in the Mannich reaction shown in Table 2-1, provided the 
enantiomeric (2R,3R) β-amino ester (2.37, Scheme 2-9). The stereochemistry of this compound is interesting, 
as it can be elaborated to provide a building block (2.41, Scheme 2-9), which will allow the synthesis of β2-
epimeric azumamides. These novel epimeric azumamides have not been reported previously and they will 
provide information about the stereochemical requirements in the 2-position and 3-postion of the β-amino 
acid.  
2.3.4 Synthesis of β2-and β3-epi-building blocks 
Silylether 2.32 was desilylated using TBAF and the Z-double bond was introduced by Dess Martin oxidation 
to the aldehyde followed by a Wittig reaction with 3-(ethoxycarbonyl)propyl] triphenylphosphonium 
bromide (Scheme 2-9). Initially, yields between 44% and 65% were observed for the desilylation step. Besides 
the desired alcohol, a byproduct was observed. NMR and LC-MS analyses indicated formation of lactone 2.34 
(Scheme 2-8).   
 
Scheme 2-8. Proposed mechanism for the synthesis of lactone byproduct. 
This lactone could be the result of an intramolecular reaction, where the forming alkoxide attacks the tert-
butyl ester. This results in a stable six-membered lactone. Similar reactions have been reported for 
methylesters.189 The problem was solved by adding one equivivalent of acetic acid, which protonates the 
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forming alkoxide, rendering it a much poorer nucleophile. The addition of acetic acid increased the yield to 
76–92%. The two step alkene formation also required optimization. Oxidation under Swern conditions, 
provided the aldehyde (2.39) in low yields (<30%). Switching to a milder Dess Martin periodinane oxidation 
gave higher crude yields (75–90%). Controlling reaction temperature and reaction time was found to be 
critical for obtaining the fragile aldehydes. Thorough drying of the Wittig reagent was crucial in order to 
achieve complete conversion of the aldehyde in the Wittig reaction. In a model study the aldehyde (2.39) 
was replaced with benzaldehyde. This reaction provided the desired alkene in quantitative yield, indicating 
that aldehydes of the type shown in Scheme 2-9, could be unstable under the conditions used. However, the 
desired Z-olefin (2.40) was obtained in 59% yield, over two steps, by addition of the crude aldehyde to an 
unstabilized phosphonium ylide. Removal of the tert-butyl ester and the sulfinyl group under acidic 
conditions, followed by reprotection of the amine with tert-butoxy anhydride, afforded β-amino acid 2.41. 
This β-amino acid could then serve as a building block in the synthesis of β2-epi-azumamides. The Boc-group 
was introduced on the nitrogen as the selective removal of the tert-butyl group with TFA was sluggish and 
resulted in cleavage of the sulfinyl group. Using the same chemical transformations as in Scheme 2-9, the β-
amino ester obtained fromTable 2-1, entry 5, was used to synthesize the (2S,3S) β-amino acid building block 
(2.31). 
  
Scheme 2-9. Reagents and conditions: (a) LDA (2.6 equiv), tert-butyl propionate (2.5 equiv), THF, –78 ºC, 30 min; then 
Ti(O-iPr)3Cl (4.5 equiv), THF, –78 ºC, 30 min; then imine (2.35), –78 ºC, 30 min. (b) AcOH (1.0 equiv), Bu4NF (1.2 equiv), 
THF, 0 ºC, 10 min. (c) NaHCO3 (1.4 equiv), Dess-Martin periodinane (1.4 equiv), dry CH2Cl2, 0 ºC, 15 min; then NaHCO3 
(0.3 equiv), Dess-Martin periodinane (0.2 equiv), 25 min. (d) KHMDS (1.9 equiv), Ph3PBr(CH2)3COOEt, (2.0 equiv), dry 
THF, –78 ºC, 30 min.; then aldehyde 2.39 in dry THF, 1 h,  –78 ºC → rt (e) TFA–CH2Cl2 (1:1, 10 mL), rt, 1 h. (f) HCl (4.0 M 
in dioxane, 6.3 equiv), dioxane, 2.5 h. (g) iPr2NEt (1.4 equiv), Boc2O (1.4 equiv), dry CH2Cl2, 16 h; then iPr2NEt (0.2 
equiv), Boc2O (0.2 equiv), 1 h. 
2.3.5 Synthesis of building block for the natural products  
With the building blocks for the two azumamide epimers in hand, we turned our attention to the building 
block required for the natural products. If the Mannich reaction proceeds through an open state transition 
state, as shown in Figure 2-4, it should be possible to modulate the stereochemistry in the 2-position by 
performing the reaction with the Z-enolate instead of the E-enolate. The expected transition states are shown 
in Figure 2-6.        
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Figure 2-6. Top: Transition states for the Mannich reaction using the Z-enolate and the (S)-imine. Bottom: Newman 
projection of the two transition states. 
In TS A the steric clash between the two tert-butyl groups is minimized, but the methyl group from the 
enolate and the R group will clash. In TS B the reverse is the case and the two tert-butyl groups will clash, 
whereas the methyl–R-group interaction will be avoided. The major diastereoisomer observed from the 
experiment is the desired (2S,3R), which can be explained from transition state A. This selectivity indicates 
that the tert-butyl–tert-butyl steric interaction is more important than the methyl–R-group interaction in 
determining the stereochemistry. This rationale is also in agreement with the selectivity observed for 
compounds 2.24 and 2.43.  
Where the E-enolate is formed by deptrotonating in THF, the Z-enolate can be prepared by deprotonating 
the tert-butyl ester with LDA in HMPA–THF (23:77, v/v).190, 191, 192 The observed selectivity can be explained 
by the transition states shown in Figure 2-7. In THF, which is a relative weak coordinating solvent, the lithium 
ion will coordinate strongly to the carbonyl oxygen resulting in an increase in bulk at this face (Figure 2-7, 
2.44). Therefore the methyl group will be oriented away from this face. In the presence of HMPA, a strong 
coordinator of lithium, the interaction with the carbonyl oxygen will be reduced significantly. This resulting 
reduction in bulk at this face, will favor the positioning of the methyl group away from the steric interactions 
with the tert-butyl group (2.45).   
 
Figure 2-7. Transition states showing the enolate formation in absence (2.44) and presence (2.45) of HMPA.  
Synthesis of azumamides and epimeric analogs 
46 
 
To determine the E:Z selectivity, the enolates were trapped as the tert-butyldimethyl silylenol ethers and the 
E:Z ratio was determined by 1H NMR. For the HMPA–THF (23:77, v/v) and THF conditions the E:Z ratio was 
18:82 and 94:6, respectively (Scheme 2-10). Attempts to improve the E:Z selectivity, by deprotonating with 
the more sterically hindered base lithium tetramethylpiperidide (LTMP)193 proved unsuccessful. 
 
Scheme 2-10. Preparation of E/Z-silylenol ethers from tert-butyl propionate and attempted Mannich-Mukayama-type 
reactions. 
With the silylenol ethers (2.46 and 2.47) in hand, the Mannich-Mukayama-type reactions, catalyzed by Lewis 
acids, were investigated. This approach would provide a simpler Mannich reaction protocol where in situ 
preparation of the enolate is avoided. Disappointingly, no conversion of the imine (2.35) was observed with 
either titanium di-isopropoxydichloride or stannic tetrachloride (Scheme 2-10). 
The Z-enolate worked well in the Mannich reaction and nicely provided the desired (2S,3R)-β-amino ester 
(2.42). This compound was elaborated to the β-amino acid building block 2.51 (Scheme 2-11). The Fmoc 
group was chosen as the amine protecting group, as this allows introduction of the β-amino acid in all 
positions of the liniar tetrapeptide. As a result, cyclization can be performed at different positions. The 
stereochemistry of the building block was confirmed by comparison of spectroscopic data from the Boc 
protected homolog (2.52) to the data previously reported for this compound.136, 194  
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Scheme 2-11. Reagents and conditions: HMPA (6.4 equiv), LDA (2.6 equiv), tert-butyl propionate (2.5 equiv), THF, –78 
ºC, 30 min; then imine (2.35), –78 ºC, 30 min. (b) AcOH (1.0 equiv), Bu4NF (2.0 equiv), THF, 0 ºC → rt, 1.5 h. (c) NaHCO3 
(1.5 equiv), Dess-Martin periodinane (1.4 equiv), dry CH2Cl2, 0 ºC → rt, 1.5 h. (d) KHMDS (1.9 equiv), 
Ph3PBr(CH2)3COOEt, (2.0 equiv), THF, –78 ºC; then aldehyde 2.49 in dry THF → rt, 18 h. (e) TFA–CH2Cl2 (1:1, 10 mL, 80 
equiv), 0 ºC → rt, 3 h. (f) HCl (4.0 M in dioxane, 3.0 equiv), dioxane, 3 h. (g) Na2CO3 (4.0 equiv), Fmoc-OSuc (1.2 equiv), 
dioxane–H2O, 0 ºC → rt, 2 h; (h) iPr2NEt (3.0 equiv), Boc2O (2.1 equiv), CH2Cl2, 3 h, then iPr2NEt (3.0 equiv), 18 h.       
The reduction in diastereoselectivity observed with the Z-enolate compared to the selectivity from Table 2-
1, entry 6, can be explained by the difference in E:Z ratio shown in scheme 2-24. Having 18% of the E-isomer 
present, compared to only 6% Z-isomer in the reverse case, will lower the selectivity. The mismatch between 
the two steric interactions, proposed for the reaction mechanism involving the Z-enolate in Figure 2-6 A, 
could also induce a reduction in selectivity.          
2.3.6 Concluding remarks 
Through the optimized Mannich conditions developed in this project, it is possible to access all four 
diastereomers of the β2,3-amino acid building block (Scheme 2-12). The (2R,3S)-diastereoisomer (2.53) was 
not prepared as β2,3-epi-azumamide E, which contains the (2R,3S)-stereochemistry, has been reported by 
DeRiccardis and co-workers.136 The scope of this reaction is discussed further in chapter 3.8.  
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Scheme 2-12. The diastereoselective Mannich reactions between chiral sulfinyl imines and tert-butyl propionate 
enolates.  
2.4  Peptide synthesis 
2.4.1 Synthesis of β2-epi-azumamide E and β3-epi-azumamide E   
The linear tetrapeptides 2.54 and 2.57 were prepared on solid support (polystyrene 2-chlorotrityl resin) using 
commercially available Fmoc-D-amino acids and the β-amino acids 2.31 and 2.41, respectively. Couplings 
were performed using HATU and 2,6-lutidine in DMF. Treatment of the resin with TFA cleaved the peptide 
from the solid support and removed the Boc-group, rendering the peptide ready for cyclization. Cyclization 
under dilute conditions (< 1mM) using HATU, followed by hydrolysis of the side chain ethyl ester, provided 
the epimeric azumamide E analogs (2.56 and 2.57, Scheme 2-13).  
 
Scheme 2-13. Reagents and conditions: (a) TFA–CH2Cl2 (1:1), 2 × 30 min; (b) HATU, iPr2NEt (8.0 equiv), DMF (0.3–0.7 
mM peptide concentration), 17–21 h; (c) LiOH, THF–H2O (1:1), 16 h. 
The low overall yield observed with the synthesis of these cyclic peptides can be attributed to two major 
obstacles; the cyclization step and solubility/purification issues. As mentioned in the retrosynthetic section, 
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cyclization of small peptides is challenging. The cyclization step will be discussed further in section 2.4.2. All 
the final macrocyclic peptides were purified using preparative HPLC. These macrocyclic peptides are poorly 
soluble in water and the risk of precipitation on the column is present, when purifying compounds with low 
water solubility by means of preparative HPLC. Purification of the same compounds by vacuum liquid column 
chromatography (VLC), resulted in higher yields (up to 25%), but the purity was unfortunately not high 
enough for biological testing (residual iPr2NEt could be detected in the NMR spectrum). This observation 
indicates that some material is lost during HPLC purification. In the HPLC purification the eluent is made 
slightly acidic by adding TFA. In retrospect it could have been interesting to purify with a slightly basic eluent 
instead, as the some of the azumamides contain a free carboxylic acid. A basic eluent might increase the 
water solubility of these compounds.   
2.4.2 Synthesis of azumamide A–E        
The same overall synthetic strategy, used to obtain the epi-analogs, was applied for synthesis of the natural 
products. The linear tetrapeptides were obtained in good yields and good purities after cleavage from the 
resin and precipitation with ether. Several cyclization positions and conditions were tested to increase the 
yield of the cyclization step. Besides the HATU-mediated cyclization using dilute conditions, the slow addition 
protocol developed by Ganesan was also tested.138 The cyclization results are summarized in Table 2-3. 
Table 2-3. Cyclization experiments. N.D = Not determined.  
entry peptide sequence conditions yield (from linear peptide) dimer (LC-MS) 
1 H2N-β-aa-(D)Val-(D)Ala-(D)Phe-OH Dilute 23% (VLC) Observed 
2 H2N-(D)Ala-(D)Phe-β-aa-(D)Ala-OH Dilute 19% (VLC) Not observed 
3 H2N-(D)Phe-β-aa-(D)Val-(D)Ala-OH Slow addition 25% (VLC) Observed 
4 H2N-(D)Val-(D)Ala-(D)Tyr-β-aa-OH Dilute 11% (HPLC) Observed 
5 H2N-β-aa-(D)Val-(D)Ala-(D)Phe-OH Slow addition N.D Not observed 
 
For all reactions we observed full conversion of the linear peptide and the only byproducts observed were 
varying amounts of dimer and trace amounts of epimeric cyclic peptide (Figure 2-8).  
 
Figure 2-8. Chromatogram showing the crude reaction mixture from Table 2-3, entry 5. 
Dimer HOAt    Product             
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In our hands, neither the peptide sequence nor the cyclization conditions seemed to alter the yields 
dramatically. The synthesis of azumamide C and B is presented in Scheme 2-14.  
 
Scheme 2-14.  Reagents and conditions: (a) TFA–CH2Cl2 (1:1), 2 × 30 min; (b) HATU, iPr2NEt (8–10 equiv), DMF (0.3–0.4 
mM peptide concentration), 3–18 h; (c) LiOH, THF–H2O (1:1); (d) DIC (11 equiv), HOBt (3.0 equiv), iPr2NEt (4.0 equiv), 
NH3–dioxane (25 equiv), DMF–CH2Cl2 (2:1), 5 d. *Yields are based on resin loadings. 
Azumamide C was prepared from the tetrapeptide 2.60, without any purification after the cyclization step. 
The hydrolysis of the ethyl ester goes “peak to peak” in the LC-MS and this step does not seem to cause any 
problems.  
Azumamide B was cyclized between the sterically demanding valine and the β-amino acid residue and the 
reaction mixture was purified by preparative HPLC (Table 2-3, entry 4). A cyclization study performed on a 
simplified model peptide had shown this cyclization site to be favorable. However, judging by LC-MS and the 
purified yields (cyclic petide 11%; dimer 5%) this cyclization site resulted in dimer formation (Figure 2-9). In 
the peptide used to perform the model study, the β2-methyl group had been removed, which decrease the 
bulk around the C-terminal. This could explain the difference in the cyclization yields. This result indicates 
that the cyclization reaction is extremely sensitive, even to small modifications in the linear peptide. The 
increase in dimer formation observed with the Val to β-aa cyclization compared to β-aa to Phe (Table 2-3, 
entry 1) can be explained by a sterically induced reduction in cylization rate. When the cyclization reaction is 
slowed down, there will be more time for the peptide to form dimers. However, Bhadra and coworkers have 
reported 79% yield for the EDCI/HOBt mediated cyclization of the H2N-(D)Val-(D)Ala-(D)Phe-β-aa-OH 
sequence, having a PMB protected alcohol in β-amino acid side chain. In their study no observation of dimer 
was reported.139          
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Figure 2-9. Chromatogram showing the crude reaction from Table 2-3, entry 4 to afford 2.63. 
The purified ethyl ester (2.63, Scheme 2-14) was converted to the corresponding carboxylic acid with LiOH 
and activated by a combination of DIC and HOBt. Addition of ammonia afforded azumamide B in good yield 
(over two steps), albeit prolonged reaction time was needed. The good yield observed for the hydrolysis and 
amidation step, indicates that the critical step is indeed the cyclization. The spectral overlay of the 1H NMR 
of the originally isolated azumamide B and our synthetic sample is shown below (Figure 2-10).   
 
 
 
 
 
Figure 2-10. Overlay of synthetic azumamide B (blue) and natural azumamide B (black).135 
Azumamide D is structurally different from the other azumamides in the cyclic peptide backbone. In 
azumamide D the valine residue is substituted for an alanine. This feature allows an alanine to alanine 
cyclization, which could be favorable in the terms of reducing sterical hindrance in the cyclization reaction 
(Scheme 2-15).181 
Dimer Product 
HOAt 
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Scheme 2-15. Reagents and conditions: (a) TFA–CH2Cl2 (1:1), 2 × 30 min; (b) HATU (1.1 equiv), iPr2NEt (8.0 equiv), DMF 
(0.5 mM peptide concentration), 19 h; (c) LiOH (50 equiv), THF–H2O (1:1), 4 h; DIC (6.0 equiv), HOBt (3.0 equiv), 
iPr2NEt (4.0 equiv), NH3–dioxane and NH3–MeOH (30 equiv), CH2Cl2–DMF (2:1), 13 d. *Yields are based on resin 
loadings. 
However, the yield was slightly lower using the alanine to alanine cyclization (Table Table2-3, entry 2) 
compared to Table 2-3, entry 1 and 3. This result could illustrate that the structural geometry of the linear 
precursor outweighs the importance of sterics and peptide sequence in this case.195, 196  The low overall 
isolated yield of azumamide D can be attributed to difficulties in the amidation reaction. Complete conversion 
was not achieved even after several days and excessive addition of coupling reagents and ammonia. 
Diphenylphosporylazide (DPPA) mediated amidation using triethylamine and ammoniumchloride did not 
produce the desired amide.137      
To avoid dimer formation, as observed for azuamide B, azumamide A was cyclized between phenylalanine 
and alanine, using the slow addition protocol reported by Ganesan (Scheme 1-5).138 LC-MS anaylsis showed 
no dimer and the cyclized product was purified using VLC. This procedure also resulted in a poor yield 
compared to the literature. Amide formation was achieved with HATU as the activating agent. Changing 
coupling reagent from DIC/HOBt to HATU resulted in a significant reduction in reaction time (6 hours vs 5 
days) and an acceptable yield (Scheme 2-16).  
 
Scheme 2-16. Reagents and conditions: (a) TFA–CH2Cl2 (1:1), 2 × 30 min; (b) HATU (2.0 equiv), iPr2NEt (4.5 equiv), 
CH2Cl2; then linear peptide in DMF–CH2Cl2 (1:10) over 3.5 h; then HATU (1.0 equiv and iPr2NEt (2.3 equiv), 14 h; (c) 
LiOH, THF–H2O (1:1); (d) HATU (5.0 equiv), iPr2NEt (5.5 equiv), NH3–dioxane (25 equiv), 6 h; (e) HATU (1.1 equiv), 
iPr2NEt (8.0 equiv), DMF (0.4 mM peptide concentration), 22 h; then HATU (0.5 equiv),  iPr2NEt (4.0 equiv), 3 h.*Yields 
are based on resin loadings. 
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Azumamide E was obtained in 15% overall yield with cyclization between the β-amino acid and phenylalanine. 
These results indicate that cyclization between phenylalanine and alanine is slightly more favorable than 
cyclization between the β-amino acid and phenylalanine. However, the two cyclizations were performed 
under different conditions, making a direct comparison difficult. 
When comparing the cyclization yields in this study with the previously reported total syntheses, it is clear 
that the yields are lower. From LC-MS analyses the reactions appear to go completion and most cyclization 
sites only produced a small amount of dimer. One possible explanation could be the use of VLC for 
purification. VLC uses silica with a smaller particle size than regular flash chromatography. The smaller 
particle size could be a problem when purifying large macrocyclic peptides, as the compounds might be 
trapped on the column. This aspect, combined with the low solubility of these compounds, could explain the 
low quantities isolated after VLC. Furthermore, the column is sucked dry after each fraction, which will lead 
to precipitation of the compound on the column. If the cyclic peptides have poor solubility in the eluent, it 
will be hard to re-dissolve the peptide and recover the material from the column. However, these 
explanations do not explain the poor overall yield obtained when all the material is taken through the 
synthesis without purification, as it is the case for azumamide C. A second problem, which is also associated 
to the solubility problems observed with these compounds, is the risk of losing material into the aqueous 
phase when doing aqueous work up. To remove HOAt after the cyclizations, a mild acidic work up was 
performed. A large excess of organic solvent (8-15 times) was used and the aqueous phase was analyzed for 
residual product. LC-MS analyses of the aqueous phases implied that the desired product had been extracted 
to the organic phase, implying that the aqueous work up is not a problem.         
2.4.3 Concluding remarks 
In summary, all five azumamides were synthesized using a combination of solution and solid phase chemistry. 
This is the first reported total syntheses of azumamide B–D and this work confirms the structures originally 
proposed by Fusetani and coworkers.135 The exploration of a diastereoselective Mannich reaction allowed 
access to two site-specifically edited azumamide analogs, which can aid in understanding the stereochemical 
requirements in the unique β-amino acid moiety. 
2.5  Methods for biochemical profiling 
2.5.1 Fluorogenic HDAC assays 
The five azumamides and the two epimeric analogs were tested on HDAC1–9 by utilization of a protocol 
reported by Bradner et al.35 The profiling of HDAC10 and 11 were conducted using protocols and substrates 
developed in our group.197, 198 The principles of the fluorogenic assay are presented in Scheme 2-17.  
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Scheme 2-17. Schematic showing the principles of the HDAC assays.  
The HDAC of interest is incubated with a known peptide substrate (2.69) containing an ε-amino acetylated 
lysine and a fluorophore. The fluorophore, 7-amino-4-methyl coumarin (2.72, AMC), is attached directly to 
the acetylated lysine at the C-terminal of the peptide sequence. The fluorescence of AMC is quenched when 
the molecule is coupled to the peptide sequence. The rest of the peptide sequence (R, in Scheme 2-17) 
depends on the HDAC isoform under investigation (see section 2.5.2). After incubation trypsin is added as a 
developer. Trypsin cleaves amide bonds C-terminal to positively charged residues. In this case the positive 
charge is found in the deacylated lysine side chain. The resulting cleavage produces the highly fluorescent 
AMC molecule, which can be detected on a plate reader at very low concentrations (<250 nM). If the acyl 
group is still present on the ε-amino group, trypsin is unable to cleave the amide bond between AMC and 
lysine and no fluorescence will be detected. Thus, potential HDAC inhibitors can be evaluated by adding them 
during the incubation and measuring the fluorescence after addition of trypsin. 
2.5.2 Substrates for HDAC screening  
The tripeptide 2.73(Scheme 2-18)  is a good substrate for HDAC1–3, 6, and 11, however the class II enzymes 
display low activity on this substrate. Therefore, the more labile trifluoroacetylated substrate (2.74) was used 
for all class II isoforms, with the exception of HDAC10.197 The peptide sequence in 2.73 and 2.74 was 
originates from the N-terminal tail of HDAC4.198 HDAC10 was used in combination with tetrapeptide 2.75, 
which originally was marketed as a HDAC8 substrate. The peptide sequence in 2.75, which is based on a 
peptide fragment from p53.198 This sequence has been reported to produce good results for HDAC10.197 
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Scheme 2-18. Peptide substrates used in the HDAC assays. 
HDAC8 is placed in class I, but has different substrate preferences compared to HDAC1–3. HDAC8 was 
therefore profiled with the trifluoroacetylated substrate (2.74) used on class II enzymes.   
2.6  Biochemical profiling of azumamides and epimeric analogs       
2.6.1 Two concentration screening  
All five natural products, as well as the two epi-analogs, were screened against the 11 recombinant human 
HDAC isoforms by a colleague in our group (Helle Esbjørn Kristensen). Initially, the compounds were tested 
at 50 µM and 5 µM concentrations to get a quick overview of the activities. Compounds which did not show 
a minimum of 50% inhibition at 50 µM were regarded as inactive.   
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Figure 2-11. Screening of compounds at 50 µM concentration. (Azumamide A shows 52% inhibition at 50 µM). 
(adapted from Olsen and co-workers)194  
Figure 2-11 shows that azumamides A–E are poor inhibitors of class IIa HDACs. These data are not in 
agreement with the previous data on azumamide E, where IC50-values between 9.7 and >50 µM have been 
reported on class IIa enzymes.136 The modest class IIa inhibitory activity observed by De Riccardis and 
coworkers is most likely an artefact, which can be attributed to the presence of co-purified class I HDACs in 
the class IIa enzyme stocks.141, 34 The decreased activity towards class IIa enzymes, could be explained by key 
structural features found in the class IIa enzymes. Ficner and coworkers have studied the crystal structure of 
a bacterial homologue to class IIa HDACs, called FB188 HDAH.199 They reported the presence of two loops 
near the entrance to the 11 Å channel. These loops are absent in class I HDACs and represent a major 
structural difference in the protein surface topology. It has been hypothesized that the two loops prevent 
binding of sterically-demanding macrocyclic peptide inhibitors to class IIa HDACs.101 Our results support this 
hypothesis and univocally establish the azumamides as poor class IIa inhibitors.         
Both epimerized analogs were inactive at 50 µM against the entire selection of enzymes. The observed loss 
of activity observed, when inverting the stereochemistry of the zinc-binding side chain (β3-epi-azumamide E, 
2.56), can be explained by the change in side chain orientation relative to the cyclic peptide backbone. This 
change in overall topology prevents the side chain from accessing the 11 Å channel and reach the zinc ion, 
while the macrolactam ring still retains its favorable interactions with the surface of the protein. 136, 130 Ghadiri 
and co-workers reported a similar observation when they inverted the stereochemistry of the zinc-binding 
side chain of another cyclic peptide (1.39, Figure 1-17). Alternatively, the cyclic peptide could adopt an 
inactive conformation, when the stereochemistry is modulated.  The complete absence of activity observed 
for the β2-epimerized analog (2.59) is somewhat surprising. One possibility could be that the β2-methyl group 
has a hydrophobic interaction with the protein, which is removed when flipping the stereochemistry. 
However, docking studies of azumamide E in histone deacteylase-like protein (HDLP) does not indicate any 
hydrophobic interactions between the β2-methyl group and the protein.136 Instead, the answer might be 
found in conformational changes in the cyclic peptide backbone. Ghadiri and coworkers have explored this 
phenomenon and reported radical changes in the conformation of cyclic tetrapeptides, when inverting the 
stereochemistry in a single amino acid residue. Especially, the cis-trans geometry of the amide bonds is 
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sensitive to changes in the stereochemistry.119 Conformational changes can affect both the important C3–C4 
vector in the β-amino acid, as well as the interactions of the macrolactam with the surface of the proteins. 
The methyl group may also serve as a guide for the orientation of the zinc-binding side chain. The rotation 
around the C4–C5 bond is limited by the methyl group, and it is possible that flipping the methyl group, will 
make the zinc-binding side chain able to adapt an unfavorable orientation. Finally, there might be a steric 
clash with the surface of protein and the inverted methyl group. From the docking of azumamide E in HDLP 
(Figure 1-22) it is difficult to see if the methyl group will clash with F198, but the distance between C2 of the 
β-amino acid and the Cβ of F198 is reported to be 3.8 Å.136 If the bond length of a typical C–C bond (1.54 Å) 
and a C–H bond (1.1 Å) is considered, it seems likely that the inverted methyl group will come dangerously 
close to F198. 
The initial screen also indicated that the carboxylic acid containing compounds are more potent inhibitors 
than their carboxyamide homologs. This was confirmed by the dose-response experiments performed on 
HDAC1–3, 8, 6, 10, and 11.  
2.6.2 Dose-response characterization of azumamides  
Dose-response experiments were performed on class I, IIb, and IV HDACs and the results are shown in Table 
2-4.  
Table 2-4. Potencies of the azumamides against the Zn2+-Dependent HDACs given as Ki Values (nM)a 
 class I class IIb class IV 
compound HDAC1 HDAC2 HDAC3 HDAC8 HDAC6 HDAC10 HDAC11 
(azuA) >5,000 >5,000 3,200 >5,000 IA IA >5,000 
(azuB) 5,000 3,000 3,000 IAb IA IA >5,000 
(azuC) 32±1 40±20 14±1 >5,000 2,000 10±4 35±3 
(azuD) >5,000 >5,000 3,700 IA IA IA >5,000 
(azuE) 67±7 50±30 25±5 4,400 >5,000 20±12 60±16 
2.56: (β3-epi-azuE) IA IA IA IA IA IA IA 
2.59: (β2-epi-azuE) IA IA IA IA IA IA IA 
aIC50 values were determined from at least two individual dose–response experiments 
performed in duplicate and the Ki values were calculated using the Cheng-Prusoff equation. bIA 
= inactive (<50% inhibition at 50 µM [inhibitor]).                           
The initial biochemical evaluations of the azumamides, reported that the carboxyamides were equipotent or 
more potent than their carboxylic acid variants, when tested on cell extract.135 Our data show up to a 120-
fold decrease in potency (HDAC3), when substituting from a carboxylic acid to a carboxyamide. This is in 
accordance with the observations reported by Ganesan and coworkers, where azumamide E is was found to 
be 53-fold more potent than azumamide A on HeLa cell extracts.138 Interestingly, azumamide C was found to 
be slightly more active than azumamide E on HDAC1–3, 6, 10, and 11, indicating that a Phe to Tyr substitution 
is favorable. This result also contradicts the initial results obtained on cell extracts. It is possible that the 
hydroxyl group from tyrosine can participate in hydrogen bonding on the surface on the enzyme, thus 
favoring binding. The only HDAC isoform which prefers a phenylalanine residue instead of a tyrosine residue, 
is HDAC8. 
The azumamides display class selectivity towards class I, class IIb and class IV over class IIa. Regarding isoform 
selectivity within class I, azumamide C and E are 120–350-fold and 60–170-fold more potent toward HDAC1–
3 compared to HDAC8, respectively. In comparison, apicidin is only 8–42 times more potent towards HDAC1–
3 compared to HDAC8.130 Isoform selectivity was also observed in class IIb. Here, >200-fold selectivity for 
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HDAC10 over HDAC6 was observed for azumamide C and E. A similar selectivity profile has been reported for 
the cyclic peptide apicidin and a series of analogs.130    
2.6.3  Concluding remarks 
This work reports the first total syntheses of azumamide B–D and verify the originally proposed structures. 
The developed flexible synthetic route, with a diastereoselective Mannich reaction as the key step, allowed 
preparation of two site-specifically edited epimeric analogs. These two analogs contributed to the overall 
structure-activity relationships for the azumamides and show that the β-amino acid is highly sensitive to 
modifications in the stereochemistry. Azumamide A–E were profiled against the entire panel of HDAC 
enzymes. In contrast to previous findings, azumamide C was found to be ∼2-fold more potent than 
azumamide E against the majority of enzymes. Furthermore, the azumamides were poor inhibitors of class 
IIb (IC50 < 50 µM) in our hands, which is in disagreement with the results reported by DeRiccardis and co-
workers (IC50 values between 9.7 and >50 µM).136 In terms of isoform selectivity, azumamide C and E were 
more potent towards HDAC1–3 compared to HDAC8 (60–350-fold). Finally, isoform selectivity was observed 
in class IIb, where azumamide C and E displayed >200-fold selectivity for HDAC10 over HDAC6. Further 
investigation of the cytotoxic properties of the azumamides is ongoing and docking studies on HDAC3 will be 
performed. 
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3  Synthesis of β2-modified azumamide analogs   
3.1  Introduction 
The poor HDAC inhibitory activity of the β2, β3 and β2,3-epimers of azumamide E underline the importance of 
the stereochemistry of the β-amino acid. However, no efforts have been made to evaluate the importance 
of the substituent in the 2-position of the β-amino acid in the azumamide scaffold. In the α3β-tetrapeptides, 
shown in Figure 1-17, there is no substituent in the 2-position of the β-amino acid. With this in mind, it would 
be interesting to investigate β2-desmethyl azumamide analogs, where the β2-methyl group has been removed 
(3.01–3.03, Scheme 3-1, left). Furthermore, it would be interesting to insert an extra methyl group in the β2-
position and obtain β2-dimethylated analogs. The introduction of β2-dimethyl β-amino acid residues in linear 
peptides induces conformational changes, but whether this effect can be transferred to cyclic peptides is not 
clear.200 To explore these modification, a series of dimethylated analogs were prepared (3.04–3.06, Scheme 
3-1, right).    
As previously mentioned, the nature of the aromatic amino acid is important for activity. Tryptophan is found 
in apicidin, but not in the azumamides. Therefore, tryptophan analogs were prepared in order to investigate 
this substitution. 
 
Scheme 3-1. Left:  Target compounds for β2-desmetylated azumamide analogs. Right:  Target compounds for β2-
dimetylated azumamide analogs.           
Having developed the diastereoselective Mannich reaction for the synthesis of the natural products, we 
envisioned that this methodology could also be used to set the stereocenters in the β-amino acids needed 
for the β2-edited analogs. Here, only one stereocenter is generated and the challenge with E and Z-enolates 
is avoided.   
3.2 Retrosynthesis 
The same retrosynthetic strategy, which was used for the synthesis of the natural products, was applied for 
the synthesis of the β2-modified analogs. This strategy reduces the synthetic challenge to the synthesis of β-
amino acids 3.07 and 3.08 (Scheme 3-2).  
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Scheme 3-2. Key building blocks for synthesis of β2-edited azumamide analogs.                                                                                                    
3.3  Synthesis of β2-dimethyl building block 
Having observed unexpected results with the propionate esters (as described in chapter 2), a screening study 
was performed with the isobutyrate esters. Different sulfinyl imines were screened against various 
isobutyrate esters, to identify the combination producing the correct stereochemistry, the best selectivity, 
and the highest yield. Different protection groups were introduced on the alcohol functionality in order to 
explore the importance of sterics at this position. The results are summarized in Table 3-1. 
Table 3-1. Screening results from the Mannich reaction shown below. 
 
entry auxiliary* R1 R2 additive d.r.b major isomer (yield, %) 
1 R PMB Si(iPr)3 TiCl(O-iPr)3 65:35 ND (47) 
2 R Et Si(iPr)3 TiCl(O-iPr)3 64:36 ND (29) 
3 R tBu Si(iPr)3  TiCl(O-iPr)3 ND 3S (36a) 
4 S tBu Si(iPr)3 TiCl(O-iPr)3 84:16 3Rc (58) 
5 R Et Bn  TiCl(O-iPr)3 53:47 ND (78b) 
6 R tBu PMB  TiCl(O-iPr)3 83:17 3Sd (70b) 
7 R Et PMB  TiCl(O-iPr)3 66:33 ND (77b)  
aFull conversion of the imine was not observed. bSeperation not possible. The reported yield 
is for both diastereomers. cDetermined by X-ray crystallography on its desilylated 
homologue. dDetermined by comparison of spectroscopic data from its desilylated derivate 
and the desilylated homologue from entry 4.     
The best selectivities were observed with tert-butyl isobutyrate in combination with either the 
triisopropylsilyl- or the PMB-protected imine (entry 4 and 6, respectively). The (S)-sulfinyl imine was again 
required to obtain the desired stereochemistry, which indicates the involvement of a nonchelated open 
transition state, as described in section 2.3.2. The results in Table 3-1 is in accordance with the results 
obtained for the propionate esters in section 2.3.2, but in disagreement with Ellman`s findings.166  
Difficulties with separation of the diastereomers from entry 6, made the triisopropylsilyl-protected β-amino 
ester (entry 4, 3.12) more attractive for further elaboration. Alcohol deprotection with TBAF afforded a 
crystalline compound (3.13) and X-ray analysis showed the desired (R)-configuration in the 3-position 
(Scheme 3-3). The alcohol (3.13) was elaborated to the desired β-amino acid building block (3.16) by the 
same chemical modifications used previously (Scheme 2-9).  
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Scheme 3-3. Reagents and conditions: (a) AcOH (1.0 equiv), Bu4NF (2.0 equiv), THF, 0 ºC → rt, 30 min, then Bu4NF (0.2 
equiv), 15 min; (b) NaHCO3 (1.5 equiv), Dess-Martin periodinane (1.5 equiv), dry CH2Cl2, 0 ºC, 20 min; then 40 min, 0 ºC 
→ rt. (c) KHMDS (1.9 equiv), Ph3PBr(CH2)3COOEt, (2.0 equiv), dry THF, –78 ºC, 30 min; then aldehyde 3.14 in dry THF, 
16 h,  –78 ºC → rt. (d) TFA–CH2Cl2 (1:1, 10 mL), 0 ºC → rt, 2 h. (e) HCl (4.0 M in dioxane, 1.5 equiv), dioxane, 2 h, then 
HCl (4.0 M in dioxane, 0.4 equiv), 30 min. (f) iPr2NEt (2.1 equiv), Boc2O (2.0 equiv), dry CH2Cl2, 20 h.  
3.4 Synthesis of β2-desmethyl building block 
3.4.1 Ester screening 
In pursuit of the desmethylated β-amino acid building block, required for preparation of desmethylated 
azumamide analogs, we conducted our own Mannich reaction screening experiments. Different acetate 
esters were screened together with the (R)-sulfinyl imine (2.14). The results are presented below. 
Table 3-2. Addition of acetate enolates to chiral the sulfinyl imine 2.14. 
OR
O
+
LDA, THF, −78 °C
N
additive
iPr3SiO
*
NHS
O
iPr3SiO
OR
O
2.14 3.17 3.18
S(R)
O
 
entry R1 additive d.r.b major isomer, yield (%) 
1 Et TiCl(OiPr)3 >99:1 3Ra (94)c 
2 tBu TiCl(OiPr)3 74:26 3Rb (68)d 
3 tBu HMPA 28:72 3Sb (19), (42d) 
4 PMB TiCl(OiPr)3 82:18 ND 
aDetermined by X-ray crystallography from the desilylated and re-
esterified tert-butyl ester. bDetermined spectroscopically by 
comparison with the crystallized alcohol from entry 1. cCrude yield. 
dDiastereomers could not be separated. The total yield is reported.        
In entry 1, only one diastereoisomer was observed and re-esterification to the tert-butyl ester, followed by 
removal of the triisopropylsilylether provided the alcohol 3.27 as a crystalline solid (Scheme 3-4). The X-ray 
structure shows the desired 3R-stereochemistry. This observation is in contrast to our previous results, where 
propionate and isobutyrate enolates required the (S)-sulfinyl imine to produce the correct stereochemistry 
in the 3-position and indicates that ethyl acetate can participate in the six-membered Zimmerman–Traxler 
transition state. Increasing the bulk of the acetate enolate (entry 2) reduced the selectivity, but still provided 
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the desired stereochemistry. This indicates that the six-membered transition becomes too sterically crowded 
(3.19, Figure 3-1) when the bulk of the ester is increased. Therefore, approximately one fourth of the reaction 
takes place through an open transition state. Attempts to remove the alcohol protection group in the crude 
PMB-protected β-amino ester, obtained in entry 4, resulted in decomposition and lactone formation and the 
PMB protecting group was not explored further. 
 
Figure 3-1. Left: The steric clash between the tert-butyl group of the ester enolate and the bulky silyl group or the 
isopropoxide ligands on the metal. Right: The same transition state performed with the less bulky ethyl ester. 
To validate the hypothesis of the open vs cyclic transition state, a control experiment was performed. Here, 
HMPA was added instead of TiCl(O-iPr)3 (Table 3-2, entry 3). In Figure 3-2 is shown an overlay of the 1H NMR 
of the major products from Table 3-2, entry 2 and 3 as well as the tert-butyl ester obtained from re-
esterfication of the ethyl ester from entry 1.  
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Overlay of 1H NMR spectra of the tert-butyl esters obtained from Table 3-2 entry 1 (EtOAc, TiCl(O-iPr)3, 
black), entry 2 (tert-butyl acetate, TiCl(O-iPr)3, blue), and entry 3 (tert-butyl acetate, HMPA, red). 
NH 3-(R)-
NH 3-(S)-isomer  
NH 3-(R)-isomer  
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3.4.2 Shimizu´s results       
Shimizu and coworkers reported similar results, when investigating the addition of tert-butyl acetate enolates 
to chiral p-tolylsulfinyl imines.184 Different metal enolates were prepared and added to chiral sulfinyl imine 
3.21 and the effects of solvents and different additives were explored (Table 3-3).  
Table 3-3. Addition of tert-butyl acetate enolates to the chiral sulfinylimine 3.21.a (Adapted from Shimizu and co-
workers)184 
 
entry metal additive (equiv) solvent 3R:3S yield (%)b 
1 Li - THF 14:86 65 
2 Li HMPA (3.0) THF 2:98 68 
3 Li HMPA (4.5) THF 4:96 71 
4 Li - Et2O 82:18 75 
5 Ti TiCl(O-iPr)3 THF 96:4 89 
6 Al AlEt2 THF 84:16 39 
7 Al AlEtCl THF 77:23 79 
8 K 18-Crown-6 (3.0) THF 6:94 51 
a Reactions were performed with 3.0 equiv. of enolate in respect to the imine at 
–78 ºC.b Isolated yield of major diastereomer. 
Table 3-3 shows a switchover in diastereoselectivity when moving from the lithium enolate in the presence 
of HMPA, to the titanium enolate in the absence of HMPA (entry 3 and 5, respectively). This observation is 
consistent with a change in transition state. The six-membered transition state, initially proposed by Davis 
and co-workers,168 can explain the stereochemical outcome of the reaction in the presence of titanium and 
the open state transition state can explain the major diastereoisomer from entries 2 and 3.   
3.4.3 Building block synthesis 
The ethyl ester from Table 3-2, entry 1 was hydrolyzed and the tert-butyl ester was prepared with tert-
butanol in the presence of Boc2O and DMAP (Scheme 3-4). Re-esterification was carried out in part because 
of the need for an orthogonal protection group, but also because the tert-butyl β-amino alcohols had proven 
to be crystalline. Upon desilylation, the alcohol (3.27) crystallized and the structure was elucidated by X-ray 
crystallography (Scheme 3-4). The alcohol was elaborated to the Fmoc- and Boc-protected β-amino acids 
using the standard chemical transformations.  
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Scheme 3-4.  Reagents and conditions: : (a) LDA (2.1 equiv), EtOAc (2.0 equiv), THF, –78 ºC, 30 min, then (Ti(O-iPr)3Cl 
(4.2 equiv), 30 min, then imine 2.14; (b) LiOH (1.5 equiv), 1h, rt, then LiOH (3.0 equiv), 16 h; (c) Boc2O (1.4 equiv), 
DMAP (0.3 equiv), tert-BuOH, 16h, then Boc2O (0.3 equiv), 1.5h; (d) AcOH (1.0 equiv), Bu4NF (2.0 equiv), THF, 0 ºC → 
rt, 15 min, then 1h, rt; (e) NaHCO3 (1.5 equiv), Dess-Martin periodinane (1.5 equiv), dry CH2Cl2, 0 ºC, 40 min; (f) KHMDS 
(1.9 equiv), Ph3PBr(CH2)3COOEt, (2.0 equiv), dry THF, –78 ºC, 30 min; then aldehyde 3.28 in THF, 30 min,  –78 ºC;  (g) 
TFA–CH2Cl2 (1:1, 10 mL), 0 ºC → rt, 2 h, then rt, 1h; (h) HCl (4.0 M in dioxane, 1.8 equiv), dioxane, 1 h, rt; (i) iPr2NEt (3.0 
equiv), Boc2O (2.0 equiv), dry CH2Cl2, 6 h, then Boc2O (1.0 equiv), 16 h or Na2CO3 (4.0 equiv), FmocOSu (1.2 equiv), 0 
ºC, 45 min.  
3.4.4 Comments on transition states 
In the Mannich reaction between chiral sulfinyl imines and acetate, propionate and isobutyrate ester 
enolates, we have observed a connection between the overall bulk of the reactants and the preferred 
transition state. The only enolates which seem to react through the predicted six-membered transition state, 
with the imines investigated in this work, are acetate enolates. When increasing the bulk of the enolate, by 
addition of a methyl group in the α-position, the cyclic transition state seemingly becomes disrupted. This 
resulted in Mannich products where the observed stereochemistry can be explained by an open transition 
state (Figure 2-6). The same is the case for the even bulkier isobutyrate enolates. In Figure 3-3 the cyclic 
Zimmerman–Traxler transition state is drawn.  
O
N M
O
Me
H
S OtBu
O
Me
Me
Me
MeMeR
 
Figure 3-3. The cyclic Zimmerman–Traxler transition state. 
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The titanium ion coordinates to the alkoxy oxygen, the imine nitrogen, and the oxygen from the sulfinyl 
group. This leaves one isopropoxide ligand still present on the metal. The tetrahedral shape of titanium(IV)-
complexes will place the rather bulky isopropoxy group on the same face of the six-membered ring as the 
imine side chain.201 In the case of the bulky tert-butyl esters, the isopropoxy group will at the same time be 
positioned close to the tert-butyl group of the incoming enolate. This scenario creates a sterically crowded 
environment at the top face of the six-membered ring. Rotation around the =C–OtBu bond in the enolate (as 
shown in Figure 3-3), will minimize the steric clash between the tert-butyl group and the isopropoxy group 
(Figure 3-4, right). 
  
Figure 3-4. Zimmerman-Traxler TS with tert-butyl propionate, viewed from two different positions. Red: oxygen, blue: 
nitrogen, Purple: titanium, yellow: sulfur. The terminal part of the imine side chain has been omitted for clarity.     
At the same time this rotation allows the isopropoxy group to move further away from the imine side chain. 
In the (E)-tert-butyl propionate enolate, the degree of rotation is limited by the presence of the cis-methyl 
group. If the tert-butyl group is rotated, to be located as far away from the isopropoxy group as possible, the 
tert-butyl group will clash with the methyl group (Figure 3-4, left). The methyl group probably forces the 
bulky tert-butyl group to flip towards the isopropoxy group and this steric interaction disrupts the six-
membered transition state.  
  
Figure 3-5. Zimmerman-Traxler TS with tert-butyl acetate, viewed from two different positions. Red: oxygen, blue: 
nitrogen, Purple: titanium, yellow: sulfur. The terminal part of the imine side chain has been omitted for clarity.         
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The same scenario is the case for tert-butyl isobutyrate enolate. However, in tert-butyl acetate, the methyl 
group is substituted to a less bulky hydrogen atom. This decrease in bulk at the α-position of the incoming 
enolate, allows the molecule to adapt a conformation where the tert-butyl group can accommodate an 
orientation, which is favorable in respect of reducing the steric clash with the isopropoxy group (Figure 3-5, 
right). This difference in the positioning of the tert-butyl group of the enolates, could explain why the tert-
butyl acetate enolate is able to react through the Zimmerman–Traxler transition state, whereas the tert-
butyl-(E)-propionate and isobutyrate enolates are not. Yet, this explanation does not account for the low 
selectivities observed with the less bulky methyl, ethyl, allyl, and PMB-esters. These enolates should be able 
to adopt a conformation where the six-membered transition state is favored. The observation that the less 
bulky propionate and isobutyrate enolates produce lower selectivities is in accordance with the open 
transition state. If the bulk of the ester is reduced, the steric interaction between the tert-butyl group on the 
sulfinylimine and the alkoxy group of the enolate will become reduced. It is this steric interaction which 
discriminates TS A from TS B (Figure 2-6) and therefore a lower selectivity would be expected. 
The only experimental difference between Ellman`s experiments and the experiments performed in this 
work, is the preparation of LDA. Ellman prepares the LDA in situ from diisopropylamine with butyllithium. We 
use a commercially available LDA solution in THF/heptane/ethylbenzene. To the best of our knowledge there 
is no literature describing any effects of different LDA preparation methods.  
3.5 Synthesis of β2-desmethyl azumamide analogs 
The building blocks 3.30 and 3.31 were elaborated to the linear tetrapeptides by coupling to three different 
tripeptides on resin (Scheme 3-5). For the tryptophan-containing peptide the cleavage was performed under 
mild conditions (trifluoroethanol–AcOH–CH2Cl2, 6:2:2 (v/v/v)) to keep the Boc-group on the indole-nitrogen.     
 
Scheme 3-5. Reagents and conditions: (a) TFA–CH2Cl2 (1:1), 2 × 30 min; (b) HATU (2.2 equiv), iPr2NEt (10 equiv), DMF, 
16 h; (c) LiOH (36 equiv), THF–H2O (1:1), 16 h; (d) Piperidine–DMF (1:4), 2 × 30 min, then piperidine–DBU–DMF 
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(2:2:96), 30 min. (e) TFA–CH2Cl2 (1:1), 2 × 45 min or trifluoroethanol–AcOH–CH2Cl2 (2:2:6), 2 × 2 h; (f) HATU (1.5 
equiv), iPr2NEt (8–10 equiv), 16h; (g) LiOH (50 equiv), THF–H2O (1:1), 17 (h) TFA–CH2Cl2 (1:1), 1h. *Yields are based on 
resin loadings.  
The linear peptides were cyclized with HATU and subsequent cleavage of the ethyl esters with LiOH afforded 
β2-desmethyl azumamides E (3.01) and C (3.02). The isolated yields are slightly higher compared to the 
synthesis of azumamide E, which was cyclized at the same position and under the same conditions. The 
removal of the methyl group at the β2-position decreases the sterical hindrance in the cyclization reaction 
and this can explain the increase in yield. In the case of the tryptophan-analog, the Boc-group was removed 
with TFA to give the final product (3.03). 
Parallel to the synthesis of the compounds in Scheme 3-5, a series of related desmethyl analogs (3.04–3.06) 
were prepared by a fellow PhD-student, Alex Maolanon (Scheme 3-6). These compounds were included in 
the study to obtain better and more elaborated structure-activity relationships (SAR).   
 
Scheme 3-6. Azumamide analogs with a modified β-amino acid side chain. Sites with modifications are marked with 
blue.   
These compounds were designed to explore the importance of the cis-double bond in the β-amino acid side 
chain.  The first series was inspired by romidepsin (1.06, Figure 1-4), and the double bond was moved one 
position closer to the macrolactam ring and changed to a trans-double bond (3.37–3.39). The compounds in 
the second series have a saturated β3-amino acid side chain linker (3.40–3.42). Saturated side chain linkers 
are found in other macrocyclic peptide HDAC inhibitors such as apicidin, HC-toxin, chlamydocin and 
microsporins (Figure 1-14 and Figure 1-15). To simplify the β-amino acid building block synthesis, a route was 
developed where the chirality was obtained from the chiral pool and the β2-methyl group was removed. 
Starting from N-Boc- and tert-butyl protected aspartic acid (3.43), an efficient, robust, and scalable synthetic 
route was developed (Scheme 3-7).    
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Scheme 3-7. (a) N-methylmorpholine (1.0 equiv), isobutyl chloroformate (1.0 equiv), NaBH4 (3.0 equiv), MeOH, THF; 
(b) (COCl)2 (1.7 equiv), DMSO (3.3 equiv), Et3N (5.0 equiv.), CH2Cl2; (c) PPh3CH3Br (2.2 equiv), KHMDS (0.5 M in 
toluene) (2.1 equiv), THF; (d) methyl 5-hexenoate (3 equiv), Hoveyda Grubbs 2nd gen. catalyst (0.1 equiv), CH2Cl2; (e) 
TFA–CH2Cl2 (1:3); (f) Boc2O (1.3 equiv.), iPr2NEt (2.6 equiv.), CH2Cl2; (g) H2, 1 wt.% Pd/C, THF. 
Building blocks 3.46 and 3.47 were elaborated to the cyclic peptides by preparation of the linear 
tetrapeptides on resin, followed by cleavage and cyclization in solution. Compounds 2.37–3.41 were cyclized 
with the β-amino acid as the N-terminal residue. The isolated yields were between 3–10%. Compound 3.42 
was cyclized with the β-amino acid as the C-terminal residue and was isolated in 58% yield over 12 steps. This 
result emphasizes the importance of the cyclization site. Unfortunately, the compounds shown in Scheme 
3-5 were prepared prior to this result and the overall yield might have been improved if the cyclization had 
been performed with the β-amino acid as the C-terminal residue.          
3.6  Synthesis of β2-dimethyl azumamide analogs. 
The synthesis of the β2-dimethylated analogs was obtained by coupling the Boc-protected β-amino acid (3.16) 
to the tripeptides on resin. After cleavage with TFA the linear peptides were cyclized under dilute conditions 
with HATU. Subsequent hydrolysis of the ethyl ester with LiOH provided the target compounds after 
preparative HPLC (Scheme 3-8).   
 
Scheme 3-8. Reagents and conditions: (a) TFA–CH2Cl2 (1:1), 2 × 30–60 min; (b) HATU (1.5–2.0 equiv), iPr2NEt (5–10 
equiv), DMF, 16–17 h; (c) LiOH (35–50 equiv), THF–H2O (1:1) 16–18 h. Yields are based on resin loadings. 
The isolated yields for the Phe and Tyr containing cyclic peptides were lower than for the desmethylated 
analogs. The geminal α-methyl groups create a bulk in the β-amino acid, close to the C-terminal of the peptide 
and this could explain the low yields in the cyclization reactions. The conformation of the linear peptide may 
also be affected by the two methyl groups. In the synthesis of the Trp-containing analog the compound was 
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purified by VLC after cyclization. Here, the dimer was isolated in 24% yield and the cyclized product in 34% 
yield. The formation of dimer indicates that the linear peptide adapts a conformation where the N-and C-
terminal have problems reaching each other. This conformation could be induced by the geminal methyl 
groups.  
3.7  Biochemical profiling of des-and dimethylated analogs        
The des- and dimethylated analogs were profiled against relevant HDAC isoforms. The nine desmethylated 
analogs (divided into three series) were characterized with dose–response experiments against class I, class 
IIb, and class IV HDAC isoforms. Single dose–response experiments data on HDAC4 and HDAC7 agreed with 
the trend observed for the natural products, as no activity could be observed towards these class IIa enzymes 
with concentrations up to 100 μM. On this background no further testing was performed on class IIa enzymes. 
Table 3-4 shows the Ki values obtained from the biochemical profiling of the nine desmethylated analogs.   
Table 3-4. Biochemical profiling of desmethylated analogs. The potencies are given as Ki values (nM)a. 
 class I class IIb class IV 
Compound HDAC1 HDAC2 HDAC3 HDAC8 HDAC6 HDAC10 HDAC11 
3.37: Phe, trans 700±180 900±20 800±160 4,300±1,800  >20,000   >20,000  1,800±300 
3.38: Tyr, trans 400±130 300±140 300±130  >20,000  1,300±480 150±2 700±210 
3.39: Trp, trans 300±40 200±150 300±220 1,700±1,030 2,200±180 130±2 600±300 
3.40: Phe, sat. 500±200 400±60 400±120 6,400±2900  >20,000  260±80 1200±640 
3.41: Tyr, sat. 400±340 200±100 100±80  >20,000  2000±1,120 80±40 500±410 
3.42: Trp, sat. 600±70 800±190 1,200±460 6,100±390  >20,000  190±30 1,600±900 
3.01: Phe, cis 300±130 500±70 500±80 6,700±870  >20,000  140±20 900±130 
3.02: Tyr, cis 200±120 100±40 200±140  >20,000  3,500±360 80±3 400±200 
3.03: Trp, cis 100±65 100±7 300±80 3000±350  >20,000  70±20 500±360 
aIC50 values were determined from at least two individual dose–response experiments performed in duplicate, and the 
Ki values were calculated using the Cheng-Prusoff equation.   
 
3.7.1 Analogs vs natural products – Importance of the β2-methyl group  
To investigate the direct effect of the β2-methyl group, compounds 3.01 and 3.02 can be compared to 
azumamides E and C, respectively. The desmethylated analogs show decreased activity towards HDAC1–3 
compared to the natural products. The level of reduction varies from 3–18-fold across the different isoforms. 
The greatest difference is observed on HDAC3, where desmethyl azumamide E (3.01) shows an 18–fold 
reduction in activity, whereas desmethyl azumamide C (3.02) only exhibits a 3-fold reduction in activity on 
HDAC2. A 7–8-fold decrease in activity was observed on HDAC10 and for HDAC11 a 13–14-fold reduction in 
activity was observed. Interestingly, all nine desmethylated analogs are more active than azumamide A, B, 
and D against the entire panel of enzymes. Azumamide A, B, and D contain a carboxyamide as their zinc-
binding group, whereas the desmethylated analogs have a carboxylic acid. The carboxyamide is a weaker 
zinc-chelator than the carboxylic acid and this can explain superior activity of desmethylated compounds.     
The methyl group is less important with regards to HDAC6 and HDAC8. A 1.5-fold reduction in activity is 
observed for desmethyl azumamide E (3.01) on HDAC8 and a 1.8-fold reduction is observed for desmethyl 
azumamide C (3.02) on HDAC 6. Instead, the inhibition of these two HDAC isoforms is dependent on the 
nature of the aromatic amino acids found in these analogs (see section 3.7.2).  
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The decrease in activity, observed on HDAC1–3, HDAC10, and HDAC 11, is interesting. Several structural or 
steric features could be responsible for the loss of activity. One possibility could be that the methyl group 
has an important hydrophobic interaction with the protein. However, as mentioned in section 2.6.1, the 
docking model in HDLP does not imply such an interaction. Instead the reduction in activity could be 
explained by alterations in the conformation of the cyclic peptide backbone. As previously mentioned, 
changes in the conformation of the cyclic peptide can affect the C3–C4 vector in the β-amino acid, as well as 
disrupt the interactions of the macrolactam with the surface of the protein.  
Removal of the methyl group can also influence the flexibility of the β3-side chain. The zinc-binding side chain 
can rotate more freely around the C4–C5 bond, when there is no methyl group in the α-position. The increase 
in rotational freedom decreases the possibility to find the side chain in the optimal orientation. In other 
words, the β2-methyl group might assist in directing the zinc-binding side chain in a favorable direction.     
To get insight into the possible structural changes induced by removal of the β2-methyl group an NMR-study 
was performed. The study was done by our colleagues in the NMR group (Charlotte H. Gotfredsen and Casper 
Hoeck). The solution state NMR structures of 3.02 and azumamide A in DMSO were elucidated using NOESY 
experiments and molecular modelling. The NMR structure of azumamide A was found to be similar to the 
reported structure of azumamide E.136 An overlay of azumamide A and 3.02 is shown in Figure 3-6.  
 
 
Figure 3-6. Top: Overlay of NMR solution structures of compound 3.02 (carbon: green, hydrogen: white, oxygen: red, 
nitrogen: blue) and azumamide A (carbon: grey, hydrogen: white, oxygen: red, nitrogen: blue). The β3-side chain 
beyond C6 have been omitted for clarity. The superimposition was made on all the atoms in the cyclic peptide 
backbone. Bottom: Highlighting the clash between the β2- methyl ground and the C5-proton of the desmethylated 
analog.  
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The two NMR structures overlay well and there is no significant changes in the conformation of the cyclic 
peptide backbones. The C3–C4 vector in the desmethylated β-amino acid (3.02) is slightly different from the 
vector observed in azumamide A. The β3-side chain in azumamide A is projected closer to the plane of the 
peptide backbone compared to desmethylated analog. Whether this small difference is enough to explain 
the reduction in activity is difficult to investigate. In spite of the C3–C4 vectors being similar, the rest of the 
β3-side chain occupy different positions (Figure 3-6, Top). The side chain of azumamide A is occupying the 
space in the plane of the peptide backbone, whereas the side chain in 3.02 is found above the ring. This 
difference could be explained by the presence of the methyl group in the 2-position. If the side chain of 
azumamide A was to adopt the same position as the desmethylated analog, the C5-alkene proton would clash 
with the β2-methyl group (Figure 3-6, bottom). This steric interaction directs the side chain away from the 
methyl group and down into the plane of the macrocycle. When the methyl group is removed, the β3-side 
chain will be more free to move around and based on the NMR structure the side chain will be found above 
the plane of the ring. The biological data suggest that the side chain position, found in the natural products 
is more favorable than the side chain position found in the desmethylated analogs. Docking of azumamide E 
in HDLP (Figure 1-22) indicates that the entrance to the 11 Å channel is found in the plane or slightly below 
the plane of the cyclic peptide backbone. The zinc-binding side chain in the natural products has a preference 
for being directed down towards the 11 Å channel by the neighboring methyl group. This “directing feature” 
is not found in the desmethylated analogs and the side chain will not be pointing towards the 11 Å channel.  
The difference in the positioning of the zinc-binding side chains in the natural products and the 
desmethylated analogs could potentially explain the different activities. However, it should be mentioned 
that due to increased rotational freedom the uncertainty associated with the NMR structures increase, when 
you move away from the conformational restricted macrolactam rings. Thus, the positioning of the β3-side 
chain may not be as well defined as shown in Figure 3-6.                     
3.7.2 Importance of the aromatic amino acid residue  
The aromatic amino acid in cyclic tetrapeptide HDAC inhibitors has been shown to participate in hydrophobic 
interactions with the surface of the proteins.136 In our study, the tyrosine and tryptophan-containing 
compounds were 2–5-fold more active against HDAC1–3, HDAC10, and HDAC 11 compared to the 
corresponding phenylalanine compounds. In contrast to Tyr and Trp, the side chain of Phe is unable to form 
hydrogen bonds. It is possible that the ability of Tyr and Trp to establish favorable hydrogen bonds on the 
surface of the protein can induce binding of these compounds. An exception to this trend is compound 3.42, 
which displayed lower activity than the phenyalanine homolog.       
Interestingly, compounds 3.37, 3.39, and 3.03 were more active against HDAC8 than the natural products. In 
the cis and trans series, incorporation of Trp promotes binding to HDAC8 compared to Phe. In contrast, 
tyrosine has a negative impact on the activity against HDAC8 in all three series. This tendency was also 
observed for the natural products, were azumamide C was more potent than azumamide E against all 
isoforms, except HDAC8.194 In HDAC6, the Phe-containing compounds were inactive up to 20 μM and only 
3.39 showed activity amongst the Trp-containing analogs. However, the three compounds containing 
tyrosine were active.             
3.7.3 Importance of the cis-double bond 
The effect of the β3-side chain modifications cannot be related directly to the azumamides, as the removal of 
the β2-methyl group clearly plays a significant role. It is not known whether the modifications are additive or 
subtractive. In general, a 1.5–3-fold reduction in activity towards HDAC1–3, 10, and 11 was observed for the 
compounds where the double bond is shifted one position closer to the macrolactam ring, and transformed 
from a cis to a trans double bond. This subtle decrease in activity could be a consequence of the side chain 
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being directed in a less favored orientation by the shifted trans double bond compared to the cis double 
bond. However, the activities on HDAC3 were comparable to the cis series and on HDAC6 and 8 the trans 
compounds were more active. Substituting to a saturated side chain did not display any clear trend for the 
activity of the Phe and Tyr analogs. A 2-fold reduction in activity was observed on HDAC1 and 2, whereas the 
saturated compounds were more active on HDAC3.  For the tryptophan analog, a 2–8-fold reduction was 
observed against all isoforms. A saturated side chain would be expected to be more flexible than the 
unsaturated cis and trans versions. The flexibility can be an advantage if the C3–C4 vector, in the β-amino acid, 
is slightly off. The increased flexibility will then enable the side chain to adapt an orientation, where it still 
fits into the 11 Å channel. On the other hand, there will be more degrees of freedom in a saturated side chain 
and the possibility to find the side chain in the optimal conformation is lower compared to a more rigid 
unsaturated side chain.                
3.7.4 Dimethylated analogs       
Preliminary results indicated low activity of the three dimethylated analogs against class I, class IIb, and class 
IV. With this in mind, these analogs were only tested at two concentrations against HDAC1–3, HDAC6, HDAC8, 
HDAC10, and HDAC11 (Table 3-5) 
Table 3-5. HDAC profiling of dimethylated analogs. Values represent %-inhibition. 
 3.51: Phe, cis 3.52: Tyr, cis 3.53: Trp, cis 
 20 μM 10 μM 20 μM 10 μM 20 μM 10 μM 
HDAC1 16±9 10±8 15±16 11±6 65±16 54±8 
HDAC2 8±4 4±2 11±3 8±2 68±9 53±25 
HDAC3 8±8 5±1 8±1 7±1 62±7 47±21 
HDAC6 IA IA IA IA 40±33 17±23 
HDAC8 IA IA IA IA 14±6 6±1 
HDAC10 IA IA IA IA 7±7 IA 
HDAC11 IA IA IA IA 26±9 22±20 
The %-values were determined from at least two individual experiments performed in 
duplicate. IA= inactive at 20 μM.   
Low activity was observed for the Phe and Tyr-containing analogs (3.51 and 3.52, respectively) against 
HDAC1–3 and no inhibition at 20 μM was observed on HDAC6, HDAC8, HDAC10, and HDAC11. However, the 
tryptophan-containing compound displayed activity against HDAC1–3, with ∼50% inhibition at 10 μM. 
HDAC6, HDAC8, HDAC10, and HDAC11 were inhibited by 3.53, albeit none of these isoforms were inhibited 
more than 50% at 20 μM. The positive effect of tryptophan indicates that this aromatic amino acid is superior 
to Phe and Tyr in establishing favorable interactions with the surface of the HDAC enzymes. Overall, the 
dimethylated analogs displayed low activity compared to the natural products. These results confirm that 
the β2-position is extremely sensitive to modifications. The NMR solution structures of the dimethylated 
analogs have not been elucidated, which makes predictions about the positioning of the zinc binding side 
chain difficult. However, if it is assumed that the overall conformation of the dimethylated cyclic peptides is 
similar to the conformation observed for the natural products, the reduction in activity could be an effect of 
the extra methyl group. The extra methyl group will be located below the ring and occupy the same space as 
the methyl group in the β2-epimerized compound (2.59). As discussed in section 2.6.1 the β2-methyl group 
found in 2.59 might class with the surface of the protein. It is possible that the extra methyl group in the 
dimethylated compounds will have a similar clash with the protein and this can explain the loss of activity.            
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Analogous to the desmethylated analogs, the reduction in activity can be explained by a change in the 
conformation of the cyclic peptides. There is also a possibility of a steric clash between the second methyl 
group and the protein (see section 2.6.1).   
3.8  Development of an azumamide C analog lacking a zinc-binding group 
In 2012, Ghadiri and co-workers reported the synthesis of α3β-tetrapeptide HDAC inhibitors lacking a Zn2+-
binding functional group (Figure 3-7).51 Compound 3.54 and 3.55, bearing a propyl side chain, showed IC50 
values around 1 µM for HDAC1–3.  
 
Figure 3-7. Left: Structures of the tetrapeptide HDAC inhibitors, lacking a zinc-binding group, reported by Ghadiri and 
co-workers.51 Right: β2-propyl azumamide C and the β-amino acid required for the synthesis. The modification is 
shown in blue.  
Inspired by these results, we designed a β2-propyl analog of azumamide C (3.56). To test the scope and utility 
of the developed Mannich reaction, the required β-amino acid (3.57) was prepared from the butanal derived  
(S)-imine (3.59) and the Z-enolate of tert-butyl propionate (Scheme 3-9). The β-amino acid (3.57) is also 
interesting from a broader perspective as this scaffold is found in various natural products.202,203   
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Scheme 3-9. Reagents and conditions: (a) CuSO4 (5.0 equiv), dry CH2Cl2, 20 h; (b) tert-butyl propionate (2.5 equiv), LDA 
(2.6 equiv), HMPA (5.7 equiv, 23 vol%), THF, –78 ºC, 30 min; then imine 3.60; (c) TFA–CH2Cl2 (1:1), rt, 5 h; (d) HCl (4.0 
M in dioxane, 3.0 equiv), dioxane, 1.5 h; (e) Na2CO3 (4.0 equiv), Fmoc-OSu (1.2 equiv), DMF–H2O, 0 ºC, 3 h.          
The dr of the key Mannich reaction is slightly higher than the dr observed for imine 2.35 used to prepare the 
natural products. However, separation of the diastereoisomers produced from the above reaction, proved 
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more difficult than for the diastereoisomers in Scheme 2-9. This explains the low isolated yield from the 
Mannich reaction. The N-Fmoc protected β-amino acid (3.57) was prepared by standard three step protocol 
(Scheme 3-9). The stereochemistry of the β-amino ester (3.61) was solved by elaborating the Mannich 
product to the N-(benzyloxy) methyl ester (3.67), which has previously been prepared by MacMillan and co-
workers (Scheme 3-10).204 
 
Scheme 3-10. Reagents and conditions: (a) HCl (4M, dioxane, 30 equiv), MeOH, 22 h; (b) thionyl chloride (3.0 equiv), 
MeOH, 0 ºC, then reflux, 23 h, then thionyl chloride (1.5 equiv), MeOH, 0 ºC→ rt, 22 h; (c) NaHCO3–ethyl acetate (1:1), 
benzylchloroformate, 18 h.   
The Mannich product was fully deprotected with hydrochloric acid in methanol, which produced a mixture 
of the free acid and the methyl ester (3.62). To ensure full conversion to the methyl ester, the mixture was 
added thionyl chloride in the presence of excess methanol. Finally, the amine was protected as the benzyloxy 
carbamate (3.67). The optical rotation and spectral data was in agreement with the previously reported data. 
The linear tetra peptide was obtained by HATU-mediated coupling of the β-amino acid to the tripeptide H2N-
(D)Val-(D)Ala-(D)Tyr on resin (Scheme 3-11). 
 
Scheme 3-11. Reagents and conditions: (a) Piperidine–DMF (1:4, 2 × 30 min, DBU–piperidine–DMF (2:2:96, 20 min); 
(b) TFA–CH2Cl2 (1:1, 2 × 30 min); (c) HATU (1.5 equiv), iPr2NEt (5 equiv), DMF (0.4 mM peptide concentration), 19 h. 
The Fmoc-group was removed with piperidine and the tetrapeptide cleaved from the resin with TFA. The 
crude linear tetrapeptide was cyclized under dilute conditions with HATU and purified by preparative HPLC 
to afford the target compound (3.56).  
Compound 3.56 was screened against HDAC3 and displayed inhibitory activity with an IC50 value of 2.9 µM 
(Figure 3-8).  
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Figure 3-8. Dose–response data on 3.56 (purple), 3.02 (desmethyl azuC, red), azumamide C (pink), and 1.01 (SAHA, 
orange). Experiments were performed in duplicate for 3.56, 3.02, and azumamide C, whereas SAHA data is based on a 
single experiment.  
This result confirms Ghadiri`s work and emphasizes that the cap group of macrocyclic peptides can inhibit 
HDAC enzymes without contribution from a zinc-binding group.51 Interestingly, the propyl analog is more 
potent than azumamide A, B, and D on HDAC3, which could question the zinc-binding properties of the amide 
functionality in the side chain of the natural products. The straightforward synthesis of β-amino acid 3.57 is 
an excellent example on the broad perspective of the developed Mannich reaction. Compound 3.56 is 
interesting from a medicinal chemistry perspective. Azumamide C and E carry a carboxylic acid functionality, 
which will be deprotonated at physiological pH. The resulting negative charge could impair the membrane 
penetrating abilities of the natural products. In contrast, the neutral propyl analog may penetrate the 
membrane more efficiently and therefore be more active in vivo. Compound 3.56 will be tested in cell assays 
within the nearest future.   
3.9  Future azumamide analogs and perspectives 
With the conditions developed in this work it is possible to access all four diastereomers of a β2,3-amino acid 
scaffold. The chirality of the sulfur auxillary directs the chirality in the 3-position and the configuration of the 
enolate dictates the stereochemistry in the 2-position (Scheme 3-12).  
 
Scheme 3-12. Diversity of the developed Mannich reaction protocol.  
In the case of the azumamides, this methodology will allow the design and synthesis of a broad variety of 
analogs, were the stereochemistry and structure of the β-amino acid side chains can be modulated. The 
Synthesis of β2-modified azumamide analogs 
76 
 
Introduction of a desired side chain in the β2-position can be achieved by utilization of different tert-butyl 
esters (3.75) in the diastereoselctive Mannich reaction (Scheme 3-13, top). It could be interesting to explore 
the steric requirements in this position and the insertion of an ethyl or isopropyl substituent could easily be 
achieved by performing the reaction with tert-butyl butyrate and tert-butyl 3-methyl butanoate, respectively.       
 
Scheme 3-13. Possible azumamide analogs. Top: Modifications in the β2-position. Bottom:  Modifications of the zinc-
binding moiety.   
A large variety of Wittig reagents are commercially available. These reagents could be utilized to incorporate 
different functionalities in the terminal part of the zinc-binding side chain of the β-amino acid by reaction 
with aldehyde 2.49. This could provide a convenient strategy for screening different zinc-binding moieties.    
The developed Mannich methodology could also be useful in structure elucidation of natural products where 
a β2,3-amino acid scaffold, with unknown stereochemistry, is present. Furthermore, the β2,3-amino acid 
scaffold is found in various known biologically active natural products and this strategy could provide a fast 
and efficient synthesis of epimeric analogs, as well as analogs with different substituents in the β-amino acid 
moeity.205, 206,207, 208 The cyclic pentapeptides, motupurin (3.79) and nodularin (3.80), are potent protein 
phosphatase type 1 inhibitors and motuporin has shown a promising cytotoxic profile (Scheme 3-14, left).209 
Both structures contain β2,3-amino acid scaffolds and our Mannich protocol could deliver the full selection of 
epimers. The ulongamides (3.81–3.83) are cyclic depsipeptides with the same β2,3-amino acid scaffold 
prepared in section 3.8.210 The stereochemistry of the β2,3-amino acid scaffold found in the ulongamides could 
be prepared from imine 3.60 (Scheme 3-9) and the E-enolate from tert-butyl propionate. Again, the epimers 
of the ulongamides are easy accessible with our methodology.  
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Scheme 3-14. Examples of bioactive natural products, which contain a β2,3-amino acid scaffold (shown in blue). 
Synthesizing epimers and substituted analogs of bioactive natural products could provide interesting 
structure activity relationships and guide optimization of these structures.  
3.10 Concluding remarks 
Two synthetic routes have been developed, providing β2-des- and dimethylated azumamide analogs. The 
synthesis of these analogs provided information about the structural requirements of the β-amino acid 
scaffold found in the azumamides. The dimethylated analogs were poor HDAC inhibitors with high IC50 values 
(> 10 µM). The desmethylated analogs showed a 3–18-fold reduction in activity compared to the natural 
products and NMR studies suggested that these analogs have the same peptide backbone conformations as 
the natural products. To explain the reduction in activity, we hypothesize that the β2-methyl group, directs 
the zinc-binding side chain towards the entrance of the 11 Å channel. When the β2-methyl group is removed, 
the zinc-binding side chain will not be directed towards the 11 Å channel and this could result in weaker 
binding.  
Disappointingly, the modified azumamide scaffold did not induce isoform selectivity. Actually, the selectivity 
observed for azumamide C and E on HDAC1–3 and HDAC10 compared to HDAC8 and 6, respectively, was 
reduced for desmethylated anaolgs. 
Furthermore, the scope of the diastereoselective Mannich reaction protocol was elaborated with the 
synthesis of a β2,3-amino acid building block required for the preparation of an β3-propyl azumamide analog. 
Even though this analog lacks a zinc-binding functionality it was able to inhibit HDAC3 with an IC50 of 3 µM. 
The analogs presented in this chapter will be tested for cytotoxicity in different cancer and healthy cell lines. 
Furthermore, docking studies on the azumamides and the desmethylated analogs are currently being 
conducted and hopefully these data can assist in identifying the important inhibitor–protein interactions.  
 
 
 
Towards a thiol-sensitive linker for antibody-drug conjugates (ADC`s) 
78 
 
4 Towards a thiol-sensitive linker for antibody-drug conjugates 
(ADC`s) 
This work was performed in the group of Professor Fernando Albericio at the Institute for Research in 
Biomedicine, Barcelona, during a three months stay abroad.  
4.1  Introduction to antibody-drug conjugates (ADC`s)  
Antibody-drug conjugates (ADC`s) are macromolecules, which show great potential as pharmaceuticals.211, 
212 The field of antibody-drug conjugates is relatively new and the first ADC (brentuximab vedotin, 4.01, Figure 
4-1)  was approved by the FDA in 2011, for treatment of Hodgkin's lymphoma and systemic anaplastic large 
cell lymphoma.213 The general ADC is built up of three fragments; antibody, linker, and drug (Figure 4-1).   
 
Figure 4-1. Brentuximab vedotin structure. (Adapted from Sievers and Senter)213 
The antibody directs the conjugate to its target, making this approach highly specific. Receptor-mediated 
endocytosis transports the ADC into the cell, where the drug is released by a carefully chosen mechanism. To 
prevent premature release of the drug, the linker should be stable in the bloodstream. On the other hand, 
the drug should be efficiently released, when the conjugate reaches its target inside the cell. In the case of 
brentuximab vedotin, a protease cleavable linker was developed. The proteases found in lysosomes of the 
cell, cleave the amide bond between valine and citrulline and release the unmodified drug after 
decomposition of the PABC-spacer (Figure 4-1).  
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Figure 4-2. General mechanism of ADCs. (Adapted from Sievers and Senter)213 
Development of good linkers for ADC systems is essential for the preparation of successful therapeutic 
agents. The target of interest is often located inside the cell and for this project, the concept is to take 
advantage of the different environments found in the bloodstream and inside the cell. The concentration of 
low molecular weight thiols is relatively low in the bloodstream. 214 The two most abundant thiol species are 
glutathione (GSH, ∼5 µM) and cysteine (∼7 µM).215 The remaining free thiols in human plasma are primarily 
found as sulphydryl groups in albumin. However, the protein bound thiols are not expected to react with 
macrostructures such as ADCs. The cytosolic concentration of GSH is estimated to be in the range 0.1–10 
mM.216, 217 This concentration is 20–2.000-fold higher than in the bloodstream. If a linker scaffold could be 
designed where the cleavage is mediated by nucleophilic attack of GSH, the drug will be selectively released 
inside the cells.   
4.2  Linker design and the Bsmoc group 
The linker design is inspired from the Bsmoc protection group, which has been used as an amine protection 
group.218 The Bsmoc group is constructed of a 1,1-dioxobenzothiophene scaffold, which is coupled to the 
amine through a carbamate linkage (Scheme 4-1). 
 
Scheme 4-1. The Bsmoc group and the deprotection mechanism. aa = amino acid. 
The deprotection step involves addition of an external nucleophile, which attacks in the 3-position (Michael 
position) and produces the free amine, carbon dioxide, and an intermediate alkene. This alkene by-product 
rearranges to the aromatic compound 4.04. The Bsmoc-scaffold can be utilized to construct a linker scaffold 
if an antibody is attached to the phenyl ring via the functionality (Y) and the drug molecule contains an amine 
functionality that allows preparation of the carbamate (4.05, Scheme 4-2). The addition of a nucleophile (low 
molecular weight thiol) will then release the drug and create carbon dioxide and an antibody–linker adduct 
Towards a thiol-sensitive linker for antibody-drug conjugates (ADC`s) 
80 
 
(Scheme 4-2). Interestingly, Ashley and co-workers have reported that the cleavage rate of similar system 
can be controlled by modulating the R-group in Scheme 4-2.219 Incorporation of electron-donating R-groups 
will decrease the reactivity of the 3-position, whereas electron-withdrawing groups will increase the 
electrophilicity of the 3-position. Hopefully, tuning of the cleavage rate in this system can be achieved by 
modulating the R-group. The oxidation state of the benzothiophene sulfur can also affect the reactivity in the 
3-position. Sulfoxides are expected to less reactive than their corresponding sulfones. 
 
Scheme 4-2. Model system for preparation of a thiol-sensitive Bsmoc-linker. 
To explore this strategy a model system was set up using the fluorophore, 7-amino-4-methyl coumarin 
(AMC), as the model drug and benzothiophene as the linker scaffold (Scheme 4-2). The use of a fluorophore 
allows quantitative detection of the cleavage reaction at low concentrations. Six target compounds were 
chosen to evaluate the model system (Scheme 4-3). An electron-donating (4.08) and an electron-withdrawing 
group (4.10) was introduced in the scaffolds. The unsubstituted analog 4.09 was prepared as well. 
Furthermore, both the sulfoxide and the sulfone-versions should be prepared for all the three compounds in 
Scheme 4-3.  
 
Scheme 4-3. Target compounds for evaluation of linker-model system. X= SO and SO2. 
4.3 Synthesis of linker scaffold and stability studies 
Our retrosynthetic analyses was based on coupling AMC to the Bsmoc scaffold in the last step. This can be 
done by coupling AMC to the chloroformates of 2-hydroxybenzothiophenesulfone derivatives. The 
benzothiophene alcohols 4.13–4.15 were obtained in good to excellent yields by deprotonating 
benzothiophene with butyllithium and subsequent addition of the respective aldehydes (Scheme 4-4). 
Oxidation of the sulfur with magnesium monoperoxyphtalate (MMPP) provided the sulfones 4.16–4.18 in 
moderate to good yields.218     
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Scheme 4-4. Synthesis of benzothiophenesulfone alcohols. Reagents and conditions: (a) BuLi (1.3 equiv), 30–50 min, 
then aldehyde in dry THF, 2–15 h; (b) MMPP (1.3–1.4 equiv), MeOH, 2–16 h.  
Attempts to oxidize the benzothiophene alcohols, to the desired sulfoxides, with mCPBA or TFA/H2O2 proved 
unsuccessful. It was envisioned that the carbamates could be accessed by preparing the chloroformates in 
situ, with triphosgene or phosgene, and then adding AMC as the nucleophile. This approach did not provide 
the target compounds. Instead, products were isolated were the AMC attacks in the Michael position or 
performs a substitution reaction on the R-substituted carbon (Scheme 4-5, compound 4.21). To lower the 
reactivity of the system the carbonyl imidazolyl compounds 4.19 and 4.20 were prepared from the 
benzothiophene alcohols  with carbonyldiimidazole (CDI).220 These compounds can be isolated and stored for 
months in the fridge. In the presence of DMAP, the coupling between compound 4.20 and benzylamine as a 
test substrate, gave the carbamate 4.22 in 62% yield. Disappointingly, using AMC in the same reaction failed 
to produce the desired carbamate. Increasing temperature and attempting a microwave induced coupling 
did not afford the carbamate.  At high temperatures the substitution product 4.21 was isolated in 30 % yield.      
 
Scheme 4-5. Reagents and conditions: (a) CDI (1.4 equiv), CH2Cl2, 1.5–2 h; benzyl amine (1.2 equiv), Et3N (1.2 equiv), 
CH2Cl, 15 h, then DMAP (6 mol%) and benzyl amine (1.0 equiv), 35 ºC, 20 h; (c) AMC (2.0 equiv), DMF, 100 ºC, 16 h. 
From these results we hypothesized that the low nucleophilicity of the coumarin, compared to benzyl amine, 
was responsible for the difference in reactivity. To circumvent this problem, the chlorocarbamate 4.23 was 
prepared in situ by the addition of triphosgene and base to AMC. The benzothiophene sulfone alcohols (4.16 
or 4.17) were then added as nucleophiles. This reverse strategy has been used in the synthesis of a 
thiocarbamate from 7-amino-4-methyl coumarin.221 In this work the ethane thiol nucleophile was added to 
the chlorocarbamate (4.23) and provided the thiocarbamate in 73% yield. As shown in scheme 54, this 
approach afforded the two desired benzothiophene sulfone carbamates (4.24 and 4.25), albeit in low yields. 
The primary alcohol 4.18 also seemed to work in this reaction, but purification by flash chromatography did 
not provide the pure carbamate.  
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Scheme 4-6. Reagents and conditions: (a) Et3N (10 equiv), triphosgene (1.5 equiv) in THF was added over 30 min, 
CH2Cl2, 0 ºC, then 1 h; (b) 4.16 (1.5 equiv) or 4.17 (1.5 equiv), 2–19 h.       
The same strategy was probed to obtain the benzothiophene sulfoxide carbamates. The benzothiophene 
alcohol 4.14 was added to the chlorocarbamate 4.23 to afford the carbamate 4.26 in 31% yield. The last step 
is oxidation of the sulfur to the sulfoxide. Several methods have been reported for the oxidation of sulfurs to 
the sulfoxides.222, 223, 224  An oxidation screen was performed to develop a protocol that would provide the 
sulfoxide (Table 4-1). The best result was observed with triflic anhydride in the presence of hydrogen 
peroxide (entry 4). However, in the interest of time, the focus of the project was switched to the evaluation 
of the sulfone series. 
Table 4-1. Screening of oxidation protocols for synthesis of sulfoxides. 
 
entry reagent solvent observations 
1 TFA/H2O2 TFA Decomposition 
2 mCPBA/BF3OEt2 CH2Cl2 Decomposition, trace of product 
3 NaIO4 THF/H2O No reaction 
4 Tf2O/H2O2 THF Incomplete conversion, peak with correct mass 
5 DMP CH2Cl2 No reaction 
 
4.4 Stability studies on the sulfone series 
To test the stability of the linker scaffold in an aqueous media, compound 4.24 (c= 100 µM) and compound 
4.25 (c= 150 µM) were dissolved in aqueous phosphate buffer (pH= 7.4) and the fluorescence measured after 
2 hours, 24 hours, and 48 hours (Figure 4-3).  
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Figure 4-3. Stability study of compound 4.24 (red) and 4.25 (blue) over 48 hours. The concentrations were calculated 
from an AMC standard curve. 
Figure 4-3 shows a slight increase in fluorescence over 48 hours, which indicates that a small amount of AMC 
is released. However, the measured concentrations correspond only to 2% cleavage, if the fluorescence after 
2 hours is considered as the background fluorescence. HPLC analysis indicated that the linker is stable in 
MeCN–H2O for a couple of hours, but after 24 hours substantial degradation was observed. These preliminary 
data indicate that the benzothiophene sulfone scaffold is relatively stable in an aqueous media and the next 
step would be to evaluate stability in human plasma and test whether addition of GSH can release the AMC 
from the linker. These studies are ongoing in Barcelona.      
4.5  Concluding remarks 
In summary, this preliminary work established the Bsmoc-based scaffold to be a potential scaffold for the 
linker moiety in antibody-drug conjugates. A model system was designed, where incorporation of a 
fluorophore as the model drug allowed evaluation of the cleavage rates.  The synthetic route provided the 
sulfone-series, but preparation of the sulfoxide series was unsuccessful. The sulfone scaffold was found to 
be relatively stable in aqueous buffer and further investigation into the release of the model drug, by addition 
of a nucleophile, will determine if the Bsmoc-based scaffold is suitable as a linker-scaffold.   
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5 Conclusion 
In pursuit of completing the total synthesis of the azumamides and constructing analogs, we have developed 
a synthetic route, which enabled the construction of the full diastereomeric matrix for the β2,3-amino acid 
scaffold. The key step in this route is a diastereoselective Mannich reaction. In our hands, the reaction is 
hypothesized to go through an open transition state, which is in disagreement with the results from other 
research groups. However, this methodology nicely provided two site-specifically edited epimeric 
azumamide analogs. These analogs were inactive against the full panel of HDAC enzymes and show that the 
β-amino acid scaffold is highly sensitive to modifications in the stereochemistry. This work also reports the 
total syntheses of azumamides A–E and presents first total syntheses of azumamide B–D. The natural 
products were subjected to full HDAC profiling and we found that the azumamides were poor inhibitors of 
class IIa HDACs, but potent inhibitors of HDAC1–3, 10, and 11 (IC50 values between 14 nM to 67 nM). 
Furthermore, the HDAC screening established azumamide C to be ∼2-fold more potent than azumamide E 
against the majority of enzymes, which is in disagreement with previous results. In terms of selectivity, 
azumamide C and E were between 60–350-fold more potent towards HDAC1–3 over HDAC8. Furthermore, 
these two compounds displayed >200-fold selectivity for HDAC10 over HDAC6. 
Our synthetic route also enabled the synthesis of β2-des- and dimethylated azumamide analogs as well as a 
β3-propyl analog. The incorporation of a methyl group in the 2-position resulted in poor HDAC inhibitors with 
IC50 values (>10 µM). The desmethylated compounds were more active, but still suffered a decrease in activity 
(IC50 values just below 1 µM). Based on NMR solution structures, we hypothesize that the β2-methyl group 
found in the natural products may guide the β3-side chain towards the active site. Judging from the 
biochemical data on the desmethylated series, this directing feature is important for activity. Ongoing 
docking studies will hopefully contribute to this hypothesis. The β3-propyl azumamide C analog was found to 
be active against HDAC3 with an IC50 of 3 µM. The straightforward synthesis of the β-amino acid required for 
this analog emphasizes the effectiveness of the developed Mannich reaction.  
Thus, this work has contributed to the structure–activity relationship for the azumamides and illustrated that 
these compounds are sensitive to modifications in the β-amino acid scaffold. The developed 
diastereoselective Mannich reaction have been shown to be a powerful tool for synthesizing β-amino acid 
scaffolds and this reaction will aid in the future production of azumamide analogs. However, obtaining potent 
and isoform selective compounds based on the azumamide scaffold seems challenging
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6 Experimental 
Experimental for chapter 2 
Biochemical profiling 
Assay Materials   
HDAC1 (Purity >45% by SDS-PAGE according to the supplier), HDAC4 (Purity >90% by SDS-PAGE according to 
the supplier), and HDAC 7 (Purity >90% by SDS-PAGE according to the supplier) were purchased from 
Millipore (Temecula, CA 92590). HDAC2 used for dose–response experiments (Full length, purity ≥94% by 
SDS-PAGE according to the supplier) and HDAC 5 (Full length, purity ≥4% by SDS-PAGE according to the 
supplier) and HDAC8 used for dose-response experiments (Purity ≥90% by SDS-PAGE according to the 
supplier) were purchased from BPS Bioscience (San Diego, CA 92121). HDAC2 used for initial screening 
experiments (Full length, purity 50% by SDS-PAGE according to the supplier), HDAC3-NCoR1* complex (Purity 
90% by SDS-PAGE according to supplier), HDAC6 (Purity >90% by SDS-PAGE according to the supplier), HDAC8 
for initial screening experiments (Purity >50% by SDS-PAGE according to the supplier), HDAC10 (Purity >50% 
by SDS-PAGE according to the supplier), and HDAC11 (Purity >50% by SDS-PAGE according to the supplier) 
were purchased from Enzo Life Sciences (Postfach, Switzerland). HDAC9 (Full length, purity 12% by SDS-PAGE 
according to the supplier) was purchased from Abnova (Taipei, Taiwan). The HDAC assay buffer [50 mM 
tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and bovine serum albumin (0.5 mg/mL)]. Trypsin 
(10,000 units/mg, TPCK treated from bovine pancreas) was from Sigma Aldrich (Steinheim, Germany). All 
peptides were purified to homogeneity (>95% purity by HPLC230 nm using reversed-phase preparative HPLC), 
and the white fluffy materials obtained by lyophilization were kept at –20 °C. For assaying, peptide substrates 
were reconstituted in DMSO to give 5–10 mM stock solutions, the accurate concentrations of which were 
determined by co-injection on HPLC with a standard of known concentration. 
 
In Vitro Histone Deacetylase Inhibition Assays  
For inhibition of recombinant human HDACs the dose–response experiments with internal controls were 
performed in black low binding NUNC 96-well microtiter plates. Dilution series (3-fold dilution, 10 
concentrations) were prepared in HDAC assay buffer from 5–10 mM DMSO stock solutions. The appropriate 
dilution of inhibitor (10 µL of 5 × the desired final concentration) was added to each well followed by HDAC 
assay buffer (25 µL) containing substrate [Ac-Leu-Gly-Lys(Ac)-AMC (40 µM) for HDAC1, 2, and 3; (80 µM) for 
HDAC6 and 11; Ac-Leu-Gly-Lys(Tfa)-AMC (40 µM) for HDAC4; (240 µM) for HDAC5; (80 µM) for HDAC7; (400 
µM) for HDAC8; and (160 µM) for HDAC9; and Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC (100 µM) for HDAC10]. Finally, 
a solution of the appropriate HDAC (15 µL) was added and the plate was incubated at 37 °C for 30 min 
[HDAC1: 150 ng/well, HDAC2: 100 ng/well, HDAC3: 10 ng/well, HDAC4: 2 ng/well, HDAC5: 40 ng/well, HDAC6: 
60 ng/well, HDAC7: 2 ng/well, HDAC8: 5 ng/well, HDAC9: 40 ng/well, HDAC10: 500 ng/well, HDAC11: 500 
ng/well]. Then trypsin (50 µL, 0.4 mg/mL) was added and the assay development was allowed to proceed for 
15–30 min at room temperature, before the plate was read using a Perkin Elmer Enspire plate reader with 
excitation at 360 nm and detecting emission at 460 nm. Each assay was performed in duplicate. The data 
were analyzed by non-linear regression using GraphPad Prism to afford IC50 values from the dose-response 
experiments, and Ki values were determined from the Cheng-Prusoff equation [Ki = IC50/(1+[S]/Km)] assuming 
a standard fast-on–fast-off mechanism of inhibition. 
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Dose-response curves and IC50 values for “active” inhibitors. 
 
IC50 values ± standard deviation [µM], derived from the above dose–response experiments
a 
 class-I class-IIa class-IIb class-IV 
compound HDAC1 HDAC2 HDAC3 HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10 HDAC11 
azuA >30 >30 14±0.7 >30 IA IA IA IA IA IA >30 
azuB 21±13 20±13 14±9 IAb IA IA IA IA IA IA 13 
azuC 0.14  
±0.004 
0.27  
±0.15 
0.06  
±0.004 
>30 IA IA IA IA 7±3.2 0.4 0.15  
±0.014 
azuD >30 >30 16 IA IA IA IA IA IA IA IA 
azuE 0.29   
±0.03 
0.4  
±0.22 
0.11  
±0.02 
9±3.9 IA IA IA IA >30 0.8 0.24 
±0.07 
aIC50 values determined from at least two individual dose–response experiments performed in duplicate using ten-point, 
three-fold dilution series of each compound (except for azuC and azuE against HDAC10, which were only performed in 
duplicate in a single assay). bIA = inactive (<50% inhibition at 50µM [inhibitor]). 
Cheng–Prusoff Ki Calculations 
Using the equation Ki = IC50/(1+[S]/Km) by assuming a standard fast-on–fast-off mechanism of inhibition, the 
above IC50 values were converted to Ki values using the substrate concentrations outlined in the experimental 
section and the Km values determined by Bradner et al.35 for HDACs 1–9 and by Inks et al.225 for HDAC11. For 
HDAC10, we derived a Km value for the applied substrate (Ac-RHKacKac-AMC) from Michaelis-Menten 
experiments as previously described197 (see figure below). AMC is the fluorophore (4-amino-7-
methylcoumarin), which is attached to the C-terminal of the substrate molecules.  
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Figure S1. Synthesis of (2S,3R)-β-amino acid building block (2.31). 
Material and Methods 
General  
All chemicals and solvents were analytical grade and used without further purification. Vacuum liquid 
chromatography (VLC) was performed on silica gel 60 (particle size 0.015−0.040 µm). UPLC−MS analyses were 
performed on a Waters Acquity ultra high-performance liquid chromatography system. A gradient with 
eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in acetonitrile) rising linearly from 0% to 95% of 
II during t = 0.00–2.50 min was applied at a flow rate of 1 mL/min (gradient A) or during t = 0.00–5.20 min 
(gradient B). Analytical HPLC was performed on a [150 mm × 4.6 mm, C18 Phenomenex Luna column (3 µm)] 
using an Agilent 1100 LC system equipped with a UV detector. A gradient, C, with eluent III (95:5:0.1, 
water−MeCN−TFA) and eluent IV (0.1% TFA in acetonitrile) rising linearly from 0% to 95% of IV during t = 
2−20 min was applied at a ﬂow rate of 1 mL/min. Preparative reversed-phase HPLC was performed on a [250 
mm × 20 mm, C18 Phenomenex Luna column (5 μm, 100 Å)] using an Agilent 1260 LC system equipped with 
a diode array UV detector and an evaporative light scattering detector (ELSD). A gradient C with eluent III and 
eluent IV rising linearly from 0% to 95% of IV during t = 5−45 min was applied at a flow rate of 20 mL/min. 1D 
and 2D NMR spectra were recorded on a Varian Mercury 300 instrument or a Varian INOVA 500 MHz 
instrument. All spectra were recorded at 298 K. Correlation spectroscopy (COSY) spectra were recorded with 
a relaxation delay of 1.5 sec before each scan, a spectral width of 6k × 6k, collecting 8 FIDs and 1k × 512 data 
points. Heteronuclear single quantum coherence (HSQC) spectra were recorded with a relaxation delay of 
1.5 sec before each scan, a spectral width of 6k × 25k, collecting 16 FIDs and 1k × 128 datapoints. 
Heteronuclear 2-bond correlation (H2BC) spectra were recorded with a relaxation delay of 1.5 sec before 
each scan, a spectral width of 4k × 35k, collecting 16 FIDs at 295 K and 1k × 256 datapoints. Heteronuclear 
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multiple-bond correlation (HMBC) spectra were recorded with a relaxation delay of 1.5 sec before each scan, 
a spectral width of 6k × 35 k, collecting 32 FIDs and 1k × 256 datapoints. Chemical shifts are reported in ppm 
relative to deuterated solvent peaks as internal standards (δH, DMSO-d6 2.50 ppm; δC, DMSO-d6 39.52 ppm, 
δH, CD3OH 3.30 ppm, δH, CDCl3 7.26 ppm; δC, CDCl3 77.16 ppm). Coupling constants (J) are given in hertz 
(Hz). Multiplicities of 1H NMR signals are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet. 
3-((Triisopropylsilyl)oxy)propan-1-ol (2.13) 
A solution of 1,3-propanediol (1.9 mL, 26.3 mmol) in dry THF (11 mL) was added dropwise 
to a stirred suspension of NaH (1.1 g, 26.3 mmol, l.0 equiv, 60 % in mineral oil) in dry THF (21 mL) under N2. 
After 35 min triisopropyl chloride (5.5 mL, 25.7 mmol) in dry THF (11 mL) was added dropwise and the mixture 
stirred for 20 hours. After addition of sat. aq. NaHCO3 (40 mL) the aqueous phase was extracted with EtOAc 
(80 mL) and ether (80 mL). The combined organic phases were dried with Na2SO4, filtered, and concentrated 
in vacuo. Purification by vacuum liquid chromatography (VLC) afforded 2.13 as a clear oil (4.54 g, 86%). 1H 
NMR (300 MHz, CDCl3) δ 3.92 (t, J = 5.6 Hz, 2H), 3.82 (t, J = 5.4 Hz, 2H), 2.77 (bs, 1H), 1.79 (pentet, J = 5.6 Hz, 
2H), 1.09–1.04 (m, 21H); 13C NMR (75 MHz, CDCl3) δ 63.8, 62.9, 34.3, 18.1, 11.9. 
(SR)-(E)-2-Methyl-N-(3-((triisopropylsilyl)oxy)propylidene)propane-2-sulfinamide (2.14)  
A solution of DMSO (2.1 mL, 28.9 mmol, 3.2 equiv) in dry CH2Cl2 (20 mL) was added 
dropwise via an addition funnel to a solution of oxalylchloride (1.3 mL, 14.5 mmol, 1.6 
equiv) in dry CH2Cl2 (44 mL) at –78° C. After stirring for 25 min a solution of alcohol 2.13 
(2.1 g, 9.0 mmol) in dry CH2Cl2 (20 mL) was added dropwise via an addition funnel. After 
30 min Et3N (6.5 ml, 46.6 mmol, 5.2 equiv) was added and after stirring for 40 min at –
78 °C the cooling bath was removed and the mixture allowed to reach room temperature. EtOAc (130 mL) 
was added and the organic phase washed with sat. aq. NH4Cl (60 mL) and brine (60 mL). The organic phase 
was concentrated in vacuo and the residue was pulled through a short plug of silica gel to afford the crude 
aldehyde as a clear oil (2.03 g, 99%), which was used directly without further purification. 1H NMR (300 MHz, 
CDCl3) δ 9.83 (t, J = 2.2 Hz, 1H), 4.07 (t, J = 6.1 Hz, 2H), 2.60 (td, J = 6.1, 2.2 Hz, 2H), 1.07–1.03 (m, 21H); 13C 
NMR (75 MHz, CDCl3) δ 202.4, 58.0, 46.9, 18.1, 12.0. 
A solution of aldehyde (2.0 g, 8.7 mmol, 1.05 equiv) in dry CH2Cl2 (7 mL) was added dropwise to a solution of 
dried CuSO4 (3.5 g, 21.9 mmol, 2.6 equiv) and (R)-(+)-2-methyl-2-propanesulfinamide (1.0 g, 8.3 mmol) in dry 
CH2Cl2 (45 mL). After stirring vigorously for 16 hours CuSO4 (0.8 g, 5.0 mmol, 0.6 equiv) was added and after 
additionally 25 hours of stirring the mixture was poured into EtOAc (120 mL) and washed with water (120 
mL). The aqueous phase was extracted with EtOAc (120 mL) and the combined organic phases were washed 
with water (120 mL) and concentrated in vacuo. Purification by VLC afforded tert-butanesulfinyl imine 2.14 
as a clear oil (1.88 g, 63%, two steps). ). [α]D: –157° (c = 0.8, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 8.11 (t, J = 
4.8 Hz, 1H), 4.00 (t, J = 6.3 Hz, 2H), 2.74 (td, J = 6.2, 4.9 Hz, 2H), 1.18 (s, 9H), 1.03 (m, 21H); 13C NMR (75 MHz, 
CDCl3) δ 168.1, 60.1, 56.7, 39.8, 22.5, 18.1, 12.0. HRMS (ESI-TOF): m/z calcld. for C16H35NO2SSiH+: 334.2236; 
found: 334.2229 [M+H]+.  
 
General method for Mannich reactions 
A solution of LDA (2.1 equiv) was added dropwise to a solution of the ester (2.0 equiv) in dry THF at –78 °C. 
After stirring for 30 min Ti(O-iPr)3Cl (4.2 equiv) in dry THF was added dropwise. The orange solution was 
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stirred for 30 min and the imine (1.0 equiv) in dry THF was added dropwise. The mixture was stirred for 3 h 
or until TLC showed full conversion of the imine. The mixture was quenched with sat. aq. NH4Cl and allowed 
to reach room temperature. Water was added and the mixture decanted into a separatory funnel. The 
remaining Ti precipitate was added EtOAc–water (1:1) and stirred vigorously for 5 min before being added 
to the separatory funnel. The aqueous phase was extracted with EtOAc and the combined organic phases 
were washed again with water, dried (MgSO4), filtered, and concentrated in vacuo.  
(2S,3S)-tert-Butyl-3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate 
(Table 2-1, entry 5, S1) 
The general procedure was followed using imine 2.14 (0.86 g, 2.60 mmol), tert-butyl 
propionate (0.78 mL, 5.20 mmol), LDA (1.8 M, 3.0 mL, 5.40 mmol) and Ti(O-iPr)3Cl 
(2.80 mL, 11.1 mmol). Diastereoselectivity was determined by 1H NMR integration 
of the crude reaction mixture (60:26:8:6). Purification by VLC afforded S1 as a 
colorless oil (0.45 g, 38%) as well as a fraction containing a mixture of diasteromers 
(0.50 g, 43%). Characterization data for the (2S,3S) diastereomer. [α]D: –30.8° (c = 0.4, CH2Cl2); 1H NMR (300 
MHz, CDCl3) δ 4.06 (d, J = 8.0 Hz, 1H), 3.85 (m, 2H), 3.56 (m, 1H), 2.74 (qd, J = 7.1, 4.9 Hz, 1H), 1.95 (m, 1H), 
1.82 (m, 1H), 1.43 (s, 9H), 1.20 (s, 9H), 1.14 (d, J = 7.1 Hz, 3H), 1.05 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 174.4, 
80.8, 60.9, 57.4, 56.2, 44.4, 36.9, 28.2, 23.0, 18.2, 14.5, 12.0; HRMS (ESI-TOF): m/z calcld. for C23H49NO4SSiNa+: 
486.3049; found: 486.3046 [M+Na]+.  
Ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate (Table 2-1, entry 
2)                                      
The general procedure was followed using imine 2.14 (179 mg, 0.54 mmol), ethyl 
propionate (155 µL, 1.34 mmol), LDA (1.2 M, 1.20 mL, 1.40 mmol) and Ti(O-iPr)3Cl 
(0.58 mL, 2.42 mmol). Diastereoselectivity was determined by 1H NMR integration of 
the crude reaction mixture (49:29:11:11). The diastereomers could not be separated 
by VLC and the purification afforded a mixture of diastereomers as a pale yellow oil (0.12 g, 51%). 
Methyl3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate (Table 2-1, 
entry 1) 
The general procedure was followed using imine 2.14 (137 mg, 0.41 mmol), methyl 
propionate (80 µL, 0.83 mmol), LDA (1.4 M, 0.62 mL, 0.86 mmol) and Ti(O-iPr)3Cl (0.41 
mL, 1.72 mmol). Unreacted imine was removed by VLC to give a mixture of 
diastereomers [(47:39:10:4), 29 mg, 17%]. 
 
Allyl 3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate (Table 2-1, entry 
3) 
The general procedure was followed using imine 2.14 (144 mg, 0.43 mmol), allyl 
propionate (110 µL, 0.86 mmol), LDA (1.4 M, 0.65 mL, 0.91 mmol) and Ti(O-iPr)3Cl 
(0.43 mL, 1.81 mmol). Unreacted imine was removed by VLC to give a mixture of 
diastereomers [(46:34:10:10), 64 mg, 33%]. 
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4-Methoxybenzyl-3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate 
(Table 2-1, entry 4) 
The general procedure was followed using imine 2.14 (165 mg, 0.50 mmol), 4-
methoxybenzyl propionate (225 µL, 1.24 mmol), LDA (1.2 M, 1.10 mL, 1.29 mmol) 
and Ti(O-iPr)3Cl (0.56 mL, 2.23 mmol). Diastereoselectivity was determined by 1H 
NMR integration of the crude reaction mixture (46:33:11:10). The diastereomers 
could not be separated by VLC and the purification afforded a mixture of 
diastereomers as a pale yellow oil (0.21 g, 81%). 
(2S,3S)-tert-Butyl 3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate 
(Table 2-1, entry 6, 2.37) 
A solution of LDA (1.3 M in THF, 0.86 mL, 1.12 mmol, 2.6 equiv) was added dropwise 
over 5 min to tert-butyl propionate (163 µL, 1.08 mmol, 2.5 equiv) in dry THF (7.0 
mL) at –78 °C. After stirring for 30 min HMPA (225 µL, 1.30 mmol, 3.0 equiv) was 
added dropwise and after additionally 10 min of stirring, imine 2.14 (144 mg, 0.43 
mmol) in dry THF (1.5 mL) was added dropwise. After 1 hour the reaction was 
quenched with sat. aq. NH4Cl and worked up according to the general procedure. Diastereoselectivity was 
determined by 1H NMR integration of the crude reaction mixture (71:15:14:0). Purification by VLC afforded 
(89 mg, 45%) of the pure (S,S) diastereomer 2.37 as a clear oil. A fraction containing a mixture of 
diastereomers (77.0 mg, 39%) was obtained as well. Characterization data for the (2S,3S) diastereomer. [α]D: 
–24.0° (c = 8.3, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 4.07 (d, J = 8.0 Hz, 1H), 3.84 (m, 2H), 3.56 (m, 1H), 2.75 
(qd, J = 7.1, 4.9 Hz, 1H), 1.96 (m, 1H), 1.83 (m, 1H), 1.43 (s, 9H), 1.21 (s, 9H), 1.15 (d, J = 7.1 Hz, 3H), 1.06 (m, 
21H); 13C NMR (75 MHz, CDCl3) δ 174.4, 80.8, 60.9, 57.4, 56.2, 44.4, 36.9, 28.3, 23.0, 18.2, 14.5, 12.0; HRMS 
(ESI-TOF): m/z calcld. for C23H49NO4SSiNa+: 486.3049; found: 486.3046 [M+Na]+.  
3-(Benzyloxy)propanal (S5) 
DMSO (3.13 mL, 44 mmol, 2.2 equiv) was added to a solution of oxalylchloride (1.91 mL, 22 
mmol, 1.1 equiv) in dry CH2Cl2 (120 mL) at –78° C under nitrogen atmosphere. After stirring for 20 min a 
solution of 3-(benzyloxy)propanol (3.32 g, 22 mmol) in dry CH2Cl2 (7.5 mL) was added dropwise. After 20 min 
Et3N (14 ml, 100 mmol, 5.0 equiv) was added and after stirring for 10 min at –78 °C, the cooling bath was 
removed and the mixture allowed to reach room temperature. After stirring for 30 min the reaction was 
quenched with sat. aq. NH4Cl (15 mL). The aqueous phase was extracted with CH2Cl2 (2 × 30 mL) and the 
combined organic phases were washed with sat. aq. NaHCO3 (2 × 20 mL), brine (20 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo. Purification by VLC afforded the aldehyde crude S5 as a clear oil (2.36 g, 
72%). 1H NMR (300 MHz, CDCl3) δ 9.79 (d, J = 1.8 Hz, 1H), 7.53–7.01 (m, 5H), 4.53 (s, 2H), 3.81 (t, J = 6.1 Hz, 
2H), 2.69 (td, J = 6.1, 1.8 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 201.2, 137.9, 128.5, 127.8, 127.8, 73.3, 63.9, 
43.9. 
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(SR)-(E)-N-(3-(Benzyloxy)propylidene)-2-methylpropane-2-sulfinamide (2.30) 
A solution of aldehyde S5 (1.49 g, 9.08 mmol, 1.1 equiv) in dry CH2Cl2 (5 mL) was added 
dropwise to a solution of dry CuSO4 (2.92 g, 18.2 mmol, 2.2 equiv) and (R)-(+)-2-methyl-2-
propanesulfinamide (1.0 g, 8.25 mmol, 1.0 equiv) in dry CH2Cl2 (60 mL). After stirring 
vigorously for 22 hours the reaction mixture was filtered and the filtercake washed with 
CH2Cl2. The organic phase was washed with brine (2 × 30 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification by VLC afforded tert-butanesulfinyl imine 2.30 as a clear oil (1.65 g, 75%). 
Spectral data were in accordance with those previously reported.226 [α]D: –155° (c = 1.4, CH2Cl2); 1H NMR (300 
MHz, CDCl3) δ 8.10 (t, J = 4.6 Hz, 1H), 7.42–7.20 (m, 5H), 4.51 (s, 2H), 3.77 (t, J = 6.2 Hz, 3H), 2.81 (td, J = 6.2 
Hz and 4.6 Hz, 2H), 1.17 (s, 9H).13C NMR (75 MHz, CDCl3) δ 167.4, 137.9, 128.5, 127.7, 73.3, 66.2, 56.7, 36.6, 
22.4. 
 
tert-Butyl 5-(benzyloxy)-3-((R)-1,1-dimethylethylsulfinamido)-2- (Table 2-1, entry 1)  
The general procedure was followed using imine S5 (187 mg, 0.70 mmol), tert-butyl 
propionate (265 µL, 1.76 mmol), LDA (1.3 M, 1.40 mL, 1.82 mmol) and Ti(O-iPr)3Cl (0.75 
mL, 3.15 mmol). Diastereoselectivity was determined by 1H NMR integration of the 
crude reaction mixture (70:18:12:0). The diastereomers could not be separated by VLC 
and the purification afforded a mixture of diastereomers as a pale yellow oil (0.184 g, 
66%). 
 
3-((4-Methoxybenzyl)oxy)propan-1-ol (2.26) 
 To a solution of 1,3-propanediol (3.20 mL, 44.3 mmol) in dry THF (50 mL) was added NaH 
(1.68 g, 42 mmol, 0.95 equiv, 60 % in mineral oil) in dry THF (21 mL) at 0 oC. The mixture was stirred under 
N2 and after 15 min TBAI (0.82 g, 2.21 mmol, 0.05 equiv) was added followed by dropwise addition of para-
methoxybenzyl chloride (6.0 mL, 44.3 mmol, 1.0 equiv). After 17 hours the mixture was concentrated to a 
small volume and added water (50 mL). The aqueous phase was extracted with EtOAc (150 mL + 75 mL) and 
the combined organic phases were dried with Na2SO4, filtered, and concentrated in vacuo. Purification by 
VLC afforded 2.26 as a yellow oil (4.19 g, 51%). Spectral data were in accordance with those previously 
reported in the literature.227 1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.4 Hz,  2H), 6.87 (J = 8.6 Hz, 2H), 4.44 (s, 
2H), 3.79 (s, 3H), 3.75 (t, J = 8.6 Hz, 2H), 3.63 (t, J = 5.8 Hz, 2H), 2.42 (bs, 1H), 1.84 (pentet, J = 5.8 Hz, 2H).;13C 
NMR (75 MHz, CDCl3) δ 159.3, 130.2, 129.4, 113.9, 73.0, 69.2, 62.0, 55.4, 32.2. 
 
(SR)-(E)-N-(3-((4-Methoxybenzyl)oxy)propylidene)-2-methylpropane-2-sulfinamide (2.28) 
Oxalylchloride (1.02 mL, 22.4 mmol, 2.2 equiv) was added dropwise to a solution of DMSO 
(1.74 mL, 48.9 mmol, 4.8 equiv) in dry CH2Cl2 (25 mL) under argon at –78 °C. After stirring 
for 30 min a solution of alcohol 2.26 (2.0 g, 5.1 mmol) in dry CH2Cl2 (5 mL) was added 
dropwise. After 30 minutes, Et3N (5.18 mL, 74.4 mmol, 7.3 equiv) was added and the 
mixture allowed to warm to room temperature. Water (50 mL) was added and the 
mixture extracted with CH2Cl2 (3 × 50 mL). The combined organics were washed with sat. aq. NaHCO3 (3 × 50 
mL), brine (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo to yield the crude aldehyde (1.98 g), 
which was used without further purification. 1H NMR (300 MHz, CDCl3) δ 9.78 (t, J = 1.8 Hz, 1H), 7.25 (d, J = 
8.2 Hz, 2H), 6.88 (d, J = 8.3 Hz, 2H), 4.46 (s, 3H), 3.80 (s, 3H), 3.77 (t, 2H), 2.68 (td, J = 6.1 Hz and 1.8 Hz, 2H). 
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A solution of aldehyde (0.99 g, 5.1 mmol) in dry CH2Cl2 (2 mL) was added dropwise to a solution of dry CuSO4 
(4.0 g, 20.4 mmol, 4.0 equiv) and (R)-(+)-2-methyl-2-propanesulfinamide (0.62 g, 5.1 mmol, 1.0 equiv) in dry 
CH2Cl2 (22 mL). After stirring vigorously for 16 hours, CuSO4 (2.0 g, 12.5 mmol, 2.5 equiv) was added and after 
additionally 4 hours of stirring the mixture was filtered and the filtercake washed with CH2Cl2. The organic 
phase was washed with water (40 mL), brine (40 mL), dried (Na2SO4), filtered, and concentrated in vacuo. 
Purification by VLC afforded tert-butanesulfinyl imine 2.28 as a colorless oil (0.95 g, 62%, two steps). Spectral 
data were in accordance with those previously reported in the literature.228 [α]D: –152° (c = 0.4, CH2Cl2); 1H 
NMR (300 MHz, CDCl3) δ 8.09 (t, J = 4.6 Hz, 1H), 7.23 (dt, J = 8.7 Hz and 2.0 Hz, 2H), 6.86 (dt, J = 8.7 Hz and 
2.0 Hz, 2H), 4.44 (s, 2H), 3.79 (s, 3H), 3.74 (t, J = 6.3 Hz, 1H), 2.79 (td, J = 6.3, 4.6 Hz, 2H), 1.17 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 167.5, 159.3, 130.1, 129.4, 113.9, 73.0, 66.0, 56.8, 55.4, 36.7, 22.4.  
 
(2S,3S)-tert-Butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-((4-methoxybenzyl)oxy)-2-methylpentanoate 
(Table 2-1, entry 2) 
The general procedure was followed using imine 2.28 (166 mg, 0.56 mmol), tert-butyl 
propionate (210 µL, 1.40 mmol), LDA (1.3 M, 1.12 mL, 1.45 mmol) and Ti(O-iPr)3Cl 
(0.63 mL, 2.51 mmol). Diastereoselectivity was determined by 1H NMR integration of 
the crude reaction mixture (77:13:10:0). Purification by silica gel chromatography 
afforded a mixture of two diastereomers [(88:12) 170 mg, 71%] and a small fraction 
containing a mixture of all three diastereomers (20 mg, 8%). NMR characterization of the major 
diastereomer: 1H NMR (300 MHz, CDCl3) δ 7.27 (dt, J = 8.7 Hz and 2.1 Hz, 2H), 6.86 (dt, J = 8.7 Hz and 2.1 Hz, 
2H), 4.44 (s, 2H), 4.32 (d, J = 7.0 Hz, 1H), 3.79 (s, 3H), 3.73–3.39 (m, 3H), 2.64 (qd, J = 7.1, 5.2 Hz, 1H), 1.89 (q, 
J = 5.7 Hz, 1H), 1.42 (s, 6H), 1.15 (s, 6H), 1.11 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 174.1, 159.3, 
130.4, 129.7, 113.8, 80.8, 72.9, 67.6, 57.1, 56.0, 55.4, 44.7, 33.1, 28.2, 23.0, 13.7. 
 
(2S,3S)-tert-Butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-hydroxy-2-methylpentanoate (S6) 
DDQ (49.0 mg, 0.21 mmol, 1.1 equiv) was added to a solution of the two PMB ethers 
obtained above [(88:12), (85 mg, 0.19 mmol)] in CH2Cl2 (5 mL) and water (0.25 mL). DDQ 
(5.0 mg, 0.02 mmol, 0.1 equiv) was added after 1 hour and the reaction quenched with 
sat. aq. NaHCO3 (20 mL) after additionally 1 hour of stirring. The aqueous phase was 
extracted with CH2Cl2 (50 mL) and the organic phase washed with sat. aq. NaHCO3 (20 
mL), brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by VLC afforded alcohol 
S6 as a pure diastereomer (44 mg, 75%) as a colorless oil, which crystallized upon standing at room 
temperature. The spectral data were identical to the alcohol obtained from Table 9, entry 5 (S2). [α]D: –23.6° 
(c = 0.4, CH2Cl2).  
3-((Triethylsilyl)oxy)propan-1-ol (2.25) 
A solution of 1,3-propanediol (1.90 mL, 26.3 mmol, 1.05 equiv) in dry THF (10 mL) was 
added dropwise to a stirred suspension of NaH (1.0 g, 25.0 mmol, l.0 equiv, 60% in 
mineral oil) in dry THF (20 mL) under N2. After 35 min triethylsilyl chloride (4.4 mL, 26.3 mmol, 1.05 equiv) in 
dry THF (8 mL) was added dropwise and the mixture stirred for 16 hours. After addition of sat. aq. NaHCO3 
(40 mL) the aqueous phase was extracted with EtOAc (70 mL) and ether (70 mL). The organic phases were 
washed with water (35 mL), dried with MgSO4, filtered, and concentrated in vacuo. Purification by VLC 
afforded alcohol 2.25 as a colorless oil (0.51 g, 11%). Due to the poor stability of this compound in solution 
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at room temperature, it was used immediately after preparation. 1H NMR (300 MHz, CDCl3) δ 3.81 (m, 4H), 
2.69 (bs, 1H), 1.77 (pentet, 5.8 Hz, 2H), 0.95 (t, J = 8.0 Hz, 9H), 0.61 (q, J = 8.0 Hz, 6H). 
(SR)-(E)-2-Methyl-N-(3-((triethylsilyl)oxy)propylidene)propane-2-sulfinamide (2.27) 
Dess-Martin periodinane reagent (1.28 g, 2.9 mmol, 1.1 equiv) was added to a stirred 
solution of alcohol 2.25 (0.51 g, 2.65 mmol) in dry CH2Cl2 (15 mL) under N2. After 45 min 
the reaction was quenched with sat. aq. Na2S2O3 (10 mL) and sat. aq. NaHCO3 (10 mL). 
After stirring for 5 min the aqueous phase was extracted with CH2Cl2 (2 × 75 mL) and the 
combined organic layers were washed with sat. aq. NaHCO3 (40 mL), brine (40 mL), dried 
(MgSO4), filtered, and concentrated in vacuo to afford the crude aldehyde (465 mg, 93%) as a yellow oil, 
which was used without further purification. 1H NMR (300 MHz, CDCl3) δ 9.80 (t, J = 2.0 Hz, 1H), 3.97 (t, J = 
6.1 Hz, 2H), 2.60 (td, J = 6.1 Hz and 2.0 Hz, 2H), 0.94 (t, J = 7.9 Hz, 9H), 0.59 (q, J = 7.9 Hz, 6H). 
A solution of aldehyde (455 mg, 2.42 mmol) in dry CH2Cl2 (5 mL) was added dropwise to a solution of dry 
CuSO4 (1.55 g, 9.68 mmol, 4.0 equiv) and (R)-(+)-2-methyl-2-propanesulfinamide (0.30 g, 2.42 mmol, 1 equiv) 
in dry CH2Cl2 (15 mL) under N2. After stirring vigorously for 16 hours the mixture was added water (20 mL) 
and extracted with CH2Cl2 (2 × 40 mL). The combined organic phases were dried (MgSO4), filtered, and 
concentrated in vacuo. VLC afforded tert-butanesulfinyl imine 2.27 as a clear oil (140 mg, 18%, two steps). 1H 
NMR (300 MHz, CDCl3) δ 8.08 (t, J = 4.8 Hz, 1H), 3.91 (t, J = 6.3 Hz, 2H), 2.72 (m, 2H), 1.17 (s, 9H), 0.93 (t, J = 
8.0 Hz, 9H), 0.58 (q, J = 8.0 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 167.9, 59.3, 56.7, 39.6, 22.5, 6.9, 4.4. 
 
(2S,3S)-tert-Butyl 3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triethylsilyl)oxy)pentanoate (Table 2-
2, entry 3, S7) 
The general procedure was followed using imine 2.27 (140 mg, 0.48 mmol), tert-
butyl propionate (181 µL, 1.20 mmol), LDA (1.3 M, 0.96 mL, 1.25 mmol) and Ti(O-
iPr)3Cl (0.54 mL, 2.16 mmol). Diastereoselectivity was determined by 1H NMR 
integration of the crude reaction mixture (75:21:4:0). Purification by VLC afforded S7 
as a pale yellow oil (83 mg, 41%) as well as a fraction containing a mixture of 
diasteromers (36 mg, 18%). Characterization data for the (2S,3S) diastereomer. 1H NMR (300 MHz, CDCl3) δ 
4.26 (d, J = 6.9 Hz, 1H), 3.77 (m, 2H), 3.58 (pentet, J = 6.0 Hz, 1H), 2.71 (pentet, J = 6.6 Hz, 1H), 1.84 (m, 2H), 
1.42 (s, 9H), 1.19 (s, 9H), 1.11 (d, J = 7.1 Hz, 3H), 0.94 (t, J = 7.9 Hz, 9H), 0.59 (q, J = 7.9 Hz, 6H). 13C NMR (75 
MHz, CDCl3) δ 174.2, 80.7, 60.5, 57.11, 56.0, 44.4, 35.9, 28.2, 23.0, 13.8, 6.9, 4.4. HRMS (ESI-TOF): m/z calcld. 
for C20H43NO3SSiNa+: 444.2564; found: 444.2574 [M+Na]+.   
 
(2S,3S)-tert-Butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-hydroxy-2-methylpentanoate (S2)   
Acetic acid (10.7 µL, 0.19 mmol, 1.0 equiv) followed by TBAF (1.0 M, 0.38 mL, 0.38 mmol, 2.0 equiv) was 
added to a stirred solution of silyl ether S7 (79.0 mg, 0.19 mmol) in dry THF (6.0 mL) at 
0 °C under N2. After stirring for 20 min the mixture was concentrated and purification 
by VLC afforded the alcohol  (48 mg, 83%) as a clear oil, which can be crystallized from 
ethyl acetate and hexane. [α]D: –28.6° (c = 0.4, CH2Cl2); mp 62–64 °C. The spectral data 
were identical to those of the alcohol obtained from Table 9, entry 5 (S2).  
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(SS)-(E)-2-Methyl-N-(3-((triisopropylsilyl)oxy)propylidene)propane-2-sulfinamide  (2.35) 
A solution of DMSO (1.0 mL, 14.1 mmol, 3.2 equiv) in dry CH2Cl2 (5 mL) was added 
dropwise to a solution of oxalylchloride (0.63 ml, 7.0 mmol, 1.6 equiv) in dry CH2Cl2 
(25 mL) at –78 °C. After stirring for 30 min, a solution of alcohol 2.13 (1.0 g, 4.3 mmol) 
in dry CH2Cl2 (5.0 mL) was added dropwise. After 30 min Et3N (3.1 mL, 22.4 mmol, 5.2 
equiv) was added and after stirring for 10 min at –78 °C, the cooling was removed and 
the mixture allowed to warm to room temperature. EtOAc (75 mL) was added and the organic phase was 
washed with sat. aq. NH4Cl (30 mL) and brine (30 mL). The organic phase was concentrated in vacuo and the 
residue was pulled through a short plug of silica gel to afford the crude aldehyde as a colorless oil (0.89 g, 
90%), which was used without further purification.  
A solution of aldehyde (0.89 g, 3.9 mmol) in dry CH2Cl2 (3.0 mL) was added dropwise to a solution of dried 
CuSO4 (4.0 g, 18.6 mmol, 4.5 equiv) and (S)-(–)-2-methyl-2-propanesulfinamide (0.50 g, 4.1 mmol, 1.05 equiv) 
in dry CH2Cl2 (22 mL). After stirring vigorously for 22 hours CuSO4 (1.0 g, 6.3 mmol, 1.6 equiv) was added and 
after additionally 2 hours of stirring the mixture was filtered and the solids washed with CH2Cl2 (250 mL). The 
filtrate was washed with water (40 mL), brine (40 mL), dried (Na2SO4), and concentrated in vacuo. Purification 
by VLC afforded tert-butanesulfinyl imine 2.35 as a colorless oil (0.95 g, 62%, two steps). [α]D: +155° (c = 0.5, 
CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 8.11 (td, J = 4.8, 1.0 Hz, 1H), 4.00 (t, J = 6.3 Hz, 2H), 2.74 (q, J = 5.7 Hz, 
2H), 1.18 (d, J = 1.1 Hz, 9H), 1.03 (m, 21H).13C NMR (75 MHz, CDCl3) δ 168.1, 60.1, 56.7, 39.8, 22.5, 18.1, 12.0. 
HRMS (ESI-TOF): m/z calcld. for C16H35NO2SSiH+: 334.2237; found: 334.2239 [M+H]+. 
 
(2R,3R)-tert-Butyl-3-((S)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate 
(2.37) 
The general procedure was followed using imine 2.35 (0.47 g, 1.4 mmol), tert-butyl 
propionate (0.53 mL, 3.5 mmol), LDA (1.8 M, 2.8 mL, 3.6 mmol) and Ti(O-iPr)3Cl (1.6 
mL, 6.3 mmol, 4.5 equiv). The diastereomeric ratio was determined by 1H NMR 
integration of the crude reaction mixture (77:18:5:0). Purification by VLC afforded 
2.37 as a colorless oil (0.35 g, 54%) as well as a fraction containing a mixture of 
diasteromers (0.26 g, 40%). Characterization data for the (2R,3R) diastereomer. [α]D: +33.4° (c = 0.6, CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 4.06 (d, J = 8.0 Hz, 1H), 3.85 (m, 2H), 3.56 (pentet, J = 6.4 Hz, 1H), 2.74 (dd, J = 
7.1 Hz and 5.0 Hz, 1H), 1.95 (m, 1H), 1.83 (m, 1H), 1.43 (s, 9H), 1.20 (s, 9H), 1.14 (d, J = 7.1 Hz, 3H), 1.05 (m, 
21H). 13C NMR (75 MHz, CDCl3) δ 174.4, 80.8, 60.9, 57.4, 56.2, 44.4, 36.9, 28.2, 23.0, 18.2, 14.5, 12.0. HRMS 
(ESI-TOF): m/z calcld. for C23H49NO4SSiH+: 464.3231; found: 464.3255 [M+H]+. 
(E)-((1-(tert-butoxy)prop-1-en-1-yl)oxy)(tert-butyl)dimethylsilane (2.47) 
To a solution of LDA (36.7 mL, 55 mmol, 1.1 equiv) in dry THF (15 mL) was added tert-butyl 
propionate (7.5 mL, 55 mmol) over 10 min at –78 °C. After 5 min a solution of TBSCl (8.6 g, 55 
mmol, 1.1 equiv) in THF–HMPA (1:1, 16 mL) was added over 5 min. After additional 5 min the 
cooling bath was removed and the mixture was stirred for 30 min. The reaction mixture was diluted with 
pentane (200 mL) and extracted with water (3 × 100 mL) and brine (100 mL). The organic phase was dried 
(Na2SO4), filtered, and concentrated in vacuo to afford the crude silyl ether. The (E:Z) ratio in the crude was 
determined by 1H NMR to be (91:9). Purification by distillation afforded a mixture of the E and Z-silyl ethers 
(91:9, 5.7 g, 47%). Characterization of the major isomer: 1H NMR (300 MHz, CDCl3) δ 3.93 (q, J = 6.6 Hz, 1H), 
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1.49 (d, J = 6.6 Hz, 3H), 1.32 (s, 9H), 0.92 (s, 9H), 0.15 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 152.4, 86.2, 78.5, 
29.3, 25.7, 18.2, 11.1, –4.6.  
(Z)-((1-(tert-butoxy)prop-1-en-1-yl)oxy)(tert-butyl)dimethylsilane (2.46) 
To a solution of LDA (37.0 mL, 55 mmol, 1.1 equiv) in a combination of dry THF (37 mL) and 
HMPA (23 mL, 23%) was added tert-butyl propionate (7.5 mL, 55 mmol) over 10 min at –78 °C. 
After 5 min a solution of TBSCl (8.6 g, 55 mmol, 1.1 equiv) in hexane (15 mL) was added over 5 min. After 
additional 5 min the cooling bath was removed and the mixture was stirred for 30 min. The reaction mixture 
was diluted with pentane (200 mL) and extracted with water (3 × 100 mL) and brine (100 mL).  The organic 
phase was dried (Na2SO4), filtered and concentrated in vacuo to afford the crude silyl ether. Purification by 
distillation afforded a mixture of the E and Z-silyl ethers (18:82, 8.8 g, 70%). Characterization of the major 
isomer: 1H NMR (300 MHz, CDCl3) δ 3.97 (q, J = 6.7 Hz, 1H), 1.49 (d, J = 6.7 Hz, 3H), 1.28 (s, 9H), 0.95 (s, 9H), 
0.16 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 151.8, 87.2, 78.4, 29.3, 28.7, 18.2, 10.7, –4.0. 
 
(2S,3R)-tert-Butyl-3-((S)-1,1-dimethylethylsulfinamido)-2-methyl-5-((triisopropylsilyl)oxy)pentanoate 
(2.42) 
A solution of LDA (1.3 M in THF, 6.4 mL, 8.3 mmol, 2.8 equiv) was added over 10 
minutes to a solution of HMPA (3.0 mL, 17.2 mmol, 5.7 equiv) in dry THF (10 mL) at 
–78 °C. After 10 minutes tert-butyl propionate (1.2 mL, 7.6 mmol, 2.5 equiv) was 
added dropwise. The resulting enolate solution was stirred for 45 minutes before 
adding the imine 2.35 (1.0 g, 3.0 mmol) in dry THF (2.0 mL) over 15 minutes. After 
30 minutes TLC showed full conversion of the imine, and the mixture was quenched with sat. aq. NH4Cl and 
allowed to warm up to room temperature. Water (30 mL) was added and the mixture extracted with EtOAc 
(2 × 100 mL). The combined organic phases were washed with 1 M HCl (50 mL) and the aqueous phase re-
extracted with EtOAc (100 mL). The combined organic phases were washed with brine (75 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Diastereoselectivity was determined by 1H NMR integration of 
the crude reaction mixture (64:25:8:2). Purification by VLC afforded the pure (2S,3R) diastereomer 2.42 as a 
clear oil (0.74 g, 52%) as well as a fraction containing a mixture of diasteromers (0.23 g, 16%). Characterization 
data for the (2S,3R) diastereomer. [α]D: +42.2° (c = 0.8, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 3.91 (m, 1H), 3.83 
(dt, J = 10.5 Hz and 5.3 Hz, 1H), 3.72 (m, 2H), 2.63 (dd, J = 7.0 Hz and 5.2 Hz, 1H), 1.86 (m, 2H), 1.43 (m, 9H), 
1.18 (s, 9H), 1.11 (d, J = 7.0 Hz, 3H), 1.05 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 173.9, 80.6, 60.6, 57.3, 56.1, 
45.2, 36.5, 28.2, 23.0, 18.2, 12.8, 12.0. HRMS (ESI-TOF): m/z calcld. for C23H49NO4SSiH+: 464.3231; found: 
464.3250 [M+H]+.  
(2S,3S)-tert-Butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-hydroxy-2-methylpentanoate (S2) 
TBAF (1.0 M, 1.75 mL, 1.75 mmol, 1.2 equiv) was added over 10 min to a stirred 
solution of silyl ether S1 (0.68 g, 1.46 mmol) in THF (20 mL) at 0 °C under N2. After 
stirring for 10 min the mixture was concentrated and purification by VLC afforded 
alcohol S2 (341 mg, 76%) as a clear oil, which can be crystallized from EtOAc and 
hexane. [α]D: –28.6° (c = 0.4 ,CH2Cl2); mp 62–64 °C; 1H NMR (300 MHz, CDCl3) δ 3.95 (d, 
J = 8.4 Hz, 1H), 3.88 (d, J = 6.5 Hz, 1H), 3.81 (m, 2H), 3.56 (tdd, J = 10.1 Hz, 6.8 Hz and, 3.9 Hz, 1H), 2.49 (qd, J 
= 7.1 Hz and 5.0 Hz, 1H), 1.94–1.62 (m, 3H), 1.44 (s, 9H), 1.24 (s, 9H), 1.15 (d, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 173.9, 80.9, 59.8, 58.3, 56.4, 46.4, 36.4, 28.3, 23.0, 14.7; HRMS (ESI-TOF): m/z calcld. for 
C14H29NO4SH+: 308.1896; found: 308.1889 [M+H]+. 
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(2S,3S)-tert-Butyl 3-((R)-1,1-dimethylethylsulfinamido)-2-methyl-5-oxopentanoate (S3) 
NaHCO3 (86.5 mg, 1.0 mmol, 1.4 equiv) and Dess-Martin periodinane reagent (0.44 g, 
1.0 mmol, 1.4 equiv) were added to a stirred solution of alcohol S2 (221 mg, 0.72 mmol) 
in dry CH2Cl2 (8 mL) at 0 °C under N2. Additional NaHCO3 (18 mg, 0.2 mmol, 0.3 equiv) 
and Dess-Martin periodinane reagent (66 mg, 0.16 mmol, 0.2 equiv) were added after 
15 min and after stirring for additionally 25 min, sat. aq. Na2S2O3 (5 mL) and sat. aq. 
NaHCO3 (10 mL) was added and the aqueous phase was extracted with CH2Cl2 (2 × 50 mL). The combined 
organic layers were washed with sat. aq. NaHCO3 (35 mL) and brine (35 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford aldehyde S3 (224 mg) as a clear oil, which was used without further 
purification. 1H NMR (300 MHz, CDCl3) δ 9.75 (t, J = 0.9 Hz, 1H), 4.20 (d, J = 10.0 Hz, 1H), 3.77 (m, 1H), 3.27–
2.81 (m, 3H), 3.08 (ddd, J = 18.5 Hz, 5.1 Hz, and 1.1 Hz, 1 H) 2.72 (m, 1 H) 1.42 (s, 9H), 1.19 (s, 9H), 1.16 (d, J 
= 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 200.5, 174.0, 81.3, 56.6, 54.8, 48.5, 44.6, 28.2, 22.8, 15.4; HRMS 
(ESI-TOF): m/z calcld. for C14H27NO4SH+ : 306.1740; found: 306.1734 [M+H]+. 
 
(7S,8S)-(Z)-9-tert-Butyl 1-ethyl 7-((R)-1,1-dimethylethylsulfinamido)-8-methylnon-4-enedioate (S4) 
A flame dried round-bottomed flask was charged with (4-ethoxy-4-
oxobutyl)triphenylphosphonium bromide  (0.68 g, 1.5 mmol, 2.0 equiv) and the 
Wittig reagent was dried under high vacuum for 18 hours. The Wittig reagent 
was dissolved in dry THF (10 mL) under argon and cooled to –78 °C. KHMDS 
(0.5 M, 2.75 mL, 1.4 mmol) was added dropwise and the resulting orange 
solution was stirred for 30 min before the crude aldehyde S3 (219 mg, 0.72 mmol) in dry THF (2.0 mL) was 
added dropwise. After 1 h at –78 °C the mixture was allowed to reach room temperature and water (30 mL) 
was added. The aqueous phase was extracted with EtOAc (2 × 60 mL). The combined organic layers were 
washed with brine (35 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification by VLC afforded 
alkene S4 as a clear oil (158 mg, 56%, 2 steps). [α]D: –32.8° (c = 0.4, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 5.55–
5.35 (m, 2H), 4.10 (q, J= 7.2 Hz, 2H), 3.82 (d, J = 8.6 Hz, 1H), 3.34 (pentet, J = 6.12 Hz, 1H), 2.65–2.28 (m, 7H), 
1.43 (s, 9H), 1.23 (t, J = 7.1 Hz, 3H), 1.20 (s, 9H), 1.14 (d, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 174.1, 
173.1, 131.3, 126.3, 81.0, 60.4, 59.4, 56.3, 43.7, 34.2, 32.5, 28.2, 23.0, 22.9, 14.8, 14.4; HRMS (ESI-TOF): m/z 
calcld. for C20H37NO5SH+: 404.2471; found: 404.2464 [M+H]+. 
 
(2S,3S)-(Z)-3-((tert-Butoxycarbonyl)amino)-9-ethoxy-2-methyl-9-oxonon-5-enoic acid (2.31) 
TFA (5 mL) was added to a solution of tert-butyl ester S4 (153 mg, 0.38 mmol) 
in dry CH2Cl2 (5 mL) under argon. After stirring for 1 hour the mixture was 
concentrated and TFA was removed by co-evaporation with CH2Cl2–toluene 
(1:1, 3 × 10 mL) to afford a mixture of the N-sulfinyl protected β-amino acid and 
the β-amino acid containing the free amine (151 mg). To a solution of this crude mixture (151 mg, 0.38 mmol) 
in dioxane (5 mL) and water (0.10 mL) was added HCl (4.0 M in dioxane, 0.14 mL, 0.56 mmol, 1.5 equiv). 
Additional HCl was added after 50 min (4.0 M, 0.30 mL, 1.2 mmol, 3.2 equiv) and after 70 min (4.0 M, 0.15 
mL, 0.6 mmol, 1.6 equiv). After stirring for 15 min after the last addition of HCl, TLC showed full conversion 
and the mixture was concentrated to afford the deprotected β-amino acid chloride salt (137 mg) as a yellow 
oil. The crude residue was dried under high vacuum for 16 hours. To a solution of the crude residue (106 mg, 
0.38 mmol) in dry CH2Cl2 (6 mL) was added Boc2O (118 mg, 0.54 mmol, 1.4 equiv) in dry CH2Cl2 (1.0 mL) 
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followed by iPr2NEt (90 µL, 0.52 mmol, 1.4 equiv) and the mixture was stirred under argon for 16 hours. To 
ensure complete protection af the amino group, additional Boc2O (19 mg, 0.09 mmol, 0.2 equiv) and iPr2NEt 
(15 µL, 0.09 mmol, 0.2 equiv) were added, and after stirring for 1 h the reaction mixture was concentrated in 
vacuo. Purification by VLC (0.2% acetic acid in the eluent) afforded the β-amino acid 2.31 (79.4 mg, 61%, 3 
steps) as a yellow oil after co-evaporation of residual acetic acid with CH2Cl2–toluene (1:1, × 3). [α]D: +12.3° 
(c = 1, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 5.41 (m, 2H), 5.27 (d, J = 9.6 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.78 
(m, 1H), 2.74 (m, 1H), 2.19 (m, 6H), 1.42 (s, 9H) 1.24 (m, 6H).  13C NMR (75 MHz, CDCl3) δ 180.0, 173.5, 156.1, 
130.5, 126.8, 79.4, 60.6, 52.6, 42.2, 34.1, 31.5, 28.5, 22.9, 14.7, 14.33; HRMS (ESI-TOF): m/z calcld. for 
C17H29NO6Na+: 366.1893; found: 366.1881 [M+Na]+. 
 
(2R,5R,8S,11S,12S)-(Z)-12-Amino-2-benzyl-8-isopropyl-5,11-dimethyl-4,7,10,18-tetraoxo-19-oxa-3,6,9-
triazahenicos-14-en-1-oic acid (2.54)      
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–
(D)Phe (246 mg, 0.081 mmol) was added to a fritted 
syringe and the Fmoc group was removed with 
piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 25 min). The resin was 
then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). β-Amino acid 2.31 (41.5 mg, 0.12 mmol, 1.5 equiv) in 
DMF (2.2 mL) was preincubated for 5 min with 2,6-lutidine (28 µL, 0.24 mmol, 3.0 equiv) and HATU (46.3 mg, 
0.12 mmol, 1.5 equiv) before addition to the resin and the reaction was allowed to proceed on a rocking table 
for 16 hours. After washing [DMF (×3), MeOH (×3), CH2Cl2 (×3)] the resin was treated with TFA–CH2Cl2 (1:1, 4 
mL) for 1 h followed by washing with CH2Cl2 (2 × 5 mL). A fresh portion of TFA–CH2Cl2 (1:1, 4 mL) was added 
to the resin and after additional 30 min the resin was drained and all the fractions were pooled and 
concentrated in vacuo to provide the linear peptide as an oily residue. Precipitation with diethyl ether 
afforded the TFA salt of the linear peptide 2.54 (52.3 mg, 96%) as a pale yellow solid.  
1H NMR (300 MHz, DMSO) δ 8.29 (d, J = 8.4 Hz, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.2 Hz, 1H), 7.75 (bs, 
2H), 7.23 (m, 5H), 5.45 (m, 2H), 4.43 (m, 1H), 4.31 (t, J = 7.3 Hz, 1H), 4.19 (dd, J = 8.5, 6.2 Hz, 1H), 4.04 (q, J = 
7.0 Hz, 2H), 3.18 (m, 1H), 3.02 (dd, J = 14.2, 5.0 Hz, 1H), 2.92 (dd, J = 14.2; 8.8 Hz, 1H), 2.86 (m, 1H), 2.42 (m, 
1H), 2.38 (m, 1H), 2.24 (m, 1H), 1.97 (m, 1H), 1.16 (m, 9H), 0.83 (d, J = 7.4 Hz, 3H), 0.80 (d, J = 7.0 Hz, 3H). 
HRMS (ESI-TOF): m/z calcld. for C29H44N4O7H+: 561.3283 found: 561.3286 [M+H]+. 
 
(Z)-Ethyl-6-((2R,5R,8R,11S,12S)-8-benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (2.55) 
The linear peptide 2.54 (50.8 mg, 0.075 mmol) was dissolved in DMF (110 mL ≈ 
0.7 mM) and iPr2NEt (131 µL, 0.75 mmol, 10 equiv) and HATU (43.7 mg, 0.11 
mmol, 1.5 equiv) were added. The solution was stirred for 16 hours and the 
reaction mixture was concentrated to a small volume and transferred to a 
centrifugation tube, where precipitation with diethyl ether afforded the crude 
cyclic peptide 2.55 (66 mg) as a brown solid, which was used without further 
purification. HPLC gradient A, tR = 1.69 min.  
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(Z)-6-((2R,5R,8R,11S,12S)-8-Benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid (2.56) 
LiOH (40 mg, 1.67 mmol, 21 equiv) in water (5 mL) was added to the cyclic peptide 
2.55 (44 mg, 0.081 mmol) in THF (5 mL) and the solution was stirred for 16 hours. 
The mixture was concentrated and aqueous HCl (1.0 M, 5 mL) was added, 
followed by extraction with EtOAc (200 mL + 50 mL). The combined organic 
phases were dried (MgSO4), filtered, and concentrated. The crude residue was 
dissolved in DMF–MeCN (8:2, 1.0 mL) and purified by preparative HPLC to afford 
epi-β3-azumamide E 2.56 (2.1 mg, 5%, 4 steps) as a white solid. [α]D: +60.0° (c = 
0.1, MeOH); 1H NMR (500 MHz, DMSO) δ 7.95 (bs, 2H), 7.59 (bs, 1H), 7.25 (m, 
2H), 7.18 (m, 3H), 6.31 (bs, 1H), 5.35 (m, 1H), 5.26 (m, 1H), 4.45 (bs, 1H), 3.99 (bs, 
1H), 3.88 (m, 2H), 3.38 (dd, J = 13.8, 3.9 Hz, 1H), 2.68 (dd, J = 13.8, 11.0 Hz, 1H), 2.53 (m, 1H), 2.21 (m, 6H), 
2.10 (m, 1H), 1.12 (d, J = 7.2 Hz, 3H), 1.06 (d, J = 7.3 Hz, 3H), 0.93 (d, J = 6.4 Hz, 3H), 0.87 (d, J = 6.3 Hz, 3H); 
HRMS (ESI-TOF): m/z calcld. for C27H38N4O6H+: 515.2870; found: 515.2882 [M+H]+. HPLC gradient C, tR = 12.34 
min (>95%). 
 
(2R,3R)-tert-Butyl 3-((S)-1,1-dimethylethylsulfinamido)-5-hydroxy-2-methylpentanoate (2.38) 
TBAF (1.0 M, 1.49 mL, 1.49 mmol, 2.0 equiv) was added over 10 min to a stirred solution 
of silyl ether 2.37 (0.35 g, 0.74 mmol) and AcOH (43 µL, 0.74 mmol, 1.0 equiv) in THF 
(20 mL) at 0 °C under N2. After stirring for 30 min the cooling was removed and the 
mixture was stirred for 1 hour at room temperature before concentration and 
purification by VLC afforded alcohol 2.38 (208 mg, 91%) as clear oil, which can be 
crystallized from ethyl acetate and hexane to give needle shaped crystals. [α]D: +21.3° (c = 0.5, CH2Cl2); mp 
66–67 °C; 1H NMR (300 MHz, CDCl3) δ 3.91 (d, J = 8.6 Hz, 1H), 3.83 (m, 2H), 3.56 (m, 1H), 2.49 (qd, J = 7.1 Hz 
and 5.1 Hz, 1H), 1.77 (m, 2H), 1.44 (s, 9H), 1.25 (s, 9H), 1.15 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
173.8, 80.8, 59.8, 58.3, 56.4, 46.3, 36.3, 28.2, 23.0, 14.6. HRMS (ESI-TOF): m/z calcld. for C14H29NO4SH+: 
308.1896; found: 308.1893 [M+H]+. 
 
(7R,8R)-(Z)-9-tert-Butyl 1-ethyl 7-((S)-1,1-dimethylethylsulfinamido)-8-methylnon-4-enedioate (2.40) 
NaHCO3 (84 mg, 1.0 mmol, 1.5 equiv) and Dess-Martin periodinane reagent (438 
mg, 1.0 mmol, 1.5 equiv) were added to a stirred solution of alcohol 2.38 (205 
mg, 0.67 mmol) in dry CH2Cl2 (8.0 mL) at 0 °C under N2. After 30 min, the mixture 
was allowed to warm to room temperature and after stirring for 1 hour, sat. aq. 
Na2S2O3 (10 mL) and sat. aq. NaHCO3 (10 mL) were added and the aqueous phase was extracted with CH2Cl2 
(2 × 35 mL). The combined organic layers were washed with sat. aq. NaHCO3 (30 mL) and brine (30 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to afford aldehyde 2.39 (186 mg, 91%) as a pale yellow oil, 
which was used immediately without further purification.  
A flame dried round-bottomed flask was charged with (4-ethoxy-4-oxobutyl)triphenylphosphonium bromide  
(0.64 g, 1.34 mmol, 2.0 equiv) and the Wittig reagent dried under high vacuum for 30 hours. The Wittig 
reagent was then dissolved in dry THF (10 mL) under argon and cooled to –78 °C.  KHMDS (0.5 M, 2.5 mL, 1.3 
mmol, 1.9 equiv) was added dropwise and the resulting orange solution was stirred for 30 min before crude 
aldehyde 2.39 (186 mg, 0.68 mmol) in dry THF (3.0 mL) was added dropwise. The mixture was allowed to 
warm to room temperature and after 16 hours, water (20 mL) was added. The aqueous phase was extracted 
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with EtOAc (2 × 60 mL) and the combined organic layers were washed with brine (35 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo. Purification by VLC afforded alkene 2.40 as a pale yellow oil (158 mg, 
59%, 2 steps). [α]D: +29.9° (c = 1, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 5.49 (m, 1H),  5.43 (m, 1H), 4.10 (q, J = 
7.2 Hz, 2H), 3.82 (d, J = 8.6 Hz, 1H), 3.34 (pentet, J = 7.1 Hz, 1H), 2.60 (qd, J = 7.2 Hz and 5.0 Hz, 1H), 2.52–
2.26 (m, 6H), 1.43 (s, 9H), 1.23 (t, J = 7.1 Hz, 1H), 1.20 (s, 9H), 1.15 (d, J = 7.2 Hz, 1H). 13C NMR (75 MHz, CDCl3) 
δ 174.1, 173.1, 131.3, 126.3, 81.0, 60.5, 59.4, 56.3, 43.7, 34.2, 32.5, 28.2, 23.0, 22.9, 14.8, 14.4. HRMS (ESI-
TOF): m/z calcld. for C20H37NO5SH+: 404.2471; found: 404.2497 [M+H]+. 
 
(2R,3R)-(Z)-3-((tert-Butoxycarbonyl)amino)-9-ethoxy-2-methyl-9-oxonon-5-enoic acid (2.41) 
HCl in dioxane (4.0 M, 0.48 mL, 1.9 mmol, 5.0 equiv) was added to a solution of 
alkene 2.40 (155 mg, 0.38 mmol) and water (0.1 mL) in 1,4-dioxane (8.0 mL). 
After 55 minutes TFA (2.0 mL) was added and after stirring for 5 hours the 
mixture was concentrated and TFA/CH2Cl2 (1:1, 10 mL) and water (0.1 mL) was 
added. After stirring for 16 hours the solution was concentrated and TFA was removed by co-evaporation 
with toluene–hexane (1:1, 3 × 10 mL) to afford the crude β-amino acid (155 mg). 
To a solution of the crude β-amino acid (155 mg) and iPr2NEt (0.21 mL, 1.2 mmol, 3.0 equiv) in dry CH2Cl2 (5.0 
mL) was added Boc2O (173 mg, 0.77 mmol, 2.0 equiv) in dry CH2Cl2 (1.0 mL) under argon. After 2.5 hours the 
reaction mixture was concentrated and iPr2NEt was removed by co-evaporation with toluene. Purification of 
the crude residue by VLC (0.2% acetic acid in the eluent) afforded β-amino acid 2.41 (80.2 mg, 61%, 3 steps) 
as a clear oil after co-evaporation of residual acetic acid with CH2Cl2–toluene (1:1, × 3). [α]D: –19.5° (c = 0.2, 
CH2Cl2); 1H NMR (300 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) δ 5.59–5.32 (m, 1H), 5.25 (d, J = 9.5 Hz, 1H), 4.12 
(q, J = 7.1 Hz, 1H), 3.78 (s, 1H), 2.84–2.60 (m, 1H), 2.49–2.12 (m, 3H), 1.42 (s, 5H), 1.30–1.16 (m, 3H). 13C NMR 
(75 MHz, CDCl3) δ 180.3, 173.5, 156.1, 130.6, 126.8, 79.4, 60.6, 52.6, 42.3, 34.1, 31.5, 28.5, 22.9, 14.7, 14.4.  
HRMS (ESI-TOF): m/z calcld. for C17H29NO6H+: 344.2070; found: 344.2080 [M+H]+. 
 
(2R,5R,8S,11R,12R)-(Z)-12-Amino-2-benzyl-8-isopropyl-5,11-dimethyl-4,7,10,18-tetraoxo-19-oxa-3,6,9-
triazahenicos-14-en-1-oic acid (2.57) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–
(D)Phe (201 mg, 0.10 mmol, 1.5 equiv) was added to a 
fritted syringe and swelled with CH2Cl2 before the Fmoc 
group was removed with piperidine–DMF (1:4, 4 mL, 2 
× 25 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), MeOH 
(×3), CH2Cl2 (×3). 
β-Amino acid 2.41 (22.8 mg, 0.067 mmol) in DMF (2.0 mL) was preincubated for 5 min with 2,6-lutidine (23.1 
µL, 0.20 mmol, 3.0 equiv) and HATU (38 mg, 0.10 mmol, 1.5 equiv) and added to the resin. The reaction was 
allowed to proceed on a rocking table for 16 hours. After washing [DMF (×3), MeOH (×3), CH2Cl2 (×3)] the 
resin was treated with TFA–CH2Cl2 (1:1, 4 mL) for 30 min followed by washing with CH2Cl2 (5 mL). A fresh 
portion of TFA–CH2Cl2 (1:1, 4 mL) was added to the resin and after additional 30 min the resin was drained, 
washed with CH2Cl2 (5 mL) and all the fractions were pooled and concentrated in vacuo to provide the crude 
linear peptide 2.57 as an oily residue (56.4 mg), which was used without further purification. UPLC-MS 
gradient B, tR = 1.46  min. 
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(Z)-Ethyl-6-((2R,5R,8R,11R,12R)-8-benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (2.58) 
The crude linear peptide 2.57 (54.6 mg, 0.07 mmol) was dissolved in DMF (200 
mL ≈ 0.33mM) and iPr2NEt (116 µL, 0.66 mmol, 10 equiv) and HATU (51 mg, 0.13 
mmol, 2.0 equiv) were added. The solution was stirred for 16 hours and the 
reaction mixture was concentrated and added EtOAc (200 mL) which afforded a 
white precipitate (HOAt). The EtOAc was decanted off, washed with aq. HCl (1.0 
M, 3 × 10 mL), and concentrated to afford the crude cyclic peptide 2.58 (95 mg) 
as a brown oil, which was used without further purification. 
 
 
(Z)-6-((2R,5R,8R,11R,12R)-8-Benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid (2.59) 
LiOH (56 mg, 2.32 mmol, 35 equiv) in water (5 mL) was added to the crude cyclic 
peptide 2.58 (95 mg) in THF (5 mL). The solution was stirred for 16 h and 
concentrated in vacuo. The resulting residue was dissolved in DMF (1.8 mL) by 
adding a few drops of TFA and then purification by preparative HPLC afforded 
β2-epi-azumamide E 2.59 (4.2 mg, 12%, 4 steps) as a white solid. [α]D: +30° (c = 
0.1, MeOH); 1H NMR (500 MHz, DMSO) δ 7.88 (d, J = 8.0 Hz, 1H), 7.65 (bs, 1H), 
7.40 (m, 1H), 7.31 (m, 1H), 7.27 (t, J = 7.1 Hz, 2H), 7.21 (m, 2H), 7.15 (d, J = 7.3 
Hz, 2H), 5.50 (m, 1H), 5.36 (dd, J = 17.7 Hz and 7.8 Hz, 1H), 4.25 (m, 2H), 3.75 (m, 
2H), 2.94 (dd, J = 13.9 Hz and 5.1 Hz, 1H), 2.76 (dd, J = 13.7 Hz and 10.0 Hz, 1H), 
2.63 (m, 1H), 2.40 (d, J = 15.0 Hz, 1H), 2.25 (m, 5H), 1.95 (octet, J = 6.7 Hz, 1H), 1.14 (d, J = 7.3 Hz, 3H), 1.02 
(d, J = 6.9 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H). HRMS (ESI-TOF): m/z calcld. for C27H38N4O6H+: 
515.2870; found: 515.2864 [M+H]+. HPLC gradient C, tR = 12.22 min (>95%). 
 
(2S,3R)-tert-Butyl 3-((S)-1,1-dimethylethylsulfinamido)-5-hydroxy-2-methylpentanoate (2.48) 
TBAF (1.0 M, 4.9 mL, 4.9 mmol, 2.0 equiv) was added over 10 min to a stirred solution 
of silyl ether 2.42 (1.14 g, 2.5 mmol) and AcOH (141 µL, 2.5 mmol, 1.0 equiv) in THF (20 
mL) at 0 °C under argon. After stirring for 10 min the cooling bath was removed and 
the mixture was stirred for 2 hours at room temperature, before concentration and 
purification by VLC alcohol 2.48 (0.70 g, 92%) as clear oil. [α]D: +25.6° (c = 0.3, CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 4.06 (s, 1H), 3.81 (d, J = 4.3 Hz, 3H), 3.72 (m, 2H), 2.42 (dd, J = 7.0, 5.1 Hz, 1H), 
1.78 (m, 1H), 1.70 (m, 1H), 1.43 (s, 9H), 1.21 (s, 9H), 1.10 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 173.5, 
80.9, 60.1, 58.4, 56.4 , 46.8, 36.2, 28.2, 22.9, 12.6. HRMS (ESI-TOF): m/z calcld. for C14H29NO4SH+: 308.1896; 
found: 308.1918 [M+H]+. 
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(7R,8S)-(Z)-9-tert-Butyl 1-ethyl 7-((S)-1,1-dimethylethylsulfinamido)-8-methylnon-4-enedioate (2.50) 
NaHCO3 (175 mg, 2.1 mmol, 1.5 equiv) and Dess-Martin periodinane reagent 
(0.80 g, 1.8 mmol, 1.3 equiv) were added to a stirred solution of alcohol 2.48 
(0.43 g, 1.4 mmol) in dry CH2Cl2 (10 mL) at 0 °C under N2. After 30 min the 
mixture was raised from the cooling bath, allowing only cooling on the bottom 
of the flask. After 1 hour the mixture was allowed to warm to room 
temperature and added sat. aq. Na2S2O3 (20 mL) and sat. aq. NaHCO3 (20 mL). The aqueous phase was 
extracted with CH2Cl2 (2 × 100 mL). The combined organic layers were washed with sat. aq. NaHCO3 (40 mL) 
and brine (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford aldehyde 2.49 (395 mg, 94%) 
as a pale yellow oil, which was used immediately without further purification. A flame dried round-bottomed 
flask was charged with (4-ethoxy-4-oxobutyl)triphenylphosphonium bromide (1.31 g, 2.8 mmol, 2.0 equiv) 
and the Wittig reagent dried under high vacuum for 24 hours. The Wittig reagent was the dissolved in dry 
THF (15 mL) under argon and cooled to –78 °C. KHMDS (0.5 M, 5.25 mL, 2.6 mmol, 1.9 equiv) was added 
dropwise and the resulting orange solution was stirred for 40 min before the crude aldehyde 2.49 (395 mg, 
1.4 mmol) in dry THF (3.5 mL) was added dropwise. The mixture was allowed to warm to room temperature 
and after 16 hours the mixture was quenched with EtOAc (2 mL) and concentrated. Water (20 mL) was added 
and the aqueous phase was extracted with EtOAc (2 × 80 mL). The combined organic layers were washed 
with brine (40 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification by VLC afforded alkene 
2.50 as a pale yellow oil (250 mg, 45%, 2 steps). [α]D: +43.6° (c = 0.3, CH2Cl2);  1H NMR (300 MHz, CDCl3) δ 5.49 
(m, 2H), 4.11 (q, J = 7.1 Hz, 2H), 3.63 (m, 1H), 3.27 (d, J = 7.9 Hz, 1H), 2.51 (qd, J = 7.1, 5.4 Hz, 1H), 2.43 (t, J =  
6.5 Hz, 1H), 2.35 (m, 4H), 1.44 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H), 1.19 (s, 9H), 1.11 (d, J = 7.1 Hz, 1H). 13C NMR (75 
MHz, CDCl3) δ 173.8, 173.2, 131.6, 126.3, 80.9, 60.6, 58.6, 56.4, 44.8, 34.2, 32.3, 28.3, 23.1, 23.0, 14.5, 12.3. 
HRMS (ESI-TOF): m/z calcld. for C20H37NO5SH+: 404.2471; found: 404.2491 [M+H]+. 
 
(2S,3R)-(Z)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-9-ethoxy-2-methyl-9-oxonon-5-enoic acid 
(2.51) 
TFA (6.0 mL) was added to a solution of alkene 2.50 (0.33 g, 0.82 mmol) in dry 
CH2Cl2 (6.0 mL) at 0° C. After stirring for 1.5 hour at room temperature the 
mixture was concentrated and the TFA was removed by co-evaporation with 
toluene (×3) to afford the crude sulfinyl protected β-amino acid (0.36 g). HCl in 
dioxane (4.0 M, 0.41 mL, 1.6 mmol, 2.0 equiv) was added to a solution of the crude sulfinyl protected β-amino 
acid in 1,4-dioxane (8.0 mL). Additional HCl (0.1 mL, 0.40 mmol, 0.5 equiv) was added after 2 hours and 2.5 
hours of stirring. After the last addition of HCl the mixture was stirred for 40 min and concentrated to afford 
the crude β-amino acid, which was used without further purification.  
A solution of the crude β-amino acid in water (4.0 mL) was added Na2CO3 (0.35 g, 3.26 mmol, 4.0 equiv) and 
cooled to 0° C. Fmoc-O-succinimide (0.33 g, 0.98 mmol, 1.2 equiv) in 1,4-dioxane (4.0 mL) was added and the 
cooling removed. After 2 hours water (60 mL) was added and the mixture washed with ether (20 mL) and 
ethyl acetate (2 × 25 mL). The aqueous phase was cooled to 0° C and acidified with concentrated HCl until pH 
≈ 2 and extracted with ethyl acetate (3 × 75 mL). The combined organic phases were washed with water (50 
mL), brine (50 mL), dried (Na2SO4) and concentrated. Purification of the crude residue by VLC (0.2% acetic 
acid in the eluent) afforded β-amino acid 2.51 (257 mg, 68%, 3 steps) as a white solid after co-evaporation of 
residual acetic acid with CH2Cl2–toluene (1:1, 3 × 10 mL). [α]D = –9.4 ° (c = 0.5, CH2Cl2); 1H NMR (300 MHz, 
DMSO) δ 7.89 (d, J = 7.4 Hz, 2H), 7.68 (d, J = 7.3 Hz, 2H), 7.41 (t, J = 7.3 Hz, 2H), 7.32 (ddd, J = 7.4, 4.3, 1.2 Hz, 
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1H), 7.15 (d, J = 9.6 Hz, 1H), 5.33 (m, 2H), 4.26 (m, 3H), 4.02 (q, J = 7.1 Hz, 1H), 3.65 (m, 1H), 2.28 (m, 7H), 
1.15 (t, J = 7.1 Hz, 3H), 1.00 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 179.6, 173.6, 156.4, 144.0, 141.4, 
130.8, 127.8, 127.1, 126.8, 125.2, 120.1, 66.8, 60.7, 53.2, 47.3, 43.8, 33.9, 29.7, 22.8, 14.3, 13.5. HRMS (ESI-
TOF): m/z calcld. for C27H31NO6H+: 466.2230; found: 466.2254 [M+H]+. 
 
(2S,3R)-(Z)-3-((tert-Butoxycarbonyl)amino)-9-ethoxy-2-methyl-9-oxonon-5-enoic acid (2.52) 
To a solution of the crude fully deprotected β-amino acid from above (2.51) (31 
mg, 0.13 mmol) and iPr2NEt (67 µL, 0.38 mmol, 3.0 equiv) in dry CH2Cl2 (3.0 mL) 
was added Boc2O (59 mg, 0.27 mmol, 2.1 equiv) in dry CH2Cl2 (1.0 mL) under 
argon. After 3 hours iPr2NEt (67 µL, 0.38 mmol, 3.0 equiv) was added and the 
reaction mixture stirred for 18 hours. After concentration the iPr2NEt was removed by co-evaporation with 
toluene. Purification of the crude residue by VLC (0.2% acetic acid in the eluent) afforded β-amino acid 2.52 
(9.3 mg, 22%, 3 steps) as a clear oil after co-evaporation of residual acetic acid with CH2Cl2–toluene (1:1, × 
3). Spectral data were in accordance with those previously reported (see figure S1).S5 [α]D: –9.8° (c = 0.4, 
CHCl3) Litt;S5 [α]D: –9.5° (c = 1, CHCl3); 1H NMR (300 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) δ 5.43 (m, 2H), 4.91 
(bs, 1H), 4.13 (q, J = 7.2 Hz, 1H), 3.89 (m, 1H), 2.67 (m, 1H), 2.44–2.21 (m, 6H), 1.42 (s, 9H), 1.25 (t, J = 7.2 Hz, 
3H), 1.21 (d, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 179.4, 173.5, 156.1, 130.4, 126.8, 79.6, 60.6, 52.6, 
43.7, 34.1, 29.8, 28.5, 22.9, 14.4, 13.4.     
(R)-2-((S)-2-((2S,3R)-(Z)-3-((R)-2-Amino-3-phenylpropanamido)-9-ethoxy-2-methyl-9-oxonon-5-enamido)-
3-methylbutanamido)propanoic acid (2.65) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val-(D)Ala (132 mg, 80 
µmol) was added to a fritted syringe and swelled with CH2Cl2 before 
the Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 × 20 
min) and DBU–piperidine–DMF (2:2:96, 4 mL, 20 min). The resin was 
then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3).     
β-Amino acid  2.51 (41 mg, 88 µmol, 1.1 equiv) in DMF (2.0 mL) was 
preincubated for 5 min with 2,6-lutidine  (30.5 µL, 263 µmol, 3.0 
equiv) and HATU (43.3 mg, 114 µmol, 1.3 equiv) before addition to 
the resin and the reaction was allowed to proceed on a rocking table for 2.5 hours. The resin was then washed 
with DMF (×3), MeOH (×3), CH2Cl2 (×3) and the Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 
× 25 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 20 min). The resin was washed again with DMF (×3), MeOH 
(×3), CH2Cl2 (×3) before added a preincubated solution of Fmoc-(D)Phe-OH (93 mg, 239 µmol, 3.0 equiv), 2,6-
lutidine (55.4 µL, 478 µmol, 6.0 equiv) and HATU (89 mg, 235 µmol, 2.95 equiv). The reaction was allowed to 
proceed on a rocking table for 16 hours. The resin was then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3) 
and the Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–piperidine–DMF 
(2:2:96, 4 mL, 20 min). The resin was washed again with DMF (×3), MeOH (×3), CH2Cl2 (×3) and treated with 
TFA–CH2Cl2 (1:1, 4 mL) for 30 min followed by washing with CH2Cl2 (5 mL). A fresh portion of TFA–CH2Cl2 (1:1, 
4 mL) was added to the resin and after additional 30 min the resin was drained, washed with CH2Cl2 (5 mL) 
and all the fractions were pooled in a tube. The solvent was removed under a stream of argon and 
precipitation with diethyl ether afforded the crude TFA salt of the linear peptide 2.65 (63 mg) as a pale yellow 
solid, which was used without further purification. UPLC-MS gradient A, tR = 1.05 min.  
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(Z)-Ethyl-6-((2R,5R,8R,11R,12S)-8-benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (2.66) 
The crude linear peptide 2.65 (63 mg, 0.093 mmol) was dissolved in CH2Cl2–DMF 
(10:1, 24 mL) and added dropwise over 3.5 hours to a solution of HATU (71 mg, 
0.19 mmol, 2.0 equiv) and iPr2NEt (73 µL, 0.42 mmol, 4.5 equiv) in CH2Cl2 (12 
mL). After the addition additional HATU (36 mg, 0.095 mmol, 1.0 equiv) and 
iPr2NEt (37 µL, 0.21 mmol, 2.3 equiv) was added. The solution was stirred for 15 
hours and concentrated. The brown residue was dissolved in CH2Cl2 (80 mL) and 
washed with aq. HCl (0.5 M, 10 mL and 1.0 M, 10 mL) and the combined aqueous 
phases were extracted with CH2Cl2 (2 × 50 mL). The combined organic phases 
were washed with brine (25 mL), dried (Na2SO4), filtered, and concentrated. 
Purification by VLC afforded a residue 2.66 (24.2 mg), which was found not to be sufficiently pure by 1H NMR 
(residual iPr2NEt was observed; yield based on 1H NMR, 25%). The residue was used without further 
purification. HPLC gradient B, tR = 1.84 min. 
Azumamide A [(Z)-6-((2R,5R,8R,11R,12S)-8-Benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enamide]. 
LiOH (89 mg, 3.72 mmol, 85 equiv) in water (4.0 mL) was added to a stirred 
solution of the impure cyclic peptide 2.66 (24.2 mg, approx. 0.045 mmol) in THF 
(4 mL). After 2.5 hours of stirring the organic solvent was removed in vacuo. The 
aqueous phase was acidified with 1 M HCl to pH 2 and extracted with EtOAc (4 
× 30 mL) and CH2Cl2 (40 mL). The organic phases were dried (Na2SO4), filtered, 
and concentrated to afford crude azumamide E (102 mg), which was used 
without further purification. HPLC gradient A, tR = 1.47 min. To a solution of the 
above crude azumamide E (102 mg, 0.045 mmol) in DMF (3.0 mL) was added 
HATU (34 mg, 0.09 mmol, 2 equiv), iPr2NEt (43 µL, 0.25 mmol, 5.5 equiv) and 
after 5 min, NH3–dioxane (0.9 mL, 0.45 mmol, 10 equiv). After 1 h NH3–dioxane (0.45 mL, 0.23 mmol, 5.0 
equiv) was added. UPLC-MS analysis showed 50% conversion after 3 hours and HATU (34 mg, 0.09 mmol, 2.0 
equiv) and NH3–dioxane (0.45 mL, 0.23 mmol, 5.0 equiv) was added. After additionally 1 hour DMF (1.0 mL) 
followed by HATU (17 mg, 0.045 mmol, 1.0 equiv) and NH3–dioxane (0.45 mL, 0.23 mmol, 5.0 equiv) was 
added and stirring continued for 1 hour before concentration in vacuo. The residue was dissolved in MeCN–
H2O and purified by preperative HPLC to give azumamide A (4.8 mg, 12%, 8 steps). [α]D: +56° (c = 0.2, MeOH) 
Litt;229 [α]D: +33° (c = 0.1, MeOH); 1H NMR (500 MHz, CD3OH) δ 8.18 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 9.0 Hz, 1H), 
7.72 (d, J = 8.2 Hz, 1H), 7.59 (m, 2H), 7.20 (m, 5H), 6.74 (bs, 1H), 5.48 (m, 1H), 5.37 (m, 1H), 4.33 (dt, J = 9.0, 
7.0 Hz, 1H), 4.24 (m, 2H), 3.81 (dd, J = 10.4Hz and 8.4 Hz, 1H), 3.10 (m, 2H), 2.72 (m, 1H), 2.57 (dt, J = 14.1 Hz 
and 6.9 Hz, 1H), 2.41 (m, 2H), 2.27 (m, 4H), 1.30 (d, J = 7.5 Hz, 3H), 1.23 (d, J = 7.3 Hz, 3H), 0.96 (d, J = 6.5 Hz, 
3H), 0.94 (d, J = 6.7 Hz, 3H). HRMS (ESI-TOF): m/z calcld. for C27H38N4O7H+: 514.3029; found: 514.3032 [M+H]+. 
HPLC gradient C, tR = 11.62 min (>95%). 
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(2S,3R)-(Z)-3-((R)-2-((R)-2-((R)-2-Amino-3-methylbutanamido)propanamido)-3-(4-
hydroxyphenyl)propanamido)-9-ethoxy-2-methyl-9-oxonon-5-enoic acid (2.62) 
Polystyrene 2-chlorotritylchloride resin was added to a fritted 
syringe and swelled with dry CH2Cl2. A solution of β-amino acid 2.51 
(47.5 mg. 0.10 mmol) and iPr2NEt (36 µL, 0.20 mmol, 2.0 equiv) in 
dry CH2Cl2 (2 mL) was added to the resin and the loading was allowed 
to proceed on a rocking table for 16 hours. After washing with CH2Cl2 
(×3) the resin was capped with CH2Cl2–MeOH–iPr2NEt (7:2:1) for 30 
min. The resin was then washed with DMF (×3), MeOH (×3), and 
CH2Cl2 (×3). The Fmoc group was removed with piperidine–DMF 
(1:4, 4 mL, 2 × 30 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min) and then washed as described above. 
Fmoc-(D)Tyr(OtBu)-OH (188 mg, 0.41 mmol, 4.0 equiv) in DMF (2.0 mL) was preincubated for 5 min with 2,6-
lutidine (95 µL, 0.82 mmol, 8.0 equiv) and HATU (153 mg, 0.40 mmol, 0.98 equiv) before addition to the resin 
and the reaction was allowed to proceed on a rocking table for 2 hours. After the washing procedure as 
outlined above the Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 × 30 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), MeOH (×3), and CH2Cl2 
(×3). 
Fmoc-(D)Ala-OH (130 mg, 0.0.41 mmol, 4.0 equiv) in DMF (2.0 mL) was preincubated for 5 min with 2,6-
lutidine (94.5 µL, 0.82 mmol, 8.0 equiv) and HATU (153 mg, 0.40 mmol, 0.98 equiv) before addition to the 
resin and the reaction was allowed to proceed on a rocking table for 2.5 hours. After the washing procedure 
as outlined above the Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 × 30 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). 
Fmoc-(D)Val-OH (139 mg, 0.41 mmol, 4.0 equiv) in DMF (2.0 mL) was preincubated for 5 min with 2,6-lutidine 
(94.5 µL, 0.82 mmol, 8.0 equiv) and HATU (153 mg, 0.40 mmol, 0.98 equiv) before addition to the resin and 
the reaction was allowed to proceed on a rocking table for 2 hours. After the washing procedure as outlined 
above the Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 × 30 min) and DBU–piperidine–DMF 
(2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), MeOH (×3), and CH2Cl2 (×3). The resin was 
treated with TFA–CH2Cl2 (1:1, 2 mL) for 30 min, followed by washing with CH2Cl2 (2 mL). A fresh portion of 
TFA–CH2Cl2 (1:1, 2 mL) was added to the resin and after additional 30 min the resin was drained, washed with 
CH2Cl2 (2 mL) and all the fractions were pooled in a tube and concentrated under a stream of argon. 
Precipitation with diethyl ether afforded the TFA salt of the linear peptide 2.62 (64 mg, 91%) as a pale yellow 
solid, which was used without further purification UPLC-MS gradient A, tR = 1.03 min (>95%) 
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(Z)-Ethyl-6-((2R,5R,8R,11R,12S)-8-(4-hydroxybenzyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-
1,4,7,10-tetraazacyclotridecan-11-yl)hex-4-enoate (2.63) 
The TFA salt of the crude linear peptide 2.62 (64 mg, 0.09 mmol) was dissolved 
in DMF (240 mL ≈ 0.4 mM) and iPr2NEt (129 µL, 0.74 mmol, 8.0 equiv) and HATU 
(39 mg, 0.10 mmol, 1.1 equiv) were added. The solution was stirred for 17 hours 
and then added HATU (18 mg, 0.05 mmol, 0.6 equiv). After additionally 1 hour 
of stirring the reaction mixture was concentrated and purified by preparative 
HPLC to afford the ethylester of azumamide C 2.63 (6.1 mg, 11%, 10 steps) as a 
white solid. HRMS (ESI-TOF): m/z calcld. for C29H42N4O7H+: 559.3131; found: 
559.3123  [M+H]+. UPLC-MS gradient A, tR = 1.60 min (purity > 95%). 
 
Azumamide B [(Z)-6-((2R,5R,8R,11R,12S)-8-(4-Hydroxybenzyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-
tetraoxo-1,4,7,10-tetraazacyclotridecan-11-yl)hex-4-enamide] 
 An aqueous solution of LiOH (0.5 M, 55 µL, 2.0 mmol, 2.5 equiv) was added to 
the cyclic peptide 2.63 (6.1 mg) in THF–H2O ((1:1), 2 mL) at 0 oC. After 30 min the 
ice-bath was removed. Additional portions of LiOH solution (55 µL, 2.0 mmol, 2.5 
equiv) were added after 2, 4, and 6 hours, and stirring was continued for 
additional 19 hours to ensure full conversion. Then water (0.5 mL) was added 
and the organic solvent removed in vacuo. The aqueous phase was acidified with 
1 M HCl and extracted with EtOAc (5 × 20 mL). The organic phase was dried 
(Na2SO4), filtered and concentrated in vacuo to afford the crude azumamide C 
(20 mg), which was used without further purification.  
To a solution of crude azumamide C (5.8 mg, 10.9 µmol) in DMF (2 mL) was added HOBt (4.4 mg, 33 µmol, 
3.0 equiv), DIC (5.1 µL, 34 µmol, 3.0 equiv) and iPr2NEt (7.6 µL, 44 µmol, 4.0 equiv). After 10 minutes NH3–
dioxane (0.5 M, 0.11 mL, 55 µmol, 5.0 equiv) was added. After 1.5 hour DIC (5 µL, 34 µmol, 3.0 equiv) followed 
by NH3–dioxane (0.5 M, 0.11 mL, 55 µmol, 5.0 equiv) were added. After stirring for 16 hours, additional DIC 
(2.0 equiv) and NH3–dioxane (5.0 equiv) were added and this procedure was repeated once more after 18 
hours. Finally, CH2Cl2 (1 mL) followed by DIC (3.0 equiv) and NH3–dioxane (10 equiv) were added and after 2 
days of stirring at room temperature, the reaction mixture was concentrated, dissolved in MeCN–H2O (2:1), 
and purified by preparative HPLC to give azumamide B (3.6 mg, 62%, two steps) as a white solid. [α]D: +65° (c 
= 0.15, MeOH) Litt;229 [α]D: +45° (c = 0.1, MeOH); 1H NMR (500 MHz, CD3OH) δ 8.13 (d, J = 7.9 Hz, 1H), 8.00 
(d, J = 8.9 Hz, 1H), 7.85 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.01 (d, J = 8.4 Hz, 3H), 6.67 (d, J = 8.4 Hz, 
3H), 5.49 (m, 1H), 5.37 (dd, J = 18.0 Hz and 7.3 Hz, 2H), 4.29 (pentet, J = 7.2 Hz, 1H), 4.15 (m, 1H), 4.05 (m, 
1H), 3.60 (m, 1H), 3.13 (dd, J = 13.7, 10.1 Hz, 1H), 3.00 (dd, J = 13.8, 6.3 Hz, 1H), 2.70 (m, 2H), 2.36 (ddd, J = 
22.3, 21.5, 7.1 Hz, 11H), 1.29  (d, J = 7.2 Hz, 3H),  1.27 (d, J = 7.4 Hz, 3H), 0.95 (d, J = 5.7 Hz, 3H), 0.93 (d, J = 
6.0 Hz, 3H). HRMS (ESI-TOF): m/z calcld. for C27H39N5O6H+: 530.2978; found: 530.2973 [M+H]+. HPLC gradient 
C, tR = 10.31 min (>95%). 
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(R)-2-((S)-2-((2S,3R)-(Z)-3-((R)-2-Amino-3-(4-hydroxyphenyl)propanamido)-9-ethoxy-2-methyl-9-oxonon-
5-enamido)-3-methylbutanamido)propanoic acid (2.60) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val-(D)Ala (249 mg, 
0.17 mmol) was added to a fritted syringe and swelled with 
CH2Cl2 before the Fmoc group was removed with piperidine–DMF 
(1:4, 4 mL, 2 × 30 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 
30 min). The resin was then washed with DMF (×3), MeOH (×3), 
CH2Cl2 (×3). β-Amino acid 2.51 (100 mg, 0.22 mmol, 1.3 equiv) in 
DMF (3.0 mL) was preincubated for 5 min with 2,6-lutidine (60 
µL, 0.52 mmol, 3.0 equiv) and HATU (86 mg, 0.23 mmol, 1.3 
equiv) before addition to the resin. The reaction was allowed to proceed on a rocking table for 16 hours. 
After the washing procedure as outlined above the resin was dried under high vacuum. The Fmoc group was 
removed with piperidine–DMF (1:4, 4 mL, 2 × 30 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). The 
resin was then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). 
Fmoc-(D)Tyr(OtBu)-OH (74 mg, 0.16 mmol, 3.6 equiv) in DMF (2.0 mL) was preincubated for 5 min with 2,6-
lutidine (37 µL, 0.32 mmol, 7.1 equiv) and HATU (59 mg, 0.16 mmol, 3.6 equiv) before being added to 
polystyrene 2-chlorotrityl-bound H2N-β-aa-(D)Val-(D)Ala (75 mg, 0.045 mmol) and the reaction was allowed 
to proceed on a rocking table for 16 hours. After the washing procedure as outlined above the Fmoc group 
was removed with piperidine–DMF (1:4, 4 mL, 2 × 30 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). 
The resin was treated with TFA–CH2Cl2 (1:1, 4 mL) for 30 min followed by washing with CH2Cl2 (5 mL). A fresh 
portion of TFA–CH2Cl2 (1:1, 4 mL) was added to the resin and after additional 30 min the resin was drained, 
washed with CH2Cl2 (5 mL) and all the fractions were pooled and concentrated in vacuo. Excess TFA was 
removed by co-evaporation with toluene to give the crude linear peptide 2.60 (34 mg), which was used 
without further purification.  
 
(Z)-Ethyl-6-((2R,5R,8R,11R,12S)-8-(4-hydroxybenzyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-
1,4,7,10-tetraazacyclotridecan-11-yl)hex-4-enoate (2.61) 
The crude linear peptide 2.60 (34 mg, 0.045 mmol) was dissolved in DMF (180 
mL ≈ 0.25 mM) and iPr2NEt (102 µL, 0.58 mmol, 13 equiv) and HATU (45 mg, 0.12 
mmol, 2.7 equiv) were added. The solution was stirred for 2 hours and the 
reaction mixture was concentrated and added EtOAc (220 mL). The organic 
phase was washed with aq. HCl (1.0 M, 3 × 10 mL) and concentrated to afford 
the crude cyclic peptide 2.61 (61 mg) as a brown oil, which was used without 
further purification.  
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Azumamide C [(Z)-6-((2R,5R,8R,11R,12S)-8-(4-Hydroxybenzyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-
tetraoxo-1,4,7,10-tetraazacyclotridecan-11-yl)hex-4-enoic acid]  
LiOH (49 mg, 2.0 mmol, 35 equiv) in water (5.0 mL) was added to the crude cyclic 
peptide 2.61 (61 mg) in THF (5.0 mL). The solution was stirred for 16 hours and 
concentrated in vacuo. The resulting residue was dissolved in THF–H2O (1:1), 10 
mL) by adding a few drops of TFA and then purification by preparative HPLC 
afforded azumamide C (2.2 mg, 9%, 8 steps) as a white solid. [α]D: +49° (c = 0.14, 
MeOH) Litt;229 [α]D: +21° (c = 0.1, MeOH); 1H NMR (500 MHz, CD3OH) δ 8.08 (d, J 
= 7.7 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.84 (s, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.01 (d, 
J = 8.4 Hz, 2H), 6.67 (d, J = 8.4 Hz, 2H), 5.48 (t, J = 8.8 Hz, 1H), 5.38 (dt, J = 10.7, 
7.0 Hz, 1H), 4.29 (pentet, J = 7.3 Hz 1H), 4.16 (m, 1H), 4.01 (m, 1H), 3.58 (m, 1H), 
3.15 (dd, J= 13.7, 10.2 Hz 1H), 3.00 (dd, J = 13.7 Hz and 6.0 Hz, 1H), 2.72 (m, 1H), 
2.67 (m, 1H) 2.39 (m, 5H), 1.29 (d, J = 7.2 Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H), 0.95 (d, J = 6.0 Hz, 3H), 0.93 (d, J = 
6.0 Hz, 3H). HRMS (ESI-TOF): m/z calcld. for C27H38N4O7H+: 531.2819; found: 531.2815 [M+H]+. HPLC gradient 
C, tR = 11.04 min (>95%). 
(R)-2-((2S,3R)-(Z)-3-((R)-2-((R)-2-Aminopropanamido)-3-phenylpropanamido)-9-ethoxy-2-methyl-9-
oxonon-5-enamido)propanoic acid (2.64) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Ala (118 mg, 0.096 mmol) 
was added to a fritted syringe and swelled with CH2Cl2 before the Fmoc 
group was removed with piperidine–DMF (1:4, 4 mL, 2 × 30 min) and 
DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then 
washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). β-Amino acid 2.51 (49 
mg, 105 µmol, 1.1 equiv) in DMF (2.0 mL) was preincubated for 5 min 
with iPr2NEt (43 µL, 249 µmol, 2.6 equiv) and PyBOP (65 mg, 125 µmol, 
1.3 equiv) and added to the resin. The reaction was allowed to proceed 
on a rocking table for 16 hours. A Kaiser test showed incomplete coupling and the resin treated with β-amino 
acid 2.51 (15 mg, 32 µmol), iPr2NEt (15 µL, 83 µmol, 2.6 equiv) and PyBOP (22 mg, 42 µmol, 1.3 equiv) for 
another 16 hours. The resin was then washed with DMF (×3), MeOH (×3), and CH2Cl2 (×3) and the Fmoc group 
was removed with piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). 
The resin was washed with DMF (×3), MeOH (×3), and CH2Cl2 (×3) before addition of a preincubated solution 
of Fmoc-(D)Phe-OH (148 mg, 382 µmol, 3.0 equiv), 2,6-lutidine (88 µL, 762 µmol, 6.0 equiv) and HATU (143 
mg, 376 µmol, 3.0 equiv) in DMF (2 mL). The coupling was allowed to proceed on a rocking table for 2 hours. 
The resin was then washed with DMF (×3), MeOH (×3), and CH2Cl2 (×3) and the Fmoc group was removed 
with piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). After washing 
[DMF (×3), MeOH (×3), and CH2Cl2 (×3)], a preincubated solution of Fmoc-(D)Ala-OH (119 mg, 382 µmol, 3.0 
equiv), 2,6-lutidine (88 µL, 762 µmol, 6.0 equiv) and HATU (143 mg, 376 µmol, 3.0 equiv) in DMF (2 mL) was 
added to the resin. The coupling was allowed to proceed on a rocking table for 15 hours. After washing, the 
Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–piperidine–DMF (2:2:96, 4 
mL, 30 min) and the resin was washed again [DMF (×3), MeOH (×3), and CH2Cl2 (×3)]. After cleavage from the 
resin with TFA–CH2Cl2 (1:1, 2 × 4 mL, 30 min) the solvent was removed under a stream of argon and 
precipitation with diethyl ether afforded the TFA salt of the crude linear peptide 2.64 (84 mg, >99%) as a pale 
yellow solid. UPLC-MS gradient B, tR = 1.06 min (purity >95%) 
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(Z)-ethyl-6-((2R,5R,8R,11R,12S)-8-Benzyl-2,5,12-trimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (2.65) 
The crude linear peptide 2.64 (79 mg, 0.12 mmol) was dissolved in DMF (250 mL 
≈ 0.5 mM) and iPr2NEt (170 µL, 0.98 mmol, 8.0 equiv) and HATU (51 mg, 0.13 
mmol, 1.1 equiv) were added successively. The solution was stirred for 19 hours 
and concentrated. To the oily residue was added EtOAc (150 mL). A precipitate 
was observed as the organic phase was acidified with aq. HCl (1.0 M, 20 mL). The 
precipitate was dissolved in CH2Cl2 (150 mL) and washed with aq. HCl (1.0 M, 20 
mL). The organic phases were pooled, concentrated, and purified by VLC to afford 
a residue 2.65 (22.7 mg), which was found not to be pure by 1H NMR (residual 
iPr2NEt was observed; yield based on 1H NMR = 19%). The residue was used 
without further purification. HPLC gradient B, tR = 1.45 min. 
Azumamide D [(Z)-6-((2R,5R,8R,11R,12S)-8-Benzyl-2,5,12-trimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enamide]  
LiOH (53 mg, 2.21 mmol, 50 equiv) in water (5.0 mL) was added to a stirred 
solution of the impure cyclic peptide 2.65 (22.7 mg, approx. 0.044 mmol) in THF 
(3 mL). After 4 hours the organic solvent was removed in vacuo and the water (0.5 
mL) was added to the aqueous, which was then acidified with 1 M HCl (2 mL) and 
extracted with EtOAc (4 × 2 mL). The organic phases were dried (MgSO4), filtered, 
and concentrated to give the crude acid (53 mg), which was used without further 
purification. To a solution of the crude acid (11 mg, 23 µmol) in CH2Cl2–DMF (8:1, 
2.3 mL) was added HOBt (10 mg, 66 µmol, 3.0 equiv), DIC (10 µL, 66 µmol, 3.0 
equiv) and iPr2NEt (15 µL, 88 µmol, 4.0 equiv). After 5 minutes NH3–dioxane (0.5 
M, 0.22 mL, 110 µmol, 5.0 equiv) was added. After 1 hour NH3–dioxane (0.5 M, 0.22 mL, 110 µmol, 5.0 equiv) 
was added. After stirring for 18 hours additional DMF (0.5 mL) followed by NH3–MeOH (2.0 M, 0.11 mL, 230 
µmol, 10 equiv) was added. After additionally 5 hours DIC (7 µL, 46 µmol, 2.0 equiv) was added. The next day 
NH3–MeOH (2.0 M, 0.06 mL, 111 µmol, 5.0 equiv) was added and the mixture was stirred for 10 days. Finally, 
DIC (3.4 µL, 23 µmol, 1.0 equiv) followed by NH3–MeOH (2.0 M, 0.055 mL, 210 µmol, 5.0 equiv) was added 
and after 2 days the mixture was concentrated, dissolved in MeCN–H2O (2:1) and purified by preparative 
HPLC to afford azumamide D (1.2 mg, 4%, 11 steps) as a white solid. [α]D: +32° (c = 0.08, MeOH) Litt;229 [α]D: 
+25° (c = 0.1, MeOH); 1H NMR (500 MHz, CD3OH) δ 8.03 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H) 7.94 (d, J = 
6.8 Hz, 1H), 7.58 (s, 1H), 7.32 (d, J = 7.5 Hz, 1H), 7.25–7.14 (m, 5H), 6.75 (s, 1H), 5.47 (m, 1H), 5.39 (m, 1H), 
4.35 (m, 1H), 4.19 (m, 1H) 4.17– 4.11 (m, 2H), 3.09 (m, 2H), 2.69 (m, 1H), 2.62 (m, 1H), 2.41 (m, 2H), 2.28 (m, 
1H), 1.47 (d, J = 7.4 Hz, 3H), 1.28 (d, J = 7.4 Hz, 3H), 1.22 (d, J = 7.3 Hz, 3H). HRMS (ESI-TOF): m/z calcld. for 
C25H35N5O5H+: 486.2716; found: 486.2710 [M+H]+. HPLC gradient C, tR = 10.55 min (>95%). 
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(2R,5R,8S,11S,12R)-(Z)-12-Amino-2-benzyl-8-isopropyl-5,11-dimethyl-4,7,10,18-tetraoxo-19-oxa-3,6,9-
triazahenicos-14-en-1-oic acid (2.67) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val-(D)Ala-(D)-
Phe (0.41 g, 0.21 mmol) was added to a fritted syringe and 
swelled with CH2Cl2 before the Fmoc group was removed 
with piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was 
then washed with DMF (×3), MeOH (×3), and CH2Cl2 (×3).     
β-Amino acid 2.51 (100 mg, 0.21 mmol, 1.05 equiv) in DMF (3.0 mL) was preincubated for 5 min with iPr2NEt 
(90 µL, 0.52 mmol, 2.4 equiv) and PyBOP (134 mg, 0.26 mmol, 1.2 equiv) and added to the resin. The reaction 
was allowed to proceed on a rocking table for 16 hours. The resin was then washed [DMF (×3), MeOH (×3), 
and CH2Cl2 (×3)] and the Fmoc group was removed with piperidine–DMF (1:4, 4 mL, 2 × 25 min) followed by 
DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). After washing [DMF (×3), MeOH (×3), and CH2Cl2 (×3)], the resin 
was cleaved with TFA–CH2Cl2 (1:1, 2 × 4 mL, 30 min each) and all the fractions were pooled in a Falcon tube. 
The solvent was removed under a stream of argon and precipitation with diethyl ether afforded the TFA salt 
of the linear peptide 2.67 (124 mg, 90%) as a pale yellow solid. UPLC-MS gradient A, tR = 1.19 min (93% purity 
as determined by the HPLC UV trace). 
(Z)-Ethyl-6-((2R,5R,8R,11R,12S)-8-benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (Table 2-3, entry 1, 2.68) 
The crude linear peptide 2.67 (120 mg, 0.18 mmol) was dissolved in DMF (450 
mL ≈ 0.4 mM) and iPr2NEt (248 µL, 1.42 mmol, 8.0 equiv) and HATU (74 mg, 0.20 
mmol, 2.1 equiv) were added. The solution was stirred for 21 hours and then 
added iPr2NEt (125 µL, 0.71 mmol, 4.0 equiv) and HATU (34 mg, 0.09 mmol, 0.5 
equiv). After additionally 3 hours of stirring the reaction mixture was 
concentrated and added EtOAc (250 mL). The organic phase was washed with 
aq. HCl (1.0 M, 10 mL) and the aqueous phase was extracted with CH2Cl2 (2 × 50 
mL). The organic phases were pooled, concentrated and purified by VLC to 
afford a residue 2.68 (36.6 mg), which was found not to be pure by 1H NMR 
(residual iPr2NEt was observed; yield based on 1H NMR, 23%). The residue was used without further 
purification. HPLC gradient B, tR = 1.84 min. 
The same peptide was obtained using the slow addition cyclization protocol (Table 11, entry 5). 
The crude linear peptide 2.67 (61 mg, 0.09 mmol) was dissolved in CH2Cl2–DMF (10:1, 24 mL) and added 
dropwise over 3.5 hours to a solution of HATU (69 mg, 0.18 mmol, 2.0 equiv) and iPr2NEt (71 µL, 0.41 mmol, 
4.5 equiv) in CH2Cl2 (12 mL).  After the addition, additional HATU (33 mg, 0.09 mmol, 1.0 equiv) and iPr2NEt 
(35 µL, 0.20 mmol, 2.3 equiv) was added. The solution was stirred for 16 hours and concentrated. The brown 
residue was dissolved in CH2Cl2 (30 mL) and washed with aq. HCl (0.25 M, 10 mL) and the aqueous phase 
were extracted with CH2Cl2 (3 × 20 mL). The combined organic phases were washed with sat. aq. NaHCO3 (15 
mL), brine (15 mL) dried (Na2SO4), filtered, and concentrated. Purification by VLC afforded a residue 2.66 (19 
mg), which was found not to be sufficiently pure by 1H NMR (residual iPr2NEt was observed). 
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Azumamide E [(Z)-6-((2R,5R,8R,11R,12S)-8-Benzyl-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid] 
LiOH (18.5 mg, 0.77 mmol, 39 equiv) in water (4 mL) was added to a stirred 
solution of the impure cyclic peptide 2.68 (10.5 mg, approx. 0.02 mmol) in THF (4 
mL). After 1 hour, LiOH (10 mg, 0.42 mmol, 21 equiv) in water (1 mL) was added 
and after 2 hours LiOH (5.0 mg, 0.21 mmol, 1.0 equiv) in water (0.5 mL) was 
added. The solution was stirred for 16 h and another portion of LiOH (6.0 mg, 
0.25 mmol, 1.3 equiv) in water (0.5 mL) was added. After additionally 2.5 hours 
of stirring the organic solvent was removed in vacuo.  The aqueous phase was 
acidified with 1 M HCl and extracted with EtOAc (4 × 25 mL). The combined 
organic phases were dried (Na2SO4), filtered, and concentrated. The resulting 
residue was dissolved in MeCN–water [(3:2), 2.5 mL] and purified by preparative 
HPLC to afford azumamide E (4.3 mg, 15%, 6 steps) as a white solid. [α]D: +66° (c = 0.2, MeOH) Litt;229 [α]D: 
+53° (c = 0.1, MeOH); 1H NMR (500 MHz, CD3OH) δ 8.10 (d, J = 7.7 Hz, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.84 (bs, 
1H), 7.63 (d, J = 8.4 Hz, 1H), 7.28–7.16 (m, 5H), 5.48 (m, 1H), 5.37 (m, 1H), 4.28 (pentet, J = 7.5 Hz, 1H), 4.16 
(m, 1H), 4.08 (m, 1H), 3.59 (m, 1H), 3.25 (dd, J = 13.6 Hz and 10.4 Hz, 1H), 3.11 (dd, J = 13.6 Hz and 6.1 Hz, 
1H), 2.72 (m, 1H), 2.68 (m, 1H), 2.39 (d, J = 1.7 Hz, 6H), 2.39 (m, 6H), 1.28 (d, J = 7.1 Hz, 3H), 1.27 (d, J = 7.4 
Hz, 3H), 0.94 (m, 6H). HRMS (ESI-TOF): m/z calcld. for C27H38N4O6H+: 515.2869; found: 515.2869 [M+H]+. HPLC 
gradient C, tR = 12.53 min (>95%). 
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Experimental for chapter 3 
Biochemical profiling 
Assay Materials  
See experimental for chapter 2.   
In Vitro Histone Deacetylase Inhibition Assays  
For inhibition of recombinant human HDACs the dose–response experiments with internal controls were 
performed in black low binding NUNC 96-well microtiter plates. Dilution series (3-fold dilution, 6 
concentrations) were prepared in HDAC assay buffer from 5–10 mM DMSO stock solutions. The appropriate 
dilution of inhibitor (5 µL of 5 × the desired final concentration) was added to each well followed by HDAC 
assay buffer (10 µL) containing substrate [Ac-Leu-Gly-Lys(Ac)-AMC (20 µM) for HDAC1, 2, and 3; (32 µM) for 
HDAC6 and (40 µM) for HDAC11; (200 µM) for HDAC8; and Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC (50 µM) for 
HDAC10]. Finally, a solution of the appropriate HDAC (10 µL) was added and the plate was incubated at 37 
°C for 30 min. Final HDAC concentrations: HDAC1: 6 ng/µL, HDAC2: 1 or 2 ng/µL, HDAC3: 0.2 ng/µL, HDAC6: 
2.4 or 3.6 ng/µL, HDAC8: 0.1 or 0.2 ng/µL, HDAC10: 10 or 14 ng/µL and HDAC11: 10 ng/µL. Then trypsin (25 
µL, 0.4 mg/mL) was added and the assay development was allowed to proceed for 15–30 min at room 
temperature, before the plate was read using a Perkin Elmer Enspire plate reader with excitation at 360 nm 
and detecting emission at 460 nm. Each assay was performed in duplicate. The data were analyzed as 
described in chapter 2. 
NMR solution structures 
NMR 
NMR spectra were acquired using standard pulse sequences on a Unity Inova 500 by Varian (499.9 MHz for 
1H, 125.7 MHz for 13C) or a Bruker Avance 800 MHz spectrometer (798.9 MHz for 1H and 200.9 MHz for 13C) 
located at the Danish Instrument Centre for NMR Spectroscopy of Biological Macromolecules at Carlsberg 
Laboratory. 
The deuterated solvent used for all compounds was DMSO-d6. For homonuclear 2D experiments 4096 data 
points were recorded in the direct dimension and 512 in the indirect dimension. Typical d1 times were from 
2 to 4 seconds, and 8 seconds. The T1 times were investigated for a model compound and all nuclei were 
found to have T1’s below 2 seconds. All J-couplings were extracted from the 1D 1H spectra. Distances were 
obtained from 2D NOESY or ROESY experiments using the initial rate approximation (IRA).230,231 The linear 
range was increased by the method suggested by Krishnamurthy et al.232 Mixing time was 150 ms for all 
compounds. Prior different mixing times were used to construct buildup curves to ensure that only 
crosspeaks which fitted the IRA were used. The J-couplings from angles were calculated by the Karplus 
equation for peptides.233  
It should be noted that it was tried to obtain NMR spectra in D2O to better simulate a biological environment. 
This was not possible due to solubility problems. Up to 15 % DMSO-d6 was added but a concentration that 
made it possible to obtain spectra was not reached.  
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Simulations 
Simulations were conducted using the program Maestro (Version 9.3.515, MMshare Version 2.1.515) from 
the Schrödinger suite. Conformational searches in implicit solvents (DMSO and H2O) were run by 
MacroModel (version 9.9, Schrödinger, LLC, New York, NY, 2012) using the force fields OPLS2005 and MMFFs. 
The natural compound was altered to avoid very stable interactions with the ring amide functionalities, as 
this structure was not supported by the NMR data. The side β3-side chain amide  was thus exchanged with a 
methyl group. Monte Carlo torsional sampling was used to generate the structures and the minimization 
method was PRCG. Only conformations within 20 kJ/mol of the found “global” minimum were considered. 
DMSO was treated as a constant dielectric constant of 47.0. Both solvents and force fields gave similar results, 
and the distances and torsion angles were optimized by applying constraints on the side groups of valine and 
the aromatic amino acid residue according to the observed J-couplings. The constraints were implemented 
by calculating the appropriate angles from J-couplings, using the structural knowledge obtained from 
NOE/ROEs. This angle was allowed to differ by 10 degrees and was governed by a force constant of 50 kJ/mol.  
The structures obtained as well as structures from non-restricted minimizations were placed in the center of 
a cubic box of 45x45x45 Å3, and explicit water was added using the program Desmond (Desmond Molecular 
Dynamics System, version 3.1, D. E. Shaw Research, New York, NY, 2012. Maestro-Desmond Interoperability 
Tools, version 3.1, Schrödinger, New York, NY, 2012) and the force field OPLS2005.234 Berendsen coupling 
was used for temperature and pressure control.235 The system was minimized by steepest decent to remove 
unwanted overlaps of atoms. The system was then heated from 30 K to 300 K in two steps; 30 to 100 K in 
100 ps and 100 to 300 K in 200 ps. This was done with temperature coupling (tT=0.1 ps). The resulting system 
was held at 300 K and 1 bar with temperature and pressure couplings (tT=0.1 ps, tP=0.5 ps) and simulations 
of 10 ns was conducted. Structures were recorded every 20 ps.  
Material and methods 
General 
All chemicals and solvents were analytical grade and used without further purification. Vacuum liquid 
chromatography (VLC) was performed on silica gel 60 (particle size 0.015−0.040µm). UPLC−MS analyses were 
performed on a Waters Acquity ultra high-performance liquid chromatography system. A gradient with 
eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in acetonitrile) rising linearly from 0% to 95% of 
II during t = 0.00–2.50 min was applied at a flow rate of 1 mL/min (gradient A) or during t = 0.00–5.20 min 
(gradient B). Analytical HPLC was performed on a [150 mm × 4.6 mm, C18 Phenomenex Luna column (3 µm)] 
using an Agilent 1100 LC system equipped with a UV detector. A gradient, C, with eluent III (95:5:0.1, 
water−MeCN−TFA) and eluent IV (0.1% TFA in acetonitrile) rising linearly from 0% to 95% of IV during t = 
2−20 min was applied at a ﬂow rate of 1 mL/min. Preparative reversed-phase HPLC was performed on a [250 
mm × 20 mm, C18 Phenomenex Luna column (5 μm, 100 Å)] using an Agilent 1260 LC system equipped with 
a diode array UV detector and an evaporative light scattering detector (ELSD). A gradient C with eluent III and 
eluent IV) rising linearly from 0% to 95% of IV during t = 5−45 min was applied at a flow rate of 20 mL/min. 
1D and 2D NMR spectra were recorded on a Varian INOVA 500 MHz instrument, a Bruker Ascend 400 MHz 
or a Varian Mercury 300 instrument. All spectra were recorded at 298 K. For the Varian INOVA 500 MHz 
instrument and the Varian Mercury 300 instrument 1D NMR spectra were recorded at 499.9 MHz and 300 
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MHz for 1H and 100 MHz and 75 MHz for 13C, respectively.  The correlation spectroscopy (COSY) spectra 
were recorded with a relaxation delay of 1.5 sec before each scan, a spectral width of 6k × 6k, collecting 8 
FIDs and 1k × 512 data points. Heteronuclear single quantum coherence (HSQC) spectra were recorded with 
a relaxation delay of 1.5 sec before each scan, a spectral width of 6k × 25k, collecting 16 FIDs and 1k × 128 
datapoints. Heteronuclear 2-bond correlation (H2BC) spectra were recorded with a relaxation delay of 1.5 
sec before each scan, a spectral width of 4k × 35k, collecting 16 FIDs at 295 K and 1k × 256 datapoints. 
Heteronuclear multiple-bond correlation (HMBC) spectra were recorded with a relaxation delay of 1.5 sec 
before each scan, a spectral width of 6k × 35 k, collecting 32 FIDs and 1k × 256 datapoints. Finally, on the 
Bruker Ascend 400 MHz the 1D NMR spectra were recorded at 400 MHz for 1H and 100 MHz for 13C. The 
correlation spectroscopy (COSY) spectra were recorded with a relaxation delay of 1.5 sec before each scan, 
a spectral width of 3k × 3k, collecting 4 FIDs and 1k × 128 data points. The heteronuclear single quantum 
coherence (HSQC) spectra were recorded with a relaxation delay of 1.5 sec before each scan, a spectral width 
of 4800 × 16600, collecting 4 FIDs and 1k × 256 datapoints.  Chemical shifts are reported in ppm relative to 
deuterated solvent peaks as internal standards (δH, DMSO-d6 2.50 ppm; δC, DMSO-d6 39.52 ppm, δH, CD3OH 
3.30 ppm, δH, CDCl3 7.26 ppm; δC, CDCl3 77.16 ppm). Coupling constants (J) are given in hertz (Hz). 
Multiplicities of 1H NMR signals are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet. 
General method for Mannich reactions  
A solution of LDA (2.1–3.1 equiv) was added dropwise to a solution of the ester (2.0 – 3.0 equiv) in dry THF 
at – 78 °C. After stirring for 30 min Ti(O-iPr)3Cl (4.2 equiv) in dry THF was added dropwise. The orange solution 
was stirred for 30 min and the imine (1.0 equiv) in dry THF was added dropwise. The mixture was stirred for 
3 h or until TLC showed full conversion of the imine. The mixture was quenched with sat. aq. NH4Cl and 
allowed to warm up to room temperature. Water was added and the mixture decanted into a separatory 
funnel. The remaining Ti precipitate was added EtOAc–water (1:1) and stirred vigorously for 5 min before 
being added to the separatory funnel. The aqueous phase was extracted with EtOAc and the combined 
organic phases were washed again with water, dried (MgSO4), filtered, and concentrated in vacuo.  
tert-butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-((triisopropylsilyl)oxy)pentanoate (Table 3-2, entry 2) 
The general procedure was followed using imine 2.14 (187 mg, 0.56 mmol), tert-butyl 
acetate (0.15 mL, 1.12 mmol), LDA (1.8 M, 0.65 mL, 1.17 mmol) and Ti(O-iPr)3Cl (0.60 
mL, 2.35 mmol). Diastereoselectivity was determined by 1H NMR integration of the 
crude reaction mixture (3R/3S; 74:26). The diastereomers could not be separated by 
VLC and the purification afforded a mixture of diastereomers as a pale yellow oil (171 
mg, 68%). 
4-methoxybenzyl 3-((R)-1,1-dimethylethylsulfinamido)hexanoate (Table 3-2, entry 4) 
The general procedure was followed using imine 2.14 (169 mg, 0.51 mmol), PMB 
acetate (0.16 mL, 1.01 mmol), LDA (1.0 M, 1.1 mL, 1.07 mmol) and Ti(O-iPr)3Cl (0.53 
mL, 2.13 mmol). To accomplish full conversion of the imine, additional enolate was 
prepared as above using PMB acetate (90 µL, 0.56 mmol), LDA (0.6 mL, 0.60 mmol) 
and Ti(O-iPr)3Cl (0.3 mL, 1.21 mmol) and added to the reaction mixture. 
Diastereoselectivity was determined by 1H NMR integration of the crude reaction mixture (82:18).   
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tert-butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-((triisopropylsilyl)oxy)pentanoate (Table 3-2, entry 3) 
A solution of tert-butyl acetate (106 µL, 0.79 mmol, 2.0 equiv) in dry THF (6 mL) was 
cooled to – 78 °C and added LDA (1.0 M, 0.83 mL, 0.83 mmol, 2.1 equiv) over 5 
minutes. After 30 minutes HMPA (0.22 mL, 1.26 mmol, 3.2 equiv) was added and after 
additional 30 minutes of stirring imine 2.14 (131 mg, 0.39 mmol) in dry THF (0.5 mL) 
was added dropwise. After 45 minutes the reaction was quenched with sat. aq. NH4Cl 
(50 µL) and allowed to warm to room temperature. The reaction mixture was diluted with ethyl acetate (50 
mL) and washed with water (10 mL). The aqueous phase was extracted again with ethyl acetate (30 mL) and 
the combined organic phases were dried (MgSO4), filtered, and concentrated in in vacuo. Diastereoselectivity 
was determined by 1H NMR integration of the crude reaction mixture (3R/3S; 28:72). Purification by VLC 
afforded the major 3S diastereomer (34 mg, 19%) as well as a fraction containing a mixture of diastereomers 
(74 mg, 42%). Characterization of major diastereomer: α[D]= –37 ° (CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 4.07 
(d, J = 6.5 Hz, 1H), 3.93–3.74 (m, 3H), 2.58 (dd, J = 15.8, 6.4 Hz, 1H)  2.47 (dd, J = 15.8, 6.4 Hz, 1H), 1.90 (m, 
2H), 1.43 (s, 9H), 1.18 (s, 9H), 1.11–0.99 (m, 21H); 13C NMR (75 MHz, CDCl3) δ 171.0, 80.9, 60.9, 55.7, 52.2, 
42.1, 37.9, 28.3, 22.8, 18.2, 12.0. HRMS (ESI-TOF): m/z calcld. for C22H47NO4SSiH+: 450.3068; found: 450.3106 
[M+H]+.   
 
(R)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-5-((triisopropylsilyl)oxy)pentanoate (Table 3-2, entry 1, 
3.25) 
The general procedure was followed using imine 2.14 (0.99 g, 2.97 mmol), ethyl 
acetate (0.59 mL, 6.0 mmol), LDA (1.0 M, 6.25 mL, 6.30 mmol) and Ti(O-iPr)3Cl (3.00 
mL, 12.5 mmol). Only one diastereomer was observed in the 1H NMR and the crude 
mixture (1.17 g, 94%) was used without further purification. 1H NMR (300 MHz, CDCl3) 
δ 4.32 (d, J = 8.9 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.78 (m, 1H), 2.89 (dd, J = 16.2 and 
5.3 Hz, 1H), 2.64 (dd, J = 16.2 and 5.0 Hz, 1H), 1.66–1.87 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H), 1.21 (s, 9H), 1.04 (m, 
21H); 13C NMR (75 MHz, CDCl3) δ 172.3, 60.7, 60.0, 56.0, 51.1, 40.5, 38.5, 22.8, 18.2, 14.3, 12.0; HRMS (ESI-
TOF): m/z calcld. for C20H43NO4SSiNa+: 444.2574; found: 444.2584 [M+Na]+. 
(R)-tert-butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-((triisopropylsilyl)oxy)pentanoate (3.26) 
 LiOH (98 mg, 4.1 mmol, 1.5 equiv) in water (25 mL) was added to a stirred solution 
of ethyl ester 3.25 (1.12 g, 2.66 mmol) in THF (25 mL). After 1 hour of stirring 
additional LiOH (190 mg, 7.9 mmol, 3.0 equiv) in water (8 mL) was added and the 
solution stirred for 16 h. The mixture was concentrated in vacuo and added CH2Cl2 
(50 mL) and water (30 mL). The pH was adjusted to approximately 2 with HCl (2 M, ≈ 
5 mL) and the aqueous phase was extracted with CH2Cl2 (60 mL) before the combined organic phases were 
dried (MgSO4) and concentrated in vacuo to afford the acid (1.21 g) as an orange oil. The crude acid was used 
without further purification. 1H NMR (300 MHz, CDCl3) δ 4.83 (d, J = 9.4 Hz, 1H), 3.86–3.70 (m, 3H), 2.96 (dd, 
J = 17.0, 4.6 Hz, 1H), 2.55 (dd, J = 17.0, 4.2 Hz, 1H), 1.94 (m, 1H), 1.77 (m, 1H), 1.25 (s, 9H), 1.12–0.94 (m, 
21H); 13C NMR (75 MHz, CDCl3) δ 173.8, 59.9, 56.7, 51.6, 39.8, 38.4, 23.0, 18.2, 12.1.  
Boc2O (0.815 g, 3.73 mmol, 1.4 equiv) and DMAP (98 mg, 0.80 mmol, 0.3 equiv) were added to a solution of 
the crude acid (1.2 g, 2.66 mmol,) in tert-butanol (30 mL) and the resulting solution was stirred under N2 for 
16 h.  To ensure complete protection of the amino group, Boc2O (200 mg, 0.92 mmol, 0.3 equiv) was added 
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and after additional 1.5 h of stirring the mixture was concentrated and the tert-butanol was removed by co-
evaporation with MeOH (× 3). Purification by VLC afforded the tert-butyl ester 3.26 (0.611 g, 44%, 3 steps) as 
a clear oil. α[D]= –20 ° (CH2Cl2);  1H NMR (300 MHz, CDCl3) δ 4.31 (d, J = 8.6 Hz, 1H), 3.88–3.67 (m, 3H), 2.79 
(dd, J = 15.9, 5.3 Hz, 1H), 2.56 (dd, J = 15.9, 5.1 Hz, 1H), 1.87–1.71 (m, 2H), 1.44 (s, 9H), 1.21 (s, 10H), 1.05 (s, 
21H); 13C NMR (75 MHz, CDCl3) δ 171.7, 81.3, 60.1, 56.0, 51.3, 41.8, 38.4, 28.3, 22.9, 18.3, 12.1; HRMS (ESI-
TOF): m/z calcld. for C22H47NO4SSiNa+: 472.2887; found: 472.2881 [M+Na]+.   
(R)-tert-butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-hydroxypentanoate (3.27) 
Glacial acetic acid (62 µL, 1.08 mmol, 1.0 equiv) and TBAF (1.0 M, 2.16 mL, 2.16 mmol, 
2.0 equiv) was added to a solution of silyl ether 3.26 (0.485 g, 1.08 mmol) in dry THF (20 
mL) at 0 °C. After stirring for 15 min the cooling was removed and the stirring continued 
for 1 hour before the mixture was quenched with methoxy trimethylsilane (0.5 mL, 3.63 
mmol, 3.4 equiv). The reaction mixture was concentrated and purification by VLC afforded alcohol 3.27 (0.298 
g, 94%) as colorless oil. Upon refrigeration white needle shaped crystals formed. α[D]= –28.6° (CH2Cl2); mp 
62–64 °C; 1H NMR (300 MHz, CDCl3) δ 4.39 (d, J = 7.9 Hz, 1H), 3.76 (m, 3H), 2.70 (dd, J = 16.0, 5.8 Hz, 3H), 2.58 
(dd, J = 16.0, 5.4 Hz, 1H (H-2B), overlapped with OH), 1.87 (m, 1 H), 1.75 (m, 1H), 1.43 (s, 9H), 1.20 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 171.3, 81.4, 60.1, 56.1, 51.7, 41.6, 37.8, 28.2, 22.8; HRMS (ESI-TOF): m/z calcld. for 
C13H27NO4SH+: 294.1734; found: 294.1725 [M+H]+. 
(R,Z)-9-tert-butyl 1-ethyl 7-((R)-1,1-dimethylethylsulfinamido)non-4-enedioate (3.29) 
NaHCO3 (178 mg, 2.1 mmol, 1.5 equiv) was added to a stirred solution of the 
alcohol 3.27 (415 mg, 1.4 mmol) in dry CH2Cl2 (18 mL). After cooling to 0 °C, Dess-
Martin periodinane reagent (0.90 g, 2.1 mmol, 1.5 equiv) was added to the 
solution. After 40 min. sat. aq. thiosulfate (20 mL) and sat. aq. NaHCO3 (20 mL) 
were added and after stirring for 5 min the aqueous phase was extracted with CH2Cl2 (140 mL + 100 mL). The 
combined organic phases were washed with sat. NaHCO3 (70 mL), brine (70 mL), dried (MgSO4), filtered, and 
concentration in vacuo to afford the aldehyde 3.28 (376 mg) as a pale yellow oil. The aldehyde was used 
immediately without further purification.  
A flame dried round-bottomed flask was charged with (4-ethoxy-4-oxobutyl)triphenylphosphonium bromide  
(1.32 g, 2.89 mmol, 2.0 equiv) and the Wittig reagent dried over high vacuum for 18 hours. Under N2 the 
Wittig reagent was dissolved in THF (25 mL) and cooled to –78 °C. KHMDS (0.5 M, 5.37 mL, 2.69 mmol, 1.9 
equiv) was added dropwise and the resulting orange solution was stirred for 30 min. The aldehyde 3.28 (376 
mg, 1.41 mmol) in dry THF (5 mL) was added dropwise over 10 min and after 30 min of stirring at –78 °C,  the 
reaction was quenched with water (0.1 mL) and the cooling was removed, allowing the reaction mixture to 
warm up to room temperature. Water (45 mL) was added and the aqueous phase extracted with EtOAc (150 
mL + 60 mL). The combined organic phases were dried (MgSO4), filtered, and concentrated in vacuo. 
Purification by VLC afforded the alkene 3.29 (175 mg, 32%, 2 steps) as a pale yellow oil. α[D]= –47.2 ° (CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 5.45 (m, 2H), 4.19 (d, J = 7.1 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.59 (m, 1H), 2.63 
(dd, J = 15.9, 5.2 Hz, 1H), 2.49 (dd, J = 15.9, 6.0 Hz, 1H), 2.35 (m, 6H), 1.45 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H), 1.20 
(s, 9H); 13C NMR (75 MHz, CDC3) δ 173.1, 171.2, 130.6, 126.5, 81.5, 71.2, 60.5, 53.4, 41.0, 34.2, 33.1, 28.3, 
23.1, 22.8, 14.4; HRMS (ESI-TOF): m/z calcld. for C19H35NO5SH+: 390.2309 ; found: 390.2310 [M+H]+. 
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(R,Z)-3-((tert-butoxycarbonyl)amino)-9-ethoxy-9-oxonon-5-enoic acid (3.31) 
TFA (5 mL) was added to a solution of tert-butyl ester 3.29 (170 mg, 0.34 mmol) in 
dry CH2Cl2 (5 mL) under argon at 0 °C. After 2 hours the cooling was removed and the 
mixture allowed to warm up to room temperature. After stirring for an additional 
hour the mixture was concentrated and TFA was removed by co-evaporation with 
CH2Cl2–toluene (1:1, 10 mL × 3) and CH2Cl2–hexane (1:1, 10 mL × 2) to afford a mixture of the N-sulfinyl 
protected β-amino acid, the β-amino acid containing the free amine and the starting material (152 mg). To 
ensure complete conversion of the starting material, TFA (5 mL) was added to a solution of the crude residue 
in dry CH2Cl2 (5 mL) under argon at 0 °. After stirring for 1 h the mixture was concentrated and TFA was 
removed by co-evaporation with CH2Cl2–toluene (1:1, 10 mL × 3) and CH2Cl2–hexane 1:1, 10 mL × 2) to afford 
a mixture of the N-sulfinyl protected β-amino acid and the β-amino acid containing the free amine (185 mg).  
To a solution of the crude mixture (185 mg, 0.44 mmol) in dioxane (10 mL) and water (0.10 mL) was added 
HCl (4.0 M in dioxane, 0.2 mL, 0.77 mmol, 1.8 equiv). After 1 h, TLC showed full conversion and the mixture 
was concentrated to afford the deprotected β-amino acid chloride salt (152 mg) as a yellow oil.  
To a solution of the crude β-amino acid (150 mg, 0.44 mmol) in dry CH2Cl2 (11 mL) was added iPr2NEt (0.23 
mL, 1.31 mmol, 3.0 equiv) and Boc2O (197 mg, 0.90 mmol, 2.0 equiv) in dry CH2Cl2 (1 mL) under argon and 
the mixture was stirred for 6 hours. To ensure complete protection of the amino group, Boc2O (100 mg, 0.045 
mmol, 1.0 equiv) was added and after stirring for additional 16 h the reaction mixture was concentrated in 
vacuo and purification by VLC (0.2% acetic acid in the eluent) afforded the β-amino acid 3.31 (75 mg, 52%, 3 
steps) as a yellow oil after co-evaporation of residual acetic acid with CH2Cl2–heptane (1:1, 10 mL × 2). α[D]= 
–5.4 ° (CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 5.43 (m, 2H), 5.15 (brs, 1H), 4.12 (q, J = 7.1 Hz, 1H), 3.95 (brs, 1H), 
2.57 (d, J = 5.3 Hz, 1H), 2.35 (m, 6H), 1.43 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.2, 
173.4, 155.6, 131.0, 126.5, 79.6, 60.6, 47.5, 38.7, 34.1, 32.2, 28.5, 22.9, 14.4; HRMS (ESI-TOF): m/z calcld. for 
C16H27NO6H+: 330.1911; found: 330.1919 [M+H]+. 
 
(R,Z)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-9-ethoxy-9-oxonon-5-enoic acid (3.30) 
TFA (5 mL) was added to a solution of tert-butyl ester 3.29 (217 mg, 0.56 mmol) in 
dry CH2Cl2 (5 mL) at 0 °C. After 15 min the cooling was removed and the mixture 
allowed to warm up to room temperature. After stirring for an additional 1 hour and 
45 minutes the reaction mixture was concentrated and residual TFA was removed 
by co-evaporation with CH2Cl2–toluene (1:1, 10 mL × 3) and CH2Cl2–hexane (1:1, 10 mL) to afford the crude 
acid. 
To a solution of the crude acid (0.56 mmol) in dioxane (10 mL) was added HCl (4.0 M in dioxane, 0.35 mL, 
1.39 mmol, 2.5 equiv). After 3 hours the mixture was concentrated to afford the deprotected β-amino acid 
chloride salt (218 mg) as a yellow oil. 
A solution of the crude β-amino acid in water (5.0 mL) was added Na2CO3 (0.24 g, 2.24 mmol, 4.0 equiv) and 
cooled to 0° C. Fmoc-O-succinimide (0.23 g, 0.67 mmol, 1.2 equiv) in 1,4-dioxane (1.0 mL) was added 
dropwise and the cooling removed. After 45 minutes water (25 mL) was added and the mixture cooled to 0° 
C. After acidification with concentrated HCl (pH 1–2) the aqueous layer was extracted with ethyl acetate (3 × 
60 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated. Purification of the 
crude residue by VLC (0.2% acetic acid in the eluent) afforded β-amino acid 3.30 (124 mg, 49%, 3 steps) as a 
white solid after co-evaporation of residual acetic acid with CH2Cl2–toluene (1:1, 3 × 10 mL). α[D]= –6.0 ° 
(CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.5 Hz, 2H), 7.58 (d, J = 7.5 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 
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7.29 (t, J = 7.4, Hz, 2H), 5.56 (d, J = 8.5 Hz, 1H), 5.52–5.35 (m, 2H), 4.35 (d, J = 6.9 Hz, 2H), 4.21 (d, J = 6.9 Hz, 
1H), 4.11 (m, 3H), 2.61 (m, 2H), 2.47 – 2.23 (m, 6H), 1.20 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.4, 
173.5, 156.2, 144.0, 141.4, 131.2, 127.8, 127.1, 126.4, 125.2, 120.1, 66.9, 60.7, 48.2, 47.3, 38.7, 33.9, 32.0, 
22.8, 14.3. HRMS (ESI-TOF): m/z calcld. for C26H29NO6H+: 452.2069; found: 452.2068 [M+H]+.  
4-methoxybenzyl 3-((R)-1,1-dimethylethylsulfinamido)-2,2-dimethylhexanoate (Table 3-1, entry 1) 
The general procedure was followed using imine 2.14 (185 mg, 0.56 mmol), PBM 
isobutyrate (0.30 g, 1.40 mmol), LDA (1.2 M, 1.21 mL, 1.44 mmol) and Ti(O-iPr)3Cl 
(0.63 mL, 2.50 mmol). Diastereoselectivity was determined by 1H NMR integration of 
the crude reaction mixture (65:35). Purification by VLC afforded the major 
diastereomer (140 mg, 47%) and the minor diastereomer (40 mg, 13%) as well as a 
fraction containing a mixture (23 mg, 8.0 %). Characterization of major diastereomer; 1H NMR (300 MHz, 
CDCl3) δ 7.26 (d, J = 8.1 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.11 (d, J = 11.9 Hz, 1H), 4.99 (d, J= 11.9 Hz, 1H), 4.16 
(d, J = 8.7 Hz, 1H), 3.80 (s, 3H), 3.72 (m, 2H), 3.37 (t, J = 9.5 Hz, 1H), 1.82 (m, 1H), 1.37 (m, 1H), 1.31 (s, 3H), 
1.25 (s, 3H), 1.14 (s, 9H), 1.03 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 176.4, 159.7, 130.0, 128.7, 128.0, 114.1, 
66.3, 60.3, 56.5, 55.4, 48.1, 36.1, 23.1, 22.9, 21.6, 18.2, 12.0. HRMS (ESI-TOF): m/z calcld. for C28H51NO5SSiH+: 
542.3335; found: 542.3337 [M+H]+.   
 
Ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2,2-dimethylhexanoate (Table 3-1, entry 2) 
The general procedure was followed using imine 2.14 (160 mg, 0.48 mmol), ethyl 
isobutyrate (0.13 mL, 0.96 mmol), LDA (1.8 M, 0.56 mL, 1.01 mmol) and Ti(O-iPr)3Cl 
(0.51 mL, 2.02 mmol). Diastereoselectivity was determined by 1H NMR integration of 
the crude reaction mixture (64:36). Purification by VLC afforded the major diastereomer 
(64 mg, 29%) and the minor diastereomer (37 mg, 17%) as well as a fraction containing 
a mixture (56 mg, 26%). Characterization of major diastereomer; 1H NMR (300 MHz, CDCl3) δ 4.23 (d, J = 8.6 
Hz, 1H), 4.20–4.07 (m, 2H), 3.74 (m, 2H), 3.38 (ddd, J = 10.4, 8.7, 1.8 Hz, 1H), 1.82 (m, 1H), 1.42 (m, 1H), 1.30 
(s, 3H), 1.25 (t, J = 7.2 Hz, 3H), 1.24 (s, 3H), 1.22 (s, 9H), 1.03 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 177.0, 60.9, 
60.8, 60.2, 56.6, 46.4, 36.7, 24.9, 23.4, 23.2, 18.1, 14.3, 12.0. HRMS (ESI-TOF): m/z calcld. for C22H47NO4SSiH+: 
450.3074; found: 450.3081 [M+H]+.   
 
Ethyl 5-(benzyloxy)-3-((R)-1,1-dimethylethylsulfinamido)-2,2-dimethylpentanoate (Table 3-1, entry 5) 
The general procedure was followed using imine 2.14 (186 mg, 0.70 mmol), ethyl 
isobutyrate (0.23 mL, 1.74 mmol), LDA (1.3 M, 1.40 mL, 1.81 mmol) and Ti(O-iPr)3Cl (0.79 
mL, 3.13 mmol). Diastereoselectivity was determined by 1H NMR integration of the crude 
reaction mixture (53:47). The diastereomers could not be separated by VLC and afforded 
a mixture of diastereomers (209 mg, 78%).  
 
tert-butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-((4-methoxybenzyl)oxy)-2,2-dimethylpentanoate (Table 
3-1, entry 6) 
The general procedure was followed using imine 2.14 (166 mg, 0.56 mmol), tert-
isobutyrate (0.21 g, 1.40 mmol), LDA (1.3 M, 1.12 mL, 1.45 mmol) and Ti(O-iPr)3Cl (0.63 
mL, 2.51 mmol). Diastereoselectivity was determined by 1H NMR integration of the 
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crude reaction mixture (83:17). The diastereomers could not be separated by VLC and afforded a mixture of 
diastereomers (172 mg, 70%).  
 
Ethyl 3-((R)-1,1-dimethylethylsulfinamido)-5-((4-methoxybenzyl)oxy)-2,2-dimethylpentanoate (Table 3-1, 
7) 
The general procedure was followed using imine 2.14 (183 mg, 0.56 mmol), ethyl 
isobutyrate (0.21 mL, 0.87 mmol), LDA (1.3 M, 1.23 mL, 1.60 mmol) and Ti(O-iPr)3Cl 
(0.70 mL, 2.77 mmol). Diastereoselectivity was determined by 1H NMR integration of 
the crude reaction mixture (66:33). The diastereomers could not be separated by VLC 
and afforded a mixture of diastereomers (208 mg, 77%).  
 
(R)-tert-butyl 3-((S)-1,1-dimethylethylsulfinamido)-2,2-dimethylhexanoate (Table 3-1, entry 4, 3.12) 
A solution of LDA (1.3 M in THF, 4.3 mL, 5.6 mmol, 2.6 equiv) was added dropwise over 
10 min to tert-butyl isobutyrate (0.76 g, 5.3 mmol, 2.5 equiv) in dry THF (15 mL) at  –
78 °C. After stirring for 45 min Ti(O-iPr)3Cl (2.4 mL, 9.5  mmol, 4.5 equiv) in dry THF 
(2.5 mL) was added dropwise. The resulting orange solution was stirred for 45 min and 
the imine 2.35 (0.70 g, 2.1 mmol) in dry THF (2.5 mL) was added over 15 minutes. After 
stirring for 30 min at –78 °C the flask raised allowing cooling only on the bottom of the flask. After additional 
20 min of stirring, TLC showed full conversion of the imine, and the mixture was quenched with sat. aq. NH4Cl 
(0.1 mL) and allowed to warm up to room temperature. Water (60 mL) was added and the mixture decanted 
into a separatory funnel containing EtOAc (120 mL). The remaining residue was added EtOAc (15 mL) and 
water (15 mL) and stirred vigorously for 5 min before added to the separatory funnel. After separation the 
aqueous phase was extracted with EtOAc (120 mL) and the combined organic phases were washed with brine 
(100 mL), dried (Na2SO4), filtered, and concentrated in vacuo. Diastereoselectivity was determined by 1H NMR 
integration of the crude reaction mixture (3R/3S; 84:16). Purification by VLC afforded the 3R diastereomer 
3.12 as a colorless oil (0.584 g, 58%), as well as a fraction containing a mixture of diastereomers (68 mg, 7%) 
and the 3S diastereomer (194 mg, 19%). Characterization data for the (3R)-diastereisomer. α[D]= 39.3° 
(CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 3.93 (dd, J = 7.6, 5.2 Hz, 2H), 3.54–3.34 (m, 2H), 1.89 (m, 1H), 1.52 (m, 
1H), 1.44 (s, 9H), 1.21 (s, 9H), 1.13 (s, 3H), 1.11 (s, 3H), 1.05 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 175.8, 80.7, 
60.5, 60.3, 56.6, 48.5, 36.6, 28.2, 23.3, 23.1, 22.5, 18.2, 12.1. HRMS (ESI-TOF): m/z calcld. for C24H51NO4SSiH+: 
478.3381; found: 478.3387 [M+H]+. 
 
(R)-tert-butyl 3-((S)-1,1-dimethylethylsulfinamido)-2,2-dimethylhexanoate (Table 3-1, entry 3) 
The general procedure was followed using imine 2.14 (172 mg, 0.52 mmol), tert-butyl 
isobutyrate (0.186 g, 1.29 mmol), LDA (1.2 M, 1.03 mL, 1.34 mmol) and Ti(O-iPr)3Cl 
(0.58 mL, 2.32 mmol). Diastereoselectivity was determined by 1H NMR integration of 
the crude reaction mixture (3R/3S; 8:92). Purification by VLC afforded the major 
diastereomer (88 mg, 36%) and a fraction containing a mixture of diastereomers (25 
mg, 10%). Characterization of major diastereomer; α[D]= –43.3 ° (CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 3.93 
(dd, J = 7.6, 5.2 Hz, 2H), 3.44 (m, 2H), 1.88 (m, 1H), 1.51 (m, 1H), 1.43 (s, 9H), 1.21 (s, 9H), 1.13 (s, 3H), 1.11 
(s, 3H), 1.05 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 175.8, 80.7, 60.5, 60.3, 56.6, 48.5, 36.6, 28.2, 23.3, 23.1, 
22.5, 18.2, 12.1. HRMS (ESI-TOF): m/z calcld. for C24H51NO4SSiH+: 478.3381; found: 478.3400 [M+H]+. 
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(S)-tert-butyl 3-((R)-1,1-dimethylethylsulfinamido)-5-hydroxy-2,2-dimethylpentanoate (S5) 
TBAF (1.0 M, 0.36 mL, 0.36 mmol, 2.0 equiv) was added over 10 min to a stirred solution 
of silyl ether from Table 13, entry 7 (86 mg, 0.18 mmol) and AcOH (10.3 µL, 0.18 mmol, 
1.0 equiv) in THF (8 mL) at 0 °C under N2. After stirring for 30 min the cooling was 
removed. After stirring for 1 h at room temperature TBAF (20 µL, 20 µmol, 0.06 equiv) 
was added and after additional 20 minutes of stirring the mixture was concentrated and purified by VLC to 
afford alcohol S5 (49.3 mg, 85%) as a white solid. α[D]= –20.0° (CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 4.29 (bs, 
1H), 3.80 (m, 2H), 3.58 (m, 2H), 1.75 (m, 1H), 1.59 (m, 1H), 1.42 (s, 9H), 1.24 (s, 9H), 1.11 (s, 3H), 1.06 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 175.6, 80.9, 62.0, 60.3, 56.8, 48.5, 34.5, 28.2, 23.2, 23.0, 21.6. HRMS (ESI-TOF): 
m/z calcld. for C15H31NO4SH+: 322.2047; found: 322.2056 [M+H]+. 
 
(R)-tert-butyl 3-((S)-1,1-dimethylethylsulfinamido)-5-hydroxy-2,2-dimethylpentanoate (3.13) 
TBAF (1.0 M, 2.4 mL, 2.4 mmol, 2.0 equiv) was added over 10 min to a stirred solution of 
silyl ether 3.12 (0.56 g, 1.2 mmol) and AcOH (68 µL, 1.2 mmol, 1.0 equiv) in THF (20 mL) 
at 0 °C under N2. After stirring for 10 min the cooling was removed. After stirring for 30 
min TBAF (0.20 mL, 0.20 mmol, 0.17 equiv) was added and after additionally 15 min of 
stirring the mixture was concentrated and purified by VLC to afford alcohol 3.13 (318 mg, 84%) as a colorless 
oil. Upon refrigeration needle shaped crystals formed. α[D]= 19.2° (CH2Cl2); mp 81–82 °C; 1H NMR (300 MHz, 
CDCl3 ) δ 4.29 (t, J= 7.2 Hz, 1H), 3.82 (m, 2H), 3.60 (m, 2H), 1.76 (m, 1H), 1.60 (m, 1H), 1.44 (s, 9H), 1.26 (s, 
9H), 1.13 (s, 3H), 1.08 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 175.5, 80.8, 62.0, 60.3, 56.7, 48.5, 34.5, 28.2, 23.1, 
23.0, 21.3.HRMS (ESI-TOF): m/z calcld. for C15H31NO4SH+: 322.2047; found: 322.2058 [M+H]+. 
 
(R,Z)-9-tert-butyl 1-ethyl 7-((S)-1,1-dimethylethylsulfinamido)-8,8-dimethylnon-4-enedioate (3.15) 
NaHCO3 (125 mg, 1.5 mmol, 1.5 equiv) and Dess-Martin periodinane reagent 
(645 mg, 1.5 mmol, 1.5 equiv) were added to a stirred solution of alcohol 3.13 
(315 mg, 0.98 mmol) in dry CH2Cl2 (15 mL) at 0 °C under N2. After 20 min the 
flask was raised from the cooling bath allowing cooling on the bottom of the 
flask. After 20 min the cooling bath was removed and after stirring for 20 min 
sat. aq. Na2S2O3 (10 mL) and sat. aq. NaHCO3 (10 mL) were added and the aqueous phase was extracted with 
CH2Cl2 (2 × 65 mL). The combined organic layers were washed with sat. aq. NaHCO3 (35 mL), brine (35 mL), 
dried (Na2SO4), filtered, and concentrated in vacuo to afford the crude aldehyde 3.14 (331 mg) as a pale 
yellow oil, which was used immediately without further purification.  
A flame dried round-bottomed flask was charged with (4-ethoxy-4-oxobutyl)triphenylphosphonium bromide  
(0.913 g, 1.9 mmol, 2.0 equiv) and the Wittig was reagent dried over high vacuum for 24 hours. The Wittig 
reagent was the dissolved in dry THF (13 mL) under argon and cooled to –78 °C.  KHMDS (0.5 M, 3.65 mL, 1.8 
mmol, 1.9 equiv) was added dropwise and the resulting orange solution was stirred for 30 min before the 
crude aldehyde 3.14 (331 mg, 0.96 mmol) in dry THF (3.0 mL) was added dropwise. After 16 hours, while 
gradually allowing the mixture to warm to room temperature, the reaction mixture was concentrated and 
water (30 mL) was added. The aqueous phase was extracted with EtOAc (2 × 70 mL). The combined organics 
were washed with brine (40 mL), dried (Na2SO4), filtered, and concentrated in vacuo. Purification by VLC 
afforded alkene 3.15 as a pale yellow oil (222 mg, 54%, 2 steps). α[D]= 42.9° (CH2Cl2);  1H NMR (300 MHz, 
CDCl3) δ 5.59 (dt, J = 11.2, 7.0 Hz, 1H), 5.46 (m, 1H), 4.09 (q, J= 7.1 Hz, 2H), 3.42 (m, 1H), 3.32 (d, J = 7.4 Hz, 
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1H), 2.30 (m, 6H), 1.43 (s, 9H), 1.20 (s, 9H), 1.15 (s, 3H), 1.10 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 175.6, 173.2, 
130.2, 127.5, 80.8, 62.4, 60.4, 56.6, 48.6, 34.0, 30.6, 28.1, 23.7, 23.1, 23.0, 21.4, 14.4. 
HRMS (ESI-TOF): m/z calcld. for C21H39NO5SH+: 418.2622; found: 418.2642 [M+H]+. 
 
(R,Z)-3-((tert-butoxycarbonyl)amino)-9-ethoxy-2,2-dimethyl-9-oxonon-5-enoic acid (3.16) 
TFA (5 mL, 126 equiv) was added to a solution of tert-butyl ester 3.15 (220 mg, 
0.52 mmol) in dry CH2Cl2 (5 mL) at 0 °C and the mixture allowed to warm to room 
temperature. After 2 hours the mixture was concentrated and excess TFA was 
removed by co-evaporation with toluene–CH2Cl2 (1:1, 10 mL × 3) and hexane–
CH2Cl2 (1:1, 10 mL × 2) to afford the crude acid (224 mg).  
 
HCl in dioxane (4.0 M, 0.20 mL, 0.79 mmol, 1.5 equiv) was added to a solution of crude sulfinyl protected 
amine in 1,4-dioxane (8.0 mL). After 2 hours additional HCl in dioxane (0.05 mL, 0.4 equiv) was added and 
after 30 minutes the mixture was concentrated to afford the crude unprotected β-amino acid (219 mg).     
To a solution of the crude β-amino (219 mg) in dry CH2Cl2 (7 mL) and iPr2NEt (0.37 mL, 2.1 mmol, 4.0 equiv) 
was added Boc2O (235 mg, 1.1 mmol, 2.0 equiv) in dry CH2Cl2 (2 mL) under argon. After 20 hours the reaction 
mixture was concentrated and iPr2NEt was removed by co-evaporation with toluene. Purification of the crude 
residue VLC (0.2% acetic acid in the eluent) afforded 3.16 (114 mg, 61%, 3 steps) as a colorless oil after co-
evaporation of residual acetic acid with CH2Cl2–toluene (1:1, 10 mL × 3). α[D]= –40.9 °; 1H NMR (300 MHz, 
CDCl3) δ 5.42 (m, 2H), 4.98 (d, J = 10.5 Hz, 1H), 4.12 (q, J = 7.1, Hz, 2H), 3.73 (td, J = 10.5, 3.4 Hz, 1H), 2.49–
2.08 (m, 7H), 1.41 (s, 9H), 1.28–1.20 (m, 9H). 13C NMR (75 MHz, CDCl3) δ 182.4, 173.5, 156.4, 129.9, 127.6, 
79.3, 60.6, 57.0, 46.5, 34.2, 29.2, 28.5, 23.5, 22.9 (×2), 14.4. HRMS (ESI-TOF): m/z calcld. for C18H31NO6H+: 
358.2230; found: 358.2240 [M+H]+. 
 
(2R,5R,8R,12R,Z)-12-amino-2-benzyl-8-isopropyl-5-methyl-4,7,10,18-tetraoxo-19-oxa-3,6,9-triazahenicos-
14-en-1-oic acid (3.32) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–
(D)Phe (224 mg, 0.11 mmol, 1.5 equiv) was added to a 
fritted syringe and the Fmoc group was removed with 
piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). 
β-amino acid 3.31 (24.6 mg, 0.075 mmol) in DMF (2.2 mL) was preincubated for 5 min with 2,6-lutidine (26 
µL, 0.22 mmol, 3.0 equiv) and HATU (44 mg, 0.12 mmol, 1.5 equiv) before addition to the resin and the 
reaction was allowed to proceed on a rocking table for 16 hours. After washing [DMF (×3), MeOH (×3), CH2Cl2 
(×3)] the resin was treated with TFA–CH2Cl2 (1:1, 4 mL) for 1 h followed by washing with CH2Cl2 (5 mL). A fresh 
portion of TFA–CH2Cl2 (1:1, 4 mL) was added to the resin and after additional 30 min the resin was drained 
and all the fractions were pooled and concentrated in vacuo to provide the linear peptide as an oily residue. 
Precipitation with diethyl ether afforded the TFA salt of the linear peptide 3.32 (45 mg, 91%) as a white solid. 
UPLC-MS gradient A, tR = 1.36 min, m/z calcld. for C28H42N4O7H+: 547.3; found: 547.4 [M+H]+. 
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(Z)-ethyl-6-((2R,5R,8R,11R)-8-benzyl-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (3.33) 
The linear peptide 3.32 (45 mg, 0.068 mmol) was dissolved in DMF (200 mL ≈ 
0.34 mM) and iPr2NEt (131 µL, 0.75 mmol, 10 equiv) and HATU (57 mg, 0.15 
mmol, 2.2 equiv) were added. The solution was stirred for 16 hours and the 
reaction mixture was concentrated. The residue was taken up in EtOAc (200 
mL), which afforded a white precipitate (HOAt). The EtOAc was decanted off 
and washed with aq. HCl (1.0 M, 10 mL × 3) and concentrated to afford the 
cyclic peptide 3.33 (127 mg) as a brown oil. UPLC-MS gradient A tR = 1.87 min, 
m/z calcld. for C28H40N4O6 : 529.3; found: 529.4  [M+H]+.  
 
(Z)-6-((2R,5R,8R,11R)-8-benzyl-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-
yl)hex-4-enoic acid (3.01) 
LiOH (38 mg, 1.59 mmol, 23 equiv) in water (5 mL) was added to the cyclic 
peptide 3.33 (127 mg, 0.068 mmol) in THF (5 mL). To ensure a pH value above 
10, additional LiOH (21 mg, 0.88 mmol, 13.0 equiv) was added and the 
solution was stirred for 16 h. The mixture was concentrated in vacuo and 
dissolved in DMF–MeCN (8:2, 3.0 mL) before purification by preparative 
HPLC  afforded β2-desmethyl azumamide E (3.01) (8.1 mg, 21%, 5 steps) as a 
white solid. Two conformations are observed in a 94:6 ratio. Characterization 
is given for the major conformation. 1H NMR (799 MHz, DMSO) δ 12.08 (s, 1H), 7.86 (d, J = 6.8 Hz, 1H), 7.66 
(d, J = 9.0 Hz, 1H), 7.43 (d, J = 9.0 Hz, 1H), 7.35 (d, J = 6.6 Hz, 1H), 7.28 (m, 2H), 7.16–7.23 (m, 3H), 5.48 (m, 
1H), 5.37 (dt, J = 10.5, 7.4 Hz, 1H), 4.30–4.21 (m, 2H), 3.93 (dd, J = 7.2, 3.6 Hz, 1H), 3.81 (t, J = 6.7 Hz, 1H), 
2.95 (dd, J = 13.8, 5.8 Hz, 1H), 2.82 (dd, J = 13.8, 9.5 Hz, 1H), 2.50 (m, 1H), 2.29 (m, 7H), 1.94 (m, 1H), 1.15 (d, 
J = 7.3 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H). HRMS (ESI-TOF): m/z calcld. for C26H36N4O6H+: 
501.2708; found: 501.2713 [M+H]+. HPLC gradient C, tR = 11.70 min (>95%). 
 
(2R,5R,8R,12R,Z)-12-amino-2-(4-hydroxybenzyl)-8-isopropyl-5-methyl-4,7,10,18-tetraoxo-19-oxa-3,6,9-
triazahenicos-14-en-1-oic acid (3.34) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–
(D)Tyr (187 mg, 0.10 mmol, 1.0 equiv) was added to a 
fritted syringe and the Fmoc group was removed with 
piperidine–DMF (1:4, 4 mL, 2 × 30 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was 
then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). β-amino acid 3.30 (51 mg, 0.11 mmol, 1.1 equiv) in DMF 
(1.8 mL) was preincubated for 5 min with 2,6-lutidine (36 µL, 0.31 mmol, 3.0 equiv) and HATU (59 mg, 0.16 
mmol, 1.5 equiv) before addition to the resin and the reaction was allowed to proceed on a rocking table for 
16 hours. After washing [DMF (×3), MeOH (×3), CH2Cl2 (×3)] the resin was added piperidine–DMF (1:4, 4 mL, 
2 × 30 min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), 
MeOH (×3), CH2Cl2 (×3) and treated with TFA–CH2Cl2 (1:1, 4 mL) for 45 min followed by washing with CH2Cl2 
(5 mL). A fresh portion of TFA–CH2Cl2 (1:1, 4 mL) was added to the resin and after additional 45 min the resin 
was drained and all the fractions were pooled and concentrated in vacuo to provide the linear peptide as an 
oily residue. Precipitation with diethyl ether afforded the TFA salt of the linear peptide 3.34 (72 mg, 100 %) 
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as a white solid. 1H NMR (400 MHz, MeOD) δ 7.04 (d, J = 8.5 Hz, 2H), 6.68 (d, J = 8.5 Hz, 2H), 5.63 (m, 1H), 
5.43 (m, 1H), 4.56 (dd, J = 7.7, 5.4 Hz, 1H), 4.39 (q, J = 7.1 Hz, 1H), 4.18 (d, J = 6.7 Hz, 1H), 4.12 (q, J = 7.1 Hz, 
2H)  3.56 (m, 1H), 3.07 (dd, J = 14.0, 5.4 Hz, 1H), 2.92 (dd, J = 14.0, 7.7 Hz, 1H), 2.73 (dd, J = 16.5, 4.3 Hz, 1H), 
2.57 (dd, J = 16.5, 8.5 Hz, 1H), 2.50–2.33 (m, 6H), 2.05 (octet, J = 6.8 Hz, 1H), 1.33 (d, J = 7.1 Hz, 3H), 1.24 (t, J 
= 7.1 Hz, 3H), 0.94 – 0.91 (m, 6H). UPLC-MS gradient B, tR = 1.10 min, m/z calcld. for C28H42N4O8H+: 563.3; 
found: 563.3 [M+H]+. 
 
(Z)-ethyl-6-((2R,5R,8R,11R)-8-(4-hydroxybenzyl)-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (3.36a) 
The linear peptide 3.34 (67 mg, 0.099 mmol) was dissolved in DMF (240 mL 
≈ 0.4 mM) and iPr2NEt (138 µL, 0.79 mmol, 8.0 equiv) and HATU (57 mg, 
0.15 mmol, 1.5 equiv) were added. The solution was stirred for 16 hours 
and the reaction mixture was concentrated. Purification by VLC afforded 
the cyclic peptide (22 mg). 1H NMR showed a mixture of the cyclic peptide 
3.36a and an unidentified impurity. The cyclic peptide was used without 
further purification. UPLC-MS gradient B, tR = 1.60 min, m/z calcld. for 
C28H42N4O8H+: 545.3; found: 545.3 [M+H]+ 
 
(Z)-6-((2R,5R,8R,11R)-8-(4-hydroxybenzyl)-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid (3.02) 
LiOH (44 mg, 1.84 mmol, 50 equiv) in water (4 mL) was added to the cyclic 
peptide 3.36a (20 mg, 0.037 mmol) in THF (4 mL). After 17 hours the 
mixture was concentrated in vacuo and dissolved in DMF–MeCN–water 
(2:1:2, 2.5 mL) and purified by preparative HPLC to afford β2-desmethyl 
azumamide C (3.02) (11.2 mg, 22%, 5 steps) as a white solid. Two 
conformations are observed in a 92:8 ratio. Characterization is given for the 
major conformation. 1H NMR (500 MHz, DMSO) δ 7.87 (d, J = 6.9 Hz, 1H), 
7.56 (d, J = 9.7 Hz, 1H), 7.43 (d, J = 9.8 Hz, 1H), 7.25 (d, J = 7.0 Hz, 1H), 6.95 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.4 
Hz, 2H), 6.52 (bs, 1H), 5.47 (m, 1H), 5.37 (m, 1H), 4.28 (dq, J = 9.7, 7.4 Hz, 1H), 4.16 (m, 1H), 3.93 (m, 1H), 3.81 
(t, J = 6.6 Hz, 1H), 2.82 (dd, J = 13.9, 5.7 Hz, 1H), 2.70 (dd, J = 13.9, 9.3 Hz, 1H), 2.47 (m, 1H),  2.27 (m, 7H), 
1.95 (m, 1H), 1.16 (d, J = 7.3 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H).  HRMS: m/z calcld. for 
C26H36N4O7H+: 517.2657; found: 517.2658  [M+H]+. HPLC gradient C, tR = 10.11 min (>95%). 
(2R,5R,8R,12R,Z)-12-amino-2-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-8-isopropyl-5-methyl-
4,7,10,18-tetraoxo-19-oxa-3,6,9-triazahenicos-14-en-1-oic acid (3.35) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–
(D)Ala–(D)Trp(N-Boc) (193 mg, 0.10 mmol, 1.0 equiv) 
was added to a fritted syringe and the Fmoc group 
was removed with piperidine–DMF (1:4, 4 mL, 2 × 30 
min) and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). 
The resin was then washed with DMF (×3), MeOH 
(×3), CH2Cl2 (×3). β-amino acid 3.30 (49 mg, 0.11 mmol, 1.1 equiv) in DMF (1.8 mL) was preincubated for 5 
min with 2,6-lutidine (34 µL, 0.30 mmol, 3.0 equiv) and HATU (57 mg, 0.15 mmol, 1.5 equiv) before addition 
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to the resin and the reaction was allowed to proceed on a rocking table for 16 hours. After washing [DMF 
(×3), MeOH (×3), CH2Cl2 (×3)] the resin was added piperidine–DMF (1:4, 4 mL, 2 × 30 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3) 
and treated with CH2Cl2–AcOH–triflouroethanol (6:2:2, 1.5 mL) for 2 hours followed by washing with CH2Cl2 
(3 mL). A fresh portion of CH2Cl2–AcOH–triflouroethanol (6:2:2, 1.5 mL) was added to the resin and after 
additional 2 hours the resin was drained and all the fractions were pooled and concentrated in vacuo to 
provide the linear peptide as an oily residue. Residual AcOH was removed by co-evaporation with toluene (3 
× 10 mL) to afford the TFA salt of the linear peptide 3.35 (37 mg, 47%) as a white solid. 1H NMR (400 MHz, 
MeOD) δ 8.05 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 7.3 Hz, 1H), 7.46 (s, 1H), 7.22 (m, 2H), 5.61 (m, 1H), 5.41 (m, 1H), 
4.43 (t, J = 5.5 Hz, 1H), 4.31 (q, J = 7.1 Hz, 1H), 4.11 (m, 3H), 3.54 (m, 1H), 3.36 (m, 1H(overlapped with solvent 
signal)), 3.20 (m, 1H), 2.68 (dd, J = 16.4, 4.3 Hz, 1H), 2.56 (dd, J = 16.4, 9.3 Hz, 1H), 2.40 (m, 6H), 2.00 (m, 1H), 
1.66 (s, 9H), 1.30 (d, J = 9.4 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H), 0.90 (m, 6H). UPLC-MS gradient B, tR = 1.84  min,  
m/z calcld. for C35H51N5O9H+: 686.4; found: 686.0 [M+H]+.  
tert-butyl-3-(((3R,6R,9R,13R)-13-((Z)-6-ethoxy-6-oxohex-2-en-1-yl)-9-isopropyl-6-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotridecan-3-yl)methyl)-1H-indole-1-carboxylate (3.36b) 
The linear peptide 3.35 (35 mg, 0.051 mmol) was dissolved in DMF (130 
mL ≈ 0.4 mM) and iPr2NEt (71 µL, 0.41 mmol, 10 equiv) and HATU (29 mg, 
0.77 mmol, 1.5 equiv) were added. The solution was stirred for 16 hours 
and the reaction mixture was concentrated. Purification by VLC afforded 
the cyclic peptide (30 mg) as a white amorphous solid. 1H NMR showed a 
mixture of the cyclic peptide (3.36b) and an unidentified impurity. The 
cyclic peptide was used without further purification.  UPLC-MS gradient B, 
tR = 2.52 min, m/z calcld. for C35H49N5O8H+: 668.4; found: 668.4 [M+H]+.  
 
(Z)-6-((2R,5R,8R,11R)-8-((1H-indol-3-yl)methyl)-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid (3.03) 
LiOH (54 mg, 2.25 mmol, 50 equiv) in water (4 mL) was added to the 
impure cyclic peptide 3.36b (30 mg, 0.045 mmol) in THF (4 mL). After 17 
hours the THF was removed in vacuo and the aqueous phase was acidified 
to pH 1–2 with 2M HCl and extracted with CH2Cl2 (3 × 50 mL) and EtOAc (2 
× 40 mL). All the organic fractions were pooled and concentrated in vacuo. 
The residue was taken up in CH2Cl2 (6 mL) and added TFA (6 mL). After 1 
hour the solvent was removed in vacuo and the residue was dissolved in 
DMF–MeCN–water (1:2:2, 2.5 mL) and purified by preparative HPLC to afford the acid 3.03 (2.6 mg, 5%, 6 
steps) as a white solid. Two conformations are observed in a 97:3 ratio. Characterization is given for the major 
conformation. 1H NMR (500 MHz, DMSO) δ 12.08 (bs, 1H), 10.87 (bs, 1H), 7.83 (m, 1H), 7.51 (m, 3H), 7.33 (d, 
J = 8.1 Hz, 1H), 7.27 (m, 1H), 7.08 (s, 1H), 7.06 (t, J = 7.8 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 5.47 (m, 1H), 5.33 (m, 
1H), 4.36 (m, 1H), 4.30 (m, 1H), 3.92 (m, 1H), 3.82 (t, J = 6.5 Hz, 1H), 3.01 (m, 2H), 2.45 (m, 1H), 2.33–2.14 (m, 
7H), 1.94 (m, 1H), 1.15 (d, J = 7.3 Hz, 3H), 0.92 (d, J = 7.4 Hz, 3H), 0.90 (d, J = 7.4 Hz, 3H). HRMS (ESI-TOF):: 
m/z calcld. for C28H37N5O6H+: 540.2817; found: 540.2814  [M+H]+. HPLC gradient C, tR = 10.53 min (>95%). 
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(2R,5R,8R,12R,Z)-12-amino-2-benzyl-8-isopropyl-5,11,11-trimethyl-4,7,10,18-tetraoxo-19-oxa-3,6,9-
triazahenicos-14-en-1-oic acid (3.48) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–
(D)Phe (239 mg, 0.12 mmol, 1.5 equiv) was added to a 
fritted syringe and the Fmoc group was removed with 
piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). 
β-amino acid 3.16 (28.5 mg, 0.080 mmol) in DMF (2.0 mL) was preincubated for 5 min with iPr2NEt (42 µL, 
0.24 mmol, 3.0 equiv) and HATU (46 mg, 0.12 mmol, 1.5 equiv) before addition to the resin and the reaction 
was allowed to proceed on a rocking table for 16 hours. After washing [DMF (×3), MeOH (×3), CH2Cl2 (×3)] 
the resin was treated with TFA–CH2Cl2 (1:1, 4 mL) for 1 h followed by washing with CH2Cl2 (5 mL). A fresh 
portion of TFA–CH2Cl2 (1:1, 4 mL) was added to the resin and after additional 30 min the resin was drained 
and all the fractions were pooled and concentrated in vacuo to provide the linear peptide as an oily residue. 
Precipitation with diethyl ether afforded the TFA salt of the linear peptide 3.48 (83 mg) as a white solid. UPLC-
MS gradient B, tR = 1.35 min, m/z calcld. for C30H46N4O7H+: 575.3; found: 575.3  [M+H]+. 
 
(Z)-ethyl-6-((2R,5R,8R,11R)-8-benzyl-2-isopropyl-5,12,12-trimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (S6) 
The linear peptide 3.48 (35 mg, 0.08 mmol) was dissolved in DMF (200 mL 
≈ 0.4 mM) and iPr2NEt (140 µL, 0.80 mmol, 10 equiv) and HATU (61 mg, 0.16 
mmol, 2.0 equiv) were added. The solution was stirred for 16 hours and the 
reaction mixture was concentrated and added EtOAc (200 mL), which 
afforded a white precipitate (HOAt). The EtOAc was decanted off and 
washed with aq. HCl (1.0 M, 10 mL × 3) and concentrated to afford the crude 
cyclic peptide S6 (76 mg) as a brown oil. UPLC-MS gradient B, tR = 1.92  min, 
m/z calcld. for C32H51N4O6H+: 557.7; found: 557.2  [M+H]+.  
 
(Z)-6-((2R,5R,8R,11R)-8-benzyl-2-isopropyl-5,12,12-trimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid (3.51) 
LiOH (67 mg, 2.79 mmol, 35 equiv) in water (5 mL) was added to the impure 
cyclic peptide S6 (30 mg, 0.08 mmol) in THF (5 mL). After 16 hours the 
mixture was concentrated in vacuo and and the residue was dissolved in 
DMF and purified by preparative HPLC to afford the acid 3.51 (2.6 mg, 4%, 
5 steps) as a white solid. Two conformations are observed in a 91:9 ratio. 
Characterization is given for the major conformation. 1H NMR (500 MHz, 
DMSO) δ 8.04 (bs, 1H), 7.38 (bs, 1H), 7.27–7.11 (m, 6H), 7.05 (d, J = 9.5 Hz, 
1H), 5.16 (m, 1H), 4.99 (m, 1H), 4.40 (m, 1H), 4.14 (dq, J = 8.4, 7.9 Hz, 1H), 4.05 (m, 1H), 3.70 (dd, J= 10.1, 8.7 
Hz, 1H), 3.00 (dd, J = 13.6, 8.0 Hz, 2H), 2.70 (dd, J = 13.6, 6.6 Hz, 1H), 2.16 (m, 5H), 2.01 (m, 2H), 1.15–1.3 (m, 
6H), 1.04 (s, 3H), 0.85–0.84 (m, 6H). HRMS (ESI-TOF): m/z calcld. for C28H40N4O6Na+: 551.2840; found: 
551.2839 [M+Na]+. HPLC gradient C, tR = 12.94 min (>95%). 
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(2R,5R,8R,12R,Z)-12-amino-2-(4-hydroxybenzyl)-8-isopropyl-5,11,11-trimethyl-4,7,10,18-tetraoxo-19-oxa-
3,6,9-triazahenicos-14-en-1-oic acid (3.49)  
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–
(D)Tyr (279 mg, 0.14 mmol, 1.5 equiv) was added to a 
fritted syringe and the Fmoc group was removed with 
piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was 
then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). β-amino acid 3.16 (33 mg, 0.082 mmol) in DMF (2.0 mL) 
was preincubated for 5 min with iPr2NEt (45 µL, 0.28 mmol, 3.0 equiv) and COMU (61 mg, 0.14 mmol, 1.5 
equiv) before addition to the resin and the reaction was allowed to proceed on a rocking table for 16 hours. 
After washing [DMF (×3), MeOH (×3), CH2Cl2 (×3)] the resin was treated with TFA–CH2Cl2 (1:1, 4 mL) for 30 
min followed by washing with CH2Cl2 (5 mL). A fresh portion of TFA–CH2Cl2 (1:1, 4 mL) was added to the resin 
and after additional 30 min the resin was drained and all the fractions were pooled and concentrated in vacuo 
to provide the linear peptide (3.49) as an oily residue (141 mg). UPLC-MS gradient B, tR = 1.17 min, m/z calcld. 
for C30H46N4O8H+: 591.3; found: 591.3 [M+H]+. 
 
(Z)-ethyl 6-((2R,5R,8R,11R)-8-(4-hydroxybenzyl)-2-isopropyl-5,12,12-trimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoate (S7) 
The linear peptide 3.48 (35 mg, 0.092 mmol) was dissolved in DMF (230 mL 
≈ 0.4 mM) and iPr2NEt (159 µL, 0.92 mmol, 10 equiv) and HATU (70 mg, 0.19 
mmol, 2.0 equiv) were added. The solution was stirred for 16 hours and the 
reaction mixture was concentrated and added EtOAc (200 mL). The EtOAc 
was decanted off and washed with aq. HCl (1.0 M, 10 mL × 3) and 
concentrated to afford the crude cyclic peptide S7 (123 mg) as a brown oil. 
UPLC-MS gradient B, tR = 1.72  min, m/z calcld. for C30H43N4O7- : 571.3; 
found: 571.3 [M-H]-.  
 
(Z)-6-((2R,5R,8R,11R)-8-(4-hydroxybenzyl)-2-isopropyl-5,12,12-trimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid (3.52) 
LiOH (77 mg, 3.2 mmol, 35 equiv) in water (5 mL) was added to the impure 
cyclic peptide S7 (123 mg, 0.08 mmol) in THF (5 mL). After 20 hours the 
mixture was concentrated in vacuo and and the residue was dissolved in 
DMF and purified by preparative HPLC to afford the acid 3.52 (1.0 mg, 2%, 
5 steps) as a white solid. Two conformations are observed in a 89:11 ratio. 
Characterization is given for the major conformation. 1H NMR (500 MHz, 
DMSO) δ 8.03 (d, J = 8.6 Hz, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.19 (d, J = 8.3 Hz, 
1H), 7.00 (d, J = 9.9 Hz, 1H), 6.95 (d, J = 8.4 Hz, 2H), 6.60 (d, J = 8.4 Hz, 2H), 5.19 (m, 1H), 5.01 (m, 1H), 4.32 
(q, J = 8.0 Hz, 1H), 4.13 (pentet, J = 7.0 Hz, 1H), 4.04 (m, 1H), 3.69 (t, J = 10.1, 8.3 Hz, 1H), 2.87 (dd, J = 13.7, 
8.0 Hz, 1H), 2.57 (dd, J = 13.7, 6.6 Hz, 1H), 2.18 (m, 5H), 2.00 (m, 2H), 1.15 (m, 6H), 1.03 (s, 3H), 0.84 (m, 6H). 
HRMS (ESI-TOF): m/z calcld. for C28H40N4O7H+: 545.2970; found: 545.2968 [M+H]+. HPLC gradient C, tR = 11.36 
min (>95%). 
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(2R,5R,8R,12R,Z)-12-amino-2-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-8-isopropyl-5,11,11-
trimethyl-4,7,10,18-tetraoxo-19-oxa-3,6,9-triazahenicos-14-en-1-oic acid (3.50) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–
(D)Trp(Boc-N-indol) (142 mg, 0.072 mmol) was added to 
a fritted syringe and the Fmoc group was removed with 
piperidine–DMF (1:4, 4 mL, 2 × 25 min) and DBU–
piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was 
then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). β-amino acid 3.16 (28.4 mg, 0.079 mmol) in DMF (1.8 
mL) was preincubated for 5 min with iPr2NEt (37.7 µL, 0.22 mmol, 3.0 equiv) and HATU (41 mg, 0.11 mmol, 
1.5 equiv) before addition to the resin and the reaction was allowed to proceed on a rocking table for 17 
hours. After washing [DMF (×3), MeOH (×3), CH2Cl2 (×3)] the resin was treated with with TFA–CH2Cl2 (1:1, 4 
mL) for 30 min followed by washing with CH2Cl2 (5 mL). A fresh portion of TFA–CH2Cl2 (1:1, 4 mL) was added 
to the resin and after additional 30 min the resin was drained and all the fractions were pooled and 
concentrated in vacuo. Precipitation with diethyl ether afforded the TFA salt of the linear peptide 3.50 (43 
mg) as a white solid. UPLC-MS gradient B, tR = 1.30  min, m/z calcld. for C32H47N5O7H+: 614.3; found: 614.4  
[M+H]+.  
(Z)-ethyl-6-((2R,5R,8R,11R)-8-((1H-indol-3-yl)methyl)-2-isopropyl-5,12,12-trimethyl-3,6,9,13-tetraoxo-
1,4,7,10-tetraazacyclotridecan-11-yl)hex-4-enoate (S8) 
The linear peptide 3.50 (43 mg, 0.059 mmol) was dissolved in DMF (150 mL 
≈ 0.4 mM) and iPr2NEt (51.4 µL, 0.30 mmol, 5.0 equiv) and HATU (34 mg, 
0.089 mmol, 1.5 equiv) were added. The solution was stirred for 17 hours 
and the reaction mixture was concentrated to afford the crude cyclic 
peptide. Purification by VLC afforded a fraction containing the cyclic 
peptide S8 (13 mg) which was found not to be pure by 1H NMR. A fraction 
containing dimer (17 mg) was obtained as well. The impure cyclic peptide 
was used without further purification. UPLC-MS gradient B, tR = 1.72  min, m/z calcld. for C32H45N5O6H+: 595.3; 
found: 596.5 [M+H]+.  
(Z)-6-((2R,5R,8R,11R)-8-((1H-indol-3-yl)methyl)-2-isopropyl-5,12,12-trimethyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-4-enoic acid (3.53) 
LiOH (26 mg, 1.09 mmol, 50 equiv) in water (4 mL) was added to the impure 
cyclic peptide S8 (13 mg, 0.022 mmol) in THF (4 mL). After 18 hours the 
mixture was concentrated in vacuo and the residue was dissolved in MeCN–
water–DMF (2:2:1, 2.5 mL) and purified by preparative HPLC to afford the 
acid 3.53 (2.6 mg, 6%, 5 steps) as a white solid. Two conformations are 
observed in a 92:8 ratio. Characterization is given for the major 
conformation 1H NMR (500 MHz, DMSO) δ 7.74 (d, J = 8.6 Hz, 1H), 7.53 (d, J 
= 7.8 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 8.1 Hz, 2H), 3.95 (td, J = 9.5, 4.1 Hz, 1H), 3.71 (dd, J = 10.0, 
8.5 Hz  1H), 3.08 (d, J = 7.6 Hz, 2H), 2.36–2.17 (m, 6H), 2.08 (m, 2H), 1.32 (s, 3H), 1.23 (d, J = 7.3 Hz, 3H), 1.09 
(s, 3H), 0.88 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 7.0 Hz, 3H). ). HRMS (ESI-TOF): m/z calcld. for C32H47N5O6H+: 
568.3130; found: 568.3135 [M+H]+. HPLC gradient C, tR = 11.57 min (>95%).    
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(S,E)-N-butylidene-2-methylpropane-2-sulfinamide (3.60) 
A solution of butyraldehyde (0.80 mL, 8.91 mmol, 2.0 equiv) in dry CH2Cl2 (1.0 mL) was added 
dropwise to a solution of dried CuSO4 (3.6 g, 22.6 mmol, 5.0 equiv) and (S)-(-)-2-methyl-2-
propanesulfinamide (0.54 g, 4.46 mmol) in dry CH2Cl2 (7 mL). After stirring vigorously for 20 
hours the reaction mixture was filtered through a pad of Celite and the filter cake washed with CH2Cl2. The 
organic phase was concentrated in vacuo and purification by VLC afforded tert-butanesulfinyl imine 3.60 as 
a colorless oil (0.72 g, 92 %). Spectral data was in accordance with that found in the literature.236 300 MHz, 
CDCl3) δ 8.03 (t, J = 4.7 Hz, 1H), 2.46 (td, J = 7.3, 4.7 Hz, 2H), 1.63 (h, J = 7.4 Hz, 2H), 1.16 (s, 9H), 0.95 (t, J = 
7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 169.7, 56.5, 38.1, 22.5, 19.0, 13.9. 
(2S,3R)-tert-butyl 3-((S)-1,1-dimethylethylsulfinamido)-2-methylhexanoate (3.61) 
A solution of LDA (1.5 M in THF, 5.0 mL, 7.5 mmol, 2.6 equiv) was added dropwise over 
5 min to a solution of HMPA (1.5 mL, 8.6 mmol, 5.7 equiv) at –78 °C. After 15 min tert-
butyl propionate (1.1 mL, 7.3 mmol, 2.5 equiv) was added dropwise and after stirring 
for additionally 30 min imine 3.60 (0.51 g, 2.90 mmol) in dry THF (2.0 mL) was added 
dropwise. After 2 hours the reaction was quenched with sat. aq. NH4Cl and warmed to rt. The mixture was 
added 1 M HCl (20 mL) and extracted with EtOAc (2 x 60 mL). The combined organic phases were washed 
with brine (40 mL), dried (MgSO4), filtered, and concentrated in vacuo. Diastereoselectivity was determined 
by 1H NMR integration of the crude reaction mixture (65:25:8:2). Purification by silica gel chromatography 
afforded 3.61 (335 mg, 38%) as needle-like crystals. A fraction containing a mixture of diastereomers (200 
mg, 23%) was obtained as well. Characterization data for the major diastereomer. α[d]= 55.0 °; 1H NMR (300 
MHz, CDCl3)  δ 3.52 (m, 1H), 3.13 (d, J = 8.1 Hz, 1H), 2.46 (m, 1H), 1.46 – 1.60 (m, 2H), 1.42 (s, 9H), 1.18 (s, 
9H), 1.07 (d, J = 7.1 Hz, 3H), 0.91 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 173.8, 80.7, 59.0, 56.3, 45.2, 
36.6, 28.2, 22.9, 19.4, 13.9, 11.8. HRMS (ESI-TOF): m/z calcld. for C15H31NO3H+: 306.2103; found: 306.2110 
[M+H]+.   
(2S,3R)-methyl 3-(((benzyloxy)carbonyl)amino)-2-methylhexanoate (3.67) 
A solution of β-amino ester 3.61 (190 mg, 0.62 mmol) in MeOH (5.0 mL) was added 4 
M HCl in dioxane (4.7 mL, 18.8 mmol, 30 equiv). After stirring for 22 hours the mixture 
was concentrated. 1H NMR showed a mixture of the fully deprotected β-amino acid 
and amine deprotected methyl ester. To ensure full conversion to the methyl ester 
the crude product was dissolved in MeOH (5.0 mL) and cooled to 0 °C. Thionyl chloride (70 µL, 0.94 mmol, 
1.5 equiv) was added dropwise under argon. After 10 min the mixture was heated to reflux and stirred for 20 
hours before additional thionyl chloride (70 µL, 0.94 mmol, 1.5 equiv) was added. After 2.5 hours of stirring 
the mixture was concentrated and re-dissolved in MeOH (5.0 mL). Thionyl chloride (90 µL, 1.23 mmol, 2.0 
equiv) was added at 0 °C and the mixture stirred for 22 hours at room temperature, before concentration 
afforded the crude amine.  
The crude amine was dissolved in aq. sat. NaHCO3–ethyl acetate (1:1, 6.0 mL) and added benzylchloroformate 
(133 µL, 0.93 mmol, 1.5 equiv). After 18 hours of vigorously stirring the phases were separated and the 
aqueous layer was diluted with water (5 mL) and extracted with ethyl acetate (2 × 5 mL). The combined 
organic phases were washed with 1 M HCl (6 mL) and brine (6 mL), dried (Na2SO4), filtered, and concentrated 
in vacuo. Purification with VLC afforded the β-amino ester 3.67 in 37%, over three steps. α[D]= –39 ° (CHCl3, 
c= 0.99), α[D]litt.= –34 ° (CHCl3, c= 1.0); 1H NMR (400 MHz, CDCl3) δ 7.3 –7.28 (m, 5H), 5.09 (s, 2H), 4.95 (d, J = 
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9.7 Hz, 1H), 3.93–3.82 (m, 1H), 3.67 (s, 3H), 2.65 (m, 1H), 1.43 (m, 1H), 1.31 (m, 1H), 1.15 (d, J = 7.2 Hz, 3H), 
0.91 (t, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.0, 156.2, 136.7, 128.6, 128.2, 128.2, 66.8, 53.2, 51.9, 
44.1, 34.2, 19.6, 13.9, 13.2. 
The spectral data was in accordance with the data report in the literature.204  
 
(2S,3R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylhexanoic acid (3.57) 
A solution of β-amino ester 3.61 (224 mg, 0.73 mmol) in dry CH2Cl2 (5.0 mL) was added 
TFA (5 mL). After 25 hours the solution was concentrated and residual TFA was removed 
by co-evaporation with toluene (3 × 10 mL). The crude residue was dissolved in dioxane 
and 4 M HCl in dioxane (0.55 mL, 2.2 mmol, 3.0 equiv) was added. After 1.5 hour the mixture was 
concentrated. The crude fully deprotected β-amino acid was suspended in water (5 mL) and added Na2CO3 
(311 mg, 2.93, 4.0 equiv) followed by Fmoc-O-succinimide (297 mg, 0.88 mmol, 1.2 equiv) in DMF (3.0 mL) at 
0 °C. The cooling was removed and DMF (2 mL) was added. After 1.5 hours, water (5.0 mL) was added and 
after additionally 1.5 hours of stirring the reaction mixture was diluted with water (60 mL) and extracted with 
Et2O ( 15 mL). After acidification with concentrated HCl, until pH ≈ 1–2, the aqueous layer was extracted with 
ethyl acetate (3 × 75 mL). The combined organic phases were dried (MgSO4), filtered, and concentrated in 
vacuo. Purification of the crude residue by VLC (0.2% acetic acid in the eluent) afforded β-amino acid 3.57 
(66 mg, 25%, 3 steps) as a white solid after co-evaporation of residual acetic acid with CH2Cl2–toluene (1:1, 3 
× 10 mL). α[D]= 1.0 ° (MeOH); 1H NMR (300 MHz, DMSO) δ 12.19 (s, 1H), 7.86 (d, J = 7.4 Hz, 2H), 7.66 (dd, J = 
7.3, 2.9 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.30 (d, J = 7.4, 2H), 7.05 (d, J = 9.5 Hz, 1H), 4.31 (m, 2H), 4.18 (t, J = 
6.7 Hz, 1H), 3.58 (m, 1H), 2.28 (m, 1H), 1.22 (m, 4H), 0.95 (d, J = 6.9 Hz, 3H), 0.79 (t, J = 6.9 Hz, 3H). 13C NMR 
(75 MHz, DMSO) δ 176.2, 156.2, 143.9, 140.8, 127.6, 127.1, 127.0, 125.2, 125.2, 120.1, 65.0, 52.4, 46.9, 44.4, 
35.0, 18.8, 14.0, 13.7. HRMS (ESI-TOF): m/z calcld. for C22H25NO4H+: 368.1862; found: 368.1863 [M+H]+.   
 
(R)-2-((R)-2-((R)-2-((2S,3R)-3-amino-2-methylhexanamido)-3-methylbutanamido)propanamido)-3-(4-
hydroxyphenyl)propanoic acid (3.68) 
Polystyrene 2-chlorotrityl-bound Fmoc-(D)Val–(D)Ala–(D)Tyr 
(140mg, 0.11 mmol) was added to a fritted syringe and the Fmoc 
group was removed with piperidine–DMF (1:4, 4 mL, 2 × 30 min) 
and DBU–piperidine–DMF (2:2:96, 4 mL, 30 min). The resin was 
then washed with DMF (×3), MeOH (×3), CH2Cl2 (×3). β-amino acid 
3.57  (43 mg, 0.12 mmol, 1.1 equiv) in DMF (2.0 mL) was preincubated for 5 min with 2,6-lutidine (37 µL, 0.32 
mmol, 3.0 equiv) and HATU (61 mg, 0.16 mmol, 1.5 equiv) before addition to the resin and the reaction was 
allowed to proceed on a rocking table for 17 hours. After washing [DMF (×3), MeOH (×3), CH2Cl2 (×3)] the 
resin was treated with TFA–CH2Cl2 (1:1, 4 mL) for 30 min followed by washing with CH2Cl2 (5 mL). A fresh 
portion of TFA–CH2Cl2 (1:1, 4 mL) was added to the resin and after additional 30 min the resin was drained 
and all the fractions were pooled and concentrated in vacuo to provide the linear peptide as an oily residue. 
Precipitation with diethyl ether afforded the TFA salt of the linear peptide 3.68 (53 mg, 84%) as a white solid. 
UPLC-MS gradient A, tR = 0.84 min, m/z calcld. for C24H38N4O6H+: 478.3; found: 479.3 [M+H]+.  
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(3R,6R,9R,12S,13R)-3-(4-hydroxybenzyl)-9-isopropyl-6,12-dimethyl-13-propyl-1,4,7,10-
tetraazacyclotridecane-2,5,8,11-tetraone (3.56) 
The linear peptide 3.68 (50 mg, 0.084 mmol) was dissolved in DMF (200 mL ≈ 0.4 
mM) and iPr2NEt (73 µL, 0.42 mmol, 5 equiv) and HATU (48 mg, 0.13 mmol, 1.5 
equiv) were added. The solution was stirred for 19 hours and the reaction mixture 
was concentrated. The residue was taken up in CH2Cl2 (80 mL) and washed with 
aq. HCl (1.0 M, 15 mL × 2) and the aqueous phase was re-extracted with CH2Cl2 (50 
mL). The combined organics were washed with brine (25 mL), dried (MgSO4), 
filtered, and concentrated. The residue was dissolved in DMF (2.5 mL) and purified 
by preparative HPLC to afford the cyclic peptide 3.56 (2.7 mg, 7%, 5 steps) as a 
white solid. Two conformations are observed in an 88:12 ratio. Characterization is given for the major 
conformation. 1H NMR (500 MHz, DMSO) δ 7.67 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 9.0 Hz, 1H), 7.46 (d, J = 8.4 Hz, 
1H), 6.96 (d, J = 8.3 Hz, 2H), 6.63 (d, J = 8.4 Hz, 2H), 4.14 (p, , J = 7.3 Hz, 1H), 4.07 (p, J = 8.8 Hz, 1H), 3.99 (m, 
1H), 3.67 (t, J = 9.4 Hz  1H), 2.89 (dd, J = 13.7, 7.2 Hz, 1H), 2.81 (dd, J = 13.7, 9.0 Hz, 1H), 2.54 (m, 1H), 2.16 
(m, 1H), 1.64 (m, 1H), 1.36 (m, 1H), 1.20 (m, 6H), 0.87 (m, 6H). HRMS (ESI-TOF): m/z calcld. for C24H35N4O5H+: 
461.2765; found: 461.2754 [M+H]+. HPLC gradient C, tR = 11.14 min (>95%).    
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Experimental for chapter 4 
Material and methods 
General  
Solvents and piperidine were obtained from SDS and all chemicals were analytical grade and used without 
further purification. Analytical HPLC-PDA was performed on a Waters instrument comprising a separation 
module (Waters 2695), an automatic injector, a photodiode array detector (Waters 996 or Waters 2998) and 
a system controller (Millenium31 login). The columns used were Xbridge C18 reversed-phase analytical 
column (2.5 × mm × 4.6mm × 75mm) and Xbridge BEH130 C18 reversed-phase analytical column (3.5 mm × 
4.6mm × 100 mm). Ultraviolet detection was at 220 and 254 nm, and linear gradients of acetonitrile (MeCN) 
(+0.036% TFA) into H2O (+0.045% TFA) were run at a 1 mL/min flow rate over 8 min.  
HPLC-MS analysis was performed on a Waters instrument comprising a separation module (Waters 2695), 
an automatic injector, a photodiode array detector (Waters 2998), a Waters Micromass ZQ spectrometer 
and, a system controller (Masslynx v4.1). The column used was a Sunfire C18 reversed-phase analytical 
column (3.5 × 2.1 × 100mm). Ultraviolet detection was at 220 and 254 nm, and linear gradients of MeCN 
(+0.07% formic acid) into H2O (+0.1% formic acid) were run at a 0.3 mL/min flow rate over 8 min. 
NMR. 1H NMR and 13C NMR spectra were recorded on a Varian MERCURY 400 (400 MHz for 1H NMR, 100 
MHz for 13C NMR) spectrometer. Chemical shifts are reported in ppm relative to deuterated solvent peaks as 
internal standards (δH, DMSO-d6 2.50 ppm; δC, DMSO-d6 39.52 ppm, δH, CD3OH 3.30 ppm, δH, CDCl3 7.26 
ppm; δC, CDCl3 77.16 ppm). Coupling constants (J) are given in hertz (Hz). Multiplicities of 1H NMR signals are 
reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. 
Benzo[b]thiophen-2-yl(3,4-dimethoxyphenyl)methanol (4.13) 
Butyl lithium (7.5 mL, 18.8 mmol, 1.3 equiv) was added dropwise to a solution of 
benzothiophene (2.0 g, 14.2 mmol) in dry THF (10 mL) at 0 °C under nitrogen. After 
30 minutes, 3,4-dimethoxybenzaldehyde (3.1 g, 18.5 mmol, 1.3 equiv) in dry THF (10 
mL) was added dropwise over 10 min. After 15 minutes the cooling bath was 
removed and after stirring for 3.5 hours at room temperature the mixture was cooled to 0 °C and quenched 
with sat. aq. NH4Cl (20 mL). The layers were separated and the aqueous phase was extracted with ethyl 
acetate (2 × 20 mL) and the combined organics were dried (MgSO4), filtered, and concentrated in vacuo. 
Purification by silica gel chromatography (hexane/ethyl acetate, 2:1) afforded the alcohol 4.13 (3.89 g, 92%) 
as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.0 Hz, 1H), 7.69 (J = 7.4 Hz, 1H), 7.30 (pd, J = 7.2, 1.4 
Hz,  2H), 7.12 (s, 1H), 7.03 (m, 2H), 6.87 (d, J = 8.1 Hz, 1H), 6.08 (bs, 1H), 3.89 (s, 3H), 3.88 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ 1493, 149.1, 149.0, 140.0, 139.5, 135.4, 124.4, 124.3, 123.7, 122.5, 121.2, 119.0, 111.0, 
109.7, 72.9, 56.0, 56.0.  
 
2-((3,4-dimethoxyphenyl)(hydroxy)methyl)benzo[b]thiophene 1,1-dioxide (4.16) 
To a solution of benzothiophene alcohol 4.13 (1.0 g, 3.33 mmol) in MeOH–2-
propanol (5:1, 30 mL) was added MMPP (2.31 g, 4.66 mmol, 1.3 equiv) in small 
portions. Over the same period of time water (7.0 mL) was added in small portions. 
After stirring for 15 hours the suspension was filtered and concentrated. The 
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concentrate was added ethyl acetate (100 mL) and sat. aq. NaHCO3 (25 mL) and stirred for 10 minutes until 
all was dissolved. The layers were separated and the organic phase was washed with sat. aq. NaHCO3 (2 × 15 
mL), water (15 mL), brine (15 mL), dried (MgSO4), and concentrated in vacuo to afford the sulfone 4.16 (0.95 
g, 86%) as a yellow crystalline solid. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 7.2 Hz, 1H), 7.53 (td, J = 7.5, 1.3 
Hz, 1H), 7.48 (td, J = 7.7, 1.2 Hz, 1H) 7.28 (d, J = 7.7, 1H), 7.04 (m, 2H), 6.91 (d, J = 8.0 Hz, 1H), 6.72 (bs, 1H), 
5.88 (bs, 1H), 3.90 (m, 6H), 2.72 (bs, 1H). 13C NMR (100 MHz, CDCl3) δ 149.4, 149.3, 146.4, 137.6, 133.8, 131.9, 
130.5, 130.3, 127.9, 125.3, 121.6, 119.3, 111.2, 109.9, 68.5, 56.1, 56.0. 
 
1-(benzo[b]thiophen-2-yl)propan-1-ol (4.14) 
Butyl lithium (15.5 mL, 38.7 mmol, 1.3 equiv) was added dropwise to a solution of 
benzothiophene (4.0 g, 29.8 mmol) in dry THF (12 mL) at 0 °C under nitrogen. After 30 
minutes propionaldehyde (2.8 mL, 38.7 mmol, 1.3 equiv) in dry THF (5 mL) was added dropwise over 10 min. 
After 15 minutes the cooling bath was removed and after stirring 2 hours at room temperature the mixture 
was cooled to 0 °C and quenched with sat. aq. NH4Cl (20 mL). The layers were separated and the aqueous 
phase was extracted with ethyl acetate (2 × 30 mL) and the combined organics were dried (MgSO4), filtered, 
and concentrated in vacuo. Purification by silica gel chromatography (hexane/ethyl acetate, 4:1) afforded the 
alcohol 4.14 (4.80 g, 84%) as a pale yellow oil, which crystalized upon storage. 1H NMR (400 MHz, CDCl3) δ 
7.75 (d, J = 7.7 Hz, 1H), 7.65 (d, J = 8.0   1H), 7.28 (td, J = 7.2, 1.2 Hz,  1H), 7.24 (J = 7.1, 1.3 Hz, 1H), 4.84 (t, J = 
6.6 Hz, 1H), 2.33 (bs, 1H), 1.86 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 149.4, 139.6, 
139.4, 124.3, 124.2, 123.5, 122.6, 120.3, 72.4, 32.0, 10.1. 
 
2-(1-hydroxypropyl)benzo[b]thiophene 1,1-dioxide (4.17) 
To a solution of benzothiophene alcohol 4.14 (2.0 g, 10.4 mmol) in MeOH (50 mL) was 
added MMPP (7.2 g, 14.6 mmol, 1.4 equiv) in small portions. Over the same period of 
time, water (15 mL) was added in small portions. After stirring for 16 hours the suspension 
was filtered and concentrated. The solid was added ethyl acetate (150 mL) and sat. aq. NaHCO3 (35 mL) and 
stirred for 10 minutes until all was dissolved. The layers were separated and the organic phase was washed 
with sat. aq. NaHCO3 (2 × 30 mL), water (30 mL), brine (30 mL), dried (MgSO4), and concentrated in vacuo to 
afford the sulfone 4.17 (1.83 g, 79%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.6 Hz, 1H), 7.54 
(td, J = 7.5, 1.2 Hz, 1H), 7.48 (td, J = 7.6, 1.1 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.04 (dd, J = 1.4, 1.0 Hz, 1H), 4.78 
(m, 1H), 2.26 (bs, 1H), 2.04 (m, 1H), 1.91 (m, 1H), 1.07 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 146.8, 
137.5, 133.8, 130.8, 130.1, 126.5, 125.1, 121.5, 68.0, 29.1, 9.5. 
 
N-(1-(benzo[b]thiophen-2-yl)propyl)-1H-imidazole-1-carboxamide (4.20) 
To a solution of carbonyldiimidazole (0.51 g, 3.12 mmol, 1.4 equiv) in dry CH2Cl2 (5 mL) 
was added a solution of alcohol 4.14 (0.42 g, 2.17 mmol) in dry CH2Cl2 (3 mL) over 5 min 
under argon. After 1.5 hours of stirring the reaction mixture was diluted with CH2Cl2 (50 
mL) and washed with water (2 × 10 mL), dried (MgSO4), filtered, and concentrated in 
vacuo to afford the carbonyl imidazole 4.20 (0.61 g, 98%). 1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.73 (m, 
1H), 7.67 (m, 1H), 7.35 (t, J = 1.5 Hz, 1H), 7.29 (s, 1H),  7.26 (m, 2H), 6.98 (m, 1H), 6.11 (t, J = 7.0 Hz, 1H) 2.15 
(sekstet, J = 7.4 Hz, 1H), 2.06 (sekstet, J = 7.4 Hz, 1H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
148.1, 141.4, 139.6, 138.9, 137.2, 130.8, 125.1, 124.7, 124.1, 123.9, 122.5, 117.2, 78.0, 29.1, 10.0.   
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1-(benzo[b]thiophen-2-yl)propyl benzylcarbamate (4.22) 
To a solution of carbonylimidazole 4.20 (127 mg, 0.44 mmol) in dry CH2Cl2 (2 mL) was 
added a solution of benzyl amine (60 µL, 0.55 mmol, 1.2 equiv) and Et3N (75 µL, 0.55 
mmol, 1.2 equiv) in dry CH2Cl2 (1 mL). After stirring for 15 hours DMAP (3.2 mg, 0.03 
mmol, 0.06 equiv) was added followed by benzyl amine (50 µL, 0.46 mmol, 1.0 equiv) 
and the mixture was heated to 35 °C. After stirring for 20 hours the mixture was diluted 
with ethyl acetate (20 mL) and washed with sat. aq. NH4Cl (2 × 10 mL), water (10 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. Purification by silica gel chromatography (hexane/ethyl acetate, 6:1) afforded the 
carbamate 4.22 (89 mg, 62%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 
7.3 Hz, 1H), 7.25 (m, J = 7H), 5.95 (t, J = 6.9 Hz, 1H), 5.14 (bs, 1H), 4.31 (m, 3H), 1.97 (dtd, J = 20.9, 13.8, 6.8 
Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 155.9, 144.7, 139.5, 139.4, 138., 128.7 (× 2), 
127.6, 127.5, 124.4, 124.3, 123.8, 122.5, 122.3, 74.1, 45.2 29.6, 10.0. 
 
benzo[b]thiophen-2-yl(3,4-dimethoxyphenyl)methyl 1H-imidazole-1-carboxylate (4.19) 
To a suspension of alcohol 4.13 (0.50 g, 3.1 mmol, 1.4 equiv) in dry CH2Cl2 (5 mL) 
was added a solution of alcohol (0.66 g, 2.2 mmol) in dry CH2Cl2 (3 mL) over 5 min 
under argon. After 2 hours of stirring the reaction mixture was diluted with CH2Cl2 
(30 mL) and washed with water (2 × 10 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification by silica gel chromatography (ethyl acetate) 
afford the carbonyl imidazole 4.19 (0.51 g, 59%) as a clear oil. 1H NMR (400 MHz, 
CDCl3) δ 7.78 (m, 1H), 7.70 (m, 1H), 7.59 (s, 1H), 7.35 (m, 2H), 7.13 (t, J = 1.1 Hz, 
1H), 7.03 (s, 1H), 6.99 (t, J = 1.3 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.79 (m, 2H), 6.69 (s, 1H), 3.90 (s, 3H), 3.81 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 149.6, 149.5, 143.3, 140.3, 139.1, 137.2, 131.0, 129.4, 125.2, 124.9, 124.3, 
124.1, 122.5, 120.2 (×2), 119.2, 111.3, 110.8, 61.3, 56.1, 56.1.  
 
7-((1-(benzo[b]thiophen-2-yl)propyl)amino)-4-methyl-2H-chromen-2-one (4.21) 
To a solution of carbonyl imidazole 4.19 (25 mg, 0.09 mmol) in dry DMF (2 mL) was 
added 7-amino-4-methylcoumarin (30 mg, 0.17 mmol, 2.0 equiv) and the solution 
heated to 100 °C. After stirring for 16 hours, the reaction mixture was diluted with ethyl 
acetate (40 mL) and washed with sat. aq. NH4Cl (2 × 15 mL), water (15 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification by silica gel chromatography 
(hexane/ethyl acetate, 2:1) afforded the amine 4.21 (10 mg, 30%) as a white solid. 1H 
NMR (400 MHz, DMSO) δ 7.83 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 7.2 Hz, 1H), 7.40 (m, 2H), 
7.29 (m, 2H), 7.22 (d, J = 7.1 Hz, 1H), 6.71 (dd, J = 8.8, 2.3 Hz, 1H), 6.47 (d, J = 2.2 Hz, 1H), 5.89 (d, J = 1.1 Hz, 
1H), 4.79 (m, 1H), 2.26 (d, J = 1.1 Hz, 4H), 1.92 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, DMSO) δ 
160.9, 155.4, 154.0, 151.8, 149.7, 139.6, 138.5, 126.1, 124.5, 124.1, 123.4, 122.6, 121.3, 111.0 (×2), 109.5, 
108.1, 54.7, 30.4, 18.1, 11.0.  
 
benzo[b]thiophen-2-ylmethanol (4.15) 
Butyl lithium (11.6 mL, 29.1 mmol, 1.3 equiv) was added over 10 minutes to a solution of 
benzothiophene (3.0 g, 22.4 mmol) in dry THF (15 mL) at –20 °C under nitrogen. After 50 
minutes of stirring the solution was cooled to –78 °C and paraformaldehyde (4.7 g, 157 mmol, 7.0 equiv) was 
added in small portions over 5 min. The mixture was allowed to warm to room temperature over 15 hours 
Experimental 
133 
 
and quenched with 2M HCl (15 mL). The mixture was extracted with Et2O (3 × 25 mL) and the combined 
organic phases were washed with brine (25 mL), dried (MgSO4), filtered, and concentrated in vacuo. 
Purification by silica gel chromatography (hexane/ethyl acetate, 4:1) afforded the alcohol 4.15 (2.64 g, 72%) 
as a white solid. The spectral data was in accordance with that previously reported.237 1H NMR (400 MHz, 
CDCl3) δ 7.82 (d, J = 7.5 Hz, 1H), 7.72 (d, J = 7.5 Hz, 1H), 7.38–7.29 (m, 2H), 7.17 (d, J = 0.8 Hz, 1H), 4.89 (d, J = 
0.9 Hz, 2H), 2.50 (bs, 1H). 13C NMR (100 MHz, CDCl3) δ 144.9, 140.0, 139.6, 124.4, 124.3, 123.6, 122.6, 121.6, 
88.7, 64.5, 60.9. 
 
2-(hydroxymethyl)benzo[b]thiophene 1,1-dioxide (4.18) 
To a solution of benzothiophene alcohol 4.15 (1.0 g, 6.1 mmol) in MeOH (7.5 mL) was added 
MMPP (4.25 g, 8.5 mmol, 1.4 equiv) in small portions at 0 °C. Over the same period of time 
water (3.5 mL) was added in small portions. After stirring this suspension for 15 minutes the 
cooling bath was removed and the resulting clear solution was stirred at room temperature for 2 hours and 
concentrated in vacuo. The residue was added CH2Cl2 (35 mL) and sat. aq. NaHCO3 (20 mL) and stirred for 10 
minutes until all was dissolved. The layers were separated and the organic phase was washed with sat. aq. 
NaHCO3 (2 × 20 mL), brine (15 mL), water (20 mL), dried (MgSO4), and concentrated in vacuo to afford the 
sulfone 4.18 (0.80 g, 67%) as a white solid. The spectral data was in accordance with that previously 
reported.237 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.3 Hz, 1H), 7.51 (td, J = 7.5, 1.2 Hz, 1H), 7.45 (td, J = 7.5, 
1.2 Hz, 1H), 7.29 (m, 2H), 7.05 (m, 1H), 4.68 (d, J = 1.6 Hz, 2H), 2.81 (bs, 1H). 13C NMR (100 MHz, CDCl3) δ 
143.7, 137.3, 133.9, 130.9, 130.1, 127.2, 125.3, 121.5, 55.7.  
 
1-(1,1-dioxidobenzo[b]thiophen-2-yl)propyl (4-methyl-2-oxo-2H-chromen-7-yl)carbamate (4.25) 
A solution of AMC (50 mg, 0.29 mmol) and Et3N (0.4 mL, 2.90 mmol, 10 
equiv) in dry CH2Cl2 (5 mL) was cooled to 0 °C and added a solution of 
triphosgene (126 mg, 0.43 mmol, 1.5 equiv) in dry THF (2 mL) over 30 
minutes under nitrogen. After stirring for an additional hour the reaction 
mixture was added alcohol 4.17 (96 mg, 0.43 mmol, 1.5 equiv). After stirring for 2 hours the reaction mixture 
was diluted with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by silica gel chromatography 
(hexane/ethyl acetate, 1:1) afforded the carbamate 4.25 (38 mg, 31%) as a yellow solid. 1H NMR (400 MHz, 
DMSO) δ 7.86 (dd, J = 7.5, 0.8 Hz, 1H), 7.74–7.69 (m, 2H), 7.66 (s, 1H), 7.65–7.59 (m, 2H), 7.56 (d, J = 2.0 Hz, 
1H), 7.47 (dd, J = 8.7, 2.1 Hz, 1H), 6.25 (d, J = 1.2 Hz, 1H), 5.75 (t, J = 6.4 Hz, 1H), 2.39 (d, J = 1.2 Hz, 3H), 2.06 
(m, 2H), 1.02 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, DMSO) δ 160.0, 153.8, 153.1, 152.3, 142.5, 141.2, 136.7, 
134.3, 130.8, 129.8, 129.3, 126.0 (×2), 121.1, 114.5, 114.4, 112.0, 104.6, 70.5, 26.1, 18.0, 9.4. 
 
(3,4-dimethoxyphenyl)(1,1-dioxidobenzo[b]thiophen-2-yl)methyl-(4-methyl-2-oxo-2H-chromen-7-
yl)carbamate (4.24) 
A solution of AMC (50 mg, 0.29 mmol) and Et3N (0.4 mL, 2.90 mmol, 10 
equiv) in dry CH2Cl2 (5 mL) was cooled to 0 °C and added a solution of 
triphosgene (126 mg, 0.43 mmol, 1.5 equiv) in dry THF (2 mL) over 30 
minutes under nitrogen. After stirring for an additional hour the reaction 
mixture was added alcohol 4.16 (143 mg, 0.43 mmol, 1.5 equiv). After 
stirring for 19 hours the reaction mixture was diluted with CH2Cl2 (20 mL) and concentrated in vacuo. 
Purification by silica gel chromatography (hexane/ethyl acetate, 1:1) afforded the carbamate 4.24 (6 mg, 4%) 
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as a yellow solid. Additional impure fractions were collected. 1H NMR (400 MHz,CDCl3) δ 7.72 (dd, J = 6.8, 1.2 
Hz, 1H), 7.57–7.47 (m, 3H), 7.44 (d, J = 2.1 Hz, 1H), 7.39 (m, 2H), 7.29 (J = 7.3 Hz, 1H), 7.12 (dd, J = 8.3, 2.0 Hz, 
1H), 7.09 (d, J = 2.0 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 6.88 (d, J = 1.7 Hz, 1H), 6.77 (s, 1H), 6.18 (d, J = 1.2 Hz, 
1H), 3.91 (s, 3H), 3.90 (s, 3H), 2.39 (d, J = 1.2 Hz, 3H). 13C NMR (100 MHz, DMSO) δ 160.0, 153.8, 153.2, 151.8, 
149.4, 148.8, 142.3, 142.0, 136.8, 134.3, 130.9, 129.9, 129.6, 128.2, 126.3, 126.1 (×2), 121.4, 121.2, 120.1, 
114.7, 112.1, 111.7, 111.2, 69.9, 55.6, 55.6, 18.0. 
 
1-(benzo[b]thiophen-2-yl)propyl (4-methyl-2-oxo-2H-chromen-7-yl)carbamate (4.26) 
A solution of AMC (200 mg, 1.14 mmol) and Et3N (1.59 mL, 11.4 mmol, 10 
equiv) in dry CH2Cl2 (20 mL) was cooled to 0 °C and added a solution of 
triphosgene (0.51 g, 1.71 mmol, 1.5 equiv) in dry THF (4 mL) over 30 
minutes under nitrogen. After stirring for an additional hour the alcohol 
5.14 (285 mg, 1.48 mmol, 1.3 equiv) in dry THF (2 mL) was added dropwise. After stirring for 1 hour and 15 
minutes the reaction mixture was diluted with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by silica 
gel chromatography (hexane/ethyl acetate, 4:1) afforded the carbamate 4.26 (142 mg, 32%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 7.5 Hz, 1H), 7.75 (dd, J = 6.8, 2.3 Hz, 1H), 7.50 (d, J = 8.6 Hz, 1H), 7.41 
(d, J = 2.1 Hz, 1H), 7.39–7.29 (m, 4H), 6.92 (bs, 1H), 6.18 (d, J = 1.2 Hz, 1H), 6.05 (t, J = 7.0 Hz, 1H), 2.39 (d, J = 
1.2 Hz, 3H), 2.13 (m, 1H), 2.04 (m, 1H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 161.2, 154.6, 152.3 
(×2), 143.5, 141.4, 139.6, 139.3, 125.5, 124.8, 124.6, 124.0, 123.1, 122.6, 115.8, 114.5, 113.4, 106.1, 75.0, 
29.5, 18.7, 10.1. 
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ABSTRACT: Cyclic tetrapeptide and depsipeptide natural
products have proven useful as biological probes and drug
candidates due to their potent activities as histone deacetylase
(HDAC) inhibitors. Here, we present the syntheses of a class
of cyclic tetrapeptide HDAC inhibitors, the azumamides, by a
concise route in which the key step in preparation of the
noncanonical disubstituted β-amino acid building block was an
Ellman-type Mannich reaction. By tweaking the reaction
conditions during this transformation, we gained access to the
natural products as well as two epimeric homologues. Thus,
the ﬁrst total syntheses of azumamides B−D corroborated the
originally assigned structures, and the synthetic eﬀorts enabled the ﬁrst full proﬁling of HDAC inhibitory properties of the entire
selection of azumamides A−E. This revealed unexpected diﬀerences in the relative potencies within the class and showed that
azumamides C and E are both potent inhibitors of HDAC10 and HDAC11.
■ INTRODUCTION
Macrocyclic peptides have played important roles in the ﬁeld of
epigenetics due to their potent activities as inhibitors of histone
deacetylase (HDAC) enzymes. One of the two HDAC target-
ing drugs (11 and 3) that are approved by the U.S. Food and
Drug Administration (FDA) for clinical treatment of cutaneous
T-cell lymphoma is the macrocyclic natural product romidepsin
(3).2 Furthermore, a cyclic tetrapeptide, trapoxin,3 played an
instrumental role in the ﬁrst isolation of a mammalian HDAC
enzyme.4,5 Thus, this class of inhibitors holds promise as tool
compounds as well as potential drug candidates targeting
HDACs.6−9
Though clearly bearing an overall resemblence to the classical
cyclic tetrapeptide HDAC inhibitors [including, for example,
apicidin (4)],10 the azumamides (5−9) are structurally unique
in that their extended Zn2+-coordinating amino acid (shown in
yellow in Figure 1) is a disubstituted β-amino acid.11 Further-
more, we found the azumamides interesting due to the relatively
strong potencies reported for azumamide E against class I
HDACs12 in spite of its weak Zn2+-coordinating carboxylic acid
functionality.13 Previously, azumamide A14,15 and azumamide
E12,14−16 have been prepared by multistep chemical syntheses,
but only azumamide E was tested against recombinant HDAC
isoforms 1−9.12 Furthermore, in vitro proﬁling with recombi-
nant HDACs has witnessed important new developments since
the publication of those results.17,18 We therefore found it
relevant to explore the properties of these macrocycles in more
detail by preparing the complete selection of natural products
(5−9), and proﬁling their activities against the full panel of
recombinant human Zn2+-dependent HDAC enzymes, HDAC1−11.
As total syntheses of azumamides B−D had not been reported
previously, this work would also allow unequivocal validation of
the proposed structures.11
For syntheses of the azumamides, we envisaged two
signiﬁcant challenges: ﬁrst, eﬃcient stereoselective synthesis
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Figure 1. Structures of archetypical HDAC inhibitors (1−4) and
target azumamides 5−9.
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of the disubstituted β-amino acid, and second, the macro-
cyclization step, which is known to be diﬃcult for small cyclic
peptides in general19 and furthermore proved challenging in
previously reported syntheses of azumamide analogues.12
■ RESULTS AND DISCUSSION
Building Block Synthesis. For our synthesis of the β-amino
acid building block, we chose a diastereoselective Ellman-type
Mannich reaction to set the stereochemistry, as also previously
reported by Ganesan and co-workers.15 However, to avoid having
this important transformation at a late stage in our synthetic route,
we decided to optimize this reaction between a propionate ester
and a simple imine as shown in eq 1.
This should give an intermediate with the correct stereo-
chemistry (2S,3R), which could be readily elaborated to give
the desired β-amino acid by robust organic synthetic trans-
formations (vide infra). Mannich reactions between ester
enolates and chiral sulﬁnylimines have been studied exten-
sively,20,21 and using previously reported conditions as our
starting point we conducted an optimization study as outlined
in Table 1. The tert-butyl ester showed superior selectivity
(entry 5) compared to the less bulky methyl, ethyl, allyl, and
PMB esters (entries 1−4), and furthermore, the methyl ester
did not proceed to completion in our hands. Somewhat
surprisingly, however, the major diastereoisomer in entry 5
proved to have (2S,3S) conﬁguration as determined by X-ray
crystallography upon desilylation (Figure 2).
This indicates that the pathway leading to our major isomer
did not proceed through the six-membered Zimmerman−
Traxler-type transition state,22 which has been proposed to be
responsible for the diastereoselectivity with similar sub-
strates.20,23 By using HMPA as an additive instead of a Lewis
acid, this reaction has previously been shown to proceed
through a diﬀerent transition state,20 and indeed we saw the
same product distribution when using HMPA and TiCl(OiPr)3
as additives with our substrates (entries 5 and 6). This indicates
that the six-membered transition state, where coordination of
titanium is crucial, is highly unlikely to play a signiﬁcant role in
the formation of our major isomer. This is not in agreement
with the diastereoselectivities observed with the substrates reported
by Ganesan and co-workers.15 Thus, to address whether the steric
bulk of the triisopropylsilyl ether was responsible for interrupting
the six-membered transition state, we performed the reaction with
diﬀerent means of protecting the alcohol (entries 7−9). No
signiﬁcant eﬀect was observed, however, indicating instead that the
steric bulk of the tert-butyl ester caused the predominance of a
diﬀerent transition state when using our substrates. This is also in
agreement with the original study by Tang and Ellman20 where the
level of selectivity decreased for 2,3-disubstituted β-amino acids
when the bulk of the ester increased from methyl to tert-butyl.
Because we were interested in taking advantage of solid-
phase synthesis methods to prepare the linear tetrapeptide
azumamide precursors with a minimum of chromatographic
puriﬁcation steps, we were keen on keeping the acid-labile tert-
butyl ester protecting group, which would allow easy protecting
group manipulation to give an Fmoc-protected β-amino acid
building block. Hence, instead of substituting this protecting
group, we decided to optimize the Mannich reaction conditions
to deliver the desired stereochemistry. First, we changed the
stereochemistry of the sulﬁnylimine to the R-enantiomer, which
expectedly furnished the enantiomer of entries 5−9 (2R,3R) as
the major isomer (entry 10). We then hypothesized that the
conﬁguration of the 2-position would be sensitive to the E/Z
conﬁguration of the enolate. Using Ireland’s conditions for
forming the enolate in the presence of HMPA,24,25 we achieved
>80% Z-isomer, which gratifyingly aﬀorded the (2S,3R)
product as major isomer (entry 11). Under the developed
conditions, we prepared compound 12, which was further
elaborated to give Fmoc-protected β-amino acid 16 in 15%
overall yield with just four column chromatographic puriﬁcation
steps from compound 10 (Scheme 1).
Table 1. Optimization of Stereochemical Outcome of the Mannich Reaction Shown in Equation 1
entry auxiliary* R1 R2 additive enolatea drb major isomer
1 R Me OSi(iPr)3 TiCl(O
iPr)3 E 47:39:10:4 ND
c
2 R Et OSi(iPr)3 TiCl(O
iPr)3 E 49:29:11:11 ND
3 R allyl OSi(iPr)3 TiCl(O
iPr)3 E 46:34:10:10 ND
4 R PMB OSi(iPr)3 TiCl(O
iPr)3 E 46:33:11:10 ND
5 R tBu OSi(iPr)3 TiCl(O
iPr)3 E 60:26:8:6 (2S,3S)
d
6 R tBu OSi(iPr)3 HMPA E 71:15:14:0 (2S,3S)
7 R tBu OBn TiCl(OiPr)3 E 70:18:12:0 ND
8 R tBu OPMB TiCl(OiPr)3 E 77:13:10:0 (2S,3S)
9 R tBu OSi(Et)3 TiCl(O
iPr)3 E 75:21:4:0 (2S,3S)
d
10 S tBu OSi(iPr)3 HMPA E 77:18:5:0 (2R,3R)
e
11 S tBu OSi(iPr)3 HMPA
f Z 64:25:8:2 (2S,3R)g
aMajor conﬁguration of the enolate as determined by NMR and by trapping with tBuMe2SiCl.
bDiastereomeric ratio determined by 1H NMR.
cND = not determined. dDetermined by X-ray crystallography on its desilylated homologue. eDetermined spectroscopically by comparison with its
enantiomer from entries 5 and 9. fHMPA (5.4 equiv) was added prior to the substrate to obtain the (Z)-enolate (>80%). gDetermined by
comparison of spectroscopic data of the fully elaborated Boc-protected β-amino acid with previously reported data.12
Figure 2. X-ray crystal structure of the (2S,3S) precursor obtained by
desilylation of the major product in entry 5 of Table 1.
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The Boc-protected homologue of 16 was also prepared to
conﬁrm the (2S,3R) stereochemistry by comparison of
spectroscopic data (optical rotation and NMR) with those
previously reported (Figure S1 in Supporting Information).12
Furthermore, the β2- and β3-epimeric building blocks were
prepared by elaboration of the major isomers from entries 10
and 5, respectively (see Supporting Information for details).
Although the achieved diastereomeric ratios were not par-
ticularly impressive, this strategy very nicely provided the
correct stereochemistry along with two novel β-amino acids,
enabling investigation of the biochemical eﬀect of stereo-
chemical conﬁguration at these two chiral centers.
Cyclic Peptide Synthesis. Because three diﬀerent points of
cyclization had been reported for azumamide E and since these
were all performed with diﬀerent coupling reagents,12,14,15 we
performed cyclization experiments using a simpliﬁed model
peptide to address the issue. Not too surprisingly, this showed
that macrolactamizations with the most sterically hindered
amino acids at the C-terminal were particularly poor, resulting
in signiﬁcant amounts of N-terminal guanidinylation, incom-
plete cyclization, epimerization, and/or dimerization (Table S1
in Supporting Information). Thus, we prepared the linear
tetrapeptides 17, 19, and 21 on solid support by standard Fmoc
solid-phase synthesis using β-amino acid 16 and commercially
available Fmoc-D-amino acids.
In Scheme 2A, the cyclization was then performed at the
β-amino acid position and in Scheme 2B at the alanine residue,
whereas the preparation of azumamide D (8) was achieved by
cyclization between the two least sterically challenging alanine
residues (Scheme 2C). After cleavage from the 2-chlorotrityl
polystyrene resin with dilute TFA, the linear tetramers were
ring-closed by use of HATU under dilute conditions (0.4−
0.5 mM),26−29 and furthermore slow addition of the linear
peptide by syringe pump to a solution of Hünig’s base and
HATU, as described by Ganesan and co-workers,15 was tested.
Judging from LC−MS analyses of the reaction mixtures, we
could not observe any signiﬁcant diﬀerences between the cycliza-
tion yields obtained with the diﬀerent methods. Although all
the couplings proceeded satisfactorily, with full conversion of
linear peptides and minor amounts of the corresponding dimers
as the only observed byproducts, the resulting overall isolated
yields were relatively low (∼10%). We ascribe this to diﬃculties
during puriﬁcation of the macrocyclic products by preparative
reversed-phase HPLC caused by poor water solubility, as we
were able to recover more material by purifying the macrocycles
by column chromatography. Unfortunately, however, this did
not provide the ﬁnal compounds in satisfyingly high purity for
the bioassays, and thus the ﬁnal compounds were all subjected
to preparative reversed-phase HPLC puriﬁcation although this
resulted in a loss of material. Carbodiimide-mediated amidation
of the side chain was attempted for conversion of 7 to 6 and 23
to 8, but the reaction was slow and gave varying yields (6 vs 8,
Scheme 2). Instead, HATU-mediated coupling was attempted
for conversion of 9 to 5, and this proved faster and gave an
acceptable yield (5). Spectral data of all the natural products
5−9 were in excellent agreement with those originally reported
for the azumamides isolated from natural sources,5 thus
corroborating the original structural assignment (Figures S2−S6
in Supporting Information). Finally, the two epimeric β-amino
acid building blocks were applied in analogous syntheses of
β3-epi-azumamide E (26) and β2-epi-azumamide E (29) as
shown in Scheme 3.
HDAC Screening. As an initial test of the HDAC inhibitory
potency of all seven compounds, we ﬁrst screened against the
full panel of recombinant human HDACs at two compound
concentrations (50 μM and 5 μM). Protocols for HDAC1−9
were adapted from Bradner et al.,18 using the ﬂuorogenic
Ac-LeuGlyLys(Ac)-AMC substrate for HDAC1−3 and 6 while
using the Ac-LeuGlyLys(tfa)-AMC substrate for HDAC4, 5,
and 7−9. For HDAC10 we used the tetrapeptide Ac-ArgThr-
Lys(Ac)Lys(Ac)-AMC,30 which was recently reported to
perform well with this enzyme.31 Finally, for HDAC11, we
also used Ac-LeuGlyLys(Ac)-AMC as substrate.32
The site-speciﬁcally epimerized compounds exhibited no
activity as previously reported for an analogue having both
stereocenters inverted.7 It was not surprising that 26 was
inactive, but it is noteworthy that the subtle change of inverting
the stereochemistry of a single methyl group in 29 had such a
detrimental eﬀect across the entire selection of enzymes
(Figure 3). Furthermore, none of the compounds 5−9 were
able to inhibit class IIa HDAC activity against a triﬂuoroacety-
lated substrate (Figure 3).
Inhibitor Ki Values. Next, we performed dose−response
experiments for all compound−HDAC combinations that gave
above 50% inhibition in the initial assay (Figure S7 and Table
S2 in Supporting Information). The obtained IC50 values were
converted to Ki values by use of the Cheng−Prusoﬀ equation
[Ki = IC50/(1 + [S]/Km)] with the assumption of a standard
fast-on−fast-oﬀ mechanism of inhibition. Reported Km values
were applied for the calculations except HDAC10, where we
determined the Km for the used substrate to be 1.5 ± 0.2 μM
(Figure 4).
Low potencies were recorded against HDACs 6 and 8, which
is in accordance with previous data for azumamide E (Table 2);6
however, compounds 7 and 9 were both potent inhibitors
of HDACs 10 and 11. Although they are classiﬁed together
Scheme 1. Synthesis of β-Amino Acid Building Block 16.a
aReagents and conditions: (a) HMPA (6.4 equiv), LDA (2.6 equiv),
11 (2.5 equiv), THF, −78 °C, 30 min; then 10, −78 °C, 30 min. (b)
AcOH (1.0 equiv), Bu4NF (2.0 equiv), THF, 0 °C → rt, 1.5 h. (c)
NaHCO3 (1.5 equiv), Dess−Martin periodinane (1.4 equiv), dry
CH2Cl2, 0 °C → rt, 1.5 h. (d) KHMDS (1.9 equiv), Ph3PBr-
(CH2)3COOEt (2.0 equiv), THF, −78 °C → rt, 18 h. (e) TFA−
CH2Cl2 (1:1, 10 mL, 80 equiv), 0 °C → rt, 3 h. (f) HCl (4.0 M in
dioxane, 3.0 equiv), dioxane, 3 h. (g) Na2CO3 (4.0 equiv), Fmoc-OSuc
(1.2 equiv), dioxane−H2O, 0 °C → rt, 2 h.
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(class IIb), HDACs 6 and 10 clearly interact very diﬀerently
with these inhibitors.
Generally, we found the compounds with a carboxylic acid
Zn2+-binding group (7 and 9) to be more potent than the
Scheme 3. Synthesis of the Two Epimers 26 and 29 of Azumamide E by Solid-Phase Synthesis Followed by Head-to-Tail
Macrolactamization in Solutiona
aReagents and conditions: (a) TFA−CH2Cl2 (1:1), 2 × 30 min. (b) HATU, iPr2NEt (8.0 equiv), DMF (0.3−0.7 mM peptide concn), 17−21 h. (c)
LiOH, THF−H2O (1:1).
Scheme 2. Synthesis of Azumamides A−E by Solid-Phase Synthesis Followed by Head-to-Tail Macrolactamization in Solutiona
aReagents and conditions: (a) TFA−CH2Cl2 (1:1), 2 × 30 min. (b) HATU, iPr2NEt (8.0 equiv), DMF (0.4−0.5 mM peptide concn), 17−21 h;
then HATU (0.5 equiv), 1−3 h [A, 11% 18 after preparative HPLC; B, 25% 20 after column chromatography; C, 19% 22 after column
chromatography]. (c) LiOH, THF−H2O (1:1). (d) DIC (11 equiv), HOBt (3.0 equiv), iPr2NEt (4.0 equiv), NH3−dioxane (25 equiv), DMF−
CH2Cl2 (2:1), 5 days, 67%. (e) HATU (2.0 equiv),
iPr2NEt (5.5 equiv), NH3−dioxane (25 equiv), DMF, 5.5 h, 40% (for steps c and e). (f) DIC
(6.0 equiv), HOBt (3.0 equiv), iPr2NEt (4.0 equiv), NH3−dioxane and NH3−MeOH (30 equiv), CH2Cl2−DMF (2:1), 13 days, 11% (for steps c and f).
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carboxamides (5, 6, and 8), which is in contrast to the originally
reported HDAC inhibition data obtained for the natural
products against an HDAC-containing cell extract.5 However,
the data presented herein agree with subsequent work from
Ganesan and co-workers15 on azumamide A (5) and azumamide
E (9). We thus show that this applies to all the azumamides,
which also conﬁrms that a carboxylate Zn2+-binding group
renders HDAC inhibitors signiﬁcantly more potent than a
corresponding carboxamide, as would be expected from
literature precendents.19,26,27 Furthermore, compound 7 was
more potent than 9 against HDACs 1−3, 6, 10, and 11, which
is also in contrast to the original evaluation that found azuE (9)
more potent than azuC (7) against crude enzymes from K562
cell extract.5 The tyrosine-containing compound (7) exhibited
∼2-fold higher potency against HDACs 1, 3, 6, 10, and 11,
whereas the phenylalanine-containing azumamide E (9) was only
more potent against HDAC8, albeit at micromolar Ki values.
Finally, the inhibition of HDAC11 by azumamides C (7) and
E (9) is, to the best of our knowledge, the ﬁrst demonstration
of potent cyclic peptide inhibitors of this isozyme.33 Notably,
these binding aﬃnities were achieved without the presence of a
strong Zn2+ chelator, such as hydroxamic acid.
■ CONCLUSIONS
In summary, we report total syntheses of all ﬁve azumamides,
including for the ﬁrst time azumamides B−D, which corro-
borate the originally proposed structures. Our synthetic route
furthermore enabled preparation of site-speciﬁcally edited
analogues for exploration of structure−activity relationships
(SAR).34−36 The HDAC proﬁling results show that the β-amino
acid residue, present in all the azumamides, is sensitive to even
slight modiﬁcations. In addition, the original HDAC testing
using cell extract indicated that azumamide E was the most
Figure 3. Single-dose HDAC inhibitory screening. Assays were per-
formed at 50 μM (shown) and 5 μM (not shown) peptide
concentrations. We chose <50% inhibition at 50 μM as our cutoﬀ to
sort away inactive compounds before performing full dose−response
experiments. All compound−enzyme combinations that were
discarded at this stage were tested in at least two individual assays
performed in duplicate. Error bars represent the standard deviation.
(*) Fusion protein of GST-tagged HDAC3 with the deacetylase
activation domain (DAD) of nuclear receptor corepressor (NCoR1).
Figure 4. Michaelis−Menten plot for HDAC10.
Table 2. Potencies of Azumamides against Zn2+-Dependent Histone Deacetylasesa
Ki values (nM)
class I class IIa class IIb class IV
compd HDAC1 HDAC2 HDAC3b HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10 HDAC11
5 (azuA) >5000 >5000 3200 >5000 52%c IAd IA IA IA IA >5000
6 (azuB) 5000 3000 3000 IA IA IA IA IA IA IA >5000
7 (azuC) 32 ± 1 40 ± 20 14 ± 1 >5000 IA IA IA IA 2000 10 ± 4 35 ± 3
8 (azuD) >5000 >5000 3700 IA IA IA IA IA IA IA >5000
9 (azuE) 67 ± 7 50 ± 30 25 ± 5 4400 IA IA IA IA >5000 20 ± 12 60 ± 16
26 (β3-epi-azuE) IA IA IA IA IA IA IA IA IA IA IA
29 (β2-epi-azuE) IA IA IA IA IA IA IA IA IA IA IA
1 (SAHA) 8 ± 1.5 7 ± 1.5 12 ± 4 700 ± 20 IA IA IA IA 22 ± 9 NTe 13 ± 2
3 (FK-228)f 0.002 0.038 0.15 0.15 20.5 550 1250 1100 10 NT NT
aIC50 values were determined from at least two individual dose−response experiments performed in duplicate (Figure S7 in Supporting
Information), and Ki values were calculated from the Cheng−Prusoﬀ equation.
bFusion protein of GST-tagged HDAC3 with deacetylase activation
domain NCoR1. cPercent inhibition at 50 μM inhibitor concentration. dIA = inactive (<50% inhibition at 50 μM [inhibitor], Figure 3). eNT = not
tested. fData from Bradner et al.18
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potent of the series, but the comprehensive proﬁling presented
herein shows that azumamide C is in fact ∼2-fold more potent
than azumamide E against the majority of the isozymes.
By taking advantage of the modular methodologies described
in this article and building on the gained SAR information, we
are currently investigating collections of azumamide analogues
in search of more potent and selective ligands based on this
promising scaﬀold.
■ EXPERIMENTAL SECTION
General. All chemicals and solvents were analytical-grade and were
used without further puriﬁcation. Vacuum liquid chromatography
(VLC) was performed on silica gel 60 (particle size 0.015−0.040 μm).
UPLC−MS analyses were performed on a Phenomenex Kinetex
column (1.7 μm, 50 × 2.10 mm) by use of a Waters Acquity ultra-
high-performance liquid chromatography system. A gradient with
eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in
acetonitrile) rising linearly from 0% to 95% II during t = 0.00−2.50
min was applied at a ﬂow rate of 1 mL/min (gradient A) or during
t = 0.00−5.20 min (gradient B). Analytical HPLC was performed on a
Phenomenex Luna column [150 mm × 4.6 mm, C18 (3 μm)] by use of
an Agilent 1100 LC system equipped with a UV detector. Gradient C,
with eluent III (0.1% TFA in water) and eluent IV (0.1% TFA in
acetonitrile) rising linearly from 0% to 95% IV during t = 2−20 min,
was applied at a ﬂow rate of 1 mL/min. Preparative reversed-phase
HPLC was performed on a Phenomenex Luna column [250 mm ×
20 mm, C18 (5 μm, 100 Å)] by use of an Agilent 1260 LC system
equipped with a diode-array UV detector and an evaporative light
scattering detector (ELSD). A gradient, with eluent V (95:5:0.1, water−
MeCN−TFA) and eluent VI (0.1% TFA in acetonitrile) rising linearly
from 0% to 95% IV during t = 5−45 min, was applied at a ﬂow rate of
20 mL/min. All tested compounds were puriﬁed to homogeneity and
shown by both analytical HPLC (gradient C) and LC−MS (gradient A)
to be of more than 95% purity. One- and two-dimensional NMR spectra
were recorded on a Varian Mercury 300 instrument or a Varian INOVA
500 MHz instrument. All spectra were recorded at 298 K. Correlation
spectroscopy (COSY) spectra were recorded with a relaxation delay of
1.5 s before each scan, a spectral width of 6k × 6k, and eight FIDs and
1k × 512 data points collected. Heteronuclear single quantum coherence
(HSQC) spectra were recorded with a relaxation delay of 1.5 s before
each scan, a spectral width of 6k × 25k, and 16 FIDs and 1k × 128 data
points collected. Heteronuclear two-bond correlation (H2BC) spectra
were recorded with a relaxation delay of 1.5 s before each scan, a spectral
width of 4k × 35k, and 16 FIDs at 295 K and 1k × 256 data points
collected. Heteronuclear multiple-bond correlation (HMBC) spectra
were recorded with a relaxation delay of 1.5 s before each scan, a spectral
width of 6k × 35k, and 32 FIDs and 1k × 256 data points collected.
Chemical shifts are reported in parts per million (ppm) relative to
deuterated solvent peaks as internal standards (δH, DMSO-d6 2.50 ppm;
δC, DMSO-d6 39.52 ppm, δH, CD3OH 3.30 ppm; δH, CDCl3 7.26 ppm;
δC, CDCl3 77.16 ppm). Coupling constants (J) are given in hertz (Hz).
Multiplicities of 1H NMR signals are reported as follows: s, singlet; d,
doublet; t, triplet; q, quartet; m, multiplet.
General Procedure for Mannich Reactions. A solution of LDA
(2.1 equiv) was added dropwise to a solution of the ester (2.0 equiv)
in dry THF at −78 °C. After the mixture was stirred for 30 min,
Ti(O-iPr)3Cl (4.2 equiv) in dry THF was added dropwise. The orange
solution was stirred for 30 min and the imine (1.0 equiv) in dry THF
was added dropwise. The mixture was stirred for 3 h or until thin-layer
chromatography (TLC) showed full conversion of the imine. The
mixture was quenched with saturated aqueous NH4Cl and allowed to
reach room temperature. Water was added and the mixture was
decanted into a separatory funnel. EtOAc−water (1:1) was added to
the remaining Ti precipitate, and the mixture was stirred vigorously for
5 min before being added to the separatory funnel. The aqueous phase
was extracted with EtOAc and the combined organic phases were
washed again with water, dried (MgSO4), ﬁltered, and concentrated in
vacuo.
Azumamide A, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2-iso-
propyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacy-
clotridecan-11-yl]hex-4-enamide (5). LiOH (89 mg, 3.72 mmol,
85 equiv) in water (4.0 mL) was added to a stirred solution of the
impure cyclic peptide 20 (24.2 mg, approximately 0.045 mmol) in
THF (4 mL). After 2.5 h of stirring, the organic solvent was removed
in vacuo. The aqueous phase was acidiﬁed with 1 M HCl to pH 2 and
extracted with EtOAc (4 × 30 mL) and CH2Cl2 (40 mL). The organic
phases were dried (Na2SO4), ﬁltered, and concentrated to aﬀord crude
azumamide E, which was used without further puriﬁcation. Analytical
UPLC−MS gradient A, tR = 1.47 min. To a solution of the above
crude azumamide E (≈0.045 mmol) in DMF (3.0 mL) were added
HATU (34 mg, 0.09 mmol, 2 equiv), iPr2NEt (43 μL, 0.25 mmol,
5.5 equiv), and, after 5 min, NH3−dioxane (0.9 mL, 0.45 mmol,
10 equiv). After 1 h, NH3−dioxane (0.45 mL, 0.23 mmol, 5 equiv)
was added. UPLC−MS analysis showed 50% conversion after 3 h, and
HATU (34 mg, 0.09 mmol, 2 equiv) and NH3−dioxane (0.45 mL,
0.23 mmol, 5 equiv) were added. After an additional 1 h, DMF
(1.0 mL) followed by HATU (17 mg, 0.045 mmol, 1 equiv) and
NH3−dioxane (0.45 mL, 0.23 mmol, 5 equiv) were added, and stirring
was continued for 1 h before concentration in vacuo. The residue was
dissolved in MeCN−H2O and puriﬁed by preperative HPLC to give
azumamide A (5) (4.8 mg, 12% overall). [α]D +56° (c = 0.2, MeOH);
previously reported11 [α]D +33° (c = 0.1, MeOH).
1H NMR (500 MHz,
CD3OH) δ 8.18 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 9.0 Hz, 1H), 7.72
(d, J = 8.2 Hz, 1H), 7.59 (m, 2H), 7.20 (m, 5H), 6.74 (br s, 1H), 5.48
(m, 1H), 5.37 (m, 1H), 4.33 (dt, J = 9.0, 7.0 Hz, 1H), 4.24 (m, 2H),
3.81 (dd, J = 10.4 Hz and 8.4 Hz, 1H), 3.10 (m, 2H), 2.72 (m, 1H),
2.57 (dt, J = 14.1, 6.9 Hz, 1H), 2.41 (m, 2H), 2.27 (m, 4H), 1.30 (d,
J = 7.5 Hz, 3H), 1.23 (d, J = 7.3 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.94
(d, J = 6.7 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C27H38N4O7H
+
514.3029; found 514.3032 [M + H]+. HPLC gradient C, tR = 11.62
min (>95%).
Azumamide B, (Z)-6-[(2R,5R,8R,11R,12S)-8-(4-Hydroxyben-
zyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tet-
raazacyclotridecan-11-yl]hex-4-enamide (6). An aqueous sol-
ution of LiOH (0.5 M, 55 μL, 2.0 mmol, 2.5 equiv) was added to the
cyclic peptide 18 (6.1 mg) in THF−H2O (1:1, 2 mL) at 0 °C. After
30 min the ice bath was removed. Additional portions of LiOH
solution (55 μL, 2.0 mmol, 2.5 equiv) were added after 2, 4, and 6 h,
and stirring was continued for an additional 19 h to ensure full
conversion. Then water (0.5 mL) was added and the organic solvent
was removed in vacuo. The aqueous phase was acidiﬁed with 1 M HCl
and extracted with EtOAc (5 × 20 mL). The organic phase was
dried (Na2SO4), ﬁltered, and concentrated in vacuo to aﬀord the
crude azumamide C, which was used without further puriﬁcation.
To a solution of crude azumamide C (5.8 mg, 10.9 μmol) in DMF
(2 mL) were added HOBt (4.4 mg, 33 μmol, 3 equiv), DIC
(5.1 μL, 34 μmol, 3 equiv), and iPr2NEt (7.6 μL, 44 μmol, 4 equiv).
After 10 min, NH3−dioxane (0.5 M, 0.11 mL, 55 μmol, 5 equiv) was
added. After 1.5 h, DIC (5 μL, 34 μmol, 3 equiv) was added, followed
by NH3−dioxane (0.5 M, 0.11 mL, 55 μmol, 5 equiv). After the
mixture was stirred for 16 h, additional DIC (2 equiv) and NH3−
dioxane (5 equiv) were added, and this procedure was repeated once
more after 18 h. Finally, CH2Cl2 (1 mL) was added, followed by DIC
(3 equiv) and NH3−dioxane (10 equiv), and after 2 days of stirring at
room temperature, the reaction mixture was concentrated, dissolved
in MeCN−H2O (2:1), and puriﬁed by preparative HPLC to give
azumamide B (6) (3.6 mg, 62%, two steps) as a white solid. [α]D +65°
(c = 0.15, MeOH); previously reported11 [α]D +45° (c = 0.1, MeOH).
1H NMR (500 MHz, CD3OH) δ 8.13 (d, J = 7.9 Hz, 1H), 8.00 (d, J =
8.9 Hz, 1H), 7.85 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.01
(d, J = 8.4 Hz, 3H), 6.67 (d, J = 8.4 Hz, 3H), 5.49 (m, 1H), 5.37 (dd,
J = 18.0 and 7.3 Hz, 2H), 4.29 (pentet, J = 7.2 Hz, 1H), 4.15 (m, 1H),
4.05 (m, 1H), 3.60 (m, 1H), 3.13 (dd, J = 13.7, 10.1 Hz, 1H), 3.00
(dd, J = 13.8, 6.3 Hz, 1H), 2.70 (m, 2H), 2.36 (ddd, J = 22.3, 21.5, 7.1
Hz, 11H), 1.29 (d, J = 7.2 Hz, 3H), 1.27 (d, J = 7.4 Hz, 3H), 0.95 (d,
J = 5.7 Hz, 3H), 0.93 (d, J = 6.0 Hz, 3H). HRMS (ESI-TOF) m/z
calcd for C27H39N5O6H
+ 530.2978; found 530.2973 [M + H]+. HPLC
gradient C, tR = 10.31 min (>95%).
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Azumamide C, (Z)-6-[(2R,5R,8R,11R,12S)-8-(4-Hydroxyben-
zyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tet-
raazacyclotridecan-11-yl]hex-4-enoic Acid (7). LiOH (49 mg,
2.0 mmol, 35 equiv) in water (5.0 mL) was added to the crude cyclic
peptide 18 (61 mg) in THF (5.0 mL). The solution was stirred for
16 h and concentrated in vacuo. The resulting residue was dissolved in
THF−H2O (1:1, 10 mL) by adding a few drops of TFA, and then
puriﬁcation by preparative HPLC aﬀorded azumamide C (7) (2.2 mg,
9% overall) as a white solid. [α]D +49° (c = 0.14, MeOH); previously
reported11 [α]D +21° (c = 0.1, MeOH).
1H NMR (500 MHz,
CD3OH) δ 8.08 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.84
(s, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.01 (d, J = 8.4 Hz, 2H), 6.67 (d,
J = 8.4 Hz, 2H), 5.48 (t, J = 8.8 Hz, 1H), 5.38 (dt, J = 10.7, 7.0 Hz,
1H), 4.29 (pentet, J = 7.3 Hz 1H), 4.16 (m, 1H), 4.01 (m, 1H),
3.58 (m, 1H), 3.15 (dd, J = 13.7, 10.2 Hz 1H), 3.00 (dd, J = 13.7,
6.0 Hz, 1H), 2.72 (m, 1H), 2.67 (m, 1H) 2.39 (m, 5H), 1.29 (d, J =
7.2 Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H), 0.95 (d, J = 6.0 Hz, 3H), 0.93
(d, J = 6.0 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C27H38N4O7H
+
531.2819; found 531.2815 [M + H]+. HPLC gradient C, tR =
11.04 min (>95%).
Azumamide D, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2,5,12-tri-
methyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-
yl]hex-4-enamide (8). LiOH (53 mg, 2.21 mmol) in water (5.0 mL)
was added to a stirred solution of the impure cyclic peptide 22
(22.7 mg, approximately 0.044 mmol) in THF (3 mL). After 4 h the
organic solvent was removed in vacuo and the water (0.5 mL) was
added to the aqueous phase, which was then acidiﬁed with 1 M HCl
(2 mL) and extracted with EtOAc (4 × 20 mL). The organic phases
were dried (MgSO4), ﬁltered, and concentrated to give the crude acid
23, which was used without further puriﬁcation. To a solution of the
crude acid 23 (≈23 μmol) in CH2Cl2−DMF (8:1, 2.3 mL) were added
HOBt (10 mg, 66 μmol, 3.0 equiv), DIC (10 μL, 66 μmol, 3 equiv),
and iPr2NEt (15 μL, 88 μmol, 4 equiv). After 5 min, NH3−dioxane
(0.5 M, 0.22 mL, 110 μmol, 5 equiv) was added. After 1 h, NH3−
dioxane (0.5 M, 0.22 mL, 110 μmol, 5 equiv) was added. After the
mixture was stirred for 18 h, additional DMF (0.5 mL) was added,
followed by NH3−MeOH (2.0 M, 0.11 mL, 230 μmol, 10 equiv). After
an additional 5 h, DIC (7 μL, 46 μmol, 2 equiv) was added. The next
day NH3−MeOH (2.0 M, 0.06 mL, 111 μmol, 5 equiv) was added and
the mixture was stirred for 10 days. Finally, DIC (3.4 μL, 23 μmol,
1 equiv) was added, followed by NH3−MeOH (2.0 M, 0.055 mL,
210 μmol, 5 equiv), and after 2 days the mixture was concentrated,
dissolved in MeCN−H2O (2:1), and puriﬁed by preparative HPLC to
aﬀord azumamide D (8) (1.2 mg, 4% overall) as a white solid. [α]D
+32° (c = 0.08, MeOH); previously reported11 [α]D +25° (c = 0.1,
MeOH). 1H NMR (500 MHz, CD3OH) δ 8.03 (d, J = 7.8 Hz, 1H),
8.01 (d, J = 8.8 Hz, 1H) 7.94 (d, J = 6.8 Hz, 1H), 7.58 (s, 1H), 7.32 (d,
J = 7.5 Hz, 1H), 7.25−7.14 (m, 5H), 6.75 (s, 1H), 5.47 (m, 1H),
5.39 (m, 1H), 4.35 (m, 1H), 4.19 (m, 1H) 4.17− 4.11 (m, 2H),
3.09 (m, 2H), 2.69 (m, 1H), 2.62 (m, 1H), 2.41 (m, 2H), 2.28
(m, 1H), 1.47 (d, J = 7.4 Hz, 3H), 1.28 (d, J = 7.4 Hz, 3H), 1.22 (d,
J = 7.3 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C25H35N5O5H
+
486.2716; found 486.2710 [M + H]+. HPLC gradient C, tR =
10.55 min (>95%).
Azumamide E, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2-isoprop-
yl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotride-
can-11-yl]hex-4-enoic Acid (9). LiOH (18.5 mg, 0.77 mmol,
40 equiv) in water (4 mL) was added to a stirred solution of the impure
cyclic peptide 20 (10.5 mg, approximately 0.02 mmol) in THF (4 mL).
After 1 h, LiOH (10 mg, 0.42 mmol, 20 equiv) in water (1 mL) was
added, and after 2 h, LiOH (5.0 mg, 0.21 mmol, 1 equiv) in water
(0.5 mL) was added. The solution was stirred for 16 h and another
portion of LiOH (6.0 mg, 0.25 mmol, 1.3 equiv) in water (0.5 mL)
was added. After an additional 2.5 h of stirring, the organic solvent was
removed in vacuo. The aqueous phase was acidiﬁed with 1 M HCl and
extracted with EtOAc (4 × 25 mL). The combined organic phases
were dried (Na2SO4), ﬁltered, and concentrated. The resulting residue
was dissolved in MeCN−water [(3:2), 2.5 mL] and puriﬁed by
preparative HPLC to aﬀord azumamide E (9) (4.3 mg, 15% overall)
as a white solid. [α]D +66° (c = 0.2, MeOH); previously reported
11
[α]D +53° (c = 0.1, MeOH).
1H NMR (500 MHz, CD3OH)
δ 8.10 (d, J = 7.7 Hz, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.84 (br s, 1H),
7.63 (d, J = 8.4 Hz, 1H), 7.28−7.16 (m, 5H), 5.48 (m, 1H), 5.37 (m,
1H), 4.28 (pentet, J = 7.5 Hz, 1H), 4.16 (m, 1H), 4.08 (m, 1H), 3.59
(m, 1H), 3.25 (dd, J = 13.6, 10.4 Hz, 1H), 3.11 (dd, J = 13.6, 6.1 Hz,
1H), 2.72 (m, 1H), 2.68 (m, 1H), 2.39 (d, J = 1.7 Hz, 6H), 2.39 (m,
6H), 1.28 (d, J = 7.1 Hz, 3H), 1.27 (d, J = 7.4 Hz, 3H), 0.94 (m, 6H).
HRMS (ESI-TOF) m/z calcd for C27H38N4O6H
+ 515.2869; found
515.2869 [M + H]+. HPLC gradient C, tR = 12.53 min (>95%).
Assay Materials. HDAC1 (purity >45% by SDS−PAGE according
to the supplier), HDAC4 (purity >90% by SDS−PAGE according to
the supplier), and HDAC7 (purity >90% by SDS−PAGE according to
the supplier) were purchased from Millipore (Temecula, CA).
HDAC2 used for dose−response experiments (full length, purity
≥94% by SDS−PAGE according to the supplier), HDAC5 (full length,
purity ≥4% by SDS−PAGE according to the supplier), and HDAC8
used for dose−response experiments (purity ≥90% by SDS−PAGE
according to the supplier) were purchased from BPS Bioscience (San
Diego, CA). HDAC2 used for initial screening experiments (full
length, purity 50% by SDS−PAGE according to the supplier),
HDAC3−“NCoR1” complex [(purity 90% by SDS−PAGE according
to supplier; fusion protein of GST-tagged HDAC3 with the
deacetylase activation domain (DAD) of NCoR1 (nuclear receptor
corepressor)], HDAC6 (purity >90% by SDS−PAGE according to the
supplier), HDAC8 for initial screening experiments (purity >50% by
SDS−PAGE according to the supplier), HDAC10 (purity >50% by
SDS−PAGE according to the supplier), and HDAC11 (purity >50%
by SDS−PAGE according to the supplier) were purchased from Enzo
Life Sciences (Postfach, Switzerland). HDAC9 (full length, purity 12%
by SDS−PAGE according to the supplier) was purchased from
Abnova (Taipei, Taiwan). The HDAC assay buﬀer consisted of
50 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2,
and bovine serum albumin (0.5 mg/mL). Trypsin [10 000 units/mg;,
from bovine pancreas, treated with L-(tosylamido-2-phenyl)ethyl chloro-
methyl ketone (TPCK)] was from Sigma Aldrich (Steinheim, Germany).
All peptides were puriﬁed to homogeneity (>95% purity by
HPLC230nm via reversed-phase preparative HPLC), and the white
ﬂuﬀy materials obtained by lyophilization were kept at −20 °C. For
assaying, peptides were reconstituted in DMSO to give 5−10 mM
stock solutions, the accurate concentrations of which were determined
by coinjection on HPLC with a standard of known concentration.
In Vitro Histone Deacetylase Inhibition Assays. For inhibition
of recombinant human HDACs, dose−response experiments with
internal controls were performed in black low-binding Nunc 96-well
microtiter plates. Dilution series (3-fold dilution, 10 concentrations)
were prepared in HDAC assay buﬀer from 5−10 mM DMSO stock
solutions. The appropriate dilution of inhibitor (10 μL of 5× the
desired ﬁnal concentration) was added to each well followed by
HDAC assay buﬀer (25 μL) containing substrate [Ac-Leu-Gly-
Lys(Ac)-AMC, 40 μM for HDAC1−3 and 80 μM for HDAC6 and
11; Ac-Leu-Gly-Lys(Tfa)-AMC, 40 μM for HDAC4, 240 μM for
HDAC5, 80 μM for HDAC7, 400 μM for HDAC8, and 160 μM for
HDAC9; Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC, 100 μM for HDAC10].
Finally, a solution of the appropriate HDAC (15 μL) was added
and the plate was incubated at 37 °C for 30 min [HDAC1, 150 ng/well;
HDAC2, 100 ng/well; HDAC3, 10 ng/well; HDAC4, 2 ng/well;
HDAC5, 40 ng/well; HDAC6, 60 ng/well; HDAC7, 2 ng/well; HDAC8,
5 ng/well; HDAC9, 40 ng/well; HDAC10, 500 ng/well; HDAC11,
500 ng/well]. Then trypsin (50 μL, 0.4 mg/mL) was added and the
assay development was allowed to proceed for 15−30 min at room
temperature, before the plate was read on a Perkin-Elmer Enspire
plate reader with excitation at 360 nm and detecting emission at 460 nm.
Each assay was performed in duplicate. The data were analyzed by
nonlinear regression with GraphPad Prism to aﬀord IC50 values from the
dose−response experiments, and Ki values were determined from the
Cheng−Prusoﬀ equation [Ki = IC50/(1 + [S]/Km)] with the assumption
of a standard fast-on−fast-oﬀ mechanism of inhibition.
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HDAC inhibitors have been found to be potential anticancer agents and isoform selective HDAC inhibitors could be useful for dissecting 10 
the individual biochemical pathways associated with each of these HDAC isoforms. In our pursuit for potent and selective HDAC 
inhibitors, we designed four series of cyclic tetrapeptide compounds, which are based on the azumamide scaffold. We have probed different 
modifications in the unique β-amino acid moiety and synthesized tryptophan-containing analogs. The biochemical profiling of the 
azumamide analogs was combined with high-resolution NMR solution structures to correlate the biological activity to specific structural 
features. We hypothesize that the β2-methyl group, found in the azumamides, has an important side chain directing function, which guides 15 
the zinc-binding side chain towards the active site.        
Introduction 
Histone deacetylases (HDACs) are a family of enzymes, which 
play a key role in the epigenetic regulation of important cellular 
functions. Interestingly, these enzymes can modulate the 20 
interactions between the DNA and the histone proteins and affect 
gene transcription. In the field of cancer research this discovery has 
encouraged the development of HDAC inhibitors as potential 
anticancer drugs.1, 2 Currently, two HDAC targeting drugs (1 and 
4) are approved by the FDA for clinical treatment of cutaneous T-25 
cell lymphoma.  The HDAC family is divided into four classes, 
where class II is further sub-divided into two groups: class I 
(HDAC1–3, 8), class IIa (HDAC4, 5, 7, and 9) class IIb (HDAC6 
and HDAC10), and class IV (HDAC11).  
Macrocyclic  peptides (3, 5a, and 5b) and depsipeptides (4) have 30 
proven to be potent HDAC inhibitors.3, 4, 5 Azumamide C (5a) and 
azumamide E (5b) are macrocyclic tetrapeptides, which 
demonstrate high activity as HDAC inhibitors in spite of their 
weak Zn2+-coordinating side chain functionality (COOH).6 The 
azumamides are structurally related to apicidin (3),4 but the 35 
macrocyclic scaffold has a disubstituted β-amino acid. 
Furthermore the azumamides are unique in having a retro-enantio 
arrangement, compared to other macrocyclic peptides (e.g.  
apicidin) where only D-amino acids are found in the ring. The 
binding mode of macrocyclic peptides and depsipeptides has 40 
previously been explored and it is hypothesized that the peptide 
side chain, bearing the Zn2+-binding group, reaches into the 
binding pocket through a narrow channel and coordinates a zinc 
ion.7, 8 The cyclic peptide core has favorable interactions with the 
surface of the protein and the presence of an aromatic amino acid 45 
in cyclic tetra peptides, related to the azumamides, was found to be 
important for activity.9 Furthermore, the interactions between the 
Figure 1. Known HDAC inhibitors (top) and target compounds (bottom) 
cyclic peptide core and the surface of the protein seem to be 
important for isoform selectivity.10, 11 The biological role of the 50 
individual isoforms have not yet been identified and isoform 
selective HDAC inhibitors could be useful for dissecting the 
individual biochemical pathways associated with each of these 
 2  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
enzymes.  Furthermore, selective inhibitors could be have potential 
as new drug candidates.2, 12 
Results and discussion 
Design and synthesis 
In pursuit of isoform-selective compounds we conducted a 5 
structure–activity relationship (SAR) study, where we synthesized 
a variety of structurally edited azumamides. The structural changes 
reported for the azumamides are limited to modification of the 
Zn2+-binding group13, incorporation of a sugar-amino acid 
residue14, and manipulation of the stereochemistry.7, 15 Our 10 
previous work has shown that changes in the stereochemistry of 
the β-amino acid substituents in azumamide E had a detrimental 
impact on activity.15 We therefore set out to explore modifications 
at the β2-position, without altering the stereochemistry. Instead we 
incorporated a dimethylated as well as a desmethylated β-amino 15 
acid in the cyclic peptides, 6a-c and 7a-c, respectively. 
Considering the saturated side chain of 3 and the trans olefin in 4, 
we speculated that the cis olefin in the azumamides would not be 
essential for activity. To explore this hypothesis, we prepared 8a–
c and 9a–c, where the required β-amino acids easily could be 20 
obtained from commercially available Boc-L-Asp-OtBu. We 
recently found that the nature of the aromatic amino acid effects 
the biological activity.15 Hence, an indole motif, also present in 3, 
was incorporated in our target compounds in addition to Phe and 
Tyr, which are found in the azumamides.  25 
Building block synthesis 
The building block, employed for the synthesis of the dimethylated 
analogs 6a–c, was prepared by a method recently developed in our 
laboratory. The diastereoselective Ellman-type Mannich reaction 
between the enolate of tert-butyl isobutyrate and the enantiomer of 30 
sulfinyl imine 10 afforded the desired Mannich product in 58% 
yield and with a diastereoselectivity of (77:23) in favour of the R-
isomer.  
Table 1. Screening of acetates for the Ellman-type Mannich reaction. 
 35 
 
 
 
a
 Determined by X-ray crystallography from the desilylated and re-
esterified tert-butyl ester 19. b Yield is reported for the crude product. c 40 
Determined spectroscopically by comparison with the crystallized 
compound from entry 1 (supplementary figure S1).d Total yield of all 
diastereoisomers.        
The absolute stereochemistry of the Mannich product was 
determined by X-ray crystallography upon desilylation with 45 
Bu4NF. The alcohol was elaborated to give the Boc-protected β-
amino acid 22 (scheme 3) in 16% overall yield from the sulfinyl 
imine (Supplementary scheme S1). The desmethylated β-amino 
Scheme 1. Reagents and conditions: (a) LDA (2.1 equiv), EtOAc (2.0 
equiv), TiCl(O-iPr)3 (4.2 equiv), THF, –78 ºC, 30 min; then 10, –78 ºC, 50 
20 min. (b) LiOH (4.5 equiv), THF–water, 17 h. (c) Boc2O (1.4 equiv), 
DMAP (0.3 equiv), tert-butanol, 16 h, then Boc2O (0.3 equiv), 15 h  (d) 
AcOH (1.0 equiv), Bu4NF (2.0 equiv), THF, 0 ºC → rt, 75 min. (e) 
NaHCO3 (1.5 equiv), Dess-Martin periodinane (1.5 equiv), dry CH2Cl2, 0 
ºC → rt, 40 min. (f) KHMDS (1.9 equiv), Ph3PBr(CH2)3COOEt, (2.0 55 
equiv), THF, –78 ºC → rt, 40 min. (g) TFA–CH2Cl2 (1:1, 10 mL, 117–
192 equiv), 0 ºC → rt, 2–3 h. (h) HCl (4.0 M in dioxane, 1.8–2.5 equiv), 
dioxane, 1–3 h. (i) iPr2NEt (3.0 equiv), Boc2O (2.0 equiv), dry CH2Cl2, 6 
h, then Boc2O (1.0 equiv), 16 h. (j) Na2CO3 (4.0 equiv), FmocOSu (1.2 
equiv) water–dioxane (5:1, 6 mL), 0 ºC → rt, 45 min. 60 
acid building blocks 15 (Boc-protected) and 16 (Fmoc-protected) 
were prepared by a similar route (scheme 1). The Boc-derivative 
only allows one cyclization site, whereas the introduction of the 
Fmoc group would allow macrolactamization at all four positions. 
Initially, an optimization study was conducted, where various 65 
acetate enolates were investigated to produce the best 
diastereomeric ratio and yield in the Mannich reaction (table 1). 
 
It is interesting, that the desired (3R) configuration is obtained from 
the (R)-auxillary in the case of tert-butyl acetates, whereas the 70 
equivalent tert-butyl isobutyrate reaction yields the (3S) 
configuration as the major diastereomer. The high dr obtained with 
ethyl acetate and the switchover in diastereoselectivity induced by 
the addition of HMPA confirms the hypothesis that the acetate 
mediated reaction proceeds through a six-membered  75 
Zimmerman–Traxler-type transition state, where coordination to 
titanium is essential for the high diastereoselectivity.16, 17  
To establish the stereochemistry of the product from entry 1, the 
compound was re-esterified to the tert-butyl ester, since the tert-
butyl ester alcohols in most cases were crystalline. Gratifyingly, 80 
the alcohol 13 crystallized and the stereochemistry was determined 
by X-ray crystallography. Furthermore, an acid labile protection 
group for the carboxylic acid was required to obtain orthogonality. 
This strategy nicely provided the Fmoc- and Boc-protected β-
entry R1 additive d.r. major isomer, (%)d 
1 Et TiCl(O-iPr)3 >99:1    3Ra (94)b 
2 tBu TiCl(O-iPr)3 74:26 3Rc (68) 
3 tBu HMPA 28:72 3Sc (61) 
4 PMB TiCl(O-iPr)3 82:18 ND 
OEt
O
+
a. LDA,
TiCl(O-iPr)3
b. LiOH
c. Boc2O, DMAP,
tert-butanol
e. Dess-Martin
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52%, 3 steps
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amino acids 15 and 16 (Scheme 1).  
 
Scheme 2.  (a) N-methylmorpholine (1.0 equiv), isobutyl chloroformate 
(1.0 equiv), NaBH4 (3.0 equiv), MeOH, THF, –30 ºC → rt, 160 min. (b) 
oxalyl chloride (1.7 equiv), DMSO (3.3 equiv), Et3N (5.0 equiv.), CH2Cl2, 5 
–78 ºC → –40 ºC → rt, 2 h. (c) PPh3CH3Br (2.2 equiv), KHMDS (0.5 M 
in toluene) (2.1 equiv), THF, –78 ºC → rt, 4 h. (d) methyl 5-hexenoate (3 
equiv), Hoveyda Grubbs 2nd gen. catalyst (0.1 equiv), CH2Cl2, 40 ºC, 
24h. (e) TFA–CH2Cl2 (1:3), 2 h. (f) Boc2O (1.3 equiv.), iPr2NEt (2.6 
equiv.), CH2Cl2. (g) H2, Pd/C (1% w/w), THF, 19 h. 10 
The building blocks used to synthesize compound 8a-c and 9a-c 
were prepared from the readily available Boc-L-Asp-OtBu 17 
(scheme 2). Using a slightly modified procedure from Bradner et 
al18, acid 17 was reduced to the corresponding alcohol and a 
subsequent Swern oxidation yielded the aldehyde, which was used 15 
immediately in a Wittig reaction to produce the terminal alkene 18. 
The optimal conditions for the succeeding cross methathesis was 
found to be Hoveyda-Grubbs 2nd generation catalyst (see table 2), 
which afforded the trans olefin in a good yield. Acidic deprotection 
followed by reprotection of the amino functionality gave the final 20 
building block (20) for synthesis of 8 whereas hydrogenation of 20 
gave the desired β-amino acid 21 for the synthesis of 9 (Scheme 
2). 
Table 2. Catalyst screening for cross-metathesis. 
 25 
 
a Isolated trans isomer. 
 
Peptide synthesis 
All the synthesized building blocks were coupled to a tripeptide on 30 
solid support, which after deprotection and cleavage were cyclized 
using HATU or COMU under dilute conditions (0.3–0.8 mM). 
Saponification of the cyclic peptides gave the final compounds 
(scheme 3). The modest isolated yields for most compounds can  
be attributed to the difficulties in the cyclization of small rings. 35 
Furthermore, solubility problems resulted in problems during the 
final HPLC purification. The synthesis of the tryptophan analogues 
proved particularly challenging, revealed by an unsuccessful 
synthesis of 9c by the original synthetic route. Changing the point 
of cyclization had previous shown to have an effect on a simplified 40 
linear tetrapeptide.15 The Boc protection group of 21 was therefore 
substituted for an Fmoc group, allowing the building block to be 
loaded directly on to the resin. Even though we expected a better 
cyclization reaction, using the less hindered and more flexible β-
amino acid at the C-terminal, we were surprised to find the 45 
dramatic effect this alteration had, when we isolated 9c with a yield 
of 48% (12 steps) from the Fmoc building block (supplementary 
scheme S2). This result emphasise the importance of the peptide 
sequence and its impact on the conformation of the linear 
tetrapeptide.19    50 
 
Biochemical profiling 
All nine desmethylated compounds were characterized with dose–
response experiments on recombinant human HDACs. The 
screening protocols were adapted from Villadsen et al.15 Full 55 
profiling was performed on class I, class IIb, and class IV. Low 
activity at concentrations between 10–100 µM was observed with 
single experiment data on HDAC4 and HDAC7 for all tested 
compounds. This result confirms the lack of class IIa activity 
previously reported with this type of inhibitors and activity towards 60 
class IIa was not explored further.15 Preliminary testing of the 
dimethylated series (6a–c) indicated low activity against class I, 
class IIb, and class IV. With this in mind, these compounds were 
only screened at two concentrations (10 and 20 µM, see SI, table 
S1).  65 
The Phe and Tyr-containing analogs (6a and 6b) were poor 
inhibitors of HDAC1–3 and no inhibition was observed on 
HDAC6, HDAC8, HDAC10, and HDAC11 at 20 µM. However, 
6c, containing a tryptophan as the aromatic residue, displayed 
activity against HDAC1–3 (∼50% inhibition at 10 µM). 6c also 70 
inhibited HDAC6, HDAC8, HDAC10, and HDAC11, albeit none 
of the isoforms were inhibited more than 50% at 20 µM. The 
positive effect of tryptophan indicates that this aromatic amino acid 
is superior to Phe and Tyr in establishing favorable interactions 
with the surface of the HDAC enzymes. Overall, the low activity 75 
of 6a–6c emphasize how sensitive the β2-position is to 
modifications. The incorporation of the extra methyl group could 
induce a change in the overall conformation of the cyclic peptides, 
which may explain the loss of activity. The second methyl group, 
which will be located trans to the Zn2+-coordinating side chain, 80 
could also be involved in a steric clash with the protein, leading to 
the reduced activity.   
 
The IC50 values obtained from the dose–response data on the 
desmethylated compounds were converted to Ki values using the  85 
entry catalyst yield (%)a 
1 Grubbs cat. 1st gen., 0.1 equiv 11 
2 Grubbs cat. 2nd gen., 0.05 equiv 54 
3 Grubbs cat. 2nd gen., 0.1 equiv 62 
4 Hoveyda Grubbs cat. 1st gen., 0.1 equiv 12 
5 Hoveyda Grubbs cat. 2nd gen., 0.1 equiv 67 
6 catalyst A 62 
7 catalyst B 52 
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Scheme 3. Reagents and conditions: (a) Resin (1.5 equiv), 22 (1.0 equiv), HATU or COMU (1.5 equiv), iPr2NEt (3.0 equiv), DMF, 16 h or 22 (1.1 equiv), 
resin (1.0 equiv), HATU (1.5 equiv), iPr2NEt (3.0 equiv), DMF, 17 h (b) TFA–CH2Cl2 (1:1), 2 × 30 min. (c) HATU (1.5–2.2 equiv), iPr2NEt (5–10 equiv), 
DMF (0.4 mM peptide concentration), 16 h. 17–21 h (d) LiOH (36–50 equiv), THF–water (1:1), 16–17 h. (e) Resin (1.0 or 1.5 equiv), HATU (1.5 equiv), 25 
2,6-lutidine (3.0 equiv), 15 or 16 (1.1 or 1.0 equiv), DMF, 16 h. (f) TFA–CH2Cl2 (1:1), 2 × 30 min or piperidine–DMF (1:4, 2 × 30 min); DBU–
piperidine–DMF (2:2:96, 30 min); AcOH–TFE–CH2Cl2 (6:2:2, 1.5 mL), 2 × 2 h. (g) TFA–CH2Cl2 (1:1), 1 h.
Cheng-Prusoff equation and the Km values reported previously.15 
The result are shown in table 2. Compounds 7a-c address the 
importance of the β2-methyl group found in the azumamide A and 30 
E. The desmethylated analogs show a 3–18-fold decrease in 
activity towards HDAC1–3. The greatest difference is observed on 
HDAC3, where 7a displays an 18–fold reduction in activity 
compared to azumamide E. A 7–8-fold decrease in activity was 
observed on HDAC10 and for class IV a 13–14-fold reduction in 35 
activity was observed. Based on these results the β2-methyl group 
may participate in a favorable hydrophobic interaction with the 
surface of the protein. However, docking studies of an NMR 
solution structure of azumamide E into Histone Deacetylase Like 
Protein  (HDLP) did not reveal any interactions for the β2-methyl 40 
group.7 Instead, the removal of the methyl group could induce 
changes in the conformation of the cyclic peptide backbone. 
Conformational changes could alter the orientation (C3–C4 vector) 
of the β3-side chain and or disrupt the favorable interactions 
between the macrolactam ring and the protein.9 Finally, the β2-45 
methyl group may provide steric direction of the Zn2+-binding side 
chain towards the 11 Å channel. The methyl group was found to 
be less important for inhibition of HDAC6 and HDAC8 where the 
reduction in activity was below 2-fold. Interestingly, these two 
enzymes were highly sensitive to the nature of the aromatic amino 50 
acid. The Tyr and Trp-containing compounds were 2–5-fold more 
active on HDAC1–3, HDAC10, and HDAC 11 than the 
corresponding phenylalanine compounds. In contrast to Tyr and 
Trp, the side chain in Phe is unable to participate in hydrogen 
bonding to the surface of the enzyme and it could be hypothesized55 
g. TFA
30a; Aa = D-Phe
30b; Aa = D-Tyr
31a; Aa = D-Phe
31b; Aa = D-Tyr
Val-Ala-Aa-OH
O
H2N
2
MeO
O
28a; Aa = D-Phe
28b; Aa = D-Tyr
28c; Aa = D-Trp
29a; Aa = D-Phe
29b; Aa = D-Tyr
29c; Aa = D-Trp
Val-Ala-Aa-OH
O
H2N
2
MeO
O
23a; Aa = D-Phe
23b; Aa = D-Tyr-OtBu
23c; Aa = D-Trp(Boc)
6a; Aa = D-Phe 4%, 5 steps
6b; Aa = D-Tyr 2%, 5 steps
6c; Aa = D-Trp 6%, 5 steps
c. HATU
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24a; Aa = D-Phe
24b; Aa = D-Tyr
24c; Aa = D-Trp
Val-Ala-Aa-OH
O
H2N
2
EtO
O
Me Me
8a; Aa = D-Phe 7%, 4 steps
8b; Aa = D-Tyr 8%, 4 steps
8c; Aa = D-Trp 3%, 4 steps
9a; Aa = D-Phe 10%, 4 steps
9b; Aa = D-Tyr 7%, 4 steps
25a; Aa = D-Phe
25b; Aa = D-Tyr-OtBu
25c; Aa = D-Trp(Boc)
7a; Aa = D-Phe 21%, 5 steps
7b; Aa = D-Tyr 22%, 5 steps
27; Aa = D-Trp(Boc)
26a; Aa = D-Phe
26b; Aa = D-Tyr
26c; Aa = D-Trp(Boc)
Val-Ala-Aa-OH
O
H2N
2
EtO
O
7c; Aa = D-Trp, 5% 6 steps
NH
H
N
HN
N
H
O
O
Me
O
O
Me
Me
O
OH
Aa
NH
H
N
HN
N
H
O
O
Me
O
O
O
OH
Me
Me
Me
Me
Aa
NH
H
N
HN
N
H
O
O
Me
O
O
Me
Me
O
OH
Aa
NH
H
N
HN
N
H
O
O
Me
O
O
O
OH
Me
Me
Aa
e. HATU
f. TFA or piperidine,
DBU; AcOH, TFE
h. HATU
b. TFA
i. HATU
b. TFA
c. HATU
d. LiOH
c. HATU
d. LiOH
c. HATU
d. LiOH
OH
O
BocHN
2
MeO
O
OH
O
BocHN
2
MeO
O
OH
O
BocHN
2
EtO
O
Me Me
OH
O
RHN
2
EtO
O
H-Val-Ala-Aa-+
H-Val-Ala-Aa-+
H-Val-Ala-Aa-+
H-Val-Ala-Aa-+
15; R = Boc
16; R = Fmoc
21
20
22
a. HATU or COMU
b. TFA
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Table 1. Activities of desmethylated compounds against selected HDAC enzymes given as Ki values (nM)a
aThe IC50 values were obtained from two individual dose-response experiments. 
that the reduced activity of Phe-containing compounds is related to 
this feature. In contrast, the tyrosine containing compounds failed 
to inhibit HDAC8 at concentration up to 20 µM, whereas the Phe- 5 
and Trp-containing compounds displayed Ki values between ~2–7 
µM. The same, but less pronounced, effect were observed in the 
natural products, where azumamide C was 2-fold more potent than 
azumamide E on HDAC8. Surprisingly, 8c, 7c, and 8a were more 
active against HDAC8 than the natural products. In terms of 10 
isoform selectivity our data suggest that the incorporation of 
tyrosine favors the inhibition of HDAC6, with the exception of 8c.  
The β3-side chain modifications (8a–c and 9a–c) cannot be related 
directly directly to the azumamides, as the removal of the β2-
methyl group had an important impact on activity. It is currently 15 
not known if the modifications are synergistic or antagonistic, but 
this study shows that the shifted trans double bond decrease 
activity towards HDAC1–3, 10, and 11 with a 1.5–3-fold reduction 
in activity compared to the cis-compounds. In contrast, the trans 
series was more active against HDAC6 and 8.   20 
Introduction of the saturated side chain did not show a clear trend 
for the Tyr- and Phe-containing compounds. On HDAC1 and 2 the 
saturated analogs were slightly less active than the corresponding 
cis-compounds, whereas 9a and 9b were more active than 7a and 
7b on HDAC3. 9c displayed a 2–8-fold reduction in activity 25 
against the entire selection of enzymes..  
Interestingly, all nine desmethylated analogs are more active 
against the entire panel of enzymes, than the natural products 
bearing a carboxyamide as the zinc-binding group (azumamide A, 
azumamide B, and azumamide D). This can be attributed to the 30 
difference in the zinc-binding groups (COOH vs CONH2). The 
carboxylic acid is a stronger zinc-chelator than the carboxyamide20 
and the loss of activity, associated with removal of the methyl  
group, is regained by having a stronger zinc-chelating 
functionality.    35 
NMR solution structures 
In order to correlate the biochemical data presented above with 
distinct structural features in the cyclic peptide structures we, 
elucidated the NMR solution structures of azumamide A15 and 7b. 
In combination with the assay date these structures can provide a 40 
powerful tool for establishing important structure activity 
relationships (SAR). The NMR experiments were performed in 
DMSO at 295 K and NMR solution structures were obtained using 
ROESY correlations. An overlay of the two structures is shown in 
figure 2. 45 
Figure 2. Overlay of NMR solution structures of compound 7b (carbon: 
green, hydrogen: white, oxygen: red, nitrogen: blue) and azumamide A 
(carbon: grey, hydrogen: white, oxygen: red, nitrogen: blue). The β3-side 
chain beyond C6 have been omitted for clarity. The superimposition was 
made on all atoms in the cyclic peptide backbone 50 
 
 class I class IIb class IV 
Compound HDAC1 HDAC2 HDAC3 HDAC8 HDAC6 HDAC10 HDAC11 
7a: Phe, cis 300±130 500±70 500±80 6,700±870 >20,000 140±20 900±130 
7b: Tyr, cis 200±117 100±35 200±143 >20,000 3,500±360 80±3 400±198 
7c: Trp, cis 100±65 100±7 300±78 3000±354 >20,000 70±18 500±357 
8a: Phe, unsat. 700±180 900±20 800±160 4,300±1,800 >20,000 >20,000 1,800±300 
8b: Tyr, unsat. 400±130 300±140 300±130 >20,000 1,300±480 150±2 700±210 
8c: Trp, unsat. 300±40 200±150 300±220 1,700±1,030 2,200±180 130±2 600±300 
9a: Phe, sat. 500±200 400±60 400±120 6,400±2900 >20,000 260±80 1200±640 
9b: Tyr, sat. 400±340 200±100 100±80 >20,000 2000±1,120 80±40 500±410 
9c: Trp, sat. 600±70 800±190 1,200±460 6,100±390 >20,000 190±30 1,600±900 
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Figure 2 illustrates that the cyclic peptide backbone for azumamide 
A and 7b overlay almost perfectly. Based on these structures the 5 
removal of the β2-methyl group does not induce any changes to the 
conformation of the peptide backbone. This observation excludes 
the hypothesis that changes in the conformation of the cyclic 
peptide is responsible for the loss of activity. As mentioned above 
the C3–C4 vector has been found to be important for activity in 10 
cyclic peptide HDAC inhibitors. In figure 2, the C3–C4 vector of 
7b is only slightly different from the vector found in azumamide A 
and both vectors are projected in the plane of the cyclic peptide 
backbone. However, beyond C4 the two structures appear to be 
different. In 7b the C4–C5 bond is projected upwards, thus 15 
positioning the β3-side chain above the cyclic peptide backbone. In 
azumamide A the C4–C5 bond is projecting downwards, which 
positions the side chain in the plane or slightly under the 
macrolactam ring. It could be hypothesixed that the zinc-binding 
side chain in azumamide A is forced away from the top face of the 20 
ring by the neighboring methyl group. In compound 7b, lacking 
the β2-methyl group, the β3-side chain is free to occupy the space 
above the ring and this could explain the difference in the side 
chain orientations. If this difference should be related to the 
biological data, it could be hypothesized that β3-side chain 25 
positioning found in azumamide A is optimal for HDAC 
inhibition.   
 
Docking in HDAC3 
In order to explore the hypothesis that the difference in β3-side 30 
chain positioning is responsible for the difference in activity, we 
are performing a docking study of 7b, azumamide C, and 6b in 
HDAC3. The investigations are ongoing.  
 
Testing in cell lines 35 
The testing is ongoing. 
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